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Abstract 
Background: Rheumatoid arthritis (RA) is a symmetric polyarthritis arising from 
autoimmune dysregulation leading to severe disability and increased risk of co-
morbidities and death. A chronic disproportionate inflammatory process lies at 
the heart of disease pathogenesis. Breach of self-tolerance, subsequent immune 
effector cell activation in the context of abundant expression of effector 
cytokines all contribute to uncontrolled inflammation. Molecular safeguards that 
normally operate to promote immune regulation appear defective in RA. 
Intensive basic and translational research over the last 30 years have contributed 
the emergence of an array of new therapeutics for the treatment of RA, which 
has transformed patient outcomes. The identity of the cytokine targeting 
treatments that have been most successful elucidates a functional hierarchy that 
implicates elements of both innate and adaptive immunity.  In particular, 
dysregulation of TNFα and IL-6 biology are at the core of effector pathways and 
as such unravelling their detailed regulation is of critical importance. Moreover 
their primary synthesis places myeloid cells, and, in particular, blood-derived 
monocytes at the heart of pathogenic circuitry.  
Best current clinical practice is to treat early disease and deploy aggressive 
treatments directed towards restoration of immune balance in virtually all 
patients. However only a proportion of such patients will actually have poor 
prognosis disease and in reality merit such aggressive interventions - the 
identification of such clinical endotypes is a major challenge for the next 
decade. The field of epigenetics and consequent regulatory control of 
inflammatory cells offers rich potential in this regard. Examples of such 
regulatory elements are small RNA species – microRNAs (miRs), which serve as 
negative regulators of cellular transcription and thereby repress protein 
translation. Importantly they do so across functionally integrated pathways, 
operating beyond individual moieties. A growing body of evidence implicates a 
significant role of miRs in the regulation of inflammatory processes in the 
context of RA. 
Objectives: To identify miR species that are differentially regulated in patients 
with poor response to therapeutic intervention, compared to patients with well-
controlled disease and healthy controls. Thereafter, to characterise candidate 
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miRs arising from these investigations to thereby determine their functional 
significance.  Together these studies will shed light on a substantially ignored 
area of RA biology, namely the underlying mechanisms that subserve drug 
resistance in RA. 
Key Results: Microarray profiling of CD14+ monocytes derived from patients with 
drug resistance upon receipt of DMARDs or biologic treatments, compared with 
good responders or matched healthy controls identified the miR-23a~24-2~27a 
cluster to be significantly repressed in monocytes from resistant RA. Further 
analysis identified that two members of the cluster, miR-23a and miR-27a are 
implicated in a feedback loop regulating the IL-6 pathway. Thus IL-6 stimulation 
of primary monocytes suppresses the expression of this miR cluster, permitting 
expression of their direct molecular target, namely IL-6R, thus sensitising cells 
to further IL-6 signalling. I also observed that cells lacking miR-23a and miR-27a 
express higher levels of the pro-inflammatory cytokines TNFα and IL-6 when 
stimulated with LPS, further confirming that lack of these miRs has direct 
implications for chronic inflammatory processes.   
The remaining member of this miR cluster, miR-24, was shown to directly target 
methylene tetrahydrofolate reductase but not dihydrofolate reductase enzymes, 
implicating it in the target pathway of methotrexate (MTX), the most commonly 
used anchor DMARD. Although this is unlikely to confer disease resistance, this 
interaction suggests that miR-24 levels could be predictive of tolerability of 
methotrexate use. The potential biomarker capabilities of miR-24 in relation to 
MTX use, or miR-23a and miR-27 with regards to responsiveness to anti-IL-6 or 
JAK signalling inhibition therapeutics will be evaluated in my future work. 
Conclusion: This series of studies has elucidated highly novel pathways that 
mediate amplification of inflammatory responses in blood-derived monocytes 
through feedback pathways operating via regulatory miRs. Furthermore, analysis 
of a distinct cohort of RA patients allowed identification of miR species that 
have the potential to be utilised as clinical biomarkers for treatment efficacy or 
tolerability evaluation. Although a separate validation study is required, the 
detailed investigation of the role of these miRs performed here provides a clear 
mechanistic insight into their function and will certainly support future 
discovery.  
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1 General Introduction 
Rheumatoid arthritis (RA) is a symmetric inflammatory polyarthritis considered 
to be a systemic autoimmune disease with as yet unknown aetiology. The 
progressive chronic nature of this condition ultimately leads to deformity 
through erosive destruction of the cartilage and bone in the affected joints. Up 
to 1% of the general population suffers from RA. If left untreated or 
unresponsive to the treatment, RA leads to a severe disability, difficulties with 
tasks of daily living and unemployment [1]. The systemic nature of the disease 
involves multiple extra articular manifestations and increased risk for 
cardiovascular events, metabolic disorder and depression [2,3]. More 
importantly, RA is associated with an independently increased risk of premature 
death, a troubling prospect for the patient and responsible physician [4,5]. RA 
management has been transformed through the implementation of translational 
research in rheumatology:  herein I will highlight new frontiers of scientific 
discovery in RA and thereafter focus upon my own question of particular 
interest.  
1.1 Historical understanding and approach to treatment 
of RA 
One common thing between historical and current approaches to RA is the 
importance of deep understanding of the pathogenesis and the wealth of clinical 
experience in the diagnosis and management of this disease. Clinical 
heterogeneity at the time of presentation and throughout the natural course of 
the disease requires a truly holistic approach. The area in which this specialty 
has struggled the most over the last few decades is how to objectively capture 
and apply the deep understanding of RA that every experienced rheumatologist 
has and to apply this to new pathway discovery. To this end, several attempts 
were made to develop diagnostic and classification criteria, disease activity 
scores with disease and treatment biomarkers. But firstly, I will review the 
historical development of thinking about RA and improvements in all aspects of 
treatment, made through the years. 
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1.1.1 Diagnostic classification criteria 
Traditionally, the diagnosis of RA was based entirely on clinical criteria. These 
have been implemented in 1958 by American Rheumatism Association (ARA) and 
were revised every 10 to 20 years [6]. The most influential criteria were 
developed in 1987 and included 5 clinical parameters, measurement of 
rheumatoid factor (RF) and radiographic changes, shown in Table 1.1 [7]. For the 
diagnosis of RA four of these criteria had to be present for at least 6 weeks. With 
this, 93.5% sensitivity and 89.3% specificity was achieved. Although this 
classification defines the staple principles of clinical diagnosis and for the first 
time includes an objective biomarker, it had multiple issues. Firstly, no other 
condition was excluded. Secondly, it included rheumatoid nodules and 
radiographic erosive changes that are features of established disease, therefore 
significantly limiting the early diagnosis. It is important to understand that these 
criteria, and their limitations, were used for diagnostic and classification 
purposes, and were included in virtually all clinical trials conducted from 1987 
until 2010.   
 
Table 1.1 The 1987 revised criteria for the classification of rheumatoid arthritis.  
Adopted from Arnett at al., A&R 1988 [7].  
 
Criterion Definition 
1. Morning stiffness Morning stiffness in and around the joints, 
lasting at least 1 hour before maximal 
improvement 
2. Arthritis of 3 or more joint areas Soft tissue swelling in at least 3 joints, 
assessed simultaneously by a physician. 
3. Arthritis of hand joints At least one swollen area in a wrist, MCP 
or PIP joint.  
4. Symmetric arthritis Simultaneous involvement of the same 
areas from both sides 
5. Rheumatoid nodules Subcutaneous nodules, over bony 
prominences or extensor surfaces, or in 
juxtaarticular regions 
6. Serum rheumatoid factor Abnormal amounts of serum rheumatoid 
factor 
7. Radiographic changes Typical radiographic changes on 
posteroanterior hand and wrist  
radiographs 
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1.1.2 Historic Treatments 
Early definition of RA as an autoimmune inflammatory disease consequentially 
led to the use of immune suppressants and anti-inflammatory agents. Since the 
introduction of corticosteroids, there has been an ongoing search for more 
efficient and less toxic treatments. Non-steroidal inflammatory drugs (NSAIDs), 
such as aspirin and indomethacin, have shown some efficacy in addition to a 
regular steroid use and were introduced in order to improve functional outcome 
and pain relief in RA patients [8,9]. NSAIDs remained a first line treatment for 
inflammatory arthritis, alongside physiotherapy and splints, until the 1990’s. 
Interestingly, measurable functional outcomes at the time included 
inflammatory index, measurement of the PIP swelling with steel jewellers tape, 
walking time and shoe-tie time in attempt to objectify trial outcomes [9]. Joint 
injections with steroids or aspirin were also popular [10-12]. These early studies 
demonstrated that achieving reduced inflammation state is not enough to 
control the disease and cross over to placebo would result in symptom flare.    
Since the 1950’s there was a growing body of cases that claimed successful use 
of cytotoxic drugs in treatment of difficult cases of RA, including methotrexate 
[13]. This prompted a double-blind placebo controlled studies of the efficacy of 
azathioprine, cyclophosphamide, chloroquine, and gold preparations [14-18]. 
The placebo controlled gold preparation study included patients meeting early 
ARA criteria for at least 6 months. This trial showed ‘slight but definite 
improvement in the measured parameters’ which was acceptable rate of 
response at the time [18]. It also demonstrated the shift towards induction and 
maintenance therapy, that proved beneficial during 2 year follow-up, with 
significant difference in active joint count, grip strength and erythrocyte 
sedimentation rate (ESR) compared to symptom triggered bolus treatment [18]. 
Sharp et al. comprehensively reviewed the effects of chrysotherapy after 2 year 
follow-up study, during which 1/3 of the patients achieved remission, 1/3 had a 
partial response and 1/3 were classified as treatment failures [19]. Most 
importantly, this study noted that the only valuable prognostic factor of long 
term benefit was initial good clinical response to treatment after 3 months, 
similar to that now observed with modern agents. Authors also clearly defined 
the need for a satisfactory method to analyse treatment response, lack of which 
was additionally confusing the way trials were reported and implemented.  
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A head-to-head comparison of the efficacy of azathioprine, cyclophosphamide 
and gold was carried out in a double blind randomised trial lasting 18 moths and 
involving 121 patients with ‘relatively early’ RA (under 3 years of duration) [16]. 
Here, two ‘immunosuppressive’ agents produced clinical improvement compared 
to gold containing agents, facilitated reduction in the background steroid dose 
and hindered radiographic joint damage. Despite this, severe side effects of the 
used at the time immunosuppressants forbad people to stay on the medications 
long term and maintenance therapy with non-steroidal anti inflammatory agents 
(NSAIDs) was given, with increased risk of repeat flares. 
Patients with progressive treatment resistant disease constituted 1/3 of all 
patients with RA and were subjected to a variety of extremely invasive 
procedures like chemical or radiation synovectomy, total lymphoid irradiation, 
lymphocytic apheresis and thoracic duct drainage [20-23]. Alternatively, early 
attempts at combination therapy were made. To this effect, a small open study 
was conducted on 15 seropositive, treatment refractory patients that were given 
cyclophosphamide, azathioprine and hydroxychloroquine for an average of 27 
months [24]. Treatment benefit onset was observed from 3 to 16 month, during 
which 5 patients achieved remission, 9 patients had a partial response and three 
patients had no improvement. This was the first demonstration that small dose 
triple therapy could be better tolerated and more efficacious in the long-term 
disease control when compared to a single high dose agent. Additionally, this has 
demonstrated the benefit of the use of ‘disease-modifying antirheumatic drugs’ 
(DMARDs) over NSAIDs, which were extremely popular due to the quick 
analgesic, antipyretic and anti-inflammatory effects. On the contrary, available 
DMARDs were slow to act and provided less symptomatic relief, therefore were 
still considered a second line treatment after physiotherapy, rest and NSAIDs 
[25].  
These early studies demonstrate how slow unravelling of the magnitude of the 
inflammatory process behind clinical arthritis clearly defined a need for the 
continuous immunosuppression over periodic flare treatment. A growing body of 
data on the long term radiographic and functional outcomes confirmed that 
therapy with gold and cyclophosphamide can retard radiographic progression of 
the disease, setting a new therapeutic goal [26]. Necessities for clinical response 
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criteria and long term safety data were clearly defined. More importantly, the 
discovery of more tolerable drugs was a matter of urgency.  
1.1.3 Modern DMARDs 
A vast array of drugs were screened for their anti rheumatic properties. 
Different approaches, from new anti-inflammatory and cytotoxic agents to 
antibiotics including antimalarial agents were tested. Clear need for randomized 
controlled studies was appreciated, however poorly controlled disease and 
ineffective therapy were major confounding factors for early controlled studies, 
that could not manage treatment compliance beyond 2 years duration [19]. From 
late 1970’s until the 1990’s a series of well designed, placebo controlled, double 
blind randomized clinical trials showed efficacy of a variety of DMARDs, 
including methotrexate (MTX), sulfasalazine (SSZ), auranofin, 
hydroxychloroquine (HCQ), D-penicillamine and cyclosporine A [27-31]. Here, I 
will review the clinical trials and mechanism of action behind DMARDs currently 
in use in the clinical practice.  
1.1.3.1 Sulfasalazine 
Nanna Svartz from Sweden introduced SSZ for the treatment of rheumatoid 
arthritis in 1941. She believed that the core rheumatoid lesions were in the 
connective tissue and inflammatory in nature, therefore the higher tissue 
affinity of the combination of salicylic acid and sulphapiridine would have 
improved tissue penetration. Her initial positive experiences with sulfasalazine 
were diminished by the open label study conducted by Sinclair and Duthie in 
1949 [32]. After a significant period of neglect, the first rigorous randomized 
double-blind placebo controlled study of SSZ and intramuscular sodium 
aurothiomalate was conducted in Glasgow in 1983 [28]. This study clearly 
demonstrated non-inferiority of SSZ compared to gold preparation as a second 
line agent that was meant to reduce laboratory inflammatory variables. Both 
treatment groups differed significantly from placebo group. Additionally, SSZ in 
the 3g daily dose had a better safety profile (predominantly gastrointestinal 
disturbance) that allowed completion of the 24 weeks trial in the majority of 
participants [28]. Following this, other controlled studies proved clinical 
effectiveness of SSZ compared to placebo, despite the slow onset of the effect. 
25 
 
Thereafter, SSZ was successfully used in the clinical practice, although initially 
still reserved for NSAIDs and gold failures. Direct comparison of SSZ to HCQ in a 
double blind randomized trial on DMARDs naïve patients showed that those 
treated with SSZ developed less joint erosions and had lower joint damage 
scores after 24 and 48 weeks of treatment [33]. The 3 year follow-up of this 
study showed persistent benefit from the treatment in 38% of patients in SSZ 
group and 24% in HCQ group with sustained retardation of radiographic 
progression [34]. Other studies in ‘early’ pre-erosion RA patients treated with 
SSZ confirmed positive radiographic outcome, however noted that SSZ is not 
excellent in inducing clinical remission in a substantial proportion of patients 
were still symptomatic [35].  
Despite obvious clinical benefits and wide use, the mode of action of SSZ is still 
not fully explored. Earlier work implicated SSZ in the regulation of nuclear 
factor kappa B (NFκB) transcription factor (TF) and production of 
proinflammatory cytokines [36]. However, a recent large genome wide 
association study (GWAS) connected SSZ to the functioning of mediator of RNA 
polymerase II transcription subunit 1 (MED1) gene, serving as a co-factor of 
peroxisome proliferator activated receptor gamma (PPARγ) TF, crucial to the 
polarization of anti-inflammatory macrophages [37,38]. Both of these pathways, 
NFκB and PPARγ, are critical for osteoclastogenesis and can impact the 
formation of bone erosions [39,40]. PPARγ is also in the centre of adipogenesis 
as it regulates the fatty acid storage and glucose metabolism, evident from the 
gene knock out mouse model, which failed to generate fat tissue [41]. Use of SSZ 
could therefore influence adipogenesis and insulin-resistance in RA patients who 
are already at a higher risk of metabolic disease, although these studies have 
not been done. On the other hand, SSZ was shown to inhibit platelet aggregation 
and exhibit cardioprotective effect in patients with inflammatory arthritis, 
similar to that of aspirin [42].   
These data suggest a relevant pathophysiologic and clinical rationale for the use 
of SSZ in subjects with RA. Further clinical studies evaluating full potential and 
combinational use of this DMARD will be reviewed below.     
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1.1.3.2 Methotrexate 
Methotrexate is the most established and most beneficial DMARD to date. It was 
first successfully used in the treatment of psoriasis before introduction to the 
rheumatic field. MTX is designed as a folic acid antagonist that inhibits de novo 
purine and deoxyribonucleic acid (DNA) synthesis by inhibiting dihydrofolate 
reductase (DHFR) enzyme in cells. The initial rational behind its use in 
autoimmune conditions was the high rate of division of immune cells during 
active inflammation, which is inhibited by MTX. Indeed, MTX treatment of THP-1 
human monocytic cell line leads to increase apoptosis of these cells [43]. 
Alternatively, MTX potentiates the expression of adenosine and leads to the 
increased intracellular cAMP (cyclic adenosine monophosphate) levels that have 
anti-inflammatory properties and reduce cytokine expression [43]. More 
recently, it was shown that CD39 (cluster of differentiation 39) generates 
adenosine upon toll-like receptor (TLR) stimulation of the cells to maintain the 
balance of the macrophage response [44]. Lack of CD39 or adenosine sustained 
the inflammation and cytokine production by myeloid cells [44]. Adenosine 
receptor agonists are now being tested in clinical trials for their antirheumatic 
and analgesic properties [45]. It would certainly be intriguing to compare these 
data with the efficacy of MTX alone.   
Nevertheless, historically MTX was classified as a cytotoxic drug and despite 
early uses in 1950s, it is not until 1980s that controlled clinical trails with low 
doses of drug were conducted in RA. In the meantime, it was used sporadically 
in difficult cases and for intraarticular injections with some minor benefits [46]. 
The first convincing 24 weeks double-blind randomized cross-over placebo 
controlled trial demonstrated significant efficacy of the low dose MTX in RA 
patients with refractory disease treated for 12 weeks or in placebo cross over 
patients at 24 weeks [27]. At the time, 2.5 mg to 5 mg dose were used every 12 
hours three times per week and it was well tolerated. 3 year follow up of the 
patients that chose to continue with MTX treatment showed that 62% of cases 
reported some side effects, predominantly nausea, mild leukopenia, mild 
thrombocytopenia and transitory liver transaminitis without cirrhosis on the 
biopsy [47]. This indicated better safety profile of MTX than other cytotoxics like 
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cyclophosphamide, known for induction of azospermia and bone marrow 
suppression.  
Similar study conducted same year included 12 patients in the placebo 
controlled double-blind cross over design testing efficacy of once weekly 
intramuscular (im) MTX in patients with progressive erosive disease that have 
failed other available treatments [48]. Once weekly MTX dose was titrated from 
5 mg to 25 mg in small increments depending on the clinical response of the 
patient. There was significant improvement in tender and swollen joint counts, 
duration of the morning stiffness, visual analogue scale (VAS) of the well-being 
and physicians global score after 13 weeks of MTX treatment. Additionally, this 
study included extensive laboratory testing that indicated no change in the titre 
of RF and decrease of previously abundant numbers of monocytes amongst 
peripheral blood mononuclear cells (PBMCs) of the MTX treated subjects [48]. It 
was common at the time for clinical trials to include a small and homogeneous 
group of patients. Nevertheless, these studies have established MTX as an 
efficacious second line treatment in patients who fail NSAIDs and slow acting 
conventional DMARDs (gold). Addition of supplemental folic acid has significantly 
improved the tolerability of long term treatment with MTX [49].  
On the contrary, little progress was made in discovery of biomarkers of clinical 
response to MTX. Early hopes with HLA-DR2 expression were disproved by the 
multicentre randomized controlled study [50]. Further use of MTX coincided with 
the understanding that it is necessary to start early treatment to prevent 
occurrence of the erosions. The field was moving towards the idea of sustained 
prolonged treatment despite clinical remission, after reports demonstrated 
severe flares following discontinuation of methotrexate in previously stable 
patients [51].  
1.1.3.3 Hydroxycloroquine 
Cloroquine and hydroxycholoquine are anti-malarial drugs that have been 
successfully used in the treatment of RA for decades. A review from 1983 
summarizes a series of open label and double-blind controlled trials concluding a 
70% moderate efficacy of HCQ in previous NSAIDs failures or early progressive 
disease, of which 15% had excellent and 55% had partial clinical response [52]. 
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Safety profile has remained very satisfactory if daily dose is limited to 6.5 
mg/kg, with the exception of late stage retinopathy requiring annual clinical 
review [52]. Low risk and comparable efficacy with gold preparations or D-
penicillamine rendered HCQ a first choice among remittive drugs [30,52]. 
Despite satisfactory clinical responses, later head-to-head comparison of HCQ 
and SSZ showed a higher rate of erosive disease in HCQ treatment group after 24 
and 48 weeks [33]. Methodological difficulties of the earlier studies failed to 
produce conclusive results. The HERA study, involving 120 patients with RA of 
less than 2 years duration treated with HCQ or placebo for a period of 36 weeks, 
unequivocally demonstrated significant benefit on synovitis, pain and disability, 
but no psychological improvement in patients treated with HCQ [53].  
The main mechanism of action was thought to be acidification of the cell 
cytoplasm and interference with protein processing of the cell resulting in 
inhibited antigen presentation [54]. This very different mode of action is what 
rendered HCQ a suitable candidate for the combination treatment with other 
slow acting DMARDs. This was the crucial step in attempting earlier, more 
aggressive disease control in 1990’s that led to development of modern 
treatment protocols. 
1.1.3.4 Combination treatment 
Interest in combination therapy has arisen form the series of published reports 
suggesting that sequential use of available DMARDs in addition to standard 
therapy with NSAIDs and corticosteroids prevents joint damage, long term 
disability and most importantly, increases life span of RA patients [23]. By the 
1990’s it was not unusual practice to utilise conventional combination therapy 
with an additional DMARD of preference, even though randomized controlled 
trials were sparse. Whether this practice was established due to then popular 
views that RA is a ‘non-malignant B-lymphoproliferative disease’ where 
cytotoxics are beneficial or from sheer desperation in cases of unresponsive 
disease, initial results were satisfactory [55]. There was even a separate session 
at the 1993 American College of Rheumatology (ACR) meeting in San Antonio 
devoted to combination therapy in RA [56]. The field was influenced by the 
seminal paper from Wilske and Healey who formulated goals of RA therapy with 
crystal clarity: “to supress RA inflammation as completely as possible for the 
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patient’s entire lifetime and, thereby, to prevent the initial, and then 
progressive, joint damage that leads to eventual disability” [57]. Needless to say 
that this statement is entirely applicable to current clinical practice.  
Clinical trials evaluating combinational treatment of RA followed. An open study 
on 32 patients treated with combination of SSZ and MTX showed clinical 
improvement with no additional toxicity compared to therapy with MTX alone 
[58]. However, it is not until the seminal study from O’Dell et al, published in 
1996, that triple DMARD therapy in treatment non responders was tested [59]. 
102 patients with RA who previously failed at least one DMARD were divided in 
three equal groups to receive MTX, a combination of SSZ and HCQ or triple 
therapy with MTX, SSZ and HCQ for 2 years. 77% of patients in triple treatment 
group achieved 50% improvement after 9 months, compared to 40% in HCQ and 
SSZ combination group and 33% in MTX only group, while safety profile was 
comparable between all groups [60]. Superior efficacy of the triple therapy over 
either combination of MTX with SSZ or HCQ was once again confirmed in the 
separate two year double blind placebo controlled trial, conducted by the same 
group [59]. As a result, superiority of triple therapy use was demonstrated in 
patients with both early and more established RA [61-63].  
Mounting data on the better long-term outcomes, financial benefit and 
satisfactory safety profile has supported the mainstream use of DMARD 
treatment as the first line therapy of RA. The next step was to establish how 
early and how intensive should treatment be. Reviewing the protocols from the 
treatment of other chronic diseases such as hypertension or type I diabetes 
raised a possibility that rigorous disease monitoring and tight control would lead 
to the improved long-term outcomes. Indeed, the Tight Control of RA (TICORA) 
study was based on the hypothesis that whatever DMARD is initially used, as long 
as the therapy is adequately escalated it will ultimately lead to the full disease 
control in a majority of patients, some of which will achieve remission with a 
single agent whilst other will require triple therapy [64]. Indeed, a striking 65% 
of patients in the intensive protocol group achieved remission after 18 months of 
the treatment, compared to 16% in the routine group - possibly due to the ~50% 
of subjects receiving triple therapy in the intensive group compared to 3% in the 
routine management group [64].      
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Lack of biomarkers, aside from acute phase reactants and clinical review, makes 
it sometimes difficult to gauge if patients are over- or undertreated. Step-up 
approaches in response to clinical inflammation left many with the feeling that 
treatment is designed to merely ‘catch up’ rather then to prevent disease 
progression.The Triple Therapy in Early RA (TEAR) trial was a crucial study 
designed to explore the benefits of the triple DMARD therapy from the onset 
compared to the step up treatment in response to clinical need [65]. Study 
results showed no additional benefit from the parallel triple therapy use above 
appropriate and timely step up treatment in poorly controlled subjects. Second 
validation of the MTX-first strategy was demonstrated in the American TEAR 
study involving 755 participants and randomizing them to receive MTX 
monotherapy, MTX with SSZ and HCQ triple therapy or MTX and etanercept 
combination with biologic therapy [66]. Results demonstrated that 30% of the 
patients will achieve good disease control on MTX monotherapy, while 70% of the 
patients will require additional treatments. Unfortunately, the later group of 
patients is not clinically or radiographically distinguishable from the good 
responders and there is an acute need for appropriate biomarkers to identify 
such individuals a priori.  
In summary, rigorous carefully designed clinical trials have transformed 
treatment approaches and outcomes of RA. Expectations have significantly 
changed as well. Disease remission is achievable and can be common with a 
treat-to-target approach. A wide variety of safer medications are now available 
and the field is moving forward with remarkable speed. Despite this, early 
clinical response to treatments is still the most valuable predictor of the long-
term outcome. Rigorous clinical monitoring and incremental treatment are still 
the best ways to improve the rate of clinical remission, reduce physical disability 
and radiographic progression [67]. The next step to truly personalized and 
stratified medicine has been slow and difficult.  
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1.2 Current classification criteria and clinical scores in 
RA 
1.2.1 2010 Classification criteria  
A major shortcoming of the 1987 classification criteria for RA was the exclusion 
of the patients with early RA. This has been recently reviewed by the ACR and 
EULAR (European League Against Rheumatism) collaboration and new 
classification criteria were implemented in 2010. These criteria of RA are based 
on the presence of synovitis in at least 1 joint, absence of the alternative 
explanation for the synovitis and the minimal score of 6 out of maximum 
possible 10 for other associated features, summarized in Table 1.2. Although 
radiographs are not necessary for the diagnosis, people with existing bone 
erosions or previously diagnosed RA would also be classified as having RA.  
 
Table 1.2 2010 ACR/EULAR classification criteria for RA.  
 
Absolute Criteria 
Synovitis (swelling in at least 1 joint) 
No better explanation of synovitis 
Additional Criterion  Score 
A. Joint involvement 
1 large joint 0 
2-10 large joints 1 
1-3 small joints 2 
4-10 small joints 3 
>10 joints (at least 1 small joint) 5 
B. Serology 
Negative RF and negative ACPA 0 
Low-positive RF or low-positive ACPA 2 
High-positive RF or high-positive ACPA 3 
C. Acute-phase reactants 
Normal CRP and normal ESR 0 
Abnormal CRP or abnormal ESR 1 
D. Duration of symptoms 
<6 weeks 0 
≥6 weeks 1 
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1.2.2 DAS score 
Implementation of clinical response criteria significantly improved and simplified 
clinical practice and clinical trial reporting. Several scores are developed for the 
assessment of disease severity, progression and effect of treatment. Most 
frequently used is the disease activity score (DAS). DAS was invented in the 
1990s in a search for a clinical composite measure that would closely correlate 
and reflect predicted clinical outcome while incorporating a minimal amount of 
meaningful components [68,69]. It has since been evaluated in many large 
clinical trials and is widely accepted in clinical practise [70-72]. This score 
produces meaningful and interpretable results at every clinic appointment and 
allows better implementation of clinical trial results in everyday practice. The 
score is based on separate counts of swollen and painful joints amongst 
preselected 28 (or 44) joints assessed by the clinician, visual analogue scale 
(VAS) for the average weekly pain estimate by the patient and inflammatory 
marker CRP or ESR, making DAS28-CRP or DAS28-ESR scores. DAS44-CRP and 
DAS44-ESR are also used. The main drawbacks of this test are variable inter-
observer reproducibility of the clinical joint examination and potential 
underestimation of low-grade arthritis [73]. Although some recent reports would 
suggest that clinical estimation of disease progression using DAS28 score is just 
as efficacious as ultrasound (US) at the treatment escalation and achieving 
remission [74,75]. Therefore, reduction in DAS28 score is an established 
treatment target and a benchmark for classifying the prescription of biologic 
agents like anti-TNFα inhibitors in the UK [76]. 
DAS28 score is a continuous scale, in which a DAS of >5.1 represents high disease 
activity, DAS28 score between >3.2 and <5.1 results in moderate activity, while 
DAS28 score in the range of 2.6-3.2 is a mark of low disease activity at the time 
of assessment. Clinical remission is classified with the DAS28 score of <2.6. A 
change of 1.2 in the score of the individual patient is considered a clinically 
significant change.  
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1.2.3 SDAI and CDAI scores 
The Simplified Disease Activity Index (SDAI) [77] and Clinical Disease Activity 
Index (CDAI) [78] are two other continuous clinically used measures that have 
served as the most recent tools for the clinical trial outcomes. Similarly to 
DAS28, the SDAI score involves 28 joint count for tender and swollen joints, 
acute reactant CRP (mg/dl) and patient’s global assessment, however, the 
additional component is the physician’s global assessment also measured on 0-10 
Likert scale. High disease activity according to SDAI core is >26, moderate range 
is 12-26, mild <3.4-11, and remission is suggested with SDAI of <3.3. 22 points 
represent a major change, while the improvement in 10 to 21 points is 
considered a minor change. 
Given that a CRP result is not always available at the time of the patient’s 
appointment, CDAI score was developed to be interpretable at the clinic and 
includes the sum of 28 TJC and SJC, patient’s global assessment and patient’s 
overall pain score. No acute phase reactant is necessary for the CDAI score [79]. 
High disease activity is represented by score >22, moderate range lies between 
11-22, low disease activity is within the score of 2.9-10, and remission is <2.8. 
Latest ACR guidelines on evaluation of disease activity in RA suggest that use of 
DAS28, CDAI and SDAI scores incorporating CRP are all valid discriminative 
measures and prediction of clinical outcomes correlate with each other [78,80]. 
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1.2.4 Clinical criteria for the trial outcomes 
Assessment of drug efficacy during clinical trials requires the measurement of 
both continuous and categorical outcomes. EULAR response criteria are based on 
DAS28 score and are the most commonly used measure, which provides results 
that are easily extrapolated to the daily clinical setting. However, categorical 
scores are preferable in comparison of study results with other trials of the same 
or other drugs. For this purpose, ACR criteria based on the reached value 
principle were developed [81].  
The ACR criteria were developed to maximally discriminate effective treatment 
from the placebo control [82]. This is achieved by setting several progressively 
more difficult to achieve goals by calculating the number of patients that have 
shown 20%, 50% or 70% improvement. Much like DAS, these criteria incorporate 
patient’s global assessment, physician’s global assessment, VAS for pain, 
disability and functional questionnaire as well as one of the acute phase 
reactants (CRP or ESR). In order to classify for ACR20, 20% improvement in at 
least three from available 5 criteria must be detected. ACR 20 response is 
considered a clinically relevant improvement, although some investigators have 
questioned this [83]. With the field moving towards frequent achievement of 
good clinical response, ACR50 and ACR70 criteria were developed, for these 50% 
and 70% improvement in three out of five measures must be observed [84]. The 
performance of EULAR and ACR response criteria has been validated in different 
clinical trials, and resulting discrepancy was found to as low as 5% [85]. 
More difficult and yet more crucial was obtaining a consensus on the definition 
of remission in patients with RA. After much investigation, RA remission in 
clinical trials can be classified when wither scores of the tender joints, swollen 
joints, CRP (mg/dl) an patient’s global assessment are all ≤1, or when SDAI score 
is ≤3.3 to ensure minimal chance of further radiographic damage and progression 
of disability [86,87]. 
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1.3 Current understanding of the pathogenesis of RA 
RA is a complex disease and our understanding of the pathogenesis has changed 
over the years with new discoveries made. Historically, it was believed to be a 
disease of the adaptive immune system, whether it was called “non-malignant B-
cell lymphoproliferative disease” in 1960’s and 70’s for its association with 
autoantibodies, or a T cell dependent disease as a part of the ‘shared epitope’ 
(SE) model. The SE model suggests self or similar to self peptide to be presented 
to T cells by antigen presenting cells (APC) in such a way that autoreactive T 
cells are selected and breach of self tolerance occurs. This hypothesis is based 
on the association of RA with MHC class II genes, and in particular, a specific 
amino acid sequences in HLA-DR1 and HLA-DR4 alleles, responsible for APC-T cell 
cross talk [88]. Preference of RA T cells for citrulinated peptides, which are 
more prevalent in smokers, also stems from the way self peptides are processed 
and presented [88]. In addition, early genetic association studies identified 
single nucleotide polymorphism in the PTPN22 locus and programmed death gene 
(PD-1) that inhibits apoptosis in auto-reactive T cells [88]. On the contrary, twin 
studies have shown that concordance rate of disease is only around 15% and the 
occurrence of the disease after the age of 40 suggests a weaker genetic 
component [89]. Overall , thought debated, heritability of RA is probably around 
60% at best.  This supports a strong environmental component and perhaps 
epigenetic influences on pathogenesis (see later).  
Clinical trials have taught us that more efficacious treatments are those that 
target broad-spectrum proinflammatory cytokines, pointing towards a significant 
involvement of the innate immune system as well as the pro-inflammatory 
aspects of the resident cells, such as fibroblast-like synoviocytes (FLS), together 
with cells of the adaptive response e.g. via co-stimulatory blockade or B cell 
depletion. One thing we can agree on is that involvement of the immune system 
in RA has to be viewed in its entirety, if further therapeutic progress is to be 
made. Unfortunately, understanding to why RA localises predominantly in joints 
and not other parts of the body, remains somewhat evasive.  
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1.3.1 T cells 
The importance of T cells in RA pathogenesis was established early, since 
increased numbers of CD3+ effector T cells were found in synovial histology 
[90,91]. In mouse models, adoptive transfer of T cells from diseased mice was 
sufficient to induce the disease in the recipient, further supporting the T cell 
oriented model of the pathogenesis [91,92]. Since then, several types of effector 
T cells were identified. Thymic differentiation of T cells generates CD4+ and 
CD8+ T cells, the former most investigated in RA.  
1.3.1.1 CD4+ T cells 
From CD4+ T helper cells TH1, TH2 and TH17 subsets are recognised. TH1 cells 
deliver a viral response; they differentiate under the guidance of IL-12 and IL-18 
and T-bet TF and are a major source of IFNγ [93]. TH2 cells mature with the 
presence of IL-33, IL-4 cytokines and gata-3 TF and they produce IL-4, IL-5, IL-9, 
IL-13, which are effective against parasites, but also mediate allergic responses 
and manifest clinically for example as asthma [94]. TH17 cells are crucial in 
defence against extracellular bacteria and fungi and differentiate under 
influence of TGFβ, IL-1, IL-6, IL-21, and IL-23 to initiate rorc TF expression and 
become mature cells producing IL-17 (IL-17A), IL-17F, TNFα and CCL20 [95]. 
Recently they have been recognised to be more plastic and some are also noted 
to express IL-10, GM-CSF and other cytokines. Less investigated types include 
TH9 for IL-9 expression and TH22 for IL-22 expression respectively, however the 
relation of these cells to other T helper subsets and their functional roles are 
still unclear [96].  
Original data supported the role of TH1 cells as the main drivers of RA synovitis, 
due to the raised levels of IFNγ in synovial fluid. With the discovery of TH17 
cells, it is now suggested that synovial IL-17 contributes to the influx of 
inflammatory cells, activation of pro-inflammatory cytokine production and 
significant bone and cartilage damage due to the direct effects on osteoclasts 
and chondrocytes [90,97]. In fact, both hypotheses are likely to be correct as 
significant plasticity occurs in synovial T cells, as might be expected from 
commentary above. A high proportion of cells co-express IFNγ with IL-17, driven 
by the activation of both RORC and T-bet TFs [98-100]. This phenomenon of 
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superactivation is specific to synovial inflammation, as PB cells remain single 
positive for either IFNγ or IL-17 [98]. More importantly, double positive TH1/ 
TH17 cells produce GM-CSF and contribute to the chemotaxis and maturation of 
synovial dendritic cells (DCs), in parallel instructing them to further prime new 
generations of TH17 type cells [101,102].  
A further major advancement was made with discovery of regulatory T helper 
cells - TREG cells – that develop in the thymus in the presence of TGFβ and IL-2 
and express foxp3 TF [103]. Their role is to suppress other T cells and APCs 
through secreting anti-inflammatory cytokines such as IL-10 and providing an 
inhibitory CTLA-4 signal instead of CD80/86 co-stimulation on APCs to induce 
tolerance [103]. Similarly to other T helper cells, inflammatory monocytes can 
induce expansion of TREG cells at the site of inflammation and increased numbers 
are found in arthritic joints [104,105]. It is, therefore, of utmost importance to 
understand whether it is the inappropriate activation of effector T cells or the 
failure of the regulatory mechanisms that allow chronicity in RA. Now, there is a 
considerable amount of evidence suggesting that both occur. Namely, T cells, 
and in particular TH17 cells, derived from the site of inflammation are 
irresponsive to suppression, especially in the presence of TNFα and IL-6 [106-
109]. On the other hand, synovial fluid TREG cells are functional in vitro, however 
activation with CD28, IL-6, IFNα and TNFα through an expressed TNF receptor 2 
(TNFR2) directly impair their ability for suppression [110-115]. This may explain 
the enhanced supressing abilities of TREG cells in patients receiving treatment 
with an anti-TNFα agent [115-117].  
1.3.1.2 CD8+ T cells 
Increased interest in CD8+ T cells is now elucidating new pathways, involved in 
RA pathogenesis. Patients with early active RA have increased absolute numbers 
of PB CD8+ T cells when compared to matched healthy controls [118]. This is 
followed by a decrease in absolute numbers of cells during remission [119]. 
Expanded populations of CD8+ T cells are noticed in RA synovial fluid where it 
negatively correlates with DAS28 clinical scores [120]. Newly defined subtypes of 
CD8+ T cells, such as CD73+ cells exhibiting anti-inflammatory properties, are 
likely to transform our view of T cells in RA and give rise to new therapeutic 
interest in the near future [121].  
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1.3.1.3 T cell targeted treatment 
Accumulating data on the importance of T cells in RA resulted in development of 
multiple anti-leucocyte, anti-CD4 and TCR compounds, which were amongst the 
first biologic treatments ever tested [122-124]. Unfortunately, anti-CD4 
treatment approach showed no sustained benefit in patients with severe RA 
despite causing severe leukopenia. With the discovery of TREG cells and co-
stimulatory pathway of activation, targeting of CD28-CD80/86 axis was more 
appealing as it was believed to prevent activation rather than cause full 
depletion of T cells. This new approach capitalised on a fusion protein of CTLA-4 
and a fragment of the Fc domain of human IgG1 named Abatacept. The 
Abatacept Trial in Treatment of Anti-TNFα Inadequate Responders (ATTAIN) was 
a phase 3, large randomized placebo controlled study involved 258 patients in 
the treatment group and 133 patients receiving placebo [125]. Patients had a 
wash-out period from TNFα agent before the trial, however they continued with 
a conventional DMARD of choice. Here, ACR 20 improvement was the primary 
outcome and was achieved by 50.4% of the actively treated patients and by 
19.5% of placebo group. Improved rate of ACR 50 and ACR 70 responses, higher 
rates of low disease activity and remission according to DAS-28 criteria and 
comparable incidence of side effects with slightly higher rate of mild to 
moderate infection in the abatacept group rendered it an efficacious treatment 
in TNFα failures [125].  
Further safety data were obtained during the ASSURE trial (The Abatacept Study 
of Safety in Use with Other Therapies) where recipients of abatacept in 
combination with DMARDs or other biologics were followed for 1 year [126]. This 
trial demonstrated similar safety profile of abatacept in the combination with 
DMARDs as the placebo control group, however a higher rate of significant 
adverse events were found in the group treated with abatacept in the 
combination with other biologics (22.3%), most commonly an anti-TNF agent 
(11.7-12.5% in placebo or DMARDs combination groups, respectively) [126]. 
Therefore, the use of abatacept in combination with other biologic agents was 
not advisable in the clinical practice. On the contrary, further evidence was 
provided for the use of abatacept in the combination with methotrexate, since 
patients who were initial responders to this treatment maintained efficacy and 
had reduced radiographic progression after 2 years follow-up [127]. 
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Subsequently, deeper understanding of osteobiology has revealed that CTLA-4 
(or abatacept) binding to CD80/86 molecules on the surface of osteoclast 
precursors prevents further differentiation of the cells despite presence of 
stimulatory factors such as M-CSF or RANKL, explaining direct influence of 
abatacept on the bone erosion formation in RA [128,129].   
Naturally, the question of efficacy of abatacept in early RA with biologics naive 
patients has arisen. This was investigated in the AMPLE trial (Abatacept versus 
Adalimumab Comparison in Biologic-naïve RA Subjects with Background 
Methotrexate) on 646 patients failing monotherapy with MTX and randomly 
assigned to receive a weekly subcutaneous (sc) injection of abatacept or twice 
weekly sc adalimumab (anti-TNFα agent) [130]. Primary outcome – ACR20 score 
at 1 year was achieved by 64.8% of patients receiving abatacept and 63.4% 
taking adalimumab. Comparable secondary outcomes in both groups confirmed 
non-inferiority of the use of abatacept in the primary DMARDs failures. 
Most recent NICE (National Institute of Health and Care Excellence) technology 
appraisal guidance [TA375] from January 2016 allow the use of abatacept in 
patients with severe RA who have failed treatment with a combination of 
DMARDs, providing this therapy is not more costly than other available choices.   
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1.3.1.3.1 Targeting IL-17 and IL-12/23 axis 
A broad spectrum of pro-inflammatory and bone remodelling effects are 
exhibited by IL-17. Higher presence in synovial fluid, association with disease 
activity and reduced response to treatments comprised the clinical potential of 
IL-17 targeting in RA [97,131]. Several human monoclonal antibodies were 
developed. Secukinumab and Ixekizumab are both targeting IL-17A cytokine, 
while Brodalumab is directed towards its receptor - IL-17RA.  
Although showing safety and modest efficacy at phase II clinical trials, large, 
multicentre placebo controlled phase III trial of Secukinumab in previous non-
responders to anti-TNF treatment were terminated due to the lack of effect and 
insignificant amount of patients achieving ACR 20 compared to placebo after 24 
weeks of the study [132,133]. Similarly, trials with Ixekizumab and brodalumab 
have been withheld after phase II trials, due to the incomparable efficacy when 
compared to the TNFα inhibitors [134,135]. Instead, targeting of IL-17 pathway 
has proven significantly more beneficial in psoriasis and psoriatic arthritis [136].  
Other approaches were taken with Ustekinumab, a monoclonal antibody 
inhibiting the p40 subunit of IL-12/IL-23 cytokines and affecting both TH1 and 
TH17 cells. Despite impressive results demonstrated in psoriasis and psoriatic 
arthritis, ustekinumab failed to achieve ACR20 response in more than 55% of 
patients in phase II dose range study after 28 weeks of treatment [137].    
These findings indicate that although pathogenic, TH1/17 cells are not cells with 
sufficient hierarchical dominance in RA. Improved outcomes with abatacept but 
failure of anti-IL-12 and anti-IL-17 treatments questions if abatacept works 
through inducing tolerance in broader spectrum of immune cells and if balance 
of T cell subsets is important for the resolution of chronicity. Additionally, 
inefficacy of full T cell depletion by earlier agents further supports the need for 
presence and balanced T cells. These data also point towards significant 
involvement of the innate immune system and, in particular, myeloid cells in RA 
inflammation.  
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1.3.2 B cells 
Since the discovery of rheumatoid factor (RF), an auto-antibodies against Fc tail 
region of hosts own immunoglobulins, by Waaler in 1937, B cells were suspected 
to play a role in the pathogenesis of RA [138]. Low specificity of RF for RA and 
presence in other autoimmune diseases soon led to the change of hypothesis 
evolving around T cells and macrophages, which resulted in development of 
related therapies [139]. Clinical efficacy of B cell depletion therapies in mice 
and human inspired new research in the role of these cells, beyond autoantibody 
production [140-142]. 
B cells originate in the bone marrow from the common haematopoietic 
progenitor and display unique B cell receptor (BCR) [143]. Lengthy processes of 
bone marrow and spleen differentiation of B cells ensures that autoreactive 
clones are deleted, edited or rendered anergic during normal development as 
they migrate to secondary lymphoid organs [144]. Induction of tolerance requires 
multiple check points for the BCR but also involves AID (activation-induced 
cytidine deaminase enzyme) and serum BAFF (B-cell activating factor) levels 
[144]. Induction of central and peripheral tolerance is defective in RA, leading to 
accumulation of autoreactive mature naïve B cells [145]. Links between PTPN22 
polymorphism and autoreactive B cells has been established, indicating that 
genetic or epigenetic changes in the bone marrow progenitors could be present 
in RA [144]. Constant replenishing of autoreactive B cells partially explains why 
treatment with cytokine neutralizing antibodies and regulation of peripheral 
inflammation is not a cure for RA [146].  
Apart from autoreactivity, naïve B cells in RA are also more resistant to Fas-
mediated apoptosis [147]. Systemic support for defective B cells is evident from 
increased levels of BAFF in the serum and the synovial fluid from RA patients 
[148]. Toll-like receptor (TLR) stimulation of myeloid cells, but also of resident 
synovial fibroblasts are main sources of BAFF survival signal in RA [149,150]. 
Independently, TLR signals can activate B cells and promote immunoglobulin (Ig) 
isotype switching in T cell independent manner outside of germinal centres 
(GCs) [151,152]. 
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In RA pathogenesis, B cells are known for their autoantibody production, T cell 
activation and cytokine secretion. A large number of autoantibodies are 
detected in patients with RA, however RF and ACPA antibodies are the mainstay 
of the disease diagnosis. Although regularly utilized in the clinical setting, 
understanding how these antibodies come to be generated is considerably more 
difficult. It is believed that autoreactive recognition of self-IgG antibodies 
(generating RFs) occurs in a T cell independent way outside of GCs through self-
antigen activation of intrinsic B cell TLRs [152,153]. Indeed, RFs are 
predominantly non-switched IgMs. In contrast, ACPA antibodies are believed to 
arise within the GCs upon encounter with autoreactive T cells, hence its strong 
association with HLA DR genes and amino acid replacement mutations [154,155]. 
Involvement of two pathogenic pathways partially explains the worse treatment 
prognosis in double seropositive patients [156].  
Autoreactive, and, in particular, RF+ B cells have a higher affinity for uptake and 
cross presentation of immune complexes and self-antigens to T cells, therefore 
serving as an autoreactive APCs [157,158]. This has also been demonstrated in 
severe combined immunodeficient (SCID) mice, where anti-CD20 treatment led 
to disappearance of tertiary follicles in transplanted inflamed synovial tissue 
[159]. Lastly, B cells are an important source of IL-6, IL-12, IL-23 and TNFα 
[160,161]. Synovial B cells produce RANKL and support osteoclastogenesis in the 
arthritic joints [161]. Most recently, CD19+ cells were identified as an additional 
source of IL-17A, which has wide range of pro-inflammatory effects [162].  
1.3.2.1 B cell targeted treatment 
The rational behind the first use of B cell depletion therapy in RA was two fold: 
firstly, RF generating B cells were considered self sufficient and pathogenic, as 
they further promote autoreactivity through uptake of self-generated 
immunocomplexes; secondly, RF antibodies and immunocomplexes were shown 
to activate other cells and facilitate TNFα production [140]. The surface B cell 
marker CD20 was a suitable, if not ideal target for the purpose. CD20 is 
exclusively and highly expressed on pre- and mature B cells and is not found on 
stem cells, plasma cells or any other immune cells, allowing replenishment of B 
cell population after the removal of autoreactive clones [163-165]. Additional 
benefits were gained from the stability of this cell marker, since it is not cleaved 
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from the cell surface, internalised or solubilized at any point [166]. Anti-CD20 
chimeric monoclonal antibody, Rituximab (RTX), was previously used for the 
treatment of non-Hodgkin’s lymphoma and was available for testing in RA 
[167,168].  
A first open label, proof of concept trial using B cell depletion therapy was 
conducted by Edwards and Cambridge and included only 5 patients with 
uncontrollable RA [140]. All subjects achieved ACR50 and 3 patients achieved 
ACR70 response after 6 months of treatment. More importantly, investigators 
witnessed stable levels of serum IgM and IgG antibodies (Ab) and replenishment 
of B cell populations after completion [140].  Following this, successful use of 
RTX in RA was demonstrated in the phase II dose ranging DANCER trial (Dose-
Ranging Assessment: International Clinical Evaluation of Rituximab in RA) in 
biologic naïve patients receiving MTX and 2 doses of RTX [169]. Success of the 
trial was defined by ACR20 score, which was achieved by 55% in lower dose and 
by 54% in higher dose RTX groups after 24 weeks, meeting primary endpoint 
[169]. The phase III Randomized Evaluation of Long-Term Efficacy of RTX in RA 
(REFLEX) Trial was done in patients with active longstanding erosive RA who 
were inadequate responders to one or more anti-TNFα agents [170]. Here, the 
primary endpoint was met when significantly higher number of patients (51%) 
achieved ACR20 in treatment group when compared to 18% in placebo controls. 
More importantly, there was significant meaningful improvement in ACR 
response parameters, including fatigue, disability and quality of life scores, 
while safety profile remained satisfactory [170]. Detailed analysis of patients 
from REFLEX trial demonstrated sustained benefit in pain relief, functional 
disability and quality of life indices [171], as well as significant inhibition of 
radiographic progression of joint damage [172], which was sustained after 2 
[173] and 5 years of follow up [174].  
Many subsequent studies investigated immunological effects of RTX treatment. 
Synovial biopsy before and 4 weeks after RTX treatment showed significant 
decrease in the total number of B cells in the synovial tissue, but only in a part 
of the patients [175]. The ARISE trial (Assessment of Rituximab’s 
immunomodulatory synovial effects) further clarified that RTX treatment leads 
to a decrease but not a full depletion of synovial B cells, unlike in the circulation 
of patients after 8 weeks of treatment [176]. Some authors suggested potential 
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gain from re-treatment with RTX at a later stage, however this remained 
controversial [177,178]. Additional use of RTX in combination with MTX and TNFα 
blocking agent in patients with active disease showed no clinical benefit from 
triple therapy, while safety profile was comparable to previously seen in MTX 
only combination during 24 weeks of the trial [179].  
The Study Evaluating Rituximab’s Efficacy in MTX iNadequate rEsponders 
(SERENE) was a phase III trial, randomly assigning patients with active disease to 
receive a course of RTX or placebo in addition to continuous use of MTX [180]. At 
24 weeks, non-responders were permitted a second course of RTX or a switch to 
the active drug from the placebo group. Active treatment group has achieved 
primary outcome with ACR20 in >50% of patients compared to 23% in placebo 
group, after 24 and 48 weeks, proving benefit from first line RTX treatment in 
biologic naïve subjects [180]. McGonagle et al have reported that use RTX is a 
suitable option when TNFα treatment is inappropriate or unavailable [181]. 
Indeed, the ORBIT (The Optimal Management of patients with rheumatoid 
arthritis who Require Biologic Therapy) study recently demonstrated that 
rituximab is a non-inferior and more affordable first line biologic agent 
compared to available anti-TNFα options [182].–  
Attempts at enhancing efficacy of RTX were made in the AUGUST III study 
(Atacicept for Reduction of Signs and Symptoms in Rheumatoid Arthritis Trial III) 
where it was combined with Atacicept, an antagonist of two B cell survival 
factors BlyS (B lymphocyte stimulator) and APRIL (a proliferation-inducing 
ligand) [183]. Unfortunately, this combinational treatment was not associated 
with clinical benefit. Alternative approach to targeting B cells with anti-BAFF 
agent Tabalumab were tested in the early clinical trials in patients with severe 
RA but were unsuccessful [184].  
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1.3.3 Fibroblasts  
In RA, fibroblast like synoviocytes (FLS) exhibit some aggressive traits; they 
increase in number, are resistant to apoptosis and produce cytokines and 
chemokines, thus aiding chronicity of the inflammation. Interestingly, these cells 
retain their behavior after removal to in vitro culture, suggesting epigenetic 
imprinting of certain features [185,186]. If transplanted into SCID 
immunedeficient mice, FLS originating from RA synovium are capable of causing 
bone erosions and arthritis [187]. Additionally, RA FLS have a capacity to migrate 
and sustain inflammation in other joints, away from initial site [188].  
Unaffected diarthrodial joints have a thin layer of synovial membrane 
responsible for the production of synovial fluid and balanced secretion of 
degrading and protecting enzymes, which are maintaining the extracellular 
matrix. Intimal lining layer consists of macrophage like synoviocytes (type A 
cells) and fibroblast like synoviocytes (FLS or type B cells). FLS produce 
vimentin, adhesion molecules and collagens as well as surface CD90 marker 
[189]. Additionally they display, CD55 molecule, an enzyme required for the 
hyaluronic acid synthesis [190]. More importantly, structure of synovial lining is 
governed by adhesion molecule Cadherin-11, which induces in vitro 
accumulation of FLS cells and regulates expression of pro-inflammatory 
cytokines, such as IL-6 by FLS [191,192]. It is possible that therapeutic targeting 
of Cadherin-11, and therefore FLS cells, could provide beneficial outcome in the 
treatment of RA [193] 
In RA, FLS are implicated in initiation, chronicity and formation of the 
inflammatory pannus, as well as the destruction of the joint anatomy. Higher 
numbers of FLS and thickening of synovial membrane is caused by inhibited 
apoptosis and reduced turnover, rather than increased proliferation of the cells 
[194,195]. Resistance to apoptosis persists during in vitro cultures and seems 
independent from RA cytokine milieu [186]. During inflammation, FLS secrete 
multiple enzymes degrading extracellular matrix, such as matrix 
metalloproteinases 1 and 13 (MMP1 and MMP13) and cathepsin [196,197]. They 
further contribute to osteoclastogenesis and formation of bone erosions by 
secreting RANKL and Dickkopf-related protein 1 (DKK-1) [198,199]. Upon 
encounter with pro-inflammatory stimuli, such as TNFα, FLS secrete IL-6, IL-18 
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and GM-CSF [200]. They directly support the influx of new inflammatory cells by 
secreting migratory chemokine CCL2 and indirectly by promoting angiogenesis 
through vascular endothelial growth factor (VEGF) [201]. Lastly, RA FLS promote 
formation of tertiary germinal centers, attract T cells and promote B cell 
survival by secreting CXCL12 chemokine and BAFF [202].  
As to causes leading to transformation of FLS cells, studies have looked at 
genetic and epigenetic changes. RA FLS were shown to have mutations of p53 
apoptosis pathway, similar to the ones found in cancer cells [203,204]. Even if 
mutation have not existed before the occurrence of inflammation, TNFα 
stimulation of FLS leads to increased accumulation of mitochondrial DNA 
mutations [205]. Epigenetically, FLS were seen to have reduced global 
methylation and altered expression of miRs regulating proliferation and 
apoptosis, such as miR-124a, miR-203 [206-208]. 
Despite the central role of FLS cells in the pathogenesis of RA and connections to 
all aspects that promote and perpetuate chronicity of this disease, therapeutics, 
targeting these cells are only just emerging. Apremilast, a selective inhibitor of 
phosphodiesterase 4 (PDE4) was shown to inhibit the spontaneous production of 
TNFα by synovial FLS and is approved for the clinical use in psoriatic arthritis 
while currently undergoing clinical evaluation for the use in RA [209]. Also, a 
new class of Janus kinase (JAK) inhibitors are shown to have a direct effect on 
RA FLSs, as they inhibit TNF induced type I IFN signatures and break the 
autoreactive loop [210]. 
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1.3.4 Myeloid cells 
1.3.4.1 Monocytes  
Monocytes are circulating cells that originate in the bone marrow from an 
erythromyeloid progenitors expressing c-Myb TF [211]. Two major subsets of 
circulating monocytes have been identified in mice, according to the expression 
of Ly6C, a membrane monocytic marker and CCR2 (C-C chemokine receptor type 
2) [212]. The subsets include ‘classical’ Ly6C+CCR2+ and alternative Ly6ClowCCR2- 
cells [213]. Classical Ly6C+ cells are also termed inflammatory monocytes and 
are the most abundant population, which requires CCR2 expression in order to 
enter the circulation and produces inflammatory cytokines upon activation in a 
GM-CSF dependent manner [214-216]. Ly6C+ monocytes are required for the 
initiation of arthritis in murine models and they differentiate into classically 
activated macrophages to drive inflammation [213,217]. A number of studies 
have shown that Ly6C+ CCR2+ monocytes are responsible for the phenotype in 
collagen induced arthritis (CIA) in mice [218]. The second subset, Ly6Clow 
monocytes are significantly less prevalent in the circulation and they are 
believed to be patrolling the endothelium and maintaining vascular integrity 
[219].  
Characterization of human monocytes led to the discovery of three distinctive 
subsets on the bases of CD14 (the TLR4 co-receptor) and CD16 (the FcγRIII 
receptor for IgG) expression: classical CD14+CD16- (resembling murine 
Ly6C+CCR2+), intermediate CD14+CD16+ and non-classical CD14lowCD16+ cells 
[220]. Data on both human and murine subsets are still sparse and any 
extrapolation should be done with caution, especially since species specific 
monocyte transcriptomes were defined [221]. Nonetheless, classical human 
monocytes, CD14+CD16-, comprise ~90% of circulatory monocytes and resemble 
inflammatory Ly6C+ CCR2+ murine cells [222]. The non-classical, CD14lowCD16+ 
are considered human endothelial patrolling cells, similar to Ly6ClowCCR2- cells in 
mice. However, it is the intermediate CD14+CD16+ monocytes that proved to be 
of particular importance in autoimmune disease. This population is significantly 
expanded in the circulation and synovial fluid of patients with RA and is 
associated with active disease and poorer treatment response [223-226]. When 
derived from patients with RA, double positive cells express high levels of CCR1, 
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CCR5, ICAM-1 and pathogen receptor TLR2 [227,228]. Stimulation of membrane 
CD16 molecule with specific immune complexes results in TNFα release, 
suggesting that CD16 expression is pathogenic as well as a marker for 
inflammatory monocytes [228-230]. Expansion of this intermediate population of 
monocytes could be explained by activation and increased proliferation of 
existing cells and/or newly triggered co-expression of CD16 upon activation of 
classical monocytes. Indeed, CD16 expression was induced in experimental 
treatment of healthy monocytes with RA synovial fluid or TGFβ [231].  
1.3.4.1.1 Tissue migration of monocytes  
In order to migrate from the bone marrow, monocytes require the expression of 
CCR2 chemokine receptor. Two ligands are capable of binding to this receptor 
and both are required to guide monocytes into inflamed or infected tissues. 
These ligands are CC-chemokine ligand 2 (CCL2 or MCP1) and CCL7 (MCP3) [232]. 
Almost all nucleated cells are capable of expressing CCL2 upon stimulation with 
inflammatory cytokines [232-235]. It is believed that CCL2 is also circulating in 
the lymph and responsible for attracting patrolling monocytes to the lymph 
nodes in a gradient dependant manner [236,237]. Deletion of either of these two 
chemokine genes in mice decreases monocyte recruitment by ~50% [238]. Other 
ligands, such as CCL8 and CCL12, have an affinity for CCR2 receptor, still 
deletion of these genes had no significant impact on monocyte trafficking [232]. 
Monocyte recruitment is thought to occur through stages of rolling, adhesion and 
endothelial transmigration. These actions are enabled by a series of integrins 
and other adhesion molecules, as well as non-redundant chemokines CCL3 and 
CCL5, which ligate CCR1 and CCR5 receptors on the cell surface of monocytes 
and aid transendothelial chemotaxis towards the higher gradient of CCL5 
expression in the tissues [239-241]. Upon tissue entry, monocytes are capable of 
differentiating into macrophages or inflammatory dendritic cells, still they can 
also remain as monocytes, upregulate MHC class II genes, acquire antigens and 
carry them to the lymph nodes [242].  
1.3.4.2 Macrophages 
Migrated monocytes, exposed to certain stimuli upregulate macrophage-
associated genes and differentiate into macrophages [243]. During this period 
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cells are capable of expressing proliferation-associated genes, yet it is not 
entirely clear whether proliferation of human inflammatory macrophages occurs 
[244]. Almost all mononuclear phagocytes and resident macrophages rely on 
macrophage colony stimulating factor (M-CSF) as the main lineage regulator and 
driver of differentiation. M-CSF 1 receptor (CSF1R) is expressed on the majority, 
if not all macrophages and some types of dendritic cells [245]. Csf1r-null mice 
have taught us that in murine development this receptor is unique, while the 
role of the ligand is split between M-CSF in bone marrow, spleen or liver 
macrophages and IL-34 for the more primitive, tissue resident macrophages in 
brain microglia or skin Langerghans cells [246,247]. Apart from M-CSF, other 
growth factors like IL-3 and VEGFA can promote development of macrophages in 
tissue culture. Mice lacking IL-3 and GM-CSF show impaired function of alveolar 
macrophages, while VEGFA is thought to promote osteoclast development in vivo 
[248-250]. While M-CSF is constitutively expressed to regulate macrophage 
numbers through negative feedback loop, GM-CSF is produced upon challenge 
[251] [216]. Despite this, blockade of M-CSF was not successful in RA clinical 
trials, while GM-CSF shows promising outcomes and will be discussed separately 
[252]. 
Diversity of macrophage phenotypes likely stems from diversity of transcriptional 
regulation, whether it is the regulation of haematopoietic progenitors by c-myb, 
or crucial myeloid lineage commitment defined by PU.1 [253]. Nevertheless, 
research in this area has been somewhat limited to the exploration of PU.1 as 
the most important of these transcription factors since its mutation leads to 
complete depletion of murine macrophages [253]. Other identified factors, like 
Gata2 were found crucial for monocyte development but had no role in tissue 
resident macrophages [254]. Its effects are so profound that a Gata2 SNP is at 
the heart of several human syndromes evolving around severe monocytopenia. 
The roles of CEBPα and RUNX1 transcription factors and PU.1 enhancers were 
recently described [255]. However, it is the role of transcription factor Ets2 to 
directly target and initiate transcription of CSF1R allowing response to M-CSF 
[256]. During inflammation, differentiation and activation of cells coincides in 
the same process, guided by the surrounding milieu of cytokines and growth 
factors.  
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1.3.4.2.1 Polarization of macrophages 
Many reports have advocated a broad classification of activated macrophages in 
to two main groups – classically activated with IFNγ and/or LPS (M1) and 
alternatively activated with IL-4 (M2) [257] [258] [259]. This view of macrophage 
activation through principle cytokines allowed association of M1/M2 with Th1 
and Th2 cells promotion, therefore pointing towards M1 involvement in bacterial 
defence and antigen presentation with high levels of class II MHC, while M2 are 
typically relevant in parasitic infections, respiratory and tumour immunity [38]. 
These differences are reflected in the transcription processes where STAT1 and 
IRF5 collaborate to promote M1 phenotype, while STAT6 and IRF4 drive to M2 
polarisations [38]. The crude nature of M1 and M2 nomenclature runs into 
difficulty when we consider other important stimuli, such as length and 
chronicity of activation and exposure to multiple potentially contradictory 
events. Recently revised nomenclature has called for more detailed description 
of laboratory generated macrophages in order to promote clear understanding of 
the cell phenotype as well as to encourage reproducibility of results [260]. 
Implementation of these guidelines should also ensure understanding of a 
spectrum of activated macrophages instead of previously binary categorization 
of M1/M2 type cells. Certainly, single cell analysis would indicate that every 
individual macrophage has unique gene signature in order to challenge that 
pathogen in its own unique way [261]. Gaps in our understanding are further 
deepened by comparison between mouse and human activated macrophages 
[262]. 
Nevertheless, several functional properties distinguish these two macrophage 
phenotypes. M1 polarized macrophages typically express high levels of IL-12, IL-
23 and TNFα, chemokines CXCL9 and CXCL10 and miR-155, while M2 cells are 
known for high IL-10 expression, CCL17 and CCL22 and miR-223 [260,263,264]. It 
is still unclear what phenotype is prevalent in the arthritic joint, yet high levels 
of TNFα and IL-1, typically released by M1 macrophages are abundant in RA, 
while IL-10 expression is relatively low [265].  
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1.3.4.2.2 The role of macrophages in RA 
The role of macrophages is broad. They are involved in early stages of 
development, maintenance of homeostasis, tissue repair and immune protection 
from the invading pathogens. Homeostasis is achieved by ‘patrolling’ tissues on 
several levels [266]. Firstly, tissue derived macrophages are resident cells 
responsible for engulfing apoptotic cells, debris clearance and tissue growth 
support. As such, they appear to have homeostatic properties and act 
predominantly in an anti-inflammatory manner to achieve that role. Recent 
investigations of murine parabiosis models indicated that tissue resident 
macrophages replenish from their tissue progenitor and do not require blood-
derived monocytes [266]. In fact they are likely never to go through a monocyte 
stage in their development, contrary to popular belief. Secondly, they play a 
role in patrolling for acute invasion by intracellular or extracellular pathogens, 
which is achieved by monocytes and blood derived macrophages present in 
organs that are turned outwards – like gut mucosal layer or skin [266]. Difficulty 
thereof lies in the understanding of the cross talk between newly recruited 
inflammatory macrophages and resident regulatory cells, especially in chronic 
conditions like cancer, obesity or in outright inflammatory conditions like RA.   
In RA, monocytes and macrophages are one of the main drivers of cytokine 
production and inflammation [257]. In synovial tissue from RA patients, 
significantly raised numbers of both inflammatory monocytes and activated 
macrophages were found [267,268]. Synovial tissue myeloid cells are the 
principle source of TNFα and IL-6 cytokines [269-271]. Reciprocally, anti-TNF 
treatment leads to depletion of the total number of synovial myeloid cells and in 
some cases resolution of inflammation [272,273].  
As main cytokine producers, monocytes and differentiated macrophages promote 
differentiation of T cells [274]. Monocyte to T cell contact is involved in the 
destruction of cartilage and bone destruction [275]. In fact, deregulated cross 
talk between T cells and monocytes has substantial implications for perpetuation 
of chronic inflammation in RA [276,277]. Macrophage accumulation in the 
synovium is clearly a determinant of the outcome of RA, and probably a useful 
disease biomarker, although not a practical one [265]. 
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Several proposals for targeting myeloid cells have been made. Unfortunately, 
targeting of chemokine pathways, such as CCR2, did not show efficacy in 
reducing synovial inflammation [278]. Furthermore, depletion of tissue resident 
MHC class II+ macrophages in serum transfer murine arthritis model had also no 
effect on the course of disease, while depletion of both circulating and tissue 
resident cells led to resolution [213]. On the other hand, depleting CD64 
expressing synovial macrophages caused an improvement of adjuvant induced 
arthritis in rats [279]. Immunotoxin targeting of CD64 is was considered for 
clinical use [280].  
A new era of repositioning of the already existing medicines led to re-thinking of 
the use of FDA approved therapeutic trabectedin, which induces apoptosis of 
mononuclear phagocytes and is used for the treatment of liposarcoma and 
leiomyosarcoma [281]. Such treatments could be useful as a myeloid depletion 
with a possibility of re-setting the way that myeloid cells respond to future 
insults and should be tested for this purpose [218].  
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1.3.4.3 Dendritic cells  
Historically, dendritic cells (DCs) are known as the main antigen presenting cells 
(APCs) for their ability to sample surrounding self and foreign antigens and 
present them to T and B cells. Now it is clearly understood that DCs directly 
instruct adaptive immune cells towards specific inflammatory or regulatory 
responses. DCs are a heterogeneous population of cells that includes several 
distinct phenotypes, summarised in the Table 1.3. 
 
Table 1.3 Main DCs subsets.  
References: pDCs –[282,283]; CD141+ DCs –[283-285]; CD1c+ DCs –[286,287]; iDCs –[283,288]. 
 
Predominantly, DCs originate from BM derived progenitor cells, with the 
exception of inflammatory DCs (iDCs), which are recruited from the circulating 
blood monocytes and mature at the site of inflammation (Table 1.3). 
Inflammatory DCs were found in the experimental models of arthritis, as well as 
in the synovial fluid from RA patients [102,288-290].  
During inflammation, monocytes and immature DCs express CXCR1 and CX3CR1 
chemokine receptors and are attracted by inflammatory homing chemokines 
such as CCL1, CCL2, CCL5 and CCL6 [291]. More recent data suggest that TNFα 
Name Surface markers Originate from Main function 
Plasmacytoid DCs  
(pDCs) 
CD123, CD303, 
CD304, CD11b 
and CD11c  
BM progenitor 
cells 
Major source of 
type I interferons. 
Classical CD141+ 
DCs 
CD141, CD11clow BM progenitor 
cells 
 
Preferentially 
Induce TH2 
phenotype. 
Classical CD1c+ 
DCs 
CD1c, CD11b, 
CD11c, CD172 
BM progenitor 
cells 
 
Preferentially 
Induce TH1 
phenotype. 
Inflammatory DCs 
(iDCs) 
CD1c, CD11b, 
CD11c, CD1a, 
CD14, HLA-DR, 
FcεR1, CD206, 
CD172a 
Blood derived 
monocytes  
Preferentially 
Induce Teff 
phenotype. 
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and IFNγ activated FLS can also guide DC migration through the expression of the 
adipokine chemerin [292-294]. Once in the tissue, there are two main ways to 
ensure DC activation. Primarily, DCs recognise pathogen associated molecular 
patterns (PAMPs) through TLRs, C-type lectin receptors, NOD-like receptors 
(nucleotide oligomerization domain) and RIG-I-like (retinoic acid-inducible 
genes) receptors [295]. Alternatively, endogenous activating signals can become 
available during necrosis of damaged and inflamed tissues. There are many 
candidates for the role of DAMPs: heat shock proteins, HMGB1 (high mobility 
group box 1), extracellular matrix proteins like hyaluronic acid and metabolites 
such as uric acid, all detected in the RA synovium [296]. 
Activation and maturation of DCs results in the upregulation of class I and II MHC 
molecules and CD40, CD80 and CD86 T cell co-stimulatory factors. Increased 
expression of CCR7 chemokine receptor is associated with CCL19 and CCL21 
guided homing to secondary lymphoid organs or to ectopic lymphoid structures in 
the RA synovium [297,298]. This allows formation of tertiary germinal centres in 
the inflamed synovial tissue, detected in almost half of RA patients [299,300]. It 
is suspected that the presence of homing markers causes accumulation of iDCs 
and reduced efflux from RA affected tissues [297,298,301]. High numbers of 
synovial iDCs certainly contribute to disease chronicity.   
The main function of activated DCs is to instruct adaptive immune cells. 
Although some specificity is suggested in Table 1.3, classical CD141+ and CD1c+ 
DCs are capable of antigen cross-presentation and induction of all TH subtypes 
depending on the surrounding stimuli [284,302,303]. On the contrary, pDCs are 
less efficient at T cell priming and contribute more to the induction of 
tolerogenic Treg cells [304]. Both cDCs and pDCs are decreased in the peripheral 
blood and increased in the synovial fluid from patients with RA [305]. On the 
other hand, iDCs are particularly effective in the generation of TH1, TH17 and 
Treg cells through secretion of polarizing cytokines (IL-12, IL-23 and IL-10, 
respectively) [288]. Expression of surface proteins such as OX40 ligand (TNF 
ligand superfamily 4) could result in TH2 polarization [306]. In RA synovium 
however, mature iDCs predominantly secrete IL-12 and IL-23 cytokines, causing 
the imbalance between TH1/TH17 and Treg cells [288,297,305,307,308]. In fact, 
purified synovial fluid iDCs induce TH17 polarisation in previously naïve CD4 T 
cells [288]. The resulting high levels of IL-17A and GM-CSF are extremely 
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inflammatory within the synovial tissue, as evident from the growing body of 
reports and successful clinical targeting of IL-17A cytokine, which will be 
discussed below [309-311].  
pDCs are also present in RA synovium, particularly in patients with raised ACPA 
antibody titres [307]. As stated previously, pDCs are predominantly tolerogenic 
under normal conditions. During inflammation, pDCs are a major source of type I 
interferons to guide monocyte differentiation and of soluble BAFF and April 
molecules, serving as B cell survival signals [312]. It is therefore suspected that 
pDCs contribute to the formation of synovial germinal centres and induction of 
autoreactive B cells [312]. Additionally, type I interferons promote antibody 
production and isotype switching in activated B cells [313].  
Summarizing data above, it is easily appreciated that there have been attempts 
at utilizing tolerogenic DCs in the therapy of autoimmune conditions. This was 
supported by the immunomodulaory effect of transferred DCs in animal models 
of arthritis [314,315]. In humans, a phase I clinical trial was recently completed. 
Here, 18 patients with RA received subcutaneous transfer of autologous DCs 
treated with NFκB inhibitor and citrulinated peptide antigens [316]. Treatment 
resulted in reduction of effector and increase in regulatory T cells, as well as 
some clinical improvement after 1 month of treatment [316]. A second trial of 
this sort utilized steroid and vitamin D3 treated DCs, which were subsequently 
activated by TLR4 and autologous synovial fluid before intraarticular transfer 
[317]. Results of the latter trial are still awaited. Apart from the cellular 
therapy, existing and newly developed cytokine targeting agents can also 
significantly influence the function of iDCs and will be discussed in the section 
below.   
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1.3.4.4 Osteobiology 
Osteobiology is at the centre of RA pathogenesis with bone erosions as a main 
disabling feature of untreated arthritis. The human skeleton is composed of 
trabecular bone enclosing the bone marrow and cortical bone providing the 
structural support. Both types of bone are prone to erosions in RA and occur as 
early as 6 months after disease onset in a half of untreated patients [318]. 
Additionally, the risks of generalised osteopenia and osteoporosis are 
independently increased in RA. 
Bone erosion is a radiological term. This feature is visible on the plain radiograph 
as a break in the cortical bone surface, and it should not be confused with bone 
cysts typically found inside of the trabecular bone. Radiographic bone erosions 
are included in the diagnostic criteria for RA and are used for treatment and 
monitoring purposes. Moreover, all currently used antirheumatic agents were 
shown to prevent structural joint damage during clinical trials.  
Osteobiology has seen increasing advancements in understanding the function of 
bone making osteoblast and bone eroding osteoclast cells. Osteoclasts are giant 
multinucleated cells derived from the monocyte lineage and are the only cells 
capable of bone absorption [319]. They form tight junctions with the surface of 
the bone along the entire perimeter of the cells in a way that secreted acidic 
components are sealed and dissolve the calcium from the bone below. 
Osteoclasts also secrete matrix enzymes like cathepsin K and matrix 
metalloproteinases (MMPs) to degrade residual bone matrix [320].  
Osteoclastogenesis occurs from blood derived monocytes and is mediated by M-
CSF and RANKL (receptor activator of nuclear factor kB ligand) [321-323]. It is 
now known that monocytes can be pre-primed for osteoclast differentiation by 
TNF exposure, which leads to surface expression of osteoclast-associated 
immunoglobulin-like receptors [324]. TLR stimulation of the synovial cells 
induces RANKL expression and further aids osteoclastogenesis [325]. Similar 
effects are achieved by synovial pro-inflammatory cytokines like TNF, IL-1, IL-6 
and IL-17, which trigger and work together with RANKL expression [90,326,327]. 
Final differentiation into osteoclasts occurs upon contact with bone.  
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In RA, presence of autoimmune antibodies is the strongest prognostic factor of 
erosive process, more so than any other measure of inflammation [328]. One 
study suggests that ACPA antibodies bind to citrulinated vimentin on the surface 
of differentiating cells and promote maturation of osteoclasts [329]. These cells 
also express PADI2 (peptidyl-arginine deaminize type 2) enzyme that is 
dependent on the calcium flux to induce protein citrullination, likely utilised in 
protein breakdown during bone resorption [329]. 
Blockade of differentiating molecules M-CSF, RANKL, or both prevents bone 
erosion in all tested animal models of experimental arthritis [330-332]. Attempts 
were made to utilise this in the clinical setting with denosumab, an antibody 
against RANKL [333]. Phase II dose finding clinical trial has shown that use of 
denosumab slowed the progression of the erosions but it did not influence the 
inflammation [333]. This suggests that there is no positive feedback loop in 
which synovial inflammation is perpetuated by the underlying bone pathology. In 
contrast, inhibition of TNFα or IL-6 cytokines are amongst the most effective 
approaches to control the inflammation, slow erosive process and systemic bone 
loss [334].  
Less successful was the search for agents capable of repairing already existing 
bone damage and at present erosions are considered irreversible. It is not due to 
the lack of osteoblasts, as they are seen to repopulate the surface of the eroded 
bone upon resolution of the inflammation in animal arthritis models [335]. Wnt 
signalling is crucial for the function of osteoblasts [336]. It is suspected that Wnt 
signalling and bone formation pathways are permanently suppressed during 
inflammation by Dkk-1 and sclerostin, as examples [335-337]. This is a 
developing topic that requires further testing, hopefully resulting in new bone 
supporting therapeutics.   
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1.3.4.5 Neutrophils  
The contribution of neutrophils to pathogenesis of RA is somewhat less explored 
than other leukocytes, despite their abundance in the circulation and in synovial 
fluid [338]. Indeed, neutrophils constitute 60% of all leucocytes in the circulation 
and are attracted to synovium by L-selectins, granulocyte and macrophage 
colony stimulating factors (G-CSF, GM-CSF, M-CSF) and cytokines such as IFNγ 
and IL-17A [339-341]. Inflammatory neutrophils exhibit similar function to 
activated macrophages and even dendritic cells, by expressing a variety of 
cytokines, including membrane bound TNFα and RANKL to promote 
osteoclastogenesis and BLyS and BAFF B cell survival factors [342,343]. Activated 
neutrophils are also a major source of IL-6 [344].  
By upregulating MHC class II molecules, neutrophils are capable of cross 
presenting antigens to T cells [345]. This ability to act as an APC might be more 
relevant to RA pathology, than initially assumed. Citrullination of proteins is one 
of the strategies of neutrophils to modify and disarm foreign peptides. In the 
context of RA, this leads to the accumulation of hypercitrullinated proteins in 
synovial fluid neutrophils, which are a potential source of anti-ACPA antibodies 
[346].  
The synovial inflammatory environment promotes neutrophil survival through key 
proteins, such as MCL-1 (myeloid cell leukemia sequence 1) [347]. During their 
short life span, neutrophils contribute to perpetuation of inflammation, but also 
directly contribute to bone and cartilage damage through the release of reactive 
oxygen species and specific enzymes [348]. In fact, a majority of current 
treatments for RA were shown to aid the onset of apoptosis in activated 
neutrophils and prevent further joint damage [349]. 
In 2004, a new way by which neutrophils trap extracellular pathogens was 
described [350]. Namely, instead of apoptosis, neutrophil death results in 
release of their chromatin and formation of neutrophil extracellular traps or 
NETs [350]. At the same time, granules with enzymes are released which help to 
capture and kill bacteria. This novel process was implicated in the break of self-
tolerance in autoimmune diseases, especially in SLE, which is associated with 
appearance of anti-nuclear and anti-DNA antibodies [351]. In RA, synovial fluid 
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neutrophils are thought to be a/the source of citrullinated peptides [346]. With 
enhanced NETosis, it is possible that this is a source of antigen for the formation 
of ACPA antibodies [352].  
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1.3.5 Cytokine targeted treatments in RA 
1.3.5.1 Targeting TNFα  
TNFα is one of the true master regulators of the RA pathogenesis [139]. It is 
believed to be at the top of the RA cytokine hierarchy as it is capable of 
inducing a complicated cascade of inflammatory mediators, including IL-1, IL-6, 
IL-8, GM-CSF as well as directly influencing angiogenesis, pain, cell migration 
and joint damage [353]. TNFα is predominantly produced by myeloid cells and is 
classified as an innate immune cytokine [218]. Although all of these effects were 
not obvious in the late 1980’s and early 1990’s when it was discovered, TNFα 
inhibition ameliorated arthritis in CIA murine model and led to development of 
truly transformative treatments for RA [354]. In fact, the idea that inhibition of 
a single cytokine could give such clinical improvement was somewhat 
revolutionary at the time and changed the way RA pathogenesis was viewed 
[355].  
Since than, 5 anti-TNFα agents have been approved and widely used in clinical 
practice: infliximab, adalimumab, golimumab and certolizumab pegol are 
monoclonal human antibodies towards the cytokine while etanercept is a 
circulating receptor fusion protein [356-361]. Although very efficacious on their 
own, the full potential of anti-TNF agents was discovered when a combination 
treatment with MTX resulted in a marked long term radiographic benefit 
[362,363]. Expected outcomes from this mode of treatment is for 60-70% of 
patients to achieve ACR20 score, while ACR50 and ACR70 are met by ~40% and 
~20%, respectively. The percentage of primary non responders varies but is 
approximately ∼30%, comprising a persistent unmet clinical need [355]. Clinical 
use of TNFα inhibitors is now enriched by the variety of biosimilar molecules, 
which are expected to make this treatment option more affordable.  
Over last 20 years, the combination of basic and clinical research revealed the 
full scope of benefits from the anti-TNFα treatment. TNFα inhibition leads to a 
rapid decrease in serum IL-6 levels, followed by reduced numbers of synovial 
neutrophils, adhesion molecules and chemokines, inhibiting overall recruitment 
to the synovium [364,365]. Also, reduced expression of VEGF and decreased 
rates of angiogenesis are noted [366]. Rapid normalization of systemic 
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inflammatory features such as anaemia and high platelet count extends further 
to improvement in fatigue, depression, metabolism and insulin resistance in 
treated patients over time [193,355]. On the cellular level, anti-TNFα treatment 
leads to abolished numbers of synovial T cells, B cells and inflammatory 
macrophages, while activating and promoting proliferation of TREG cells [353]. 
This effect appeared specific to agents targeting cytokine and binding both 
membrane and soluble forms, rather than to etanercept which captures only 
soluble TNF. This observed contradiction was explained by the hypothesis that 
anti-inflammatory role of anti-TNF treatment is mediated by blocking of TNFR1 
while TREG activation is, in fact, possible through binding and activation of 
TNFR2, which is predominantly expressed on the surface of regulatory cells 
[353]. Indeed, it is accepted that adalimumab, for example, has a superior 
efficacy compared to etanercept in a range of autoimmune conditions [367]. 
Additionally, this finding reiterates the importance of immunological balance in 
restoration of health in patients with RA. Lastly, long-term data on the efficacy 
of TNFα agents show a distinctive percentage of people maintaining good clinical 
outcome years after it was initiated, indicating that RA pathogenesis, once 
established, might be very stable and early stratification of patients is of utmost 
importance [355].  
1.3.5.2 Targeting IL-1  
IL-1 and its family of cytokines, including IL-1a, IL-1b, IL-1Ra, IL-18, IL-33 and IL-
36, are highly detectable in RA synovial inflammation [368]. It is believed that 
IL-1 expression is triggering formation of bone erosions in RA synovium [369]. 
Animal models of inflammatory arthritis have shown that IL-1 mediates cartilage 
and bone loss during inflammation [370,371]. Even though blockade of IL-1 is not 
sufficient to contain the inflammation during active RA it provides protection 
from occurrence of bone erosions [372]. Despite lack of efficacy in RA, IL-1 
directed treatment is considered in other inflammatory disease associated with 
bone deformities such as gout and broader inflammatory conditions, such as 
juvenile idiopathic arthritis, where benefits are substantial [129,368]. 
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1.3.5.3 Targeting IL-6  
IL-6 is another pleotropic cytokine displaying a wide variety of inflammatory but 
also hormone-like traits [373]. IL-6 was initially discovered as a cytokine 
promoting T cell (TH17) and B cell differentiation, while regulating an acute-
phase response [374,375]. More recently, new functions were discovered, were 
IL-6 plays a role in atherosclerosis, lipid metabolism, insulin resistance, 
mitochondrial metabolism and depression [376-379]. Additionally, transgenic 
expression of IL-6 in mouse strains led to neurological disorders when cytokine 
was overexpressed in the brain and pulmonary fibrosis with hypertension when 
IL-6 was overexpressed in the lungs. Deficiency of IL-6, on the other hand, leads 
to impaired immune responses to viral, bacterial or parasitic infections, 
confirming its importance [380]. Some of these functions are very similar to 
those of TNFα, hence the overlap between these pathways in research and 
clinical data.  
IL-6 cytokine is almost undetectable during homeostasis with rapid increase in its 
expression during infection, autoimmunity or cancer where it can be used as a 
better disease activity biomarker than corresponding CRP levels [381,382]. Its 
receptor (IL-6R) is expressed by leukocytes, megakaryocytes and hepatocytes, 
yet broad spectrum of IL-6 effects stretches far beyond immune cells by the 
virtue of trans signalling, where soluble IL-6 and IL-6R form a functional complex 
which then signals through the membrane bound receptor subunit GP130 (CD130, 
IL6ST) [383-385]. GP130 is a ubiquitously expressed cytokine receptor shared 
between IL-6, IL-11, IL-27, oncostatin-M, ciliary neutrotrophic factor, 
cardiotrophin-1, cardiotropin-like cytokine and leukemia inhibitory factor, all of 
which belong to type I family of cytokines [386,387]. While deletion of GP130 in 
murine models leads to embryonic death, mice lacking IL-6 or IL-6R are fully 
viable and show impairment in defence against infections, wound healing and 
glucose metabolism [388,389]. Both classical or alternative (trans-) signalling 
require the formation of IL-6-IL-6R-GP130 complex, where IL-6R is membrane 
bound or soluble, respectively [390]. When fully formed, IL-6 membrane 
complex can utilise Ras and Raf signalling effector pathways to control 
proliferation or differentiation of the cells, although its proinflammatory effects 
are predominantly mediated by the engagement of Jak tyrosine kinase family 
(Jak1, Jak2 and Tyk2) that leads to phosphorylation of STAT1, STAT3 and, less 
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so, of STAT5 [390]. SOCS (suppressors of cytokine signalling), CIS (cytokine 
inducible SH2 domain containing) inhibitors of cytokine receptors and PIAS 
(inhibitors of activated STATs) tightly control this signalling pathway [390]. From 
these, SOCS3 has been recognized as a major regulator of IL-6 signalling [391].    
It is believed that classical IL-6 signalling is responsible for haematopoiesis and 
induction of acute immune response including hyperthermia, while also 
regulating glucose metabolism, fatigue and loss of appetite [392]. On the 
contrary, the IL-6 trans signalling is implicated in perpetuating chronic 
inflammation by the recruitment of leucocytes, activation of effector T cells, 
proliferation of B cells, survival of plasma cells and involvement of stromal 
resident cells, like FLS [373]. During inflammation, soluble IL-6R is expressed by 
activated monocytes and T cells and serves as an alarmin, creating an 
inflammatory milieu at the site of infection [393,394]. Alternatively, multiple 
inflammatory mediators, including CRP can induce shedding of the surface IL-6R 
[395,396]. Additionally, IL-6R can be cleaved from the surface of the cell by 
aminopeptidases such as ERAP-1 (endoplasmic reticulum aminopeptidase 1, or 
ARTS-1) and adamolysin proteases such as ADAM10 or ADAM17, also responsible 
for shedding of TNFR1 [397,398]. Shedding is not the only mechanism that 
creates a soluble IL-6R, since a distinct transcript lacking the exon of the 
membrane domain is also expressed and will be discussed in details in chapter 6.  
In RA, the IL-6 pathway exhibits a multitude of effects on both innate and 
adaptive cells. By inhibiting CXCL1, CXCL8 (IL-8) and CX3CL1 chemokines and 
upregulating expression of CXCL5, CXCL6, CCL2 and CCL8 as well as adhesion 
molecules ICAM-1 and VCAM-1, IL-6 attracts migration of neutrophils, which in 
turn promote the shedding of membrane IL-6R and amplify the immune response 
[399,400]. In myeloid cells, IL-6 regulates the expression of CSF1R to promote 
differentiation of recruited monocytes into macrophages at the expense of DCs 
[401,402]. In joint resident FLS cells, IL-6 induces expression of RANKL, MMP1, 3 
and 13 to promote osteoclastogenesis and sustain bone resorption [403].  
Despite considerable effects on innate cells, IL-6 is still considered to be a link, 
coordinating T cell and B cell activity, through promotion of follicular T helper 
cells in the immunological synapse [404]. This was confirmed by the lack of 
humoral response in IL-6-/- mice immunized with a T cell-dependant antigen 
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[380]. In models of arthritis, IL-6 deficiency leads to reduced numbers of TH17 
cells and IL-17 cytokine [405]. Its effects on T cell extends further with IL-6 
inhibition leading to increased functionality of TREG cells in mice models and 
human subjects with arthritis [405]. In the absence of IL-6, ever-present TGF훽 
supports differentiation of TREG cells, while the combination of TGF훽 and IL-6 are 
required for the induction of RORC TF and TH17 differentiation. Resulting 
expression of IL-17 has a multitude of inflammatory roles, including B cell 
differentiation and class-switching, that are discussed above. This provides a 
mechanism by which, therapeutic targeting of IL-6 causes functional modulation 
of inflammatory T and B cells, while supporting development of regulatory cells 
[406].  
Nonetheless, the role of IL-6 is not at all straightforward. A recent investigation 
of T cell plasticity has identified cells, which upon IL-6 stimulation co-express 
FoxP3, T bet and RORγt, although it is not yet clear if this occurs during synovial 
inflammation [407]. The anti-inflammatory role of IL-6 was also seen in 
circumstance when it promotes IL-10 production by T cells [408,409]. Moreover, 
inhibition of SOCS3 regulator allowed IL-6 to behave in a manner similar to IL-10 
and aid the resolution of the inflammation [391,410]. This might be the 
mechanism by which IL-6 promotes polarization of M2 macrophages associated 
with wound healing and termination of inflammatory processes [389,410].  
Association of IL-6 biology with RA was also confirmed when GWAS studies 
identified SNP close to the transcriptional start site of IL-6 causing 
overexpression of the cytokine leading to increased risk of coronary artery 
disease, idiopathic juvenile arthritis and other arthropathies [411-413]. 
1.3.5.3.1 IL-6 targeted treatment of RA  
This abundance of experimental data resulted in development of IL-6 targeting 
treatments. It was known from earlier cancer trials that targeting of the IL-6 
cytokine leads to its compensatory overexpression and, to overcome this issue, 
new therapies, directed towards IL-6R were developed [414,415]. Tocilizumab 
(TCZ), an anti-IL-6R agent was tested for its use in RA. The first large phase II 
‘CHARISMA’ trial (the Chugai Humanized Anti-Human Recombinant Interleukin-6 
Monoclonal Antibody) involved 359 patients with active RA and poor response to 
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MTX treatment [416]. This was a dose ranging, placebo controlled study that 
included option of combination treatment with MTX. Primary endpoint, an ACR20 
improvement after 16 weeks, was met by 63% of patients on higher dose of TCZ 
treatment alone, compared to 74% in combination group and 41% in 
methotrexate with placebo group [416]. This study clearly demonstrated the 
direct effect of IL-6 inhibition on the generation of acute response parameters, 
CRP and ESR, as well as hepatic transaminases, total cholesterol, triglycerides, 
high-density lipoprotein levels and total neutrophil count. Rapid normalization of 
CRP and ESR parameters, independently from disease activity was later 
recognized as a confounding factor for the use of disease activity scores that 
incorporate these measures in evaluating IL-6 blocking therapeutics.    
A further phase III clinical trial TOWARD (Tocilizumab in Combination With 
Traditional DMARD Therapy) has confirmed benefits of addition of TCZ treatment 
to a range of individual DMARDs or triple DMARD therapy with ACR 20 response 
ranging from 57.7-65.7% in all combination groups, apart from treatment with 
TCZ and Azathioprine where response was 33.3% [417]. True clinical benefit was 
reflected in improved quality of life index score (SF-36), disability index (HAQ) 
and fatigue score (FACIT-F), while the overall incidence of adverse events was 
also higher in the TCZ treated group, consistent with previously seen [417]. 
Subsequent trials have shown that combination treatment with TCZ and MTX 
prevents structural joint damage and reduces systemic bone resorption as well 
as secretion of bone degrading mediators [418,419].  
The most interesting are studies directly comparing TCZ with other modes of 
biologic treatment. One such example is the ADACTA study comparing 
tocilizumab with adalimumab monotherapy in 326 patients with severe RA, 
poorly controlled with MTX over 6 months or longer and who cannot tolerate 
further DMARD treatment [420]. This study showed superiority of TCZ compared 
to the anti-TNFα agent, yet the primary clinical endpoint was measured by the 
mean change in DAS score, which is partially confounded by the inclusion of CRP 
and ESR measures. Nevertheless, this study allowed direct comparison of serum 
and synovial samples for the identification of therapy specific signatures in a 
search for predictive biomarkers [421]. A synovial gene expression signature 
allowed identification of lymphoid, myeloid, low inflammatory and fibroid 
synovial phenotypes. Furthermore, serum samples from myeloid type had higher 
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expression of soluble ICAM1 and low levels of CXCL13 chemokine, associated 
with a good response from anti-TNFα treatment; while lymphoid type had 
opposite low serum levels of sICAM1 and raised CXCL13 expression and 
responded well to TCZ treatment [421]. These results support the broad division 
between innate control of TNF and adaptive effects of IL-6.       
Summaries of previous data resulted in several conclusions about the clinical use 
of TCZ. Firstly, network meta-analysis suggested similar efficacy of TCZ with 
MTX combination to that of other biologics with MTX [422]. Secondly, 
monotherapy of TCZ is superior to monotherapy of anti-TNFα agent, as 
evidenced above [420,422]. These conclusions were behind the design of the 
recent U-Act-Early strategy trial recruiting 317 patients with very early (median 
symptom duration of 25 days) active RA (median DAS28 score was >5.0 for all 
groups), who were blindly randomized to receive combination of TCZ with MTX, 
or either agent alone for 2 years [423]. More importantly, primary outcome of 
this study was sustained clinical remission, which was attained by 86% of 
patients receiving combination treatment, compared to 84% in the TCZ only arm 
and 44% in the MTX only arm. These data are impressive since stricter definition 
of DAS28 remission based on score of <2.6 but also 4 or fewer swollen joints was 
used. A placebo group was deemed unethical and was not included. Design of 
this trial did not allow the comparison between medications, but only between 
treatment strategies, as patients with poorly controlled disease on MTX only 
treatment received TCZ at a later stage. Interestingly, a treat to target 
approach resulted in similar rates of achieved remission despite TCZ first or MTX 
first approaches. This study, although not truly generalizable, indicated that 
early treatment with effective and quick acting treatments such as TCZ can be 
beneficial in early induction of remission, in keeping with the early window of 
treatment opportunity hypothesis [424]. The authors speculate that tapering of 
TCZ does also work, and maintenance of remission on MTX only would be 
possible, increasing the cost-effectiveness of this approach. However, long term 
data on efficacy, dropout rates and radiographic progression will be available 
after an additional 3-year follow-up is complete in due course. Certainly, if 
these results are confirmed in other larger and multinational trials, this could 
provide a precedent for the change of current guidelines, which call for DMARDs 
first treatment approach, and place IL-6 targeting at the center of management 
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of RA and its most common co-morbidities. Additionally, direct comparison of 
TCZ with T cell targeting abatacept and B cell depleting rituximab are needed to 
evaluate if IL-6 effects are entirely dependent on the regulation of adaptive 
immune responses, or new pathways could be discovered to explain the 
differences found.   
1.3.5.4 Targeting of common γ chain cytokines  
Type I cytokines include a family of factors sharing a common γ chain receptor 
subunit (γc, or IL-2Rγ subunit). This group includes IL-2, IL-4, IL-7, IL-9, IL-15 
and IL-21 [425]. The primary cytokine of this group, IL-2, exhibits a multitude of 
pro- and anti- inflammatory effects including T cell survival and reduction of 
cytolytic activity of CD8 T cells and NK cells. Blockade of IL-2R with daclizumab 
is used to support adherence of transplantation tissue and in treatment of 
multiple sclerosis [90,426]. 
IL-4 is known for promoting differentiation of M2 macrophages, but also for its 
role in allergic disease [427]. Raised levels of IL-4 were found in synovial tissue 
from patients with established disease, yet not enough evidence was gathered to 
suggest that targeting of this pathway would be beneficial in treatment of 
arthritis [427].   
Next, IL-7 and IL-15 are considered to be a homeostatic cytokines playing a role 
in the maintenance of circulating T cell numbers [428]. Links with RA were made 
when increased expression of IL-15 cytokine was detected in synovial fluid and it 
was shown to mediate osteoclastogenesis and bone erosions [429]. 
Demonstration of its ability to support T cell and NK cell activation as well as to 
lower the T cell activation threshold and mediate T cell-macrophage cross talk 
in the RA synovium supported the hypothesis for potential targeting in RA [430-
432]. More so, a genetic link with RA was provided by the discovery of SNP in the 
gene encoding IL-15, which correlated with the rate of joint destruction in 
patients with active disease [433]. Despite this, targeting of neither IL-15 nor IL-
21, known for effects on T cell activation and B cell maturation, have not 
yielded any benefit in the treatment of RA [432].     
68 
 
1.3.5.5 Targeting GM-CSF  
GM-CSF is a pluripotent cytokine that regulates a variety of important cellular 
functions in myeloid cells. It shares its common β chain with cytokines IL-3 and 
IL-5 and is also considered a type I cytokine. GM-CSF is primarily known for 
activation, survival and differentiation of blood derived monocytes into 
inflammatory DCs, while also regulating phagocytosis, expression of MHC class II 
and pattern recognition receptors and the production of inflammatory cytokines 
and chemotactic molecules [216,434,435]. Mouse knock-out studies have shown 
that GM-CSF inhibition does not prevent development of myeloid cells but 
severely impairs the infection response, rendering GM-CSF more relevant in 
provoked immune responses. More recently it has been established that GM-CSF 
also enhances upregulation of MHC class I molecules and cross presentation of 
antigens to CD8+ T cells by CD103+CD8+ tissue resident DCs [436].  
Apart from myeloid cells, T cells and specifically TH17 cells are a significant 
source of GM-CSF, while the corresponding RORγt TF directly initiates its 
expression [437]. Additionally, natural killer (NKT) cells trigger GM-CSF 
expression to attract neutrophils during antifungal response [438]. In RA models, 
RF+ autoreactive B cells were capable of producing GM-CSF in response to TLR 
stimulations, which, in turn, close the autocrine loop by further promoting IgM 
production [439].  
Severe bone ache is a common side effect during treatment with GM-CSF agents 
[440]. Indeed, GM-CSF is expressed by sensory neurons of the dorsal root ganglia, 
while its receptor directly sensitizes pain receptors in these neurons and 
mediates hyperalgesia [441,442]. This pathway directly mediates pain in mouse 
models of arthritis in response to prostaglandin activation [443]. 
Both, immunopathologic and nociceptive roles of GM-CSF are desirable targets 
for the treatment of RA. Several agents targeting GM-CSF (Namilumab, MOR103) 
and GM-CSFR (Mavrilumab, MORAb 002) are currently tested in the phase I and II 
clinical trials (https://clinicaltrials.gov, NCT02354599, NCT01317797, 
NCT02129777, NCT02393378, NCT02379091, NCT01023256, NCT01517282, 
NCT01603277, NCT02546284, NCT01357759, NCT00771420, NCT01050998, 
NCT01715896, NCT01706926).  
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Most of the currently available data concern Mavrilumab, a fully human anti-GM-
CSF receptor alpha monoclonal antibody with high affinity for human protein, 
yet more data is available on mouse models tested with mouse analog, a CAM-
303 antibody [444]. Exposure of mice to very high doses of CAM-303 agent led to 
microscopic granulomatous changes in the lungs, in keeping with the role of GM-
CSF in maintenance of alveolar macrophages. In murine model of collagen-
induced arthritis (CIA), administration of CAM-303 inhibited disease progression 
as effectively as the use of anti-TNF agents. 
A double blind, placebo controlled, randomized phase II trial of efficacy and 
safety of Mavrilumab included 233 patients with active RA on concomitant MTX 
therapy [445]. The primary end point was described as achieving clinically 
meaningful improvement in DAS28-CRP score (reduction of >1.2 points) after 12 
weeks of treatment and was met by ~55% of active treatment group and 34.7% of 
placebo group [445]. A second multicenter, randomized double-blind, placebo 
controlled dose ranging study also met its primary endpoint, set as >1.2 point 
improvement in baseline DAS28-CRP at 12 weeks and ACR20 score at 24 weeks of 
the study [446,447]. Here, the highest dose group also demonstrated significant 
benefit of the treatment with 40.5% in the active treatment group and 12.4% in 
the placebo group achieving ACR50 response, while ACR70 improvement was 
seen in 13.9% and 3.7% of patients from respective groups [446,447]. 
Interestingly, treatment with Mavrilumab had an almost immediate effect with 
improvement in patient reported parameters after one week and continuous 
incremental benefit registered until week 12. Results from a phase IIb clinical 
trial comparing Mavrilumab to anti-TNFα agent golimumab were recently 
presented at the annual ACR meeting and suggest similar efficacy between the 
groups [448].  
1.3.5.6 Interferons in RA  
IFNs are a group of molecules eliciting antiviral responses and together with IL-
10 related cytokines comprise the type II cytokine family. There are three main 
types of IFNs: type I family consists of α, β, ω, ε, κ, δ and t forms, type II 
includes one member – IFNγ and type III IFNs involve IFNλ or IL-28 and IL-29. 
Separation into 3 groups is made according to the corresponding receptors, as 
type I family signals through ubiquitously expressed type I receptor (subunits 
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IFNAR1 and IFNAR2), while IFNγ signals through type II receptor (IFNGR1 and 
IFNGR2) and IFNλ signals through a heterodimer of IL10R2 and IFNLR1 [449,450]. 
Effects of all three IFN families largely overlap due to the utilization of same 
intracellular signal transduction pathways, of which JAK kinases and STAT signal 
transducers are most investigated [451,452]. Downstream interferon response 
elements or IREs are well characterized in a large number of microarray 
datasets, which suggest that only 37% of IREs are specific for type I interferons, 
while 69% of IFNγ IREs can also be induced by type I IFNs [452]. From these, 
some genes encode antiviral defence programs, while others are responsible for 
apoptosis, cell proliferation and angiogenesis, with part still unclear [453,454]. 
Triggering of IREs sets in motion several feedback loops, some of which facilitate 
type I IFN production genes, such as TLR7 or IRF5, while others are regulating 
same pathways through SOCS family of inhibitors [454].  
Increased expression of interferon regulated genes (IRGs) was detected in a 
multitude of autoimmune diseases, including systemic lupus erythematosus (SLE) 
and RA, therefore the term ‘Type I IFN signature’ was introduced [455,456]. It 
appears that one quarter of RA patients have a pronounced type I interferon 
signature and form a specific pathogenic subgroup [457]. From all type I IFNs, 
IFNα is most commonly studied. In RA, pDCs are the main source of IFNα, while 
FLS cells were found to secrete high levels of IFNβ [282,283,458]. Autoantibodies 
and immune complexes with nucleic acids can trigger TLR7 and 9 signalling, also 
resulting in upregulation of IFNα [459]. Upon TNFα stimulation, synovial 
macrophages express large numbers of IRGs [460].  
Overexpression of type I interferons and associated IRGs likely have major 
impact on the pathogenesis of RA. Primarily they are meant to inhibit viral 
replication, however they can serve as immune adjuvants [461]. The resulting 
increase in expression of MHC class I molecules potentiates antigen presentation 
and enhances engagement of cytotoxic T cells, in keeping with recently 
emerging data on pathogenicity of CD8 T cells in RA. IFNα is also capable of 
prolonging survival of T cells and B cells, inducing immunoglobulin switching and 
potentiating antibody production, while its effects on innate cells include 
increased uptake of oxidized low-density lipoproteins by activated macrophages 
and formation of foam cells within atherosclerotic plaques [462]. On the 
contrary, both type I and type II interferons also display some anti-inflammatory 
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traits. IFNα is a potent suppressor of osteoclastogenesis and have bone 
protective effects, while IFNβ is effective treatment for the multiple sclerosis 
[129,425]. In CIA models, mice lacking Ifnγ gene are not protected from 
developing arthritis and IFNγ deficiency can exacerbate the symptoms [425]. 
In an attempt to utilize this in the clinical setting, three monoclonal anti-IFNα 
antibodies were developed (Rontalizumab, Sifalimumab and AGS-009). Efficacy 
of these agents is currently being investigated in SLE, a disease with significantly 
stronger IFN signature than RA [463,464]. However, transcriptomic studies in RA 
derived PBMCs have shown that suppression of the type I IFN signature is the 
only marker for good clinical response to the treatment with current biologic 
agents [465,466]. In fact, it is proposed that anti-malarial treatments, such as 
hydroxychloroquine inhibit intracellular TLRs and suppress induction of IRGs and 
could be of particular clinical benefit in patients with increased IFN signature 
[467].  
1.3.5.7 New DMARDs targeting cytokines – Jakinibs  
The Janus kinases (JAKs) are functional intracellular domains of specific 
extracellular membrane bound receptors of type I and II cytokines. This family of 
kinases includes JAK1, JAK2, JAK3 and TYK2 (tyrosine kinase) members, 
different combinations of which are associated with different cytokine receptors 
(reviewed in [425])[468]. For example, JAK3 signalling is downstream from all γ 
chain (γc) cytokines and its mutations resemble γc deficiency resulting in severe 
combined immunodeficiency syndrome (SCID) [469,470].  
Upon activation of receptor, JAKs transfer phosphate from ATP (adenosine 
triphosphate) to the tyrosine residue of their substrates, which are most 
commonly STAT signalling molecules. JAKs are also capable of 
autophosphorylating or transferring a phosphate group to other JAKs in the 
vicinity. Downstream STAT signalling transducers include seven members: STAT1-
4, STAT5A, STAT5B and STAT6. Upon phosphorylation, activated STATs 
translocate into the nucleus and serve as TF for target genes, therefore 
completing the signalling pathway [468].  
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As stated above, combinations of JAK-STAT signal transducers are downstream 
from type I and II family of cytokines. Type I cytokines include common γ chain 
family (IL-2, IL-4, IL-5, IL-7, IL-9, IL-15, IL-21) targeting of which gave equivocal 
results in RA; common β chain cytokines (IL-3, IL-5 and GM-CSF) with promising 
studies in GM-CSF inhibition; cytokines sharing GP130 receptor subunit (IL-6, IL-
11, IL-27) with excellent results in IL-6 targeting; and, additionally, an IL-12 
family of cytokines (IL-12, IL-23, IL-35) that have proinflammatory traits and 
proved much more important for the pathogenesis of psoriatic arthritis. Type II 
cytokines include all members of the interferon family with specific implication 
of type I IFNs in RA; and a range of cytokines sharing similarities with IL-10 (IL-
10, IL-19, IL-20, IL-22, IL-24 and IL-26) that are believed to contribute to the 
resolution of inflammation and wound healing [90,471]. It is therefore clear that 
inhibition of JAK kinases has a potential of combining the effects of successful 
treatments, such as targeting of IL-6, GM-CSF and type I interferons, while 
potentially having unwanted effects on anti-inflammatory functions of IL-10, IL-2 
and IFNβ, as well as some growth factors for example.  
Several JAK inhibitors, or Jakinibs, are being tested for clinical use. Although 
these are considered as new synthetic DMARDS, they essentially prevent cytokine 
signalling and exhibit efficacy closer to that of biologic agents than of 
conventional DMARDs. First approved in the treatment of RA was Tofacitinib, a 
JAK1/3 inhibitor with less affinity for JAK2 [472]. Initial proof of concept trials 
were very promising [473], and Tofacitinib was than tested in the series of phase 
II and III trials where it showed efficacy as monotherapy, or in combination with 
DMARDs (most commonly MTX) and as a first line agent in early disease, or in 
DMARDs and biologics failures [474-478]. Tofacitinib is considered as effective as 
adalimumab in patients requiring biologics and superior to MTX in treatment of 
naïve patients, similarly to that demonstrated by Tocilizumab [423,478,479]. At 
present, FDA approved Tofacitinib for a single treatment use in inadequate 
responders to MTX, yet it remains non-licenced in Europe due to safety 
concerns.  
JAK1/2 inhibitor Ruxolitinib was the first FDA approved Jakinib demonstrating 
efficacy against myeloiproliferative conditions [480]. Its use in RA is now being 
investigated in phase II clinical trials. However, Baricitinib, also a JAK1/2 
inhibitor, has shown efficacy in the treatment of RA in patients with inadequate 
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response to DMARDs and biologics [481,482]. Moreover, Baricitinib reduces 
radiographic progression, joint space narrowing and formation of erosions 
[481,482].  It is expected to be approved for use in RA in early 2017. 
So far, clinical experiences with Jakinibs were positive despite specific safety 
signatures. The most common adverse events are upper respiratory tract 
infections, urinary tract infections and viral gastroenteritis, which are more 
common in Tofacitinib treated patients. However, serious cases of tuberculosis, 
bacterial and pneumocystis pneumonias and fungal infections were reported 
[483,484]. The overall risk of infections is believed to be comparable with other 
biologic treatments, with potentially higher incidence of varicella zoster virus 
recurrence [483,485]. This could be mediated by reduced functioning of NK cells 
through inhibited IL-15 or inhibited interferon signalling leading to impaired viral 
responses [486]. Certainly, impaired vaccination responses were also noted in 
Tofacitinib treated patients [487]. Additionally, all first generation Jakinibs 
inhibit JAK2 to a certain degree and therefore inhibit effects of erythropoietin, 
thrombopoietin and colony stimulating factors resulting in anaemia and 
neutropenia, yet these are usually not a cause for the discontinuation of the 
treatment.     
Of more importance is the metabolic effect of Jakinibs. Treatment with 
Tofacitinib leads to increased levels of total cholesterol, LDL and HDL 
cholesterol levels [473,483]. Despite this, Tofacitinib improves arterial stiffness 
and overall cardiovascular outcomes in RA patients [488]. These effects were 
also observed with IL-6R blockade by Tocilizumab [489]. In both instances, 
altering lipoprotein kinetics and improving lipid metabolism seems to be net 
beneficial for the disease outcome and management of co-morbidities [490,491]. 
Jakinibs provide a new and improved alternative for the oral treatment of RA, 
with efficacy comparable to that of biologic agents. More insight will be gained 
with the testing of new, more selective JAK inhibitors, also referred to as the 
second generation Jakinibs. Early phase I and II trials suggest that selective JAK1 
inhibitor Filgotonib is effective in the treatment of RA [492]. Side effects remain 
a major focus of the clinical outcomes and long term data as well safety profiles 
of new selective agents remain to be evaluated. Overall summary of the RA 
pathogenesis and currently used treatments is depicted below in Figure 1.1.   
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Figure 1.1 Summary of the pathogenesis and currently approved treatments for the 
treatment of RA.  
Schematic of the arthritic joint, illustrating the influx of immune cells. RA pathogenesis revolves 
around the activation of antigen presenting cells (APCs), such as dendritic cells (in black), 
macrophages (in green) or even B cells (in purple). The resulting activated T cells (in red) produce 
cytokines such as IL-6 and GM-CSF, while activated B cells (in purple) secrete cytokines along 
with autoreactive ACPA and RF antibodies, causing further activation of APCs. Additionally, pro-
inflammatory cytokines and co-activation molecules trigger maturation of osteoclasts and promote 
bone resorption. Orange boxes represent currently used therapeutic agents and their targets.   
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1.4 Lessons from the Genetics of RA 
RA is a partially heritable disease. The largest GWAS study is a meta-analysis 
that involved 29,880 patients with established, predominantly seropositive RA 
and 73,758 healthy individuals from European and Asian populations [37]. As a 
result, genetic susceptibility is thought to comprise around 65% of the total risk 
for RA and is overwhelmingly associated with the immunological component of 
the disease [493,494]. Population studies on patients with RA have identified 
over 100 genetic loci, which collectively account for approximately 15% of the 
phenotypic variability of RA [37,495]. This is a strong indicator that RA is a 
highly polygenic disease. Despite significant progress, the analysis of GWAS data 
is complicated by the fact that single nucleotide polymorphisms (SNPs) that are 
truly associated with RA are hidden among a multiplicity of sites with little to no 
importance, and individual analysis of each loci is necessary [496].  
1.4.1  Association with MHC loci 
Variation in MHC loci account for most (>60%) of the genetic susceptibility of RA 
[37]. The major histocompatibility region comprises over 250 functional genes, 
including some complement factors, cytokines, and antigen processing and 
presentation genes, such as HLAs [497]. Several HLA-DR alleles were identified 
under the SE hypothesis [498]. Within this hypothesis, certain HLA-DRB1 alleles 
(*04:01, *04:04, *04:05, *04:08, *10:01, *01:01 and 01:02) directly increase the 
risk of developing ACPA antibodies and RA in Caucasian population [498]. 
Changed amino acid residues, encoded by these HLA variants, are positioned 
within the epitope-binding pockets of HLA molecules on the surface of APCs, and 
display increased affinity for cross presentation of citrullinated peptides [499]. 
Moreover, heterozygotes for HLA-DRB1 alleles are found to be at even higher risk 
of developing RA, possibly due to the cross presentation of a greater variety of 
autoantigens [495]. Recent logistic regression models of MHC alleles, which 
include hierarchical dominance models, explained an additional 1.4% of the risk 
for developing ACPA positive RA, increasing to total to 9.5% explained by these 
genetic loci.  
On the contrary, the association of MHC loci with ACPA negative RA remains 
largely controversial [500]. Partially, this could be explained by low sensitivity of 
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commonly used ACPA detection methods, as >10% of patients turn out to be 
antibody positive on retesting [501]. Otherwise this could be explained by the 
possibility of other autoimmune diseases masquerading as ACPA-negative RA and 
introducing more heterogeneity. Some progress was made with a rigorous 
investigation of a homogeneous ACPA negative RA cohort, which identified 
distinct HLA-DRβ1 and HLA-B variants associated only with ACPA-negative 
arthritis, still more work is needed in this field [502].  
1.4.2  Association with non-MHC loci  
Amongst loci identified by GWAS studies there are 58 previously reported non-
MHC loci and 42 newly identified sites, which together account for 5.5% 
heritability in European and 4.7% in Asian populations [37]. Some authors argue 
that these 100 loci include up to 377 genes, identified on the basis of prior 
knowledge of pathways and protein-protein interactions, yet this is still 
controversial. Although this approach can potentially introduce bias it also 
identified genes that were previously implicated in the pathogenesis of RA, such 
as PTPN22, PADI4, STAT4, TNFAIP3 (A20), ANKRD55, CTLA4 and CD40, some of 
which are shared with other autoimmune disease and used as successful 
therapeutic targets [37,503].  
Of most importance is to dissect which cell types and pathways are associated 
with genetic susceptibility of RA and how these can be utilized in the search for 
new or repurposing of available treatments to benefit our patients. Here, 
platforms utilizing gene ontology networks and biological pathways, such as 
MAGENTA (meta-analysis gene-set enrichment of variant associations) have 
identified T cell, B cell and cytokine signalling pathways to respond to identified 
100 non-MHC loci [37]. For example, 27 out of 100 RA risk variants are mapped 
to gene enhancement regions that are specific for CD4+ T cells [504]. As well as 
the majority of identified long noncoding transcripts, which are crucial to CD4+ T 
cell functioning [505]. 
Great examples of association of genetically identified susceptibility genes and 
successful therapies are Abatacept targeting CTLA4 co-stimulatory pathway and 
Tocilizumab, or IL-6 inhibition. The most recent published investigation of the 
possible drug benefits has identified 871 drug-target gene interactions, of which 
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247 had basis for further investigation in RA [37]. One of the examples of 
successful implementation of such analysis is identification of a single SNP 
rs4810485, which accounts for entire susceptibility of CD40 (TNF receptor 
superfamily member 5) locus and corresponding small molecule inhibitor [506]. 
In fact, silencing of CD40 expression in human B cell line resulted in decreased 
NFκB signalling and will be further evaluated for the clinical use [506]. 
Alternatively, attempts were made at gene editing therapy in RA, however a 
greater understanding of current data and further investigations are needed 
before this will become a fruitful approach to treatment [507-509].  
Clinical genetic studies in well-defined cohorts are just as important, not only 
for the discovery of new therapeutics, but also for the investigation of the 
potential clinical biomarkers. One such example is given by the study that 
identified HLA-DRβ1 susceptibility loci as a clinical marker for RA severity, 
mortality and efficacy of anti-TNFα agents [510]. A translational approach and 
clinical understanding is just as important to genetic studies, as it is to 
pathogenesis, immunologic or drug discovery investigations. 
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1.5 MiRs in RA  
“Epigenetics is the study of heritable information that is carried by genetic 
material but is not encoded in the DNA sequence” [511]. According to this 
definition, epigenetic phenomena include DNA methylation and histone 
modifications, such as acetylation and small RNA species – micro RNAs (miRs). 
Epigenetic changes play a significant pathogenic role in RA were they also 
explain the link between smoking and the increased risk of the disease [511]. 
While other epigenetic phenomena involve modification of structures supporting 
DNA, miRs belong to a large family of small RNAs, capable of supressing 
unwanted genetic materials and transcripts in eukaryotes [512]. Moreover, miRs 
themselves are also controlled by epigenetic events, such as histone 
modification and methylation of the DNA, alike all other genes in the genome 
[513]. Given the expanding body of data implicating miRs in the pathogenesis of 
RA and regulation of blood or tissue derived immune cells this work will further 
solely focus on the biogenesis and role of miRs in disease context rather than 
other epigenetic mechanisms.  
1.5.1 Biogenesis of miRs 
MicroRNAs are a class of small RNAs ~22 nucleotides long that control gene 
expression via the translational repression, degradation or destabilisation of the 
mRNAs they target (Reviewed in [514]). In this role, they act by providing 
sequence specificity to Argonaute as part of the RNA-induced silencing complex 
(RISC). Early studies revealed that miRs recognise partially complementary 
sequences in the 3' untranslated region (3'UTR) of their target mRNAs. Base-
pairing between the target sequence and positions 2-7 of the miR, called the 
seed region, were found to be particularly important for target recognition. This 
highly conserved class of molecules play fundamental roles in all cellular 
processes. Individual miR can regulate 100s of genes often coordinating the 
expression of entire pathways. Their importance is underlined by the fact that 
dysregulation of miRs is associated with a broad range of human diseases, 
including cancer, heart disease, neurodevelopmental disorders, and 
autoimmunity [515,516]. For these reasons, it is not surprising that their 
biogenesis is tightly regulated. 
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As the number of miRs identified rapidly increased a numerical nomenclature 
was adopted in which miRs were numbered sequentially according to the order 
in which they were discovered (e.g. miR-23). These names also include a prefix 
describing the species in which they occur (e.g. hsa-miR-23, human miR-23). 
MiRs that share seed sequences are classed as belonging to the same ‘miR 
family’ and are distinguished by lettered suffixes (e.g. hsa-miR-23a and hsa-miR-
23b). If two mature miRs arise from different genes but retain identical 
sequences they are distinguished by number suffixes, such as miR-24-1 and miR-
24-2, to indicate their gene of origin. Further complexity arises as each miR 
locus can produce two mature miRs, one from the 5' strand the other from the 3' 
strand and are designated accordingly, for example, hsa-miR-23a-5p or hsa-miR-
23a-3p. In most cases, one form predominates over the other.  
1.5.1.1 Transcription of miR genes. 
Primary miR transcripts share many structural features with protein coding 
genes. Nearly all are synthesised by RNA polymerase II, contain 5' caps and are 
polyadenylated ([517]. They can be synthesised individually or together with 
other miR in polycistronic clusters. MiRs can also be co-transcribed in the introns 
of host genes. MiRs originating from the same cluster are, generally, co-
transcribed yet, single miRs can be preferentially expressed at the post-
transcriptional level. For example, miR let-7 is post-transcriptionally suppressed 
in the embryonic stem cells, while other members of the cluster miR-100~let-
7~miR-125 are processed into their mature forms [518]. 
Conventional methods used to characterise mRNA transcripts are ill-suited for 
the study of primary miR transcripts, which are short-lived due to rapid 
processing into their mature forms. The identification of transcription start sites 
(TSS) has proved to be particularly challenging for this reason. Consequently 
mapping the precise location of miR promoters lags behind that of protein-
coding genes. However, recent developments in high-throughput technologies 
such as RNAseq, ChIPseq (Chromatin Immunoprecipitation followed by 
sequencing) and mapping of CpG islands, has begun to change this. These 
approaches revealed that miRs in many cases have multiple promoters, allowing 
miR genes to be expressed in numerous cell types or respond to a range of 
different stimuli [519]. miRNA genes like protein-coding genes are regulated 
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directly by interactions of transcription factor binding to sequences in their 
promoters. Additional layers of regulation are applied by histone modifications 
and DNA methylation [520]. 
Once transcription of pri-miR is complete, it undergoes several maturation steps 
(Figure 1.2, steps 2-5). Primary miR transcripts contain a 33-35 bp hairpin loop, 
containing the mature miR sequences is recognised by microprocessor complex 
containing Drosha and DGCR8 (Pasha). This complex clips the hairpin structure 
out of the primary transcript producing a ~65 nucleotide precursor-miR (pre-miR) 
intermediate. This essential step in miR biogenesis pathway is itself tightly 
regulated. A particularly elegant mechanism involves DGCR8 stabilising Drosha 
through protein-protein interaction, while Drosha itself destabilised DGCR8 
mRNA [521]. In addition, the stability, nuclear localisation and activity of the 
microprocessor is regulated by post-translation modifications [522]. This first 
stage in the miR biogenesis pathway takes place in the nucleus and once 
complete, pre-miR are exported into the cytoplasm by the protein exportin 5 
(EXP5) [523]. Here pre-miR is cleaved by Dicer enzyme near the terminal loop, 
liberating a small double strand RNA, approximately 22 nucleotides in length 
[524]. This small RNA duplex is loaded onto one of four available Argonaute 
proteins (AGO1-4) to form the RNA-induced silencing complex (RISC) [525]. From 
the RNA duplex, one strand will become the effector ‘guide’ strand, while the 
other, known as the ‘passenger’ strand is quickly degraded upon AGO loading. 
This explains a strong bias towards the guide strand in the mature miR pool 
[513]. On rare occasions, passenger stands are also incorporated and have 
distinct functions.  
RNA silencing function of miRs is guided by the complementary base pairing of 
its sequence with 3' untranslated region (UTR) of the target mRNA, while 
associated RISC protein complex acts as an effector by instigating translational 
repression, deadenylation and decay (Figure 1.2, 6)[526]. Although binding is 
predominantly guided by the complementarity of the ‘seed’ region, pairing is 
aided if other parts of the miR sequence are also complimentary. Some reports 
have shown that imperfect base-pairing at positions 8-10 of the miR promotes 
target repression via sequestration rather than degradation or destabilisation. 
(Figure 1.2, 7)[513]. Either way protein translation is prevented. The next 
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section will explain how this principle is utilised in the search for potential 
miR:mRNA interactions.  
 
Figure 1.2 Schematic representation of miR biogenesis in mammalian cells. 
(1). MiR gene is transcribed by polymerase II (Pol II) and forming the hairpin loop structures of the 
pri-miR (2). Next, microprocessor complex containing DROSHA and DGCR8 enzymes cleaves off 
the loop containing single pre-miR from the rest of the transcript. (3). Once the pre-miR is formed it 
is transported from the nucleus to the cytoplasm by exportin 5 (EXP5) (4). In the cytoplasm, DICER 
enzyme cleaves the ‘loop’ end of the pre-miR and forming the mature miR duplex. (5) The guide 
strand from the miR duplex is incorporated into the Argonaut protein (AGO) and forms a functional 
RISC complex which can initiate the degradation of the target mRNA transcript (6) or instigate its 
sequestering (7). Further details are in the text.   
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1.5.2 Methodology of miR research 
The foundation of all research into the roles of miRs is the identification of 
miR:mRNA interactions. Since their discovery in 2001 more than half a million 
experimentally validated miR:mRNA interactions have been reported [527]. 
Along with the ever-growing number of interactions, the number of techniques 
and tools used to predict or identify them has also increased in the last ten 
years. There are many excellent reviews describing various strategies that have 
been developed to identify these interactions, ranging from individual miR:mRNA 
pairings through to techniques that capture pan-cellular miR:mRNA interaction 
(Reviewed in [528-530]). 
The formation of functional miR:mRNA interactions is assumed to require Watson 
and Crick base pairing between miR, in particular, its ‘seed' region, and its 
target binding site. Despite intense efforts to understand these interactions at 
the molecular level no formula or set of rules has been able to explain why a 
miR selects one target over another. This has led to the development of a 
variety of approaches to miR target prediction, with the complementarity 
between the seed region and the miR binding site (MBS) at their heart. On top of 
these criteria, some programs infer an MBS's importance from its conservation 
amongst mammalian species, while others analyse secondary structure 
surrounding the MBS thereby inferring likely accessibility of RISC complex. 
Currently, target prediction algorithms have false-positive rates between 20 and 
50% [531]. Despite this, such programs are invaluable and inexpensive tools 
enabling researchers to make rapid theoretical assessments of the miRs that 
have the potential to regulate their genes of interest. Other options include 
investigation of direct miR:mRNA interactions through complex 
immunopurification techniques or through sequencing of the manipulated cells 
and tissues that overexpress or silence the miR of interest. Whichever approach 
is employed, the interaction must eventually be confirmed by the appropriate 
validation method. Workflows for identification of miR:mRNA interactions are 
summarised in Figure 1.3. 
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Figure 1.3 Overview of miR:mRNA interaction methodologies. 
HITS-CLIP - high-throughput sequencing of RNA isolated by crosslinking immunoprecipitation; 
PAR-CLIP - photoactivatable ribonucleoside–enhanced crosslinking and immunoprecipitation; 
CLASH - crosslinking, ligation, and sequencing of hybrids; RNAseq – RNA sequencing; SILAC - 
Stable Isotope labelling by/with amino acids in cell culture. 
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1.5.2.1 Theoretical identification of miR targets 
1.5.2.1.1 TargetScan (Human) 
The algorithm used by Targetscan restricts its predictions to sites found in the 
3'UTR of transcripts annotated in the Ensembl human database [532]. Here it 
searches for sequences that have full complementary to the seed regions of 
know human miRs. Potential miR:mRNA interactions are ranked according to 
whether MBSs are evolutionary conserved [533]. An additional score is given for 
interactions that have an adenosine at position one of the MBS which is thought 
to be conserved - possibly acting as an anchor for the RISC complex [534]. One of 
every two predicted targets are considered to represent legitimate targets 
[535].  
1.5.2.1.2 PITA 
The algorithm used in PITA is unusual in that it uses the accessibility of miR to 
potential MBS as a parameter [536]. Like other algorithms PITA initially searches 
for sequences complementary to miR-seed regions within 3'UTR sequences. Once 
identified, it then infers miR accessibility to this region by estimating the local 
secondary structure. The assumption being that a miR cannot regulate a 
transcript if it is unable to access a potential MBS. PITA predicts correct targets 
26% of the time [535]. 
1.5.2.1.3 PicTar 
PicTar searches for seed region matches in conserved 3'UTRs calculating the free 
energy of miR:MBS duplex [531]. Identified MBSs are then aligned against the 
homologous sequences from 8 vertebrate species; the degree of conservation is 
taken into account when scoring the potential interactions. Predictions made by 
PicTar have an experimental validation rate of 49% [535].  
1.5.2.1.4 miRanda 
Like Targetscan and PicTar, MiRanda screens 3'UTR regions for sequences 
complementary to miR, binding energy and evolutionary conservation [537]. 
Additionally, the location of the MBS in the 3'UTR is also scored, with binding 
sites at the beginning and the end of the 3'UTR scored highest. Unlike 
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TargetScan, miRanda recognises complementarity outwith the seed region, 
taking into account different types of miR:mRNA interactions. miRanda 
predictions are correct 29% of the time [535]. 
1.5.2.1.5 RNA22 
RNA22 tackles the problem of target prediction in an entirely different way to 
that of other target prediction algorithms [538]. The premise behinds RNA22’s 
algorithm is that the reverse compliment of miRs, using pattern discovery 
techniques, should permit the identification of MBS in a provided sequence. 
Once target MBS has been located a targeting miR can be identified using an 
algorithm that calculates RNA:RNA duplexes. Unlike the other programs 
discussed here, RNA22 does not rely on cross-species conservation or base 
pairing of the seed region. RNA22 has the highest false positive rate, correctly 
predicting targets in only 24% of the time [535].  
With the exception of miRanda and RNA22, most target predictions algorithms 
identify targets based on seed region complementarity with the MBS sequence in 
the 3'UTR of the target gene. Recent studies have found that only 40% of 
miR:mRNA interactions identified using techniques such as HITS-CLIP are located 
in 3'UTRs, the other 60% are spread amongst sequences in the 5'UTR and ORF 
[539]. Indeed, these interactions have biological significance. Takagi and 
colleagues showed that miR-24 down-regulated Hepatocyte Nuclear Factor 4 
alpha (HNF4a) via a binding site in the coding region [540]. With this in mind, it 
is likely that an overreliance on the above mentioned programs for target 
discovery can cause a large number of highly significant miR:mRNA interactions 
to be overlooked. Fortunately, more accurate high-throughput techniques have 
been developed that capture the majority of miR:mRNA interactions within the 
cell and allow the unprejudiced identification of MBS. These will be discussed 
below. 
1.5.2.2 Indirect identification of miR targets 
The limitations of one-to-one miR:mRNA investigation and a desire to obtain a 
more comprehensive picture of the miR regulatory network led to a flood of 
studies that employed miR overexpression coupled to a microarray analysis to 
investigate the miR's role in its totality. This approach has the advantage of 
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sampling total transcriptomic changes. While this data set will undoubtedly 
include changes in target genes and related pathways, it, however, cannot 
differentiate between primary and secondary effects limiting its use as a miR 
discovery tool. Nor can it detect interactions in which translational repression 
but not transcript destabilisation is induced. Again this technique relies on 
supra-physiological over-expression of miR and identified targets do not 
necessary reflect what is happening in the cell under homeostatic conditions 
where miR levels are in most cases low [541]. 
This can be overcome to some extent by adopting a miR-inhibition strategy. The 
merit of this approach is that only transcripts that are actively being repressed 
by the miR-inhibited should exhibit changes in expression levels. However, as 
before, this does not differentiate between primary or secondary effects, nor 
does it identify targets that have been translationally repressed. This method 
can be improved by using a proteomic-based approach where changes in protein 
levels after the modulation of miR levels are measured [542]. This method uses 
Stable Isotope Labelling with Amino acids in Cell culture (SILAC) followed by 
mass spectrometry. 
1.5.2.3 High-throughput identification of miR targets 
One-to-one or overexpression methods have been superseded by high throughput 
RNA-immuno-purification technologies capable of capturing and characterising 
the entire miR:mRNA interactome of the cell in a single experiment. The first of 
these techniques called ‘high-throughput sequencing of RNA isolated by 
crosslinking immunoprecipitation’ or HITS-CLIP was developed in the laboratory 
of Robert Darnell [543]. This method involves UV cross-linking of miR-RISC 
complexes to the mRNAs that they are associated with. Samples are then treated 
with RNases, which degrades unbound RNA leaving the mRNA regions underlying 
the miR-RISC complexes protected. The miR-RISC-mRNA complexes are then 
isolated using an antibody against Ago2. Isolated RNAs are sequenced by RNAseq, 
generating a map of miR-binding sites. A similar method called PAR-CLIP makes 
use of photoactivatable nucleosides that reversibly cross-link miR to their mRNA 
targets when exposed to UV light [539].  
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These techniques, although powerful, do have some limitations. Firstly, their 
reliance on anti-Ago2 antibodies to retrieve miR-mRNA complexes means that 
miR-complexes involving the other Argonaute proteins are ignored. Secondly and 
perhaps most seriously, both of these techniques require that miRs be 
disassociated from its target mRNA before analysis. Interactions are then 
inferred computationally using target prediction algorithms. One technique, 
known as CLASH (crosslinking, ligation and sequencing of hybrids) ingeniously 
overcomes this limitation by ligating the miR-mRNA fragments together before 
sequencing allowing the miR and binding site to be captured together [544]. 
However, this method is relatively inefficient with less than 2% of reads 
corresponding to miR:mRNA interactions.  
Lastly, Biotin-linked chromatography captures miR:mRNA interactions of a single 
miR species by introducing synthetic biotinylated miRs into cells [545]. These are 
then incorporated into the RISC complex, cells lysed and the biotin labelled 
miR:mRNA complexes purified using streptavidin-linked beads. Finally captured 
RNAs are then sequenced. The main merit of this technique is that it captures 
miR along with its target mRNA allowing interactions to be shown directly. While 
the data collected represents all the potential binding sites of a single miR 
species, it does not reveal which ones are occurring under physiological 
conditions. 
The techniques described above represent powerful resources for the study of 
miR-target interactions. While being technically challenging, they will be hugely 
informative as we move away from the one-miR-one-target studies that make up 
most of the miR research to date. However, even with these rich data sets, it is 
important to establish that a particular miR:mRNA interaction does occur. In 
other words, just because a miR can target an mRNA it does not necessarily 
mean that it does in a given cell type at a given time. Transcripts can limit or 
extend the repertoire of miRs that regulate them via the utilisation of 
alternative polyA signals. The selective use of polyadenylation sites allows a 
transcript to alter the length of its 3'UTR thereby rendering them sensitive or 
insensitive to miR that would otherwise target them. It is estimated that 70% of 
human genes use more than one polyA signal with 50% using 3 or more [546]. 
This has significant biological consequences and can explain why a miR regulates 
a target in one cell type and not another [546]. 
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1.5.2.4 Validation of miR:mRNA interaction with reporter gene assay. 
Whatever the method used to identify potential miR:mRNA interactions, they 
must be experimentally challenged, most frequently using reporter gene assay. 
In these studies, regions containing putative MBS are cloned downstream of a 
reporter gene (luciferase or GFP) if the interaction is real, the expression of the 
reporter will be sensitive to the corresponding miR when co-transfected into an 
appropriate cell line[547]. Loss of inhibition upon mutation of MBS provides the 
final, conclusive proof of a miR regulation of that target. Although this proves 
that physical interaction occurs and is functional, whether it occurs in a 
particular cell under specific conditions has to be inferred from other in vitro 
studies. Additionally, as these studies involve the massive over-expression of 
both miR and target they can reveal interactions that would never occur under 
normal physiological conditions. With these caveats in mind, reporter gene 
assays provide the ultimate evidence of miR:mRNA interactions.  
1.5.3 miRs in RA 
The functions of miRs are cell and context dependent. With their ability to 
target many targets at the same time and tendency to regulate many members 
of the same pathway, differential expression can have significant consequences 
for the cell. MiRs are implicated in every physiologic process currently known, 
from embryogenesis to normal immune response to a pathogen (as evidenced by 
55614 PubMed citations). They are also involved in many diseases, from cancers, 
in which they are now being considered for therapeutic targeting, through to 
dementia. They play a profound role in autoimmune diseases, where they 
regulate many aspects of immune cells, such as differentiation, activation, 
apoptosis and cytokine secretion [548]. This is a rapidly evolving field, and new 
miR-target interactions are discovered every day. Nevertheless, the most 
studied miRs in the context of RA remain miR-155, miR-146 and miR-223. 
1.5.3.1 miR-155  
MiR-155 is one of the first recognised pro-inflammatory miRs. MiR-155 transgenic 
mice have increased serum levels of TNFα and are susceptible to endotoxin 
shock [549]. Overexpression of miR-155 directly leads to increased production of 
TNFα through the repression of inflammatory suppressors SHIP-1 
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(Phosphatidylinositol-3,4,5-trisphosphate 5-phosphatase 1) and SOCS1 [550,551]. 
Macrophages and dendritic cells upregulate miR-155 upon stimulation with LPS 
[549] is essential to mounting an adequate inflammatory response since mice 
lacking miR-155 have defective T- and B-cell functions, as well as impaired 
antigen presentation capabilities of DCs [549]. Additionally, expression of miR-
155 is raised in both, PB and synovium of RA patients [550]. Exposure of healthy 
PB monocytes to synovial fluid from RA patients triggers expression of miR-155 
and increases levels of TNFα, IL-6 and IL-1β [550]. Conversely, inhibition of miR-
155 limits the expression of TNFα, while miR knock-out mice are protected from 
arthritis in CIA model [550]. More recent work has shown that increased miR-155 
in RA monocytes promotes secretion of chemokines and triggers recruitment of 
inflammatory cells to the joints, while raised expression in PB B cells stimulates 
antibody secretion and is associated with ACPA+ RA [552,553].  
1.5.3.2 miR-146a 
MiR-146a is considered to play an anti-inflammatory role in RA, despite the fact 
that it is raised in PB cells, synovium and synovial fluid and correlates with 
disease activity score [554,555] [556,557]. Stimulation of FLS and CD4 T cells 
with LPS induces miR-146a expression [556]. In turn, miR-146a directly disrupts 
TLR activation by targeting TRAF6 and IRAK1 downstream signalling molecules; 
however, this feedback loop is not functional in RA cells as high levels of miR-
146a does not inversely correlate with that of its targets [554]. Additionally, 
Zhou et al. have shown that failure of miR-146a to regulate STAT1 expression in 
TREG cells is at the heart of their impaired ability to control cytokine production 
in RA [558]. If, however, miR-146a is injected intra-articulately in mice model of 
arthritis, it ameliorates formation of bone erosions through impairing 
osteoclastogenesis and regulating targets mentioned above [559]. It is therefore 
believed that the anti-inflammatory properties of miR-146a are curtailed in the 
chronic inflammatory setting of RA and contribute to the chronicity of the 
disease. In this case, overexpression of regulatory miR in a failed attempt to 
control the immune response exemplifies that function of miRs should not be 
judged solely on its presence or absence, especially when multiple contradictory 
events are involved, such as in chronic disease. 
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1.5.3.3 Other miRs in RA 
MiR-223 is considered to play both pro- and anti-inflammatory roles in RA. This 
miR is abundantly detected in serum and synovium of RA patients and negatively 
correlates with the tender joint count [557]. MiR-223 promotes TH1 polarisation 
and IFNγ expression while reducing the synthesis of pro-inflammatory IL-17 
[560]. In keeping with this, it is highly present in naïve CD4 T cells and absent in 
TH17 [561]. However, in murine SF myeloid cells, high levels of miR-223 
promoted osteoclastogenesis and its inhibition prevented bone erosions, while 
reducing the severity of arthritis indicating cell and context-dependent functions 
of miR-223, which is why its association with RA requires further investigation 
[562]. 
The exploration of RA FLS cells has identified increased expression of miRs-203, 
miR-221, miR-222 and miR-323, which are believed to support expansive 
phenotype of FLS cells and their resistance to apoptosis [208,563]. In contrast, 
RA FLS were reported to have lower levels of miR-22, miR-34a*, miR-124a, miR-
152 and miR-375 [564]. Amongst them, miR-22 was shown to target matrix 
protein Cyr61, implicated in angiogenesis, inflammation and matrix remodelling, 
while low levels of miR-22 coincided with overexpression of Cyr61 in RA 
synovium [564]. Downregulation of two other members, miR-34a* and miR-124a 
leads to overexpression of anti-apoptotic molecules, such as XIAP (E3 ubiquitin-
protein ligase) and CKD2 (cyclin-dependent kinase 2); and migratory chemokine 
CCL2, respectively [207,565]. Remaining miR-152 and miR-375 were implicated 
in the control of Wnt signalling and bone remodelling in arthritis models in rats. 
[566].  
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1.5.4 MiR-23~24~27 clusters 
All three of miRs in this cluster are implicated in a multitude of diseases, 
including prominent roles in inflammation and bone metabolism [567]. MiRs from 
this cluster were the first described in myeloid lineage commitment during 
development [568]. Since then, they have been actively investigated in many 
cancers for their ability to regulate cell proliferation and apoptotic pathways, 
while their immunomodulatory role is just emerging.  
There are two genes in the mammalian genome expressing miR-23~24~27 
cluster. These paralogs have arisen by gene duplication and are highly conserved 
among vertebrates. Both clusters contain three miRs: miR-23, miR-24 and miR-
27. The miR-23a cluster is localised in the intragenic position on the 
chromosome 19q22 and contains miR-23a, miR-24-2 and miR-27a. This ‘a’ cluster 
exists as a separate gene and has its own promoter sequence upstream from the 
transcriptional start site (TSS) (Figure 1.4, A) [569]. In fact, this was the first 
miR cluster to be investigated for the transcription of consecutive miRs, where it 
was shown that miR clusters, such as this one, are transcribed by Pol II as a 
single primary transcript [517,570]. In contrast, its paralog, miR-23b~24-1~27b 
cluster is located on the chromosome 9 and is placed in intron 14 of the host 
C9ORF3 (chromosome 9 open reading frame 3) gene, whose function has yet to 
be determined (Figure 1.4, B). This ‘b' cluster contains miR-23b and miR-27b, 
which have a single nucleotide difference from their respective ‘a' cluster 
paralogs, while the sequence of miR-24-1 is identical to the one of miR-24-2. 
Hence they are distinguished by the numbered suffix. Recently, a new miR-3074 
was described on the opposite strand of miR-24, however, it is unknown if this 
interferes with the expression of miR-24-1. Lastly, a third copy of miR-23c, but 
not other miRs from the cluster, has been recently discovered on the X 
chromosome. Unfortunately data on its expression and regulation are still 
sparse. Interspecies conservation and sequences of all miRs from these clusters 
are depicted in Table 1.4. 
There have been several attempts at investigating the reason for miR gene 
duplication and conservation. It has been suggested that such events allows miRs 
to perform redundant functions in different cell types or under different 
circumstance, guided by distinct transcription factors [571]. Retained similarity 
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in sequence indicates that their portfolio of target genes are likely shared, and 
differences in function are guided by differential expression [572]. Co-expressed 
miRs, derived from the same cluster, were shown to work in synergy to 
accomplish targeting of designated pathways [573]. Nevertheless, significant 
posttranscriptional regulation can promote the expression of some miR members 
over others in a context-dependent manner. For example, overexpression of 
miR-23a~24-2~27a cluster in HEK293 (human embryonic kidney) cells leads to the 
accumulation of miR-24-2 and miR-27a, but not miR-23a [574].    
 
Table 1.4 Interspecies conservation of miR-23~24~27 paralogs.   
 
miR	 Species	 Unique	ID	number	 Sequence	
miR-23a	
human	 MIMAT0000078	 AUCACAUUGCCAGGGAUUUCC	
mouse	 MIMAT0000532	 AUCACAUUGCCAGGGAUUUCC	
miR-23b	
human	 MIMAT0000418	 AUCACAUUGCCAGGGAUUACC	
mouse	 MIMAT0000125	 AUCACAUUGCCAGGGAUUACC	
miR-23c	 human	 MIMAT0018000	 AUCACAUUGCCAGUGAUUACCC	
miR-24-1/2	
human	 MIMAT0000080	 UGGCUCAGUUCAGCAGGAACAG	
mouse	 MIMAT0000219	 UGGCUCAGUUCAGCAGGAACAG	
miR-27a	
human	 MIMAT0000084	 UUCACAGUGGCUAAGUUCCGC	
mouse		 MIMAT0000537	 UUCACAGUGGCUAAGUUCCGC	
miR-27b	
human	 MIMAT0000419	 UUCACAGUGGCUAAGUUCUGC	
mouse	 MIMAT0000126	 UUCACAGUGGCUAAGUUCUGC	
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1.5.4.1 The role in cancer 
Increased expression of all members of miR-23a~24~27a cluster was found in 
acute lymphoblastic and myeloid leukaemia, chronic lymphocytic leukaemia, 
breast and gastric cancers, as well as hepatocellular carcinoma cells (HCC) 
(reviewed in [567]). Although it is not clear if this upregulation is a driver of the 
underlying pathology or a consequence of it, this miR cluster was implicated in 
regulating TGFβ driven cell apoptosis with overexpression of entire miRs cluster 
promoted TGFβ resistance and the growth of HCC cells [575]. Here the effect on 
apoptosis was mediated by direct targeting of the downstream signalling 
molecules SMAD 3, 4 and 5 by both miR-23a and miR-23b [542]. A report by Wang 
et al. showed that miR-24 inhibits type I activin receptor (ALK4) which 
phosphorylates SMAD2 and SMAD3, further inhibiting TGFβ pathway [576]. 
Moreover, TGFβ driven upregulation of miR-27a inhibits DC-mediated 
differentiation of TH1/TH17 cells and promotes TREG phenotype through secretion 
of IL-10, thus securing immune evasiveness of the tumour [577].  
Supporting angiogenesis is another way of promoting tumour growth and 
metastases. Repression of TRIB3 (Tribbles-like protein-3) by miR-24 attenuates 
the effect of TGFβ and BMP and promotes angiogenesis in response to wound 
healing [578]. In breast cancer, miR-27a was shown to indirectly increase the 
activity of Sp1 TF and promote proliferation and angiogenesis by upregulating 
VEGF and its receptors [579]. Similarly, miR-27b was shown to target Notch 
ligand Dii4, Sprouty 2, PPARγ and semaphorin 6A to exhibit its pro-angiogenic 
effects, while its overexpression led to improved tissue revascularization [580-
582]. In fact, high constitutive expression of miR-23a by human umbilical vein 
endothelial cells (HUVECs) suggests an important role of this cluster in vascular 
homeostasis [583]. 
Naturally, the most direct way of promoting tumour growth is through the 
regulation of the cell proliferation and apoptosis pathways. Here, miR-27a 
together with miR-96 and miR-182 are shown to inhibit FOXO-1 TF involved in 
apoptosis, cell cycle and metabolism which may be crucial to the maintenance 
of an aggressive phenotype in breast cancer cells [584]. Inhibition of miR-27a 
encourages cells to enter G2-M phase through the induction of Myt-1 [585]. In 
oral squamous cell carcinoma overexpression of miR-24 targeted kinase 
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inhibitory protein 2 (KIP2 or p57) tumour suppressor and promoted tumorigenesis 
[586]. In hormone-insensitive prostate cancer miR-24 regulated Fas-associated 
factor-1 (FAF-1) and displayed significant anti-apoptotic effect [587]. At the 
same time, miR-24 appears to repress cell proliferation through a repression of 
MYC, E2F2 cyclins and associated genes [588].  
In some cases, loss of miR-23~24~27 clusters also led to disease development. 
For example, reduced expression of all members of miR-23~24~27a cluster was 
described in acute promyelocytic leukaemia, while the lack of miR-27a and miR-
23b was found in malignant melanoma cells [589,590].  Interestingly, reduced 
expression of miR-23a and miR-27a was associated with autism disorders and 
miR-24 with schizophrenia, implicating this miR cluster in a broad range of 
tissues and pathologies [591,592].  
1.5.4.2 The Role in Immunity 
Just after the beginning of this project, a seminal paper by Zhu et al 
unequivocally implicated miR-23b in IL-17 driven inflammation, demonstrating a 
correlation between low levels of the miR and high levels of the cytokine in the 
synovial tissue from RA patients [593]. This was mirrored in the CIA murine 
arthritis model, where miR-23b was downregulated in the synovium after 15 days 
of the arthritis onset. Moreover, adenoviral delivery of miR-23b prevented the 
formation of bone erosions, while adenoviral delivery of miR-23b inhibitor-
induced dramatic erosive bone loss. The authors have demonstrated that IL-17 
inhibited the expression of miR-23b via NFκB in human FLS cells. Reduced 
expression of miR-23b, in turn, fails to regulate IKKα, TAB2 and TAB3 signalling 
molecules perpetuating inflammation. Unfortunately, it is unclear to which 
promoter sequence authors allude to since the given primer sequences do not 
correspond to any murine genome. Considering the intronic placement of both 
human and murine miR-23b it is possible that IL-17 also inhibits host gene 
expression, which was not acknowledged by authors of this work. An additional 
shortcoming of this study was the lack of consideration given to possible roles 
that miR-23a play in this process. Nevertheless, this was the first significant 
demonstration of the critical involvement of a member of the miR-23~24~27 
cluster in autoimmune disease and, particularly, RA. 
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1.5.4.2.1 The role in monocytes and macrophages 
Regulated by the TF PU.1, miR-23a~24~27a cluster plays a decisive role in 
promoting myelopoiesis over lymphopoiesis [568]. This miR cluster is also more 
abundant in myeloid progenitors and mature myeloid cells than in lymphocytes 
[568]. On an individual level, all members of the cluster were shown to have an 
effect on the function of monocytes and macrophages. For example, rapid 
downregulation of miR-24 is essential for both M-CSF-induced differentiation of 
monocytes to macrophages and GM-CSF-IL-4 induced differentiation into 
monocyte-derived DCs [594]. Re-introduction of miR-24 resulted in impaired 
immune response to LPS stimulation and lower production of TNFα, IL-12 and IL-
6 cytokines by mature macrophages [594]. Additionally, overexpression of miR-
24 led to impaired antigen presentation capabilities of both macrophages and 
DCs [595].  
In concordance with this, other members of the cluster play roles in myeloid 
activation. IFNα induced repression of miR-23a relives Blimp-1 (B lymphocyte-
induced maturation protein 1) and promotes differentiation of pDCs, aiding anti-
viral immune response [451]. In contrast, Zheng et al. have shown that IFNα 
inhibition of miR-27a forms part of a negative feedback loop, whereby miR-27a 
targets two negative regulators of type I IFNs – Siglec1 (sialic acid-binding Ig-like 
lectin) and TRIM27 (E3 ubiquitin ligase tripartite motif-containing protein 27) 
[596]. In this model, the initial expression of IFNα leads to a reduction in miR-
27a and consequential de-repression of IFNα inhibitors, thus safeguarding the 
extent of inflammatory response providing the mechanism by which mice lacking 
miR-27a exhibit aggravated viral replication in vivo [596]. In a separate work, 
miR-27a was shown to inhibit IL-12 production by DCs and, consequently, DC-
mediated differentiation of TH1/TH17 cells [577]. Anti-inflammatory role of miR-
27a was also demonstrated when the overexpression of this miR triggered the 
release of IL-10 in primary transfected monocytes [597].  
Given the profound role of miR-23a~24~27a cluster on the differentiation of 
monocytes, it is no surprise that it also impacts differentiation of osteoblasts. In 
bone remodelling, miR-23a cluster expression was directly suppressed by Runx2 
TF, an essential regulator of osteoblastogenesis [598]. In turn, each member of 
the miR cluster targets SATB2, a protein that synergizes with Runx2 to promote 
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bone formation.  The authors believe that this allows a twofold activation of the 
osteoblastogenesis, by which initially upregulated Runx2 induces the activation 
of accessory protein by repressing corresponding miRs [598]. Unfortunately, no 
data is yet available on the function of this pathway during inflammation, where 
overexpression of paralogue miR-23b exhibited a strong protective role [593]. 
Certainly, in RA FLS cells miR-27a expression inhibited the invasive phenotype 
and limited in vitro migratory capacity [599]. High levels of miR-27a also 
reduced the expression of damaging molecules, such as MMP2, MMP9 and MMP13. 
Understandably, miR-27a levels were low in the serum, synovial tissue and FLS 
cells from RA patients with active disease [599].  
MiR-23~24~27 clusters may play additional roles in the RA co-morbidities beyond 
the regulation of the inflammation. New data has emerged describing their 
ability to suppress differentiation of adipocytes, control atherosclerosis and 
mediate cardiac hypertrophy [600-605]. It would certainly be of interest to 
investigate these pathways in the context of RA.   
1.5.4.2.2 The role in T cells 
During last year several significant reports have implicated miR-23a~24~27a 
cluster in the development and, more importantly, the phenotype of T cells. 
MiR-23a expression is crucial to the early expansion of CD4 T cells, as it protects 
the cells from reactive oxygen species (ROS) induced necrosis [606]. In murine 
CD4 T cells, overexpression of the entire cluster negatively impacted all TH 
lineages, mainly affecting TH2 cells through the inhibition of IL-4 and GATA3 
[607]. Although the function of miR appears coordinated, the authors noted that 
overexpression of miR-24 alone can promote TH1, TH17 and induced TREG 
polarisation [607]. Parallel reports have confirmed that miR-24 and miR-27 
suppress allergic response by mediating TH2 differentiation in murine models 
[608]. Raised expression of miR-23a was also shown to inhibit cytotoxicity of 
both CD8 T cells and NK cells [609,610]. The only human study to date showed 
that miR-27a was increased in the PB CD4 T cells from patients with relapsing 
multiple sclerosis when compared to the remitting phase, with miR-27a playing a 
pro-inflammatory role [611]. These studies are technically very challenging and 
more data is required before the roles of different members of this cluster can 
be concluded. 
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1.5.4.2.3 The role in drug resistance 
Interestingly, the miR-23~24~27 cluster is implicated in several pathways 
underlying drug resistance in cancer patients. Since some therapeutics are 
shared between the treatment of RA and certain cancers, this warrants further 
discussion.  
MiR-27a expression has been described in relation to the multi-drug resistance 
gene 1 (MDR1) in many human cancer cells, thus conferring resistance to a broad 
range of treatments [612,613]. It appears that inhibition of miR-27a somehow 
suppresses MDR1 and P-glycoproteins, thus allowing the intracellular 
accumulation of cytotoxic drugs. With regards to other cluster members, p53 
mediated apoptosis was shown to increase the expression of miR-23a resulting in 
the direct inhibition DNA topoisomerase I, and promotion of apoptosis [614]. It is 
this mechanism that miR-23a expression aids the effect of etoposide, a 
topoisomerase inhibitor often used for its cancer suppression properties [614]. 
Similarly, miR-24 was also shown to target topoisomerase I and promote 
etoposide-induced apoptosis [615,616]. Nevertheless, of most relevance is the 
report describing a polymorphism in DHFR gene, which impairs its regulation by 
miR-24 and promotes resistance to the treatment with MTX [617]. Authors 
describe a naturally occurring change in the 3'UTR region of DHFR gene that 
renders it insensitive to the miR-24. However, the effect of miR upregulation or 
inhibition on the levels of DHFR were carried out in the HT1090 cells, and the 
frequency of SNP or its impact on the MTX in primary human cancer was never 
tested.  
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1.6 Objectives 
We hypothesise that peripheral blood monocytes from patients with drug-
resistant RA have distinct miR signatures, which could be informative of 
underlying pathogenic processes. Therefore the aims of this study were: 
1. To identify miR species, which are differentially regulated in patients 
with poor response to treatment with conventional DMARDs agents, or 
biologics therapies compared to those who have good disease control with 
one or two DMARD agents  
2. Once identified, to determine factors that regulate these novel miRs in PB 
monocytes 
3.  To identify and utilise an experimental model, which allows manipulation 
of the miR expression, aiding the discovery of molecular targets and 
function of these miRs 
4. To explore the role of these miRs in the inflammation and drug resistance 
of RA  
2 Materials and Methods 
2.1 General Buffers and Reagents 
Complete RPMI- RPMI 1640 media supplemented with 10% foetal calf serum 
(FCS), 2mM L-Glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin (all 
Invitrogen).  
Complete DMEM- DMEM media supplemented with 10% FCS 2 mM L-Glutamine, 
100 U/ml penicillin, 100 µg/ml streptomycin (all Invitrogen).  
Wash media- RPMI 1640 medium supplemented with 100 U/ml penicillin, 100 
µg/ml streptomycin.  
MACs/FACs Buffer- Dulbeccos Phosphate Buffered Saline (dPBS) supplemented 
with 2 % FCS and 100 U/ml penicillin, 100 µg/ml streptomycin.  
ELISA Wash buffer- 1x dPBS was supplemented with Tween 20 to a final 
concentration of 0.05 % (v/v).  
ELISA Assay Buffer- 1x dPBS was supplemented with bovine serum albumin (BSA) 
(Sigma) to a final concentration of 0.5 % (w/v). 
Tris-acetate EDTA (TAE) buffer- concentrated 50x stock solution of TAE 
includes dissolved 242 g Tris base in 750 ml deionized water. To this, add 57.1 
ml glacial acetic acid and 100 ml of 0.5 M EDTA (pH 8.0). Adjust the solution to a 
final volume of 1 litre.  
SOC medium- 2 g of Tryptone, 0.5 g yeast extract, 2 ml of 5 M NaCl, 2.5 ml of 1 
M KCl, 10 ml of 1 M MgCl2, 10 ml of 1 M MgSO4 and 20 ml of glucose made up to 
100 ml with distilled water and autoclaved. 
5X STOP Dye- 4 gram of sucrose, 1.5 ml of 0.5 M EDTA (pH 8.0), 1 ml of 1 M KCl 
and 0.2 ml of Tris-HCl (pH 8.0), 20 mg of bromophenol blue made up to 10 ml 
with distilled water. 
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Luria Bertani (LB) media- 10 g tryptone, 5 g yeast extract, 10 g NaCl made up 
to 1 litre with deionised water, pH adjusted to 7.5 with NaOH and autoclaved.  
Luria Bertani (LB) Agar media- 10 g tryptone, 5 g yeast extract, 10 g NaCl made 
up to 1 litre with distilled water and autoclaved.  
TE buffer- 1ml of Tris-HCl (pH 8.0) and 0.2 ml of 0.5M EDTA made up to 100 ml 
with distilled water.  
2.2 Cell Culture 
Cell culture experiments were performed in the laminar flow hood. Cells were 
cultured in the appropriate medium (see below), in an incubator with 5% CO2 
/95% O2 at 37°C, unless otherwise stated.  
2.2.1 Culture of Primary Human Cells 
2.2.1.1 Patient blood samples 
Recruitment of patients took place between March 2010 and September 2011 
under the ethical approval from Local research Ethics Committee (West of 
Scotland) REC ref Number 10/S0703/4 (R&D Ref: GN09RH699). All participants 
gave their written informed consent to participation. Study patients were 
recruited across three different sites: at Glasgow Royal Infirmary, Stobhill 
General Hospital and Gartnavel General Hospital as a part of rheumatology 
outpatient clinic or day unit. Dr Derek Baxter primarily conducted recruitment 
with the help from Professor Iain McInnes, Dr Duncan Porter and fellow Dr Eva 
Ruzicka. All participating patients had a clinical diagnosis of RA meeting 1987 
ACR criteria. Other inclusion and exclusion criteria are listed in Table 2.1. 
Clinical assessment and blood samples for epigenetic analysis were taken on the 
same day to minimise variation in the clinical status between the patients. 
Patients were categorised as Responders or Non-responders to the treatment 
according to the disease activity score based on the 28 joints count (DAS28 
score) at the time of the recruitment.  
The treatment category of disease modifying anti-rheumatic drugs (DMARDs) 
involved patients who were on active treatment with Methotrexate, 
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Sulphasalazine, Hydroxycholoquine or combination of 2 or 3 of these 
medications. The other category included patients on biological agents, such as 
anti-TNFα therapy (Infliximab, Etanercept and Adalimumab) or patients 
receiving either anti-CD20 agent Rituximab or anti-IL-6R agent Tocilizumab.  
 
Table 2.1 Inclusion and exclusion criteria for healthy controls and patient cohort study. 
 
2.2.1.2 Separation of peripheral blood mononuclear cells 
Blood samples from RA patients and healthy volunteers were processed by senior 
technician Lynn Stewart. Buffy coats obtained from Scottish National Blood 
Transfusion Service (SNBTS) were processed by myself. For the separation of 
PBMCs samples or buffy coats: each was diluted with equal amounts of wash 
media and layered over Histopaque®-1077 (Sigma) and centrifuged at 21,00 rpm 
for 20 minutes at room temperature. Next, the layer of mononuclear cells was 
collected in a new sterile 50 ml tube and washed with equal amount of wash 
media. After this step, cells were resuspended in 25 ml of cold MACS buffer and 
Group& Inclusion&Criteria& Exclusion&Criteria&
1.&Healthy&Controls& •  Lack%of%current%inﬂammatory,%degenera4ve%or%otherwise%
symptoma4c%disease%at%the%4me%of%recruitment%
•  Current%or%recent%joint%injury%
%
•  Family%history%of%established%inﬂammatory%or%
autoimmune%disease%
2.&DMARDs&Responder&
Pa?ents&
•  Rheumatoid%Arthri4s%(mee4ng%ACR%1987%criteria)%
•  DAS28JESR%(or%CRP)%less%then%3.2%
•  Disease%dura4on%greater%then%ten%years%
•  Prior%therapy%with%two%or%fewer%DMARDs%las4ng%greater%
then%three%months%
•  DAS28JESR%or%CRP%above%3.2%at%the%4me%of%
recruitment%
•  Previous%use%of%third%DMARD%or%biologic%agent%
•  Ac4ve%disease%within%recent%3%months%
3.&DMARDs&Resistant&
Pa?ents&
Eligibility%of%biologic%therapy%according%to%BSR%2010%criteria:%
%
•  DAS28JESR%or%CRP%>5.1%on%2%occasions%a%month%apart%
•  Failing%at%least%2%previous%DMARDs,%including%
Methotrexate%
and%
%
•  Posi4ve%RF%or%an4JCCP%an4bodies%
•  Ac4ve%infec4on,%sep4c%arthri4s%of%na4ve%or%
prosthe4c%joint%within%last%year%
•  NYHA%grade%3%or%4%heart%failure%
•  Demyelina4ng%disease%
•  Malignancy%
4.&Biologics&Resistant&
Pa?ents&
•  Rheumatoid%Arthri4s%(mee4ng%ACR%1987%criteria)%
•  DAS28JESR%or%CRP%>%3.2%
•  Previous%treatment%with%two%or%more%biologic%agents%
•  Ac4ve%infec4on%
•  Recent%surgery%
•  Malignancy%
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kept on ice for further processing. Live cell number was counted with trypan 
blue exclusion (Sigma).  
2.2.1.3 Isolation of CD14+ monocytes from PBMCs 
Isolation of CD14+ monocytes in RA patient’s cohort and healthy volunteers was 
performed by senior technician Lynn Stewart. Isolations of CD14+ monocytes 
from buffy coats and subsequent RA patient samples were performed by myself. 
AutoMacs (Miltenyi Biotec) separator was used for this procedure and original 
protocol was followed. According to it, cells were resuspended in 80 µl MACs 
buffer per 1x107 cells and appropriate volume (usually 500 µl), depending on the 
required number of cells, was transferred to a new sterile 15 ml tube and 
filtered using 70 µm filters (BD Falcon). Samples and anti-CD14 conjugated 
magnetic beads (Miltenyi Biotec) were then placed in the appropriate AutoMacs 
racks, the PosselD programme, which ensures highest resulting cell purity, was 
used for automatic separation. Purity of cells was assessed by flow cytometry 
and was typically >95%.   
2.2.1.4 Culture of primary human monocytes 
For the experiments with primary human monocytes, cells were cultured at a 
density of 0.25x106 cells per well of 48-well plate in 250 µl of complete RPMI 
medium, supplemented with 50 ng/ml of M-CSF or GM-CSF medium (both 
Peprotech). Cells were kept in these conditions for 24 hours before any stimuli 
were added..  
2.2.1.5 Culture of primary human macrophages 
For differentiation of human macrophages, isolated CD14+ cells were cultured at 
a density of 0.25x106 cells per well in a 24-well plate in 500 µl of complete RPMI 
medium, supplemented with 50 ng/ml of M-CSF or GM-CSF medium for 7 days 
(both Peprotech). The medium was replaced on day 3.   
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2.2.2 Culture of Human Cell Lines 
2.2.2.1 THP-1 Cells  
THP-1 cell line cells were cultured in 25 ml of complete RPMI medium in T75 
tissue culture flasks (Corning). Cells were passaged three times a week. Before 
passage, cells were washed in complete RPMI, centrifuged at 1,500 rpm for 5 
minutes and then counted. Cells were seeded at a density of 2x106 in 25 ml of 
complete RPMI and cultured under normal culture conditions.  
2.2.2.2 miR-23a~24-2~27a sponge THP-1 cells 
THP-1 cells were stably transfected with of miR-sponge constructs or empty 
vector control and were cultured in 25 ml of complete RPMI medium in T75 
tissue culture flask or in 10 ml of complete RPMI medium in T25 tissue culture 
flask (Corning; details of sponge constructs are described in Chapter 5). For 
selection, these cells were cultured along with 800 µg/ml of the antibiotic 
Geneticin (G418, Invitrogen). Cells were seeded at a density of 1x105/ml in 
complete RPMI. 
2.2.2.3 PMA differentiation of THP-1 cells and THP-1 miR sponges 
Before plating, THP-1 cells were counted and washed with wash medium. Cells 
were seeded at 0.25x106 cells per well of a 24-well plate in 500 µl of complete 
RPMI medium, supplemented with 25 ng/ml of PMA medium and cultured for 7 
days. Optimisation of culture conditions indicated that best results were 
achieved if complete RPMI medium was replaced on day 3 only. 
2.2.2.4 HEK293 Cells 
HEK293 cells were cultured in complete DMEM medium in T75 tissue culture 
flasks (Corning) and passaged twice a week. To dissociate cells from the flask: 
media was removed, cells gently washed with sterile Dulbeccos PBS (Gibco; 
dPBS) and then incubated for 3 minutes at 37°C with 5 ml 0.05% Trypsin EDTA 
(Invitrogen). Following this, 7 ml of complete DMEM was added to the flask to 
inactivate trypsin and cells centrifuged at 1,500 rpm for 5 minutes at room 
temperature. Cells were then seeded at a density of 5x104/ml in a fresh T75 
Flask in 15 ml complete DMEM and cultured under normal culture conditions.  
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2.2.2.5 Cryopreservation of the cell lines 
For future use, cell lines were stored in liquid nitrogen. Cells were frozen in 
cryovials at a concentration of 1x106 in 10% DMSO and complete RPMI medium. 
Cells were stored at -80°C overnight and then transferred to liquid nitrogen. 
2.2.3 Cell Stimulation 
Primary human CD14+ monocytes, differentiated human macrophages and THP-1 
cells were stimulated with cytokines and TLR ligands to determine their effects 
on the expression of miR-23a~24~27a cluster and cytokine production. Stimuli 
were added to individual wells in the pre-concentrated form in 50 µl of medium. 
Stimulatory conditions varied for each experiment and details are stated in the 
figure legend for each graph.  
2.2.4 Cell Transfection  
Transfection of primary cells and cell lines were performed using transfection 
protocols and reagents that were deemed most effective from published 
literature and previous experience within the laboratory. 
2.2.4.1 Transfection of primary human monocytes 
Primary human monocytes isolated from buffy coats or from freshly donated 
samples were transfected with miR mimics and miR inhibitors using N-TER™ 
reagent (Sigma). N-TER™ is a peptide-based transfection reagent optimised 
specifically for the delivery of siRNA and miR.  
Enriched peripheral blood (PB) or buffy coat CD14+ monocytes were seeded in 
24-well plates at a concentration of 3.5x105 cells in complete RPMI 1640 media. 
Cells were transfected with either mimics for miR-23a, miR-24, miR-27a or 
scrambled control at a concentration of 20 nM. N-TER™ peptide and 5 µM stock 
of mimic were thawed at room temperature for ~10 minutes. Samples were 
prepared as shown in Table 2.2. Contents of Tube A were added to Tube B, 
vortexed briefly and allowed to sit at room temperature for 15-20 minutes. 
Transfection complex was then added directly onto the cells. Cells were placed 
in incubator for 24-48 hours prior to analysis.  
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Reagent  Tube A  Reagent  Tube B 
miRNA (5 µM) 3.25 µl  N-TER™ 2 µl 
siRNA Dilution 
Buffer 
9.25 µl  Water 10.5 µl 
Final Volume 12.5 µl  Final Volume 12.5 µl 
Table 2.2 Preparation of N-TER™ transfections for single well of 24-well plate. 
 
2.2.4.2 Transfection of HEK293 cells 
HEK293 cells were seeded shortly before transfection at a density of 1x105 per 
well of 24-well plate in 500 µl of complete DMEM. Next, 400 ng of plasmid DNA 
was diluted in 60 µl of OPTIMEM (Invitrogen). To this 2.8 µl of 2 µM miR mimic 
was added to the diluted DNA giving a final concentration when added to the 
cells of 10 µM. To the DNA-miR mix, 1.5 µl of Attractene (Qiagen) transfection 
reagent was added then mixed by vortexing. Sample was then incubated for 10-
15 minutes at room temperature before being added drop-wise to the cells. Cells 
were incubated for 24-48 hours prior to analysis. 
Transfections with plasmid alone were performed as described above omitting 
miR. 
2.2.4.3 Generation of stably transfected THP-1 cells 
Prior to transfection, 10 µg of plasmid DNA was linearized using 20 units of AseI 
(NEB) in a 50 µl reaction in CutSmart™ Buffer. Once digested DNA was sterilized 
by ethanol precipitation. The DNA pellet was resuspended in 100 µl of dPBS. 
Next, 1x107 THP-1 cells were spun down at 300 g for 5 minutes, supernatant 
removed and cell pellet resuspended in 700 µl of dPBS before being added to the 
linearized plasmid DNA. The cell/DNA mixture was then added into a 4 mm 
electroporation cuvette (Invitrogen) and placed into Gene Pulser II (Bio-Rad). 
The electroporation cuvette was pulsed using parameters set to 310 V, 950 µF 
and resistance infinite. Cells were then removed into 20 ml of complete RPMI 
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media in a T75 tissue culture flask and incubated overnight. The following day 
G418 (Invitrogen) was added to a concentration of 800 µg/ml. After 1 week cells 
were split 1 in 5 in fresh media containing G418 and allowed to grow undisturbed 
for 2-3 weeks until stably transfected clones appeared. 
2.3 Flow Cytometry 
2.3.1 Extracellular staining protocol 
Before staining, 1x106 cells were resuspended in 1 ml of FACS staining buffer 
and, from this, 100 µl of cells were added per FACS tube (BD). Each experiment 
had tubes for unstained cells, viability staining, individual fluorochrome tubes 
for the compensation setting, isotypes, fluorescence minus one (FMO) tubes that 
had all other antibodies apart from the antibody of interested (instead, isotype 
was added) and final tube with all staining antibodies. For the purity check 
CD14-PE conjugated and associated IgG-PE isotype controls were used (Miltenyi 
Biotech). For the surface IL-6R staining Il-6R-PE conjugated and IgG-PE isotype 
were used (Biolegend). 
After each step cells were washed with 500 µl of FACS buffer followed by 
centrifugation at 300 g for 5 minutes. First, cells were incubated with 10 µl of 
Human Fc block (Miltenyi Biotech) for 20 minutes at room temperature to 
prevent non-specific binding. After second wash, appropriate antibodies and 
isotypes were added in the quantities indicated by the manufacturer’s and cells 
were incubated for 25 minutes at 4°C. Following this, cells were washed with 
500 µl of FACS buffer and resuspended in 300 µl of FACS buffer, if there were to 
be analysed immediately.  
If analysis was to be done the next day, cells were resuspended in 300 µl of 4% 
v/v paraformaldehyde solution (PFA; diluted in dPBS from 16% w/v formaldehyde 
solution, methanol free, Pierce) vortexed and stored in the dark at 4°C until 
required . FACSCalibur™ (BD) or MACS Quant (Miltenyi Biotech) were used for the 
analysis.  
108 
 
2.3.2 Intracellular staining of phosphorylated STAT3 
Intracellular phosphorylated STAT3 staining was performed using mouse anti-
human STAT3 (pY705) antibody from (BD Biosciences). THP-1 cells were stained 
as follows. Prior to staining, BD Cytofix™ buffer was pre-warmed at 37°C for 5-10 
before use. 1x106 of THP-1 cells in a volume of 1 ml were placed in FACS tubes 
(BD Biosciences) and stimulated with IL-6 (Biolegend) at a final concentration 
100 ng/ml for 13 minutes at 37°C before being fixed with 1 ml of BD Cytofix™ 
followed by incubation at 37°C for 10 minutes. Cells were then centrifuged at 
300 g for 5 minutes and supernatant removed. Pellet was then disrupted by 
vortex and cells permeablised by adding BD™Phosphflow Perm Buffer II followed 
by incubation on ice for 30 minutes. Cells were spun at 300 g for 5 minutes, 
supernatant removed and cells washed with BD Pharmingen™ Stain Buffer, this 
step was repeated twice. After the second wash, cell pellet was resuspended in 
100 µl BD Pharmingen™ Stain Buffer. To this 10 µl of mouse anti-STAT3 (pY705) 
was added directly to the cells. Cells were mixed gently and incubated at room 
temperature for 30 minutes. Cells were then pelleted by centrifugation at 300 g 
for 5 minutes, supernatant discarded and finally the pellet was resuspended in 2 
ml of BD Pharmingen™ Stain Buffer. FACS analysis was performed using either 
FACSCalibur™ (BD) or MACS Quant (Miltenyi Biotech). Mouse IgG2a κ-PE was used 
as an isotype control (BD Bioscience).	 
2.3.3 Assessment of transfection efficiency 
For the assessment of transfection efficiency fluorescent Dy547-labeled control 
mimic of scrambled miRs derived from C. elegans (cel-miR-67) was used (Thermo 
Scientific). This compound has absorbance/emission of 557/570 nanometres 
allowing detection on the FACS analyser. In experiments where cells were 
transfected with cells transfected with Dy547-labeled control were also included 
to allow estimation of transfection efficiencies. Cells were collected into a FACS 
tube and washed with FACS buffer, before centrifugation at 400 g for 5 minutes. 
Cells were then resuspended in 300 µl of FACS buffer and analysed by FACS. 
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2.3.4 Assessment of cellular viability  
If cells were to be analysed live then 5 µl of 7AAD viability staining solution 
(Biolegend) was added direct to cells 10 minutes before analysis on the flow 
cytometer.  
If cells were to be fixed and stored overnight in 4% PFA solution, Fixable Viability 
Dye eFluor®506 (eBioscience) was used. The viability staining was performed in a 
separate step, after completing surface staining. For this cells were resuspended 
in 1 ml of FACS buffer and 1 µl of viability dye added per test tube during 
vortexing. Cell where than incubated for 30 minutes at 4°C in the dark, before a 
final wash with FACS buffer and re-suspension in 300 µl of 4% PFA fixing solution. 
2.4 Quantitative Polymerase Chain Reaction (qPCR) 
2.4.1 RNA Isolation from Cells 
Total RNA was purified using Qiagen’s miRNeasy kit, which is specifically 
formulated to retrieve the maximal amount of miRs from cells. Mature miRs in 
particular are purified with lower efficiencies from standard RNA isolation kits 
due to their tight association with the RISC complex. In all cases the protocol 
was used as described in the manufacturer’s instructions. I will therefore discuss 
it only briefly here.  
Cells, either purified CD14+ cells isolated from PB or buffy coats, or THP-1 cells 
were initially spun at 300 g for 3 minutes to remove media. Cells were then 
washed with dPBS, spun again at 300 g for 3 minutes and dPBS removed. The 
cells were lysed by the addition of 700 µl of Qiazol reagent. As a rule of thumb, 
700 µl was used for any cell number up to 3 million cells. Cell lysates were 
vortexed for 30 seconds and allowed to stand at room temp for 5 minutes. At 
this stage 140 µl of chloroform was added to each sample and shaken vigorously 
by hand. Samples were then spun at 12,000 g for 15 minutes at 4°C. After 
centrifugation the upper (clear) aqueous phase was carefully removed and 
transferred in to a new 1.5 ml tube followed by 525 µl of 100 % ethanol. The 
samples were mixed by inversion before being pipetted into individual RNeasy 
spin columns. Columns were spun at 8,000 g for 15 seconds at room temperature 
and the flow through discarded. The RNA at this stage is bound to the column. 
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Columns were then washed with 700 µl of RWT buffer and spun at 8,000 g for 15 
seconds. Flow-through from columns were discarded as before. The next stage of 
the protocol involves the columns being washed with 500 µl of RPE buffer, spun 
at 8,000 g for 1 minute and the flow-through discarded, this step was repeated 
twice. The samples were then spun for 1 minute at 8,000 g to dry the columns. 
In the final elution step, the columns were transferred into fresh RNAse-free 1.5 
ml micro-centrifuge tubes and 30-50 µl of nuclease free water added carefully to 
the bottom of each column. Columns were allowed to stand at room 
temperature for 1 minute before being centrifuged at 8,000 g for 1 minute. 
Finally, the column was discarded and the RNA samples placed on ice for 
immediate use or stored at -20°C or -80°C for short or long-term storage 
respectively.  
Note DNAse digests were not generally performed on samples as all qPCR assays 
were designed to span or overlap exon-intron junctions meaning that they were 
specific for cDNA. 
2.4.2 Measuring Nucleic Acid Concentration 
The quantity and quality of RNA or DNA samples were determined using a 
Nanodrop ND-1000 spectrophotometer (ThermoScientific). Depending on the 
type of nucleic acid being quantified the Nanodrop was set to measure DNA or 
RNA. The sample was blanked against nuclease free water prior to 
measurements. Two microliters of sample was typically measured. The Nanodrop 
returns readings of nucleic acid concentration (ng/ml) along with 260/280 and 
230/260 ratios. A 260/280 reading of ~1.8 and ~2.0 are expected from pure DNA 
and RNA samples respectively. The 230/260 measurement gives a secondary 
indication of sample purity, ideal readings should be ~2.0, values significantly 
lower than this generally indicate contamination with carbohydrates or phenols.  
2.4.3 SYBR Green Protocol 
SYBR green qPCR was used to detect both mRNA and miR expression levels.  
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2.4.3.1 cDNA Synthesis from mRNA 
Depending on the nature of the target RNA to be quantified different cDNA kits 
were used.  
Where only target mRNA levels were to be quantified I used the High Capacity 
cDNA kit (Applied BioSystems). cDNA reactions were performed according to 
manufacturer’s instructions and will be described only in brief here. 
Initially nanodrop quantified RNA samples were normalised to a concentration of 
10 ng/µl. A 2x cDNA reaction master-mix was prepared in thin-walled 200 µl PCR 
tubes (Starlab) as shown in Table 2.3. To this 10 µl (100 ng) of RNA was added 
and samples incubated in a thermocycler using the cycling conditions shown in 
Table 2.4. Prior to use samples were diluted 1 in 10 in nuclease-free water. For 
short-term storage, 1 or 2 days, samples were stored at 4°C or at -20°C for 
longer-term storage. 
Component Volume per reaction (µl) 
10xRT Buffer 2.0 
dNTP (100mM) 0.8 
10XRT Random Primers 2.0 
MultiScribe™ Reverse Transcriptase 1.0 
RNase Inhibitor 1.0 
Nuclease-free water 3.2 
Total per reaction 10.0 
Table 2.3 High Capacity 2x master mix. 
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Settings Step 1 Step 2 Step 3 Step 4 
Temp 25°C 37°C 85°C 4°C 
Time 10 minutes 120 minutes 5 minutes ∞ 
Table 2.4 Cycling parameters High Capacity cDNA synthesis 
 
2.4.3.2 cDNA synthesis miRNA & mRNA 
In instances where miRNA or miRNA and mRNA levels were required to be 
quantified Qiagen’s miScript II Reverse Transcription kit was used. This kit 
offered two options depending on whether miR only or both miRNA and mRNA 
were to be measured. The miRNA-only protocol used the HiSpec buffer, while 
the HiFlex buffer was used for miRNA and mRNA quantification. In either 
instance the manufacturer’s instructions were followed. Briefly, RNA samples 
were normalised to concentrations of 10 ng/ml. A 2x cDNA reaction master-mix 
was prepared in thin-walled 200 µl PCR tubes (Starlab), as shown in Table 2.5 
below. To this 10 µl (100 ng) of RNA was added and samples incubated in a 
thermocycler using the cycling conditions shown in Table 2.6. Prior to use 
samples were diluted 1 in 10 in nuclease-free water. For short-term storage, 1 or 
2 days, samples were stored at 4°C, for longer term at -20°C. 
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Component Volume per reaction (µl) 
5xHiFlex or HiSpec Buffer 4.0 
10x Nucleics mix 2.0 
Nuclease free water 2.0 
Reverse Transcriptase 2.0 
RNA 10.0 
Total per reaction  20.0 
Table 2.5 miScript II RT reaction. 
 
Settings Step 1 Step 2 Step 3 
Temp 37°C 95°C 4°C 
Time 60 minutes 5 minutes ∞ 
Table 2.6 Cycling parameters miScript II cDNA synthesis 
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2.4.3.3 SYBR green PCR mRNA detection 
SYBR green PCR were performed using SYBR® Select master-mix (Applied 
Biosystems). Reactions were set up according to manufacturer’s instructions, 
outlined in Table 2.7. 
Component Volume per reaction (µl) 
SYBR® Select master-mix 5.0 
Forward and Reverse Primers  
(5nM each primer) 
1.0 
cDNA template 1.0 
Nuclease free water 3.0 
Total per reaction  10.0 
Table 2.7 Components per well SYBR® Select reaction. 
 
Reactions were plated in triplicate into either 96 or 384-well plate formats 
depending on the size of the experiment. Plates were sealed with a MicroAmp 
optical adhesive cover (Applied Biosystems). A no template control was included 
for each primer set used. Plates were centrifuged for 300 g for 1 minute before 
being placed in a StepOnePlus™ Real-Time PCR System, for 96-well plate or a 
QuantStudio™ 12K Flex Real-Time PCR System for a 384-well plate format. 
Cycling parameters used are shown in Table 2.8. A melt curve was performed 
after each run to confirm the presence of a single amplified product. QPCR 
primers used in this thesis are listed in Table 2.11. 
  
115 
 
Step Temperature Duration Cycles 
UDG* Activation 50°C 2 minutes 1X 
AmpliTaq Fast 
DNA polymerase, 
UP activation 
95°C 2 minutes  
1X 
Denature 95°C 1 seconds  
40X Anneal/Extend 60°C 30 seconds 
Table 2.8 Fast cycling parameters for SYBR® select qPCR  
* Uracil DNA Glycosylase  
2.4.3.4 SYBR green PCR for microRNA quantification 
SYBR green PCR for miRs were performed using miScript SYBR Green PCR kit 
(Qiagen). Reactions were set up according to manufacturer’s instructions, 
outlined in Table 2.9. 
Component Volume per reaction (µl) 
QuantiTect SYBR Green master mix 5.0 
10x miScript Universal Primer 1.0 
10x miScript miR-specific primer 1.0 
Template* 1.0 
Nuclease free water 2.0 
Total per reaction  10.0 
Table 2.9 Components per well QuantiTect SYBR® reaction 
* cDNA prepared using miScript II Reverse Transcription kit (Qiagen). 
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Reactions were plated in triplicate into either 96 or 384-well plate format 
depending on the size of the experiment. Plates were sealed with a MicroAmp 
optical adhesive cover (Applied Biosystems). No template controls were included 
for each primer set used. Plates were centrifuged for 300 g for 1 minute before 
being placed in a StepOnePlus™ Real-Time PCR System, for 96-well plate or a 
QuantStudio™ 12K Flex Real-Time PCR System for a 384-well plate format. 
Cycling parameters used are shown in Table 2.10. Primer assays for hsa-miR-23a, 
hsa-miR-24, hsa-miR-27a, hsa-miR-23b, hsa-miR-27b and RNU6 were purchased 
from Qiagen. 
Step Temperature Duration Cycles 
Taq Polymerase 
activation 
95°C 2 minutes 1X 
Denature 95°C 15 seconds  
40X Annealing 55°C 30 seconds 
Extension 70°C 30 seconds 
Table 2.10 Cycling conditions for miScript SYBR green PCR. 
 
2.4.4 Analysis of PCR Results 
For each target gene a relevant and unchanging housekeeping gene was 
included, GAPDH or 18S for mRNA or RNU6 for miRs. The Cycle Threshold (Ct) 
values of each well were exported in to an EXCEL spreadsheet (Microsoft) for 
analysis as described in the next two sections. 
2.4.4.1 2-ΔCt quantification 
The expression of target genes was expressed as 2-ΔCT. This involved the 
subtraction of the Ct value of the housekeeping gene from the Ct value of the 
target gene producing a ΔCt value for each sample. The final value was then 
expressed as 2-ΔCT. 
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2.4.4.2  2-ΔΔCT Quantification- Fold change Relative Quantification 
Relative Quantification (RQ) represents gene expression values as fold change 
relative to control samples. Initially the Ct value of housekeeping gene was 
subtracted from target gene generating ΔCt value for each sample. The ΔCt 
value of the control sample was then subtracted from the experimental sample 
giving the samples ΔΔCt value. The final value was then expressed as 2-ΔΔCt , the 
resulting value indicating the fold change of experimental sample relative to 
control. 
2.4.4.3 Absolute quantification 
Standard curves of known target template copy numbers were generated by 
dilution of plasmid DNA containing the amplicon of the qPCR primers. A top 
standard of 107 copies was diluted 1 in 10 to 100 copies. Standards were 
generated for both target and housekeeping genes. Standards were run on qPCR 
machine to generate Ct values. The standard curve was created by plotting 
log10(copy number) versus Ct value. Copy numbers of experimental samples were 
interpolated from the standard curve. Values then presented as copies of target 
per 10,000 copies of GAPDH or per 106 copies of 18S.  
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2.4.4.4 QPCR primers 
Primer name Sequence 
sIL-6R Fw TCTCCACAAGCGCCTTCG 
sIL-6R Rev CTCAGGGCTGAGATGCCG 
mIL-6R Fw TGCAATAACCACCCCTGACC 
mIL-6R Rev GTGCCCATGCTACATTTGCC 
Total IL-6R Fw AGGGAGACAGCTCTTTCTACATA 
Total IL-6R Rev AGGCTGCAAGATTCCACAA 
GAPDH Fw GAAGGACTCATGACCACAGT 
GAPDH Fw GTAGAGGCAGGGATGATGTT 
Pri-miR-23a Fw CGTGTTCACAGTGGCTAAGT 
Pri-miR-23a Rev AACTGTGTTTCAGCTCAGTAGG 
MTHFR Fw CTTCATGTTCTGGAAGGACGAG 
MTHFR Rev GTCGTGGATGTACTGGATGATG 
DHFR Fw AATCACCCAGGCCATCTTAAAC 
DHFR Rev ACACCTGGGTATTCTGGCA 
Table 2.11 List of QPCR primers 
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2.5 Molecular Cloning 
2.5.1  Creation of Luciferase reporter plasmids 
To validate the interaction between miR and its target mRNAs, I created a 
luciferase reporter plasmid in which regions containing putative miR-binding site 
were cloned downstream of luciferase open reading frame (ORF) in the 
pGLOMS2BD vector (gift of Dr Derek Gilchrist) Figure 2.1. Regions of interest 
were amplified by PCR using proof reading polymerase Pfu (Stratagene). A 
typical reaction is shown in Table 2.12. Genomic DNA isolated from HEK293 cells 
was used as template. Primers for the amplification of putative miR-23a cluster 
binding sites were designed using Integrated DNA Technologies (IDT) online 
PrimerQuest program (https://eu.idtdna.com/site). Primer melting temperature 
design parameter were set at 60°C.  
Regions to be amplified were screened for presence of PmeI and XhoI sites; if 
none were present these restriction enzymes (RE) were used for sub-cloning into 
pGLOMS2BD vector (Figure 2.1 A). If not, alternative compatible restriction 
enzymes were selected. Once their presence had been excluded, PmeI site 
(GTTTAAAC) would be added onto the 5'end of the Fw primer and XhoI site 
(CTCGAG) onto the 5' end of Rev primers. Primers were manufactured by IDT. A 
list of the primers used in this work can be found in Table 2.17. Once amplified, 
PCR reactions were run on a 0.8 % (w/v) agarose TAE gel. Bands of the correct 
size were excised from the gel and DNA fragments purified using Qiagen’s 
QIAquick gel extraction kit (See section 2.5.6.4). 
  
120 
 
Component Volume per Reaction (µl) 
10X PfuUltra II buffer 5.0 
dNTP mix (25 mM) 0.5 
Genomic DNA template  1.0 
Fw Primer (10 µM) 1.0 
Rev Primer (10 µM) 1.0 
PfuUltra II fusion HS DNA polymerase 1.0 
Nuclease free water 40.5 
Total Reaction Volume 50.0 
Table 2.12 Components of PfuUltra PCR reaction. 
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Step Temperature Duration Cycles 
Denaturation of 
genomic DNA 
template 
95°C 2 minutes  
1X 
Denature 95°C 20 seconds  
30X Annealing 55°C 20 seconds 
Extension 72°C 15 seconds per 
kilobase 
Final extension 72°C 3 minutes 1X 
Table 2.13 PCR cycling parameters for the amplification of putative MBS from genomic DNA. 
 
As target regions had been amplified using the proof-reading polymerase Pfu, 
they did not contain terminal 3' adenosine overhangs that are required for the 
subsequent TOPO cloning into pCR2.1 TOPO (Invitrogen). To overcome this, 
purified PCR products were incubated with Taq DNA polymerase that adds 3' A 
overhang onto the template DNA. A typical ‘A-tailing’ reaction is shown in Table 
2.14. Reactions were prepared in 200 µl thin walled PCR tubes (Starlab) and 
incubated in a thermocycler for 30 minutes at 72°C. After treatment with Taq 
polymerase, samples were directly cloned using the TOPO TA Cloning® kit into 
pCR2.1 TOPO, described in section 2.5.6.4. 
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Component Volume per Reaction (µl) 
10x Taq DNA polymerase buffer 2.5 
dATP (25 mM) 0.5 
Purified PCR product  20.0 
Taq DNA polymerase (5 units/ µl) 1.0 
Nuclease free water 1.0 
Total Reaction Volume 25.0 
Table 2.14 Components of A tailing reaction.  
Samples incubated at 72°C for 30 minutes. 
 
Plasmids containing the correct insert were identified by RE digest. The cloning 
site of pCR2.1 TOPO vector is flanked by EcoRI sites, which was used to identify 
the presence of inserts of the correct size. A typical restriction digest is shown 
in Table 2.15. Once confirmed, plasmid DNAs were digested with PmeI and XhoI 
along with pGLOMS2BD which was digested with PmeI and SalI (SalI and XhoI 
generate compatible ends). After RE digestion, 5 µl of STOP dye was added to 
each sample before being run on a 0.8 % TAE agarose gel alongside a 1 Kb(+) DNA 
ladder (Invitrogen). Bands corresponding to the insert and cut pGLOMS2BD DNAs 
were excised from the gel and subsequently purified using QIAquick gel 
purification kit (Qiagen) described in section 2.5.6.4. 
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Component  Volume per reaction (µl) 
10X CutSmart™ Buffer 2.0 
Plasmid DNA (500ng) Variable 
Nuclease free water Variable 
Restriction Enzyme (New England 
BioLabs) (10 units/µl) 
0.5 
Total per reaction  20.0 
Table 2.15 Standard restriction enzyme digest reaction. 
HF enzymes from New England BioLabs were used in these experiments. Reactions were 
incubated at 37°C for 1 hour. 
  
Purified insert and pGLOMS2BD DNAs were then ligated together using T4 DNA 
ligase (NEB). A typical ligation reaction is shown in Table 2.16. Ligations were 
incubated at room temperature for 10 minutes before being transformed into 
competent DH5α as described in section 2.5.5. Plasmid DNA was isolated from 
the resulting clones as described in section 2.5.6.1. The correct identity of the 
plasmids was confirmed by RE digest with BamHI (NEB). Example DNA fragment 
patterns of pGLOMS2BD and pGLOMS2BD-IL10 are shown in Figure 2.1. Plasmids 
were then sequenced using the sequencing service provided by Source 
Bioscience. A forward sequencing primer located at the 3' end of the luciferase 
ORF, called GLOseq was used (see Table 2.23 for primer sequence). Cultures 
containing the correct plasmids were next used to inoculate 100 ml of LP broth 
containing 50 µg/ml ampicillin and grown overnight at 37°C with shaking (200 
rpm). Plasmid DNA was then purified from the resulting cultures using the 
method described in section 2.5.6.2. 
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Component  Volume per reaction (µl) 
10X T4 DNA ligase Buffer 2.0 
 Vector (100ng) Variable 
Insert (3x molar excess of vector) Variable 
T4 DNA ligase (NEB) (20 units/µl) 1.0 
Nuclease free water  Variable 
Total per reaction  20.0 
Table 2.16 Standard T4 DNA ligase reaction.  
Reactions were incubated at room temp for 10 minutes before being transformed in E. coli.  
Primer name Sequence 
IL-6R 3'UTR (1) Fw AGATATCAAGCATGCATCCGCCGTACTCTTT 
IL-6R 3'UTR (1) Rev AGTCGACACAGGGTCTCACTTGCTCTGTCA 
IL-6R 3'UTR (2) FW AGTTTAAACTAATCCTAGCACTTTGGGAGGCCA 
IL-6R 3'UTR (2) Rev AGTCGACCAGCCTTTGGTATTTGCTTTCAGG 
IL-6ST 3'UTR Fw AGTTTAAACGCTACATGCCTCAGTGAAGGACTA 
IL-6ST 3'UTR Rev AGTCGACACTGTCCCTAAGCCACTCTGATGA 
ERAP1 3'UTR Fw AGTTTAAACCTTGCCAGGTTCCTGTTATCT 
ERAP1 3'UTR Rev AGTCGACCCAACACTTGGGTTTACGTTG 
Table 2.17 List of luciferase assay primers  
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Figure 2.1 Plasmid map of pGLOMS2BD and representative screening RE digests of 
pGLOMS2BD-3’UTR clones. 
(A) Luc2 the luciferase gene driven by the Phospho-glycerate kinase (PGK) promoter, a multiple 
cloning site containing unique PmeI, SacI and SalI sites is positioned immediately downstream of 
the luc2 ORF and terminated by SV40 late poly(A) signal. Plasmid contains a humanised Renilla-
neo fusion (hRluc-neo) gene driven by the SV40 early enhancer/promoter terminated by synthetic 
poly(A) signal. Bacterial resistance gene conferring Ampr encodes Beta lactamase. (B) Virtual 
digest produced using the SerialCloner program. Original pGLOMS2BD is shown for comparison. 
 
pGLOMS2BD 
(7735 bp) 
 
4xMS2BD 
      
PmeI-SacI-SalI 
A 
B 
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2.5.2 Generation of miR-23a~miR-24~miR-27a sponge expression 
constructs. 
In this section I will describe the methods used to design and create miR-sponge 
expression constructs. miR-sponges specific for each member of the miR-23a 
cluster individually and in all combinations were created, see Figure 5.7. miR-
sponges are essentially concatomers of near perfect MBS for the miRs they are 
designed against. To decrease Slicer activity associated with highly 
complementary miR/MBS interactions that results in the rapid degradation of 
target mRNAs, a 3 bp mismatch was introduced into the MBS corresponding to 
position 8 in the miR. This was intended to cause the sponge transcript and with 
it its Ago2 complexed miRs to be sequestered rather than degraded [618]. Here I 
developed a novel strategy to create miR-sponges taking advantage of recent 
availability of bespoke gene synthesis. One of the main limitations of this type of 
gene synthesis is that it cannot include significant regions of repetitive 
sequence. This obstacle was over come by introducing different sequences in the 
bulge regions of the sponge MBS and in the sequences linking the MBS. Using this 
approach I was able to design a single sequence that contained 5 MBS for each 
member of the miR-23a cluster that was capable of being synthesised by IDT. 
Sponge sequence is shown Table 2.18. 
miR23-24-27 sponge sequence 
AGTTTAAACCTCGAGCCCGGGTAATCCGACCAATGTGATAATGGTAATCCGCTCAATGTGA
TGCAGGTAATCCTCACAAT 
GTGATTATGGTAATCCAACCAATGTGATTTGGGTAATCCAGTCAATGTGATAGTACTGTTC
CTGCCTGACTGAGCCAAAT 
CTGTTCCTGCAACACTGAGCCAGCACTGTTCCTGCGACACTGAGCCATATCTGTTCCTGCG
CTACTGAGCCATTGCTGTT 
CCTGCAACACTGAGCCAGCTGCGGAACTCGACACTGTGAAATTGCGGAACTGCTCACTGTG
AAGGCGCGGAACTACGCAC 
TGTGAAGGCGCGGAACTGTCCACTGTGAATATGCGGAACTGGTCACTGTGAAGATATCGtc 
Table 2.18 Multiple sponge sequence. 
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The resulting plasmid called pIDT23~24~27 sponge is shown in Figure 2.2. Each of 
the different sponge units is separated with sites for different blunt cutting 
enzymes- SmaI, ScaI, PvuII and EcoRV, this allowed for all combinations of the 
sponge to be generated from a single construct by restriction digest followed by 
re-ligation. For example, miR-23 sponge was made by digesting pIDT23~24~27 
sponge with ScaI/EcoRV. Digested vector was run an 0.8% agarose TAE gel and 
the band corresponding to the vector excised, gel purified and re-ligated in a T4 
DNA ligation reaction. The same approach was used to generate the other 6 
sponge combinations. The combinations of RE used to generate sponge 
combinations is shown in Table 2.19. 
Next, the number of MBS per sponge was doubled by digesting the sponge 
constructs produced in the previous step (e.g. pIDT23) with XhoI and XhoI+SalI. 
The XhoI linearized vector and the XhoI/SalI released insert containing the 
sponge sequence were excised and gel purified.  The XhoI cut vector was treated 
with Calf Intestinal Phosphatase (NEB) to remove phosphate from the 5' end. 
This prevented the re-ligation of the vector. The sponge fragment released in 
the XhoI+SalI digest was then ligated into the XhoI site, doubling the size of 
sponge (10x MBS). As inserts were not cloned directionally, plasmids were 
sequenced to confirm orientation.  
Finally, the sponge sequences were cloned into the mammalian expression 
construct pGLOMS2BD (shown in Figure 2.1). This was achieved by digesting the 
doubled sponge constructs with PmeI and NotI, the released insert was then 
cloned into the same sites in pGLOMS2BD creating final constructs. 
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 Figure 2.2 Schematic showing sponge cloning strategy 
 
 
Sponge plasmid Parental Plasmid Enzyme Combination 
pIDT23 pIDT23~24~27 sponge ScaI+EcoRV 
pIDT24 pIDT24+27 PvuII+EcoRV 
pIDT27 pIDT23~24~27 sponge PvuII+SmaI 
pIDT23+24 pIDT23~24~27 sponge PvuII+EcoRV 
pIDT23+27 pIDT23~24~27 sponge ScaI+PvuII 
pIDT24+27 pIDT23~24~27 sponge SmaI+ScaI 
pIDT23+24+27 pIDT23~24~27 sponge NA 
Table 2.19 Restriction digest used in the generation of sponge combinations 
  
Kan R 
PmeI/XhoI/SmaI* ScaI* PvuII* EcoRV*/SalI/NotI 
 
pIDT23~24~27 sponge 
              (2395bp) 
 
miR23 binding site 
miR24 binding site 
miR24 binding site 
* blunt cutting RE 
ScaI+EcoRV 
pIDT23 
(2160bp) 
ScaI and PvuII 
re-ligation 
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2.5.2.1 Creation of pEF6-sponge constructs. 
The human Phospho Glycerate Kinase promoter in the pGLOMS2BD sponge 
vectors was replaced by the Elongation factor 1 alpha promoter (EF1α). This was 
achieved by synthesising a G-block encoding the EF1α promoter containing 20 bp 
homology arms at the 5' and 3' ends corresponding to the sequences 5' to the 
MluI site and 3' to the SmaI site of pGLOMS2BD. The G-block was then inserted 
into pGLOMS2BD digested with MluI and SmaI using Gibson assembly (see section 
2.5.4) creating pEF6-Luc. The various sponge inserts were then cloned into the 
PmeI and NotI sites of this vector producing the final pEF6-Sponge vectors.  
2.5.3 TOPO cloning of PCR products. 
Taq DNA polymerase amplified or treated PCR products were cloned directly in 
pCR2.1 TOPO using the TOPO TA Cloning® kit (Invitrogen). Four microlitres of 
PCR reactions were added directly into a TOPO cloning reaction, along with 1 µl 
of salt solution and 1 µl of pCR2.1 TOPO. The reaction was incubated for 10 
minutes at room temperature then 2 µl removed and transformed into 
chemically competent One Shot
® 
TOP10 E. coli that were provided with the kit. 
A detailed transformation protocol can be found in Section 2.5.5. 
2.5.4 Gibson Assembly® Method 
During the course of my PhD the availability of G-blocks and the development of 
the Gibson Assembly cloning meant that the generation of luciferase reporter 
constructs could be streamlined. Instead of using the PCR and conventional sub-
cloning methods described in section 2.5.1 to produce these constructs, I could 
using G-blocks and Gibson Assembly to generate luciferase reporter constructs 
along with constructs in which MBS were mutated in a single cloning step.  
Regions containing putative miR-23a cluster binding sites within genes of 
interest were identified using one of the miR target prediction programs 
described in section 2.9. Sequences containing these regions were copied from 
ENSEMBL genome browser (http://www.ensembl.org/index.html) and pasted 
into SerialCloner where the 20 bp homology arms specific for the insertion into 
the PmeI/SalI sites of pGLOMS2BD were added (see Table 2.20). 
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Generally sequences of approximately 450 bp were used with the target MBS 
positioned close to the middle. This could be extended to 700 bp if the inclusion 
of nearby MBS was required. Once designed the G-blocks were ordered from 
Intergrated DNA technologies. pGLOMS2BD was digested with PmeI/SalI, 
separated by gel electrophoresis and purified using QIAquick gel purification kit 
(Qiagen). The resulting gel fragment was used in a Gibson Assembly reaction 
along with the previously designed G-block, see Table 2.21. Samples were 
prepared in 200 µl thin walled PCR tubes (Starlab) and incubated at 50°C for 60 
minutes. The reactions where then transformed into MAX Efficiency® DH5α™ 
(Invitrogen) as described in section 2.5.5. Table 2.22 shows the sequences of G-
block used in this thesis. 
 
5' Homology arm 3'UTR Sequence 3' Homology arm 
GTCTGCAGAGATCTGTTT <Target sequence> GTCTAGAGTCGACCTGCAG 
Table 2.20 Luciferase reporter G-block template. 
 
 
Component  Volume per reaction (µl) 
2X Gibson Assembly master mix (NEB) 10.0 
 Vector (100ng) Variable 
G-block (3x molar excess of vector) Variable 
Nuclease free water  Variable 
Total per reaction  20.0 
Table 2.21 Standard Gibson Assembly reaction 
  
131 
 
 
Table 2.22 List of G-blocks sequences 
 
2.5.5 Transformation 
Transformation of bacterial cells, in this case E. coli, refers to the introduction 
of DNA, most often in the form of a plasmid containing a bacterial origin of 
replication and a gene conferring antibiotic resistance to the bacteria that have 
taken up the foreign DNA. This is most commonly achieved using either 
chemically competent or electro-competent E. coli. In my studies I used only 
chemically competent E. coli. Chemically competent E. coli are made by 
incubating bacteria until the mid log phase of their growth in culture. At this 
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point cells are pelleted then incubated on ice in the presence of various salts, 
classically calcium chloride.  This process renders the cells permeable to DNA.  
The type of E. coli used in transformation depended on the source of the 
plasmid DNA being used. Plasmids generated from TOPO cloning were 
transformed into highly competent One Shot
® 
TOP10 E. coli provided with the 
kit (Invitrogen). Plasmids generated using Gibson Assembly or site-directed 
mutagenesis were transformed into MAX Efficiency® DH5α™ (Invitrogen). Finally, 
plasmids generated by conventional sub-cloning methods, using T4 DNA ligase 
were transformed into Sub-cloning Efficiency™ DH5α™ (Invitrogen). The 
transformation method used in each case was the same and outlined below. 
1. Competent E. coli were thawed on ice. 
2. Two microlitres of plasmid DNA was added to 50 µl of competent cells in a 
sterile 1.5 micro-centrifuge tube, gently mixed by flicking and incubated on ice 
for 30 minutes. 
3. Cells were then ‘heat shocked’ at 42°C in a water bath for 30 seconds before 
being returned to ice for 2-3 minutes. 
4.  Competent cells were then transferred to 15 ml falcon tube along with 300 µl 
of SOC media and incubated at 37°C with shaking (200 rpm) for 45 minutes. This 
gives the transformed bacteria time to express the plasmid’s antibiotic 
resistance gene. 
6. Finally, 100 µl of bacterial culture was spread onto LB agar plates containing 
50 µg/ml ampicillin and incubated overnight at 37°C.  
The following day, 2 or 3 colonies were picked and used to inoculate 5 ml of LB 
broth containing 50 µg/ml ampicillin and grown overnight at 37°C with shaking 
(200 rpm). The next morning bacterial cultures where E. coli had grown were 
visibly turbid. These cultures were selected for plasmid purification, described 
in detail in section 2.5.8. 
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2.5.6 DNA Extraction 
2.5.6.1 Small scale plasmid purification from bacterial cultures 
Plasmid DNA was isolated from small (5 ml) bacterial cultures using QIAprep Spin 
Miniprep Kit (Qiagen) kit according to manufacturer’s instructions. Briefly, 1.5 
ml of overnight culture was transferred in to 1.5 ml micro-centrifuge tube and 
spun at 17,900 g for 3 minutes. The supernatant was discarded and the pellet 
resuspended in 250 µl of Buffer P1, supplemented with RNAse A (100 µg/ml final 
concentration). Next, 250 µl of P2 was added followed by mixing by inversion. At 
this stage the bacterial solution becomes clear and viscous as the bacteria are 
lysed. This is followed by the addition of 350 µl of buffer N3 followed by mixing 
by inversion. This serves to neutralise buffer P2, causing the precipitation of the 
proteins and genomic DNA that are bound by the SDS in buffer P2. The samples 
are then clarified by centrifugation at 17,900 g for 10 minutes. The supernatant 
was then added to the Qiaprep spin column and spun for 15 seconds at 17,900 g. 
The flow through was discarded and 500 µl of PB buffer added to the column. 
The columns were spun at 17,900 g for 15 seconds and the flow through 
discarded. The columns were washed with 750 µl PE buffer and spun at 17,900 g 
for 15 seconds. The columns were then spun for 2 minutes at 17,900 g to remove 
any residual wash buffer. Finally, the columns were transferred to a fresh 1.5ml 
micro-centrifuge tube and 50 µl of nuclease free water added. Columns were 
allowed to stand for 1 minute before being centrifuged at 17,900 g for 1 minute. 
The plasmid DNA eluted from the column was collected in the tube. Plasmid DNA 
was stored at 4°C until required. 
2.5.6.2 Large-scale plasmid purification from bacterial cultures 
For purification of plasmid DNA from larger bacterial cultures Qiagen’s Plasmid 
Maxi kit was used. For plasmid DNAs that were intended for transfection into 
mammalian cells Qiagen’s Endofree Plasmid Maxi kit was used. Both kits involved 
essentially the same steps apart from an endotoxin removal step that will be 
discussed below. In both cases, the purifications were performed according to 
the manufacturer’s instructions.  
Briefly, 100 ml overnight cultures were spun in two 50 ml falcon tubes at 3,000 
rpm for 30 minutes. The supernatants were discarded and the pellets 
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resuspended in a single volume of 10 ml. Next, 10 ml of buffer P2 was added to 
the resuspended sample and mixed thoroughly by inversion. Samples were 
allowed to stand at room temperature for 5 minutes. Samples were then 
neutralised by the addition of cold buffer P3, mixed by inversion and allowed to 
sit on ice for 5 minutes. Samples were then centrifuged at 5,000 rpm for 30 
minutes at 4°C.  
For endotoxin free preparations, supernatants were carefully removed into a 
fresh 50 ml falcon tube and 2.5 ml of ER (endotoxin removal) buffer added. 
Samples were mixed by inversion and placed on ice for 30 minutes. During this 
time maxi-prep columns were equilibrated by the addition of 10 ml of QBT 
buffer. This was allowed to pass through the column under gravity.  
At this stage both non-endofree and endofree samples were poured into 
equilibrated columns and allowed to drain by gravity. After the sample has 
passed through the column, 30 ml of QC buffer was added and allowed to flow 
through, this was repeated twice. The plasmid DNA was eluted from the column 
into a fresh 50 ml falcon tube, by the addition of 15 ml of QF buffer. The eluted 
plasmid DNA was then precipitated by the addition of 10 ml of 100% isopropanol. 
The samples were carefully mixed before being centrifuged at 5,000 rpm for 30 
minutes at 4°C. The supernatants were carefully poured off and pellet washed 
with 5 ml of 70% ethanol followed by centrifugation at 5,000 rpm for 10 minutes 
at room temperature. The supernatant was carefully poured off and the visible 
DNA pellet allowed to air dry for 5 minutes. Finally the DNA was dissolved in 500 
µl of TE buffer. Plasmid DNAs were stored at 4°C until required. 
2.5.6.3 Genomic DNA isolation 
Genomic DNA was isolated from mammalian cells using the Cell Lysis solution 
from the GeneArt Genomic cleavage detection kit (Invitrogen) according to 
manufacturer’s instructions. Typically, genomic DNA was prepared from 5x105 
cells. Cells were spun at 300 g for 3 minutes and culture media discarded. The 
cell pellet was resuspended in 50 µl of Cell Lysis buffer supplemented with 2 µl 
of Protein Degrader and sample transferred to 200 µl thin walled PCR tube.  
Samples were incubated at 68°C for 15 minutes, followed by 95°C for 10 min. At 
this stage samples could be used directly in PCR reactions or stored at -20°C. 
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2.5.6.4 DNA isolation from Agarose Gels 
DNA was purified from gel slices excised from agarose TAE gels using the 
QIAquick Gel purification kit (Qiagen) according to manufacturer’s instructions. 
Briefly, DNA containing gel slices were incubated with 450 µl of QG buffer, at 
55°C for 10 minutes with mixing every 2 minutes. This served to dissolve the 
agarose gel, liberating the DNA. To this, 150 µl of isopropanol was added and 
mixed by vortex. The sample was then pipetted into the QIAquick spin column 
and spun at 17,900 g for 15 seconds. The flow through was discarded and 750 µl 
of PE wash buffer added to the column followed by centrifugation at 17,900 g 
for 15 seconds. The flow through was discarded and the column spun again at 
17,900 g for 2 minutes to dry the column’s filter. The column was then placed 
into a fresh tube and 50 µl of nuclease free water added. Samples were allowed 
to stand at room temperature for 1 minute before being centrifuged at 17,900 g 
for 1 minute. The purified DNA sample was collected in the flow through in the 
tube and the column discarded.  
2.5.7 Agarose Gel Electrophoresis 
DNA samples were separated according to their size by agarose gel 
electrophoresis. The concentration of agarose used varied according to the size 
of the fragments that were run.  Typically for fragments from 500 bp to 8,000 bp 
a 0.8% (w/v) agarose gel was used. Gels were made by weighing the required 
amount of agarose into a Pyrex conical flask. To this 100 ml of 1xTAE buffer was 
added and the sample heated in the microwave until the agarose had completely 
dissolved. The agarose-TAE mixture was allowed to cool for 1-2 minutes. Next, 
10 µl of ethidium bromide (10 mg/ml, Sigma) was added and the agarose poured 
into the casting tray of the Sub-Cell GT electrophoresis gel apparatus (Bio-Rad). 
The gel was allowed to set at room temperature for 15-30 minutes. In the 
meantime samples were prepared for loading by the addition of 5X STOP dye 
solution. Once set the agarose gel was placed into the gel tank and submerged in 
1xTAE running buffer. Samples were then pipetted into wells alongside 1 Kb(+) 
DNA ladder (Invitrogen) and run at 100V for approximately 30 minutes. The DNA 
bands in the gel were then visualized in UV trans-illuminator (Gel Logic 200).  
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2.5.8 Sequencing of Plasmids 
Plasmids were sequenced by SourceBioscience using primers listed in Table 2.23. 
Primer Name Sequence 
GLOseq GAGAAGGAGATCGTGGACTATG 
M13 Fw GTAAAACGACGGCCAG  
M13 Rev CAGGAAACAGCTATGAC  
Table 2.23 List of Sequencing Primers 
 
2.5.9 Site directed mutagenesis  
Site-directed mutagenesis was used to mutate the seed regions of putative miR 
target sequences cloned into luciferase reporter constructs using the QuikChange 
Lightning Site-Directed Mutagenesis kit (Agilent Technologies) according to 
manufacturer’s instructions. In brief, the sequence to be mutated was pasted 
into the online QuikChange Primer design program 
(www.agilent.com/genomics/qcpd). This program allows the user to make 
desired changes in the sequences. The program then generates two 
complimentary sequences corresponding to the desired mutations. These are 
generally between 25 and 45 bases in length and have melting temperature of 
≥78°C. Oligonucleotides were synthesised and HPLC purified by IDT. These 
primers were then used to amplify the template plasmid. A standard reaction is 
shown in Table 2.24. Reactions were prepared in 200 µl thin walled PCR tubes 
(Starlab) then incubated in thermocycler using the cycling parameters outlined 
in Table 2.25. Once finished, 2 µl of DpnI enzyme was added to the reaction, 
mixed gently and incubated at 37°C for 5 minutes. Two microlitres of reaction 
was transformed into MAX Efficiency® DH5α™ (Invitrogen) as described in section 
2.5.5. In all cases, mutations were confirmed by sequencing. Site-directed 
mutagenesis primers used in this thesis are shown in Table 2.26. 
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Component Volume per Reaction (µl) 
10x QuikChange buffer 5.0 
dNTP (25 mM) 1.0 
Plasmid Template (25 ng/µl)  1.0 
Fw Primer (100 ng/µl) 1.25 
Rev Primer (100 ng/µl) 1.25 
QuikSolution Reagent 1.5 
QuikChange Lightning Enzyme 1.0 
Nuclease free water 34.0 
Total Reaction Volume 50.0 
Table 2.24 Standard QuikChange Lightning Site-directed mutagenesis reaction. 
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Step Temperature Duration Cycles 
Denaturation of 
genomic DNA 
template 
95°C 2 minutes  
1X 
Denature 95°C 20 seconds  
18X Annealing 60°C 10 seconds 
Extension 68°C 30 seconds/kb of 
plasmid length 
Final extension 68°C 5 minutes 1x 
Table 2.25 Cycling parameters for QuikChange Lightning Site-directed Mutagenesis. 
  
Primer 
name 
Sequence 
IL6R1-
23SDM+ 
GCCTCTGTATTCAGCAAATGCCTAGGATCATCATTGGATCCTAGCAAAAT
GCTAATGAGGAACTAATTATAATTCT 
IL6R1-
23SDM- 
AGAATTATAATTAGTTCCTCATTAGCATTTTGCTAGGATCCAATGATGATC
CTAGGCATTTGCTGAATACAGAGGC 
IL6R1-
27SDM- 
TCCAAAGAGTCTTGATATGGTTCTCTTGGATCCGGCCCAAGTTCACTCTA
GCCCCTTTAA 
IL6R1-
27SDM+ 
TTAAAGGGGCTAGAGTGAACTTGGGCCGGATCCAAGAGAACCATATCAAG
ACTCTTTGGA 
Table 2.26 Site-directed mutagenesis primers 
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2.6 Characterisation of 5' and 3' of mRNA ends 
2.6.1 5' Rapid Extension of cDNA ends (5'RACE) 
5'RACE was used to amplify the 5' ends of primary-miR-23a cluster transcript 
(pri-miR-23a). In the initial step the 5' end of the pri-miR-23a was converted into 
cDNA using a gene-specific primer (Pri23a 5'RACE GSP1). 200 ng of total RNA in a 
volume of 9 µl was added to 200 µl thin walled PCR tube and denatured by 
heating at 75°C for minutes in a thermocycler then rapidly chilled on ice. The 
denatured RNA was then used as template in the reverse transcription reaction 
shown in Table 2.27. Reaction was incubated at 37°C for 60 minutes. Next the 
excess primers were removed by diluting the reaction to a final volume of 2 ml 
in water which was then applied to a Centricon-100 micro-concentrator and 
centrifuged at 1,000 g at 4°C for 20 minutes. This step was then repeated. The 
flow-through containing pri-miR-23a cDNA was then transferred to a fresh 0.5 ml 
micro-centrifuge tube and the volume reduced to ~10 µl in a rotary vacuum 
evaporator. The resulting 9 µl of cDNA was then added into terminal transferase 
reaction (Shown in Table 2.28) that adds a polyadenosine tail onto the 3' end of 
the cDNA corresponding to the 5' end of the pri-miR-23a. Reaction was incubated 
at 37°C for 15 minutes followed by 80°C for 3 minutes to inactivate the terminal 
transferase. The sample was then diluted in TE buffer to a final volume of 1 ml. 
Finally the following PCR reaction was performed using a Gene-specific primer 
(Pri23a 5'RACE GSP2) nested within the first gene-specific primer and QT-
adaptor primer 5' shown in Table 2.29. PCR reaction was performed using 
AmpiTaq Gold® 360 master mix set up as shown Table 2.30. The cycling 
parameters used are shown in Table 2.31. Finally PCR products were analysed 
using gel electrophoresis (see section 2.5.7) 5'RACE bands were excised and 
cloned into pCR2.1 TOPO before being sent off for sequencing. Sequences were 
aligned against the human genome using BLAST 
(https://blast.ncbi.nlm.nih.gov/Blast.cgi). Primer sequences used in 5'RACE of 
the pri-miR-23a cluster are shown in Table 2.32. 
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Component Volume per Reaction (µl) 
5x Reverse Transcriptase buffer 4.0 
dNTP (20 mM) 1.0 
Denatured RNA (200 ng)  9.0 
Gene-specific primer (10 µM) 4.0 
Placental RNase inhibitor (20 units/µl) 1.0 
Reverse Transcriptase (100 units/µl) 
(Applied Biosystems) 
1.0 
Total Reaction Volume 20.0 
Table 2.27 5'RACE Reverse transcription reaction 
 
Component  Volume per reaction (µl) 
5X TdT Buffer (NEB) 5.0 
 CoCl2 (2.5 mM) 5.0 
dATP (10 mM) 1.0 
cDNA 10.0 
Terminal Transferase (20 units/µl) NEB  1.0 
Total per reaction  20.0 
Table 2.28 5'RACE terminal transferase reaction. 
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Primer Name Primer Sequence 
QT CCAGTGAGCAGAGTGACGAGGACTCGAGCTCAAGC 
TTTTTTTTTTTTTTTTT 
Q0 CCAGTGAGCAGAGTGACG  
QI GAGGACTCGAGCTCAAGC  
 
 Table 2.29 Primers used in 5' and 3' RACE 
 
Component Volume per Reaction (µl) 
2x Amplitaq Gold 360 master mix 
(Invitrogen) 
25.0 
QT primer (10 µM)  1.6 
Q0 primer (10 µM)  3.2 
GSP2 primer (10 µM) 3.2 
Diluted cDNA from previous step 5.0 
Nuclease free water 10.5 
Total Reaction Volume 50.0 
Table 2.30 Final stage PCR 5'RACE reaction. 
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Cycle Number Denature Annealing Extension 
1 5 min at 94°C 5 min at 55°C 40 min at 72°C 
2-31 40 sec at 94°C  1 min at 55°C 3 min at 72°C 
Table 2.31 Cycling parameters used in 5'RACE PCR. 
 
Primer Name  Sequence 
Pri23a 5'RACE GSP1 GCCAGTGTACACAAACCAAC 
Pri23a 5'RACE GSP2 CGGAACTTAGCCACTGTGAA 
Table 2.32 Primers used in 5'RACE of pri-miR-23a transcript. 
 
2.6.2 3' Rapid Extension of cDNA ends (3'RACE) 
The protocol described here has been adapted from the excellent Nature 
Protocols method described by Scotto-Lavino et al. [619]. A schematic of the 
technique is shown in Figure 2.3. 
 
Figure 2.3 Overview of 3'RACE protocol 
Figure adapted from Scott-Livino et al., Nature Protocols, 2007.  
AAAAAAAAAAAAAA
TTTTTTTTTTTTTTCGAACTCGAGCTCAGGAGCAGTGAGACGAGTGACC
QI 
Q0 
First strand cDNA 
Reverse transcription cDNA 
QI Q0 TTTT 
First round amplification 
GSP1 
Q0 
GSP2 
Second round amplification 
QI Final 3’RACE product 
mRNA of Interest 
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In the first step of this protocol 500 ng of total RNA in a volume of 10 µl, isolated 
from THP-1 cells, was placed into a 200 µl thin-walled PCR tube and heated to 
80°C for 3 minutes. The sample was then rapidly cooled on ice. The denatured 
RNA was then used as template in the reverse transcription reaction shown in 
Table 2.33. Reaction was incubated at room temperature for 5 minutes then 
placed into a thermocycler were the sample was incubated at 42°C for 60 
minutes followed by 10 minutes at 55°C. The reverse transcriptase was 
inactivated at 70°C for 5 minutes. Next 1.5 units of RNase H (Invitrogen) was 
added to the sample and incubated at 37°C for 20 minutes to destroy RNA 
template. Sample was then diluted to 1 ml in TE.   
Component Volume per Reaction (µl) 
5x Reverse Transcriptase buffer 4.0 
dNTP (20 mM) 1.0 
Denatured RNA (500 ng)  10.0 
QT primer (10 µM)* 0.5 
Placental RNase inhibitor (20 units/µl) 1.0 
Reverse Transcriptase (100 units/µl) 
(Applied Biosystems) 
1.0 
Nuclease free water  2.5 
Total Reaction Volume 20.0 
Table 2.33 3' RACE Reverse transcription reaction  
* Sequence of QT primer shown in Table 2.29. 
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The cDNA generated from the first step was then used as template in PCR 
containing the nested primer (QI) incorporated into the cDNA by the QT primer 
and a forward primer specific for my gene of interest (GSP1). The reaction was 
set up according Table 2.34. Sample was the incubated in a thermocycler using 
the cycling parameters shown in Table 2.35.  
Component Volume per Reaction (µl) 
2x Amplitaq Gold 360 master mix 
(Invitrogen) 
25.0 
Q0 primer (10 µM)  1.25 
GSP1primer (10 µM) 1.25 
Diluted cDNA from previous step 1.0 
Nuclease free water 21.5 
Total Reaction Volume 50.0 
Table 2.34 First round PCR 3'RACE reaction 
 
Cycle Number Denature Annealing Extension 
1 5 min at 98°C 2 min at 55°C 40 min at 72°C 
2-30 10 sec at 94°C  10 min at 55°C 3 min at 72°C 
31 10 sec at 94°C 10 min at 55°C 15 min at 72°C 
Table 2.35 Cycling parameters used in first and second round 3'RACE PCRs 
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Reaction from the first round PCR was then diluted 1 in 20 in TE before being 
used as template in the second round PCR. The reaction is as shown in Table 
2.34, except Q0 and GSP1 primers were replaced with QI and GSP2. The PCR was 
performed using the parameters shown in Table 2.35. Finally PCR products were 
analysed using gel electrophoresis (see 2.5.7) 3'RACE bands were excised and 
cloned into pCR2.1 TOPO before being sent off for sequencing. Sequences were 
screened for presence of non-genomic stretches of polyA sequences and 
presence of consensus polyA signal located 5' of polyA tail. Gene specific primers 
used in this thesis are shown in Table 2.36. 
Primer Name Sequence 
IL6R GSP1 GAGGGTGAGTGGGTGAATAAT 
IL6R GSP2 CCTGGGTAACTAGGGAAGATAA 
sIL6R GSP2 CCTCCCAGGTTCAAGAAGAC 
CSFR1 GSP1 TGCAGCCCAACAACTATCA 
CSFR1 GSP2 CTCCCACAAACTTCAACTCCT 
pri23a 3'Race GSP1   CATTGCCAGGGATTTCCAAC 
pri23a-3'Race GSP2  GATTTCCAACCGACCCTGA 
Table 2.36 Gene specific 3'RACE primers 
 
2.7 Luciferase reporter assay 
Luciferase reporter assays have become the de facto method for validating miR 
target interactions. In these experiments sequences containing putative miR 
binding sites were cloned down stream of a luciferase reporter conferring 
sensitivity to the miR thought to bind it. Co-transfection of luciferase reporter 
plasmid into a cell line (commonly HEK293 cells) along with miR mimic should 
reduce luciferase activity compared to scrambled miR control if the MBS is 
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targeted by the test miR. If the ability of the miR to reduce luciferase activity is 
lost upon the mutation of the MBS’s seed region, the miR is deemed to directly 
regulate target mRNA expression via this MBS. The method used to create 
Luciferase reporter constructs is described in section 2.5.1. Here I shall briefly 
describe the Dual Luciferase® reporter assay system (Promega). Cells were co-
transfected with luciferase reporter constructs containing the putative MBS 
along with the miR mimic that targets it or scrambled control using the method 
described in 2.2.4.2. Cells were grown for 24 hours after which they were 
washed once in dPBS. The dPBS was then removed and replaced with 250 µl of 
1x Passive Lysis Buffer, included in kit, and incubated with shaking for 15 
minutes at room temperature. 50 µl of each sample was plated in duplicate into 
white 96-well plate (Greiner) followed by 50 µl of LAR II solution. Samples were 
incubated for 10 minutes at room temperature with shaking. The luminescence 
produced by each sample was measured using luminometer counter (MicroBeta 
Trilex, Perkin Elmer). Next, 50 µl of STOP & GLO® solution was added to each 
well and the plate incubated for a further 10 minutes at room temperature. This 
solution quenches luciferase activity while providing a substrate for renilla 
internal control. The plate was then read again in the luminometer counter. 
Values were normalised by dividing luciferase activity by renilla activity. Values 
of miR-treated samples were then expressed as a percentage of those treated 
with scrambled control.  
2.8 Cytokine quantification 
2.8.1 Enzyme-Linked-Immunosorbent assay (ELISA) 
Human ELISA Cytoset kits (Invitrogen) for detection of IL-6, sIL-6R, TNFα and IL-
10 were used to determine cytokine concentrations in cell supernatants 
according manufacturer’s instructions. A generalized protocol will be briefly 
described here. A 96-well microtitre plate was coated with capture antibody in 
dPBS, covered and incubated overnight at 4°C. The following day the plate was 
washed once with ELISA Wash buffer (dPBS, 0.05% Tween 20) and blocked by the 
addition of 200 µl of Assay buffer (dPBS, 0.5% BSA) for 1 hour at room 
temperature. Next, a standard curve was generated using recombinant human 
cytokine standards dissolved in Assay buffer. A top standard of 2,000 pg/ml was 
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serially diluted 1:2 across 7 samples. 100 µl of each standard was added in 
duplicate to the plate along with two wells containing only assay buffer. Samples 
were tested neat or diluted with assay buffer, depending on cytokine and 
experimental set up, with 100 µl being added to each well in duplicate. The 
detection antibody was then added in to each well. The plate was then covered 
and incubated for 2 hours at room temperature with shaking. Next, the plate 
was washed 5 times with ELISA wash buffer and 100 µl of streptavidin-HRP added 
to each well. Plates were then incubated for 30 minutes at room temperature, 
washed as before and 100 µl of TMB chromagen (Biosource) added to each well. 
The reaction was then stopped by addition of 50 µl of Stop solution to each well 
(Biosource). Finally, plates were read at 450 nm on a MTX TC II microplate 
reader (Dynex Technologies). 
2.8.2 Luminex Assay 
A human cytokine 25-plex assay (Invitrogen) was used to determine the 
concentration of 25 cytokines and chemokines simultaneously within RA patient 
cohort and health control serum samples. The assay was carried out by senior 
technician Lynn Stewart following manufacturer’s instructions. Briefly, the plate 
was pre-wetted using the wash buffer provided. Antibody beads were vortexed 
for 30 seconds then sonicated for 30 seconds immediately before being added 
into each well. Wells were then washed twice with 200 µl of 1x Wash buffer. 
Next 50 µl of Incubation buffer was added into each well followed by the diluted 
standards. Samples were diluted 1:1 with Assay buffer and 100 µl added per 
well. Plate was then covered with an opaque lid and incubated on an orbital 
shaker at 500-600 rpm for 2 hours at room temperature. Next wells were washed 
twice in Wash buffer followed by the addition of 1x biotinylated antibody 
solution. Plate was then incubated at room temperature on an orbital shaker for 
1 hour. Wells were then washed twice in Wash buffer and 100 µl of 1x 
streptavidin-RPE added to each well followed by shaking for 30 minutes. Liquid 
was then removed and each well washed 3X in Wash buffer. Finally, 150 µl of 
Wash buffer was plated into each well, plate then shaken for 3 minutes in 
orbital shaker before being read on the Luminex® 100/200™ system. 
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2.9 Target prediction 
There are a number of well established online miR-target prediction tools that 
can be used to identify potential miR-mRNA interactions (Reviewed in Chapter 
1). They have their own strengths and weaknesses and generally rely on 
identifying sequences complementary to miR seed region as the basis for their 
predictions. A list of the programs used in this work is shown in Table 2.37. As a 
starting point I used human Targetscan to identify miR-23a cluster binding sites 
in RA and monocyte relevant genes. Targetscan has the advantage of being 
simple to use and has one of the better false positive rates with respect to the 
other prediction programs available. Once identified I then screened the other 
databases listed in Table 2.37. MBS that are predicted by more than one 
program in most cases have an increased predictive value [620]. A list of the 
programs used together with their web addresses is shown in Table 2.38. I used 
Diana tools-TarBase website which is a curated database of miR-target 
interactions supported by experimental evidence to search for previously 
identified interactions or interactions that were supported by HITS-CLIP, PAR-
CLIP or CLASH methodologies. 
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Target 
Prediction 
Algorithm 
Features Accuracy 
Parameters used in 
binding site prediction 
Cross-species 
conservation 
Targetscan Seed match, 3' 
complementarity local 
AU content and position 
contribution 
Given scoring for 
each result 
21-48%* 
miRanda Complimentary and free 
energy binding  
Uses conservation 
filter 
49% 
PicTar Seed match Requires pairing at 
conserved positions 
48% 
PITA  Target site accessibility 
energy 
User-defined NA 
Rna22 Pattern recognition and 
folding energy 
Not used  NA 
Table 2.37 List of Target prediction programs. 
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Target prediction 
program  
Web address 
Targetscan-Human http://www.targetscan.org/vert_71/ 
miRanda http://www.microrna.org/microrna/home.do 
PITA https://omictools.com/pita-tool 
PicTar https://omictools.com/pita-tool 
Rna22 https://cm.jefferson.edu/rna22/Interactive/ 
miRwalk http://zmf.umm.uni- 
heidelberg.de/apps/zmf/mirwalk2/index.html 
Diana Tools http://diana.imis.athena-
innovation.gr/DianaTools/index.php?r=tarbase/index 
Table 2.38 Web addresses of online miR target prediction algorithms  
 
2.10 Statistical Analysis 
Statistical analysis was done using PRISM6 platform. Results from measurements 
conducted in the RA patient cohort were analysed by non-parametric Kruskal-
Wallis test with Dunn’s correction for multiple comparisons. Experiments with 
primary human cells were analysed by non-parametric methods, such as Kruskal-
Wallis test with Dunn’s correction for multiple comparisons, Mann-Whitney test 
for the comparison of unpaired samples and Wilcoxon test for the paired samples 
accordingly. Data from THP-1 cells lines were analysed with parametric 
methods, such as Ordinary One-Way ANOVA with Dunnett’s correction for 
multiple comparisons and paired or unpaired t test. In all analysis p<0.05 was 
considered significant. Details of all statistical methods used and number of 
experimental replicates for each experiment are stated in the figure legend.   
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3  Profiling of miR species in drug resistant RA  
3.1 Introduction 
Rheumatoid arthritis is a chronic autoimmune condition and as such has a 
diverse spectrum of intensity and presentation in patients. This is rarely 
reflected in the therapeutic approach such that standard treatment protocols 
are offered to new patients during the first six months post diagnosis. Although 
it is likely that a variety of clinical presentations exhibit subtle differences in 
pathological processes from the start, they are not readily exploitable in the 
clinical setting due to the lack of biomarkers or other measurable parameters to 
inform clinical decision making from the onset. In essence we lack a suitable 
clinically relevant endotype. Moreover, it has been previously shown that 
patients failing multiple modes of treatment are likely to respond less well to 
newer biologic medications such as anti-TNFα, regardless of the mode of action, 
especially if they are female with high disease activity and multiple co-
morbidities [621]. Based on this we hypothesise that aligning the right patients 
with the right drug, particularly in early RA, could deliver improved treatment 
outcome.  
Inability to stratify patients and to accurately predict clinical response is a 
significant stumbling block in the era of readily available new therapeutics. The 
importance of this task goes hand-in-hand with a well-excepted general strategy 
to treat aggressively from the onset in an attempt to establish early disease 
control and limit “chronicity” of the active disease [64]. Understanding how 
available treatments intersect with disease pathogenesis is both informative of 
undergoing pathological processes and will highlight pitfalls in current clinical 
practice. Further understanding and stratification of patients according to their 
response to therapy will undoubtedly lead to more tailored evidence-based 
treatment of RA.  
This chapter will introduce a cohort of patients with rheumatoid arthritis (RA) 
selected on the basis of clinical response to or failing of different modes of 
treatment. Furthermore, emerging evidence of the importance of epigenetics 
and, particularly, miRs in the pathogenesis of RA prompted us to study miR 
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signatures in peripheral blood monocytes from these patients to identify 
pathways that correlate with pathology and drug response in RA [511].  
3.2 Patient cohort 
We gathered a cohort of patients with established diagnosis of RA and matched 
healthy controls. Patients were recruited by Dr Derek Baxter at the Glasgow 
Royal Infirmary and by Dr Duncan Porter at the Gartnavel General Hospital. 
Patients were selected and stratified by their clinical response to different 
modes of treatment, resulting in three distinct patient groups plus an additional 
group of healthy sex-matched controls.  
The first group consisted of 21 healthy controls recruited predominantly from 
patient’s family members and amongst the staff in the Institute of Infection, 
Immunity and Inflammation of the University of Glasgow. The second group was 
formed from 16 patients with disease duration more than ten years with good 
clinical response to treatment with a maximum of two DMARD agents (ever), 
designated ‘DMARDs responders’. The third group, ‘DMARDs resistant’ comprised 
of 22 patients with high disease activity (measured by DAS28-ESR or CRP). These 
patients had recently qualified for biological treatment after failing several 
DMARDs but did not start the treatment yet. Finally, the fourth group involved 
41 patients with active disease despite treatment with two or more biologic 
agents; this group was termed - ‘Biologics Resistant’.  
3.2.1 Patient demographics 
Patient information regarding disease duration, severity and clinical findings are 
summarised in Table 3.1, together with information on 21 Healthy controls 
recruited in the study. Due to the nature of RA, the majority of recruited 
patients were females, percentages ranging from 56% in DMARDs responders 
group to 77% in DMARDs resistant group and 85% in Biologics resistant group. This 
was reflected in healthy control group, as 86% of volunteers were female (Table 
3.1). Average age between patient groups was 61 years. However, healthy 
control were recruited from the volunteers in the institute and were younger at 
an average of 48 years of age. All patients had established longstanding disease 
at the time of recruitment, with the average duration of 18, 12 and 21 years for 
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the DMARDs responsive, DMARDs resistant and Biologics resistant groups 
respectively (Table 3.1). Patients in the DMARD resistant group had significantly 
shorter disease duration than patients from the DMARD responders group, 
indicating more aggressive disease despite multiple DMARD therapies. 
RF and anti-CCP antibodies were measured in all groups as ‘gold standard’ 
biomarkers of RA [622]. The vast majority of patients (81%, 90% and 78% in 
DMARD responders, DMARD resistant and Biologic resistant patient groups 
respectively) were RF positive, while only one person in healthy controls group 
(5%) had a weakly positive result. Similarly, the majority of patients had a high 
titre of anti-CCP antibodies (81%, 84% and 68% in DMARD responders, DMARD 
resistant and Biologic resistant patient groups respectively) while the same 
person in the controls group had a very weakly positive test for anti-CCP and 
comprised 5% of the healthy controls, Table 3.1. This indicates that in a majority 
of cases our patients suffered from seropositive RA, associated with increased 
risk of erosive joint damage and functional impairment [623-625]. 
CRP and ESR levels were measured as indicators of overall inflammation. In the 
healthy controls group both measurements were within normal limits, that is 
within the upper limit of 1.0mg/dl (10mg/L) CRP and 10 mmHg ESR as per 
laboratory guidelines. Median CRP levels in all three patient groups were on 
average within normal limits (Median (25%, 75%) of 0.98 (0.34, 1.5), 1.0 (0.6, 
3.4) and 1.0 (0.5, 3.3), respectively) and were significantly higher than in the 
healthy controls group. The second parameter, ESR, was on average above the 
accepted normal range limit in patient groups, and was particularly raised in 
patients failing DMARDs treatment when compared to healthy controls, 
indicating higher level of inflammation (Median (25%, 75%) of 27 (11, 57) vs. 8.0 
(4.0, 15) mm/h, respectively, Table 3.1). Moreover, clinical evaluation of 
patients revealed a significant difference in tender joint count (TJC) between 
DMARDs responders group and both groups failing treatment (Mean±SD of 1.4±2.5 
vs. 14±7.1 and 9.5±5.4, respectively). Additionally, average swollen joint counts 
(SJC) were also higher in DMARDs resistant and biologics resistant groups when 
compared to DMARDs responders (11.0±5.1 and 9.4±3.0 vs. 2.1±1.5, 
respectively), Table 3.1.  
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3.2.2 Disease activity scores 
To assess disease severity, progression and effect of treatment, several 
validated clinical scores were used, amongst which was the primary clinical 
measurement tool – disease activity score 28 (DAS28) [69,70,626]. The score is 
based on separate counts of swollen and painful joints amongst preselected 28 
joints assessed by the clinician, visual analogue scale (VAS) for the average pain 
estimate by the patient and inflammatory marker CRP or ESR, making DAS28-CRP 
or DAS28-ESR scores, as described in Chapter 1. DAS28 score is a continuous 
scale, in which a DAS of >5.1 represents high disease activity, DAS28 score 
between >3.2 and <5.1 results in moderate activity, while the DAS28 score in the 
range of 2.6-3.2 is a mark of low disease activity at the time of assessment. 
Clinical remission is classified with the DAS28 score of <2.6. A change of 1.2 in 
the score of the individual patient is considered a clinically significant change.   
In our patient cohort, mean values (±SD) of the DAS28-CRP were 3.0±0.7 for the 
DMARDs responders, 5.7±1.2 for the DMARDs resistant and 5.1±0.9 for biologics 
resistant patients as stated in Table 3.2. Similarly, DAS28-ESR was 3.2±0.6, 
6.0±1.3 and 5.3±1.2 in DMARD responders, DMARD resistant and Biologic resistant 
groups respectively (Table 3.2). Overall, there was a significant difference 
between DAS28-CRP and DAS28-ESR scores between DMARDs responders and both 
groups of patients failing current treatment, p<0.0001. DMARDs responders 
group included patients with low disease activity (DAS28 ≤3.2) established and 
maintained on the current DMARD treatment despite longer overall disease 
duration compared to other patient groups. This group also had the highest 
number of male subjects (7/16, 44%). Since male sex has been associated with 
higher chance of achieving drug related low disease activity [621] we have 
confirmed that there was no difference in disease activity scores between males 
and females across DMARDs responders group (Mean±SD, 2.9±0.4 vs 3.0±0.9 in 
DAS28-CRP, respectively; 3.1±0.15 and 3.2±0.8 in DAS28-ESR, respectively). 
Maintained DAS28 response is also a good prognostic factor and predicts a better 
long-term outcome for all patients [70,71]. In contrast to this, the two later 
disease groups included patients with high disease activity on current DMARDs 
and/or biologics treatment as evident from DAS28 scores ≥5.1 indicating poor 
prognostic outcome despite shorter disease duration in the case of DMARDs 
resistant patients (Table 3.2). Patients in the later two groups have also 
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experienced a variety of DMARDS or biologic agents and as such can be classified 
as patients with true treatment resistant disease.   
Regarding individual components of DAS28 score, the significant disparity was 
found in counts of tender and swollen joints in both treatment failure groups 
compared to good responders (Table 3.1). Additionally, we observed an increase 
in the patient’s global score in DMARDs resistant group when compared to 
DMARDs responders (61±25 vs. 38±23, respectively, Table 3.2), indicating a 
significant overall impact of high disease activity. As stated previously, all 
patient groups had normal CRP levels and raised ESR marker. However, no 
significant difference was measured between the groups (Table 3.1).    
The Clinical Disease Activity Index (CDAI) and the Simplified Disease Activity 
Index (SDAI) are two other continuous measures used in this study as the most 
recent tools for the clinical trials outcomes [77,627]. Similarly to DAS28, the 
SDAI score involves 28 joint counts for tender and swollen joints, acute reactant 
CRP (mg/dl) and patient’s global assessment, with addition of the physician’s 
global assessment also measured on 0-10 Likert scale. Although more details on 
clinical scoring using SDAI can be found in Chapter 1, most importantly high 
disease activity is measured by scoring >26, moderate range is 12-26, mild <3.4-
11, and remission is suggested with SDAI of <3.3. 22 points represent a major 
change, while an improvement in 10 to 21 points is considered a minor change. 
Given that CRP results are not always available at the time of the patient’s 
appointment, CDAI score was developed to be interpretable at the clinic and 
includes the sum of 28 TJC and SJC, patient’s global assessment and patient’s 
overall pain score. No acute phase reactant is necessary for the CDAI score. High 
disease activity is represented by score >22, moderate range lies between 11-22, 
low disease activity is within the score of 2.9-10, and remission is <2.8. Latest 
ACR guidelines on evaluation of disease activity in RA suggest that use of DAS28, 
CDAI and SDAI scores incorporating CRP are all valid discriminative measures and 
prediction of clinical outcomes correlate with each other [80,627].  
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In this patient cohort, SDAI and CDAI scores did not exhibit normal Gaussian 
distribution and are represented as median values with 25th and 75th percentile.  
The SDAI score in the group of patients responding to DMARDs treatment was 
below the active disease threshold and was significantly lower compared to both 
treatment failure groups (Median (25, 75%) of 8.7 (6.2,10) in DMARD responders 
group vs. 40 (28,47) in DMARD resistant group and 31 (24,38) in Biologic resistant 
group, p<0.0001, Table 3.2). Similarly, median CDAI score in DMARDs responders 
group confirmed low disease activity (7.6 (4.9, 9.5)), while the median score in 
DMARDs resistant and biologics resistant groups was significantly higher at 37 
(27, 44) and 29 (20,34), p<0.0001, respectively (Table 3.2).  
With regards to individual components of the scores, significantly higher TJC and 
SJC in therapy failing groups were major indicators of high disease activity, as 
shown previously in Table 3.1.  Besides those, high patient global assessment 
(30±20 vs. 66±24, p<0.0001 and vs. 50±25, p<0.01 in DMARD responders vs. 
DMARD resistant and Biologic resistant groups respectively) and higher 
physician’s global assessment (1.6±0.6 vs. 6.4±2.4 and vs. 4.5±1.9, p<0.0001 in 
DMARD responders vs. DMARD resistant and Biologic resistant groups 
respectively) were significantly higher in the latter two groups failing treatment 
and were other main contributors to the overall raised clinical scores.  
In summary, the DMARDs responders group comprised patients with long-
established but well-managed disease with low disease activity recorded by all 
clinical tools used. The DMARDs resistant group included patients with shorter 
disease duration compared to the previous group, with high disease activity as 
evident from the clinical tools used and additionally with increased 
inflammatory response, significantly higher patients pain and global scores and 
higher physician’s global assessment indicating poorly controlled disease despite 
current treatment. Finally, biologic resistant patients also exhibited high disease 
activity on all clinical scores, raised ESR inflammatory marker and significantly 
higher patient’s and physician’s global scores confirming the presence of disease 
refractory to the use of more than one biologic agent. 
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3.2.3 Treatment protocols in patient groups 
All patients in the DMARDs responsive group received a single treatment agent at 
the time of the recruitment. The majority of these were on monotherapy with 
Sulfasalazine (10 patients, 62.5%), and then Methotrexate (5 patients, 31.25%), 
with one remaining patient (6.25%) on historically established gold therapy 
(Table 3.3). DMARDs resistant patients have previously experienced a median of 
3 DMARDs ranging from 2 to 6 different agents, including double or triple therapy 
with Sulfasalazine, Methotrexate and/or Hydroxychloroquine or historically used 
single agents like Leflunomide, Azithromycin, Gold or Penicillamine. At the time 
of recruitment 13 patients (59.5%) were on Methotrexate, 2 patients (9%) on 
Sulfasalazine, four patients (18%) on Leflunomide, and one patient (4.5%) 
receiving Hydroxychloroquine, Gold or Penicillamine each. Patients in the 
biologics resistant group were also highly experienced with DMARDs agents with 
a median of 6 drugs, ranging from 2 to 8. Alike previous group, majority of 
patients (29 patients (71.2%)) were on therapy with Methotrexate, with 3 
patients (7.2%) on Sulfasalazine or Hydroxycholoquine, 2 patients (4.8%) on 
Leflunomide and 1 subject (2.4%) with no DMARD treatment or rarely used single 
agents like Azithromycin, Gold or even Prednisolone respectively, Table 3.3.  
Similar to the DMARDs treatment group, patients in the biologic resistant group 
had also experienced a wide range of biologic agents before recruitment for this 
study, listed in Table 3.4. Overwhelmingly, first choice biologic was a TNFα 
inhibitor, mainly Adalimumab (19 patients, 46.3%), Etanercept (17 patients, 
41.5%) or Infliximab in 4 patients (9.75%). One patient (2.45%) was started on 
treatment with Abatacept, an anti-T cell agent, as a part of a clinical trial. The 
mean number of biologic agents per patient was 3, ranging from 2 to 5. Most 
popular second choice, for 73.2% of patients, was a second TNFα inhibitor or, 
alternatively, 26.8% were switched to a B-cell inhibition with Rituximab. Later 
choices have seen an addition of anti-IL-6 agent Tocilizumab and, again, anti-T 
cell agent Abatacept, while the last choice was based entirely on options 
alternative to an anti-TNFα agent.    
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Table 3.3 The list of current DMARDs in each of patient groups.  
Table shows numbers of patients and the percentage of all patients in the group being treated with 
particular disease modifying anti-rheumatic drugs (DMARDs) at the time of the study recruitment. 
 
 
 
Table 3.4 The list of current biologic therapy and history of different agents used in the 
treatment of biologics resistant patient group.  
The column of current biologics shows the total number and the percentage of patients treated with 
specific biologic agent at the time of recruitment for the study. Additionally, the table shows the 
most popular choices for the alternative therapy switch in this patient group.  
  
DMARDs&
Responders&&
DMARDs&
Resistant&
Biologics&
Resistant&
Current&DMARDs& 16#total# 22#total# 41#total#
None& *# *# 1#(2.4%)#
Methotrexate& 5#(31.25%)# 13#(59.5%)# 29#(71.2%)#
Sulfasalazine& 10#(62.5%)# 2#(9%)# 3#(7.2%)#
Hydroxychloroquine& *# 1#(4.5%)# 3#(7.2%)#
Leﬂunomide& *# 4#(18%)# 2#(4.8%)#
Azithromycin& *# *# 1#(2.4%)#
Gold& 1#(6.25%)# 1#(4.5%)# 1#(2.4%)#
Prednisolone& *# *# 1#(2.4%)#
Penicillamine& *# 1#(4.5#%)# *#
Current'
biologic'
1st'' 2nd'' 3rd'' 4th'' 5th''
Adalimumab' !" 19" 15" 4" !" !"
Etanercept' 4"(9.6%)" 17" 13" 4" 1" !"
Inﬂiximab' !" 4" 2" 7" 1" !"
Rituximab' 20"(49%)" !" 11" 14" 1" 1"
Abatacept' 1"(2.4%)" 1"(Trial)" !" !" 1" 2"
Tocilizumab' 5"(12%)" !" !" 4" 3" 1"
None' 11"(27%)" !" !" !" !" !"
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There are many causes of treatment failure in patients. In this case, 
discontinuation of the first biologic agent could be explained by either primary 
or secondary loss of efficacy or the presence of side effects. Amongst them, 11 
patients (27%) have not achieved a meaningful clinical improvement (measured 
by DAS28 ESR or CRP change of >1.2) within 6 months of treatment initiation and 
were classified as a primary failure. A secondary failure occurred in 14 patients 
(34%) that had meaningful improvement within first 6 months but progressed to 
develop active disease with an increase in the DAS28 score to the level observed 
prior to the start of the treatment at a later point. However, the majority of 
patients (16, 39%) had to stop with first therapeutic due to the side effects, 
most common ones being the injection/infusion site reaction and infection. 
Study entry criteria for the Biologic resistant group were, therefore, based on a 
failure of 2 or more biologic agents to reflect a true inefficacy rather than the 
presence of side effects.  
Along with the above treatment, all patients with high disease activity were 
given ’rescue’ steroids in the intramuscular or intra-articular form to rapidly 
reduce the inflammation and provide symptomatic relief until the onset of 
action of DMARD or biologic therapy. Daily oral steroids were used in one patient 
from DMARD responders group, while intravenous methylprednisolone was 
routinely administered before Rituximab infusion in an effort to prevent an 
adverse reaction to the drug.    
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3.3 MiR array in RA patients and healthy controls 
Here I set out to investigate the miR expression profile of purified CD14+ 
monocytes derived from the peripheral blood of rheumatoid arthritis patients 
and comparable healthy controls. Our hypothesis was that global analysis of miR 
expression profiles would highlight miR-regulated disease pathways. To this end, 
the Affymetrix 3.0 miR Array platform was used for these experiments. Principal 
component analysis of all patient and healthy control groups is shown in Figure 
3.1. It uses statistical test with orthogonal transformation to identify a possible 
correlation between parameters within one group that are linearly uncorrelated 
at first glance. Here we see that principal component 1 (PC1) is clearly 
distinguishing the group of DMARDs responsive patients, likely due to the 
meticulous clinical categorisation. However, neither PC1 nor PC2 is capable of 
distinguishing between all other groups as they show increased variability. 
Inability to clearly separate clinically distinctive groups of patients from each 
other or healthy controls even in the single cell study points to difficult and, 
likely, multifactorial pathogenesis of this disease. Even so, monocytes and 
macrophages continue to be the cell type of interest for this study as we sought 
to analyse the effects of treatment or the lack thereof in RA.    
Further miR array analysis identified 493 differentially expressed miRs between 
biologics resistant and DMARDs responder patients, while the smallest difference 
(63 miRs) was found between good responders and healthy controls groups, 
pointing towards different epigenetic changes in high disease activity state 
(Venn diagram, Figure 3.2). Therefore, we decided to focus on differences in 
miRNA expression between DMARDs responders and both patient groups failing 
multiple modes of treatment to highlight pathways in progressive disease and 
treatment resistance.    
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Figure 3.1 Principal component analysis of miR Array in all patient groups and healthy 
controls.  
Principal component analysis identified two principle components – PC1 and PC2 shown above, to 
allow categorisation of each group. MiR Array was performed on CD14+ monocytes isolated from 
peripheral blood of participants. DMARDs responder patients (DMARDresCD14) have formed a 
tight expression cluster and are clearly distinguished by PC1. DMARDs resistant 
(DMARDresCD14), Biologics resistant (BiologicresCD14) patients and healthy controls 
(HealthyCD14) have disseminated expression patterns and could not be easily distinguished by 
PC1 or PC2.   
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Figure 3.2 Venn diagram
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3.3.1 MiR-27 and miR-23 are differentially expressed between 
treatment responders and non-responders. 
Comparing miR signatures in treatment-responsive and resistant RA: here we list 
the top 50 miRs differentially expressed between DMARDs responders and 
DMARDs resistant groups (Figure 3.3). We identified miR-27a and miR-27b as 
being expressed significantly lower in DMARDs resistant patients when compared 
to good responders. Similarly, analysis of top 50 differentially expressed miRs 
between DMARDs responders and biologic resistant groups (Figure 3.4) identified 
hairpin miR-27a probe, miR-23a and miR-23b to be downregulated in difficult to 
treat patients.  
Interestingly, these miRs derive from two almost identical miR clusters - miR-
23a~24-2~27a and miR-23b~24-1~27b each of them expressed as a single primary 
transcript. Multiple studies have gathered data to support a strong synergistic 
effect of miRs derived from a single cluster, as they have the capacity to target 
multiple molecules of the same pathway and, therefore, exhibit increased 
overall impact. For example, miR-19, miR-212 and miR-132 are a part of the 
cluster collectively targeting transcription factor FOXO3 in haematopoietic stem 
cells regulating cell survival [628]. Moreover, the previous investigation of this 
particular miR-23a~24~27a cluster has shown the cooperative function of cluster 
members in several human diseases and cancer [567]. Given that multiple 
members of miR-23a and miR-23b clusters were differentially expressed in 
patients failing multiple modes of treatment when compared to good 
responders, here we chose to further investigate the expression of miR-23-24-27 
clusters in peripheral blood monocytes in treatment-resistant RA.  
Expression of mature miRs from both miR 23~24~27 clusters across all treatment 
and control groups is shown in Figure 3.5. MiR-27a is downregulated in both 
groups failing treatment when compared to healthy controls (Median (25, 75%), 
10.38 (9.7, 10.8) and 10.52 (10.2, 10.8) vs. 10.8 (10.7, 10.9) in DMARD resistant, 
Biologic resistant vs. healthy control groups, p<0.01 in both comparisons 
respectively) and when compared to DMARDs responders (Median (25, 75%) 10.7 
(10.6, 10.8) in DMARD responders vs. 10.4 (9.7, 10.8) in DMARD resistant groups, 
p<0.05; hp-hsa-miR-27a_st probe, 1.96 (1.84, 2.18) in DMARD responders vs. 1.5 
(1.3, 1.7) in Biologic resistant groups, p<0.01 respectively).   
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Figure 3.3 Heat-map of top 50 differentially expressed miRs in DMARDs responders and 
DMARDs resistant groups.  
This figure shows the heat-map of differentially expressed miRs between DMARDs responders 
(x=DMARDrespCD14) and DMARDs failures (x=DMARDresCD14). The left side of the plot shows 
Log2 expression intensity scale where red stipulates overexpressed (max +3.4) and green 
symbolises underexpressed genes (min -4). The right side of the heat-map lists miR probes. Star 
symbol is marking probes identifying mature miR-27a and miR-27b and hairpin miR-27a probe.  
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Figure 3.4 Heat-map of top 50 differentially expressed miRs between DMARDs responders 
and Biologics resistant groups.  
This figure shows the heat-map of differentially expressed miRs between DMARDs responders 
(x=DMARDrespCD14) and Biologics treatment failures (x=BiolodicresCD14). The left side of the 
plot shows Log2 expression intensity scale where red stipulates overexpressed (max +3.2) and 
green symbolises underexpressed genes (min -4.2). The right side of the heat-map lists miR 
probes. Star symbol is marking probes identifying mature miR-23a and miR-23b and hairpin miR-
27a probe.  
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Similarly, miR-27b is downregulated in DMARDs resistant patients when 
compared to healthy controls (Median (25,75%) 6.56(6.1,6.93) in DMARD resistant 
vs. 7.2(7.1,7.4) in healthy controls, p<0.01) and in both treatment failure groups 
when compared to good responders (6.56(6.1,6.93) and 6.9(6.6,7.2) vs. 
7.35(7.2,7.5) in DMARD resistant, Biologic resistant and DMARD responders 
groups, respectively, p<0.0001). There was no statistical difference in miR-27a 
or miR-27b expression between healthy controls and good responder groups.  
Next, we investigated the expression of miR-24. The sequence of mature miR-24 
is identical in both miR-23~24~27 clusters and could not be distinguished in 
detection in this assay. Therefore a single probe can identify its total expression. 
The log2 intensity of miR-24 probe is decreased in DMARDs responders group 
compared to all other groups (Mean±SD 12.75±0.19 in DMARD resistant vs. 
12.87±0.07 in healthy controls, 12.88±0.07 in DMARD responders and 12.93±0.11 
in Biologic resistant groups, p<0.05, p<0.05 and p<0.0001 respectively), Figure 
3.5 plot D.  
Lastly, Figure 3.5 plots E shows expression of miR-23a to be significantly 
increased in DMARDs responders group compared to healthy controls (Median 
(25, 75%) 13.3 (13.2, 13.4) in DMARD responders vs. 13.13 (13.1, 13.2) in control 
groups, p<0.01), but also in comparison with biologics resistant patients (13.3 
(13.2, 13.4) in DMARD responders vs. 13.15 (13.1, 13.2) in Biologic resistant 
groups, p<0.001). Moreover, this pattern is consistent with expression of miR-
23b, Figure 3.5 plot F, which is found to be higher in DMARDs responders 
compared to all other groups (Median (25, 75%) 11.3 (11.2, 11.4) in DMARD 
responders vs. 11.1 (11, 11.2) in healthy controls, 11.2 (11, 11.3) in DMARD 
resistant and 11.1 (11, 11.2) in Biologic resistant groups, p<0.05, p<0.05 and 
p<0.001 respectively). 
DMARDs and biologics treatment resistant groups have varied only in expression 
of mature miR-23a, which is found to be decreased in the Biologic resistant 
group (Median (25, 75%) 13.2 (13.1, 13.4) in DMARD resistant and 13.15 (13.1, 
13.2) in Biologic resistant groups, p<0.05) and in miR-24 expression, which was 
decreased in DMARDs treatment failures (Mean±SD 12.75±0.19 in DMARD 
resistant vs. 12.93±0.11 in Biologic resistant groups, p<0.0001), Figure 3.5.  
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Figure 3.5 Expression of mature miRs from miR-23a~24-2~27a and miR-23b~24-1~27b 
clusters in miR Array from CD14+ monocytes of RA patients and healthy controls.  
This figure shows Log2 intensity of the miR Array probes identifying mature miR-27a (A), mature 
miR-27b (B), hairpin loop probe of miR-27a (C), mature miR-24 (D), mature miR-23a (E) and 
mature miR-23b (F). Statistical analysis for all probes apart from miR-24 was done using non-
parametric multiple comparisons Kruskal-Wallis test with Dunn’s correction. Expression of miR-24 
across all groups passed D’Agostino and Pearson’s normality test and was analysed using one-
way ANOVA test with Tukey’s test for multiple comparisons. Statistical significance is shown by * - 
p<0.05, ** - p<0.01, *** - p<0.001, **** - p<0.0001. 
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3.3.2 Mature miRs derived from the single cluster do not correlate 
in their expression.  
Figure 3.6 shows the relative log2 intensity of expression of mature miRs derived 
from both miR-23~24~27 clusters. All probes are expressed at different 
intensities and are within the assay’s detection limit as evident from standard 
array platform controls, here exemplified by positive AFFX-CreX-3_at and 
negative AFFX-ThrX-3_st controls (Mean±SD 14.90±0.06 and 1.13±0.13, 
respectively).  
Unexpectedly, no significant correlation was found between expression of miR-
23a and miR-27a. This was true for expression in all patient and healthy controls 
groups, as well as in all samples analysed together (Table 3.5). MiR-24 also did 
not correlate with expression with other two members of miR-23a~24-2~27a 
cluster. This finding could be explained by the nature of the miR-24 sequence 
and our inability to distinguish its origins between ‘a’ or ‘b’ clusters.   
In the second cluster, miR-27b has correlated with miR-23b levels (r=0.37, 
p=0.0001) and with miR-24 (r=0.25, p=0.012) across all samples. However, 
individual group analysis has shown that significant moderate correlation 
occurred only in DMARDs resistant group (Table 3.5).  
These data point towards likely posttranscriptional regulation of mature miR 
expression from the primary transcript, which has been described previously for 
miR-23~24~27 clusters [629].  
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Table 3.5 Expression correlation of mature members of miR-23a~24-2~27a and miR-23b~24-
1~27b clusters across all samples or individual groups.  
Table shows correlation intensity (r) and significance (p) between all mature miR members of the 
same miR cluster believed to be expressed from a single primary transcript. Numbers in bold mark 
statistically significant correlations according to Pearson’s correlation coefficients.  
 
miR$23a~24$2~27a+cluster+
(r,+p+values)+
miR$23b~24$1~27b+cluster+
(r,+p+values)+
miR$23a(vs(
miR$24(
miR$23a(vs(
miR$27a(
miR$24(vs(
miR27a(
miR$23b(vs(
miR$24(
miR$23b(vs(
miR$27b(
miR$24(vs(
miR27b(
All(groups( $0.03,(0.77( $0.1,(0.32( $0.002,(0.98( $0.045,(0.65( 0.37,+0.0001+ 0.25,+0.0122+
Healthy(Controls( 0.27,(0.23( 0.06,(0.79( $0.37,(0.1( 0.03,(0.9( 0.29,(0.21( $0.15,(0.51(
DMARDs(
Responder(
PaHents(
$0.23,(0.39( 0.13,(0.63( $0.08,(0.77( $0.45,(0.08( 0.43,(0.09( $0.35,(0.19(
DMARDs(
Resistant((
PaHents(
0.22,(0.32( $0.37,(0.09( $0.06,(0.8( 0.04,(0.87( 0.43,+0.0459+ 0.52,+0.013+
Biologics(
Resistant(
PaHents(
0.097,(0.55( $0.046,(0.78( $0.13,(0.42( 0.23,(0.16( 0.29,(0.07( 0.03,(0.84(
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Figure 3.6 Intensity of m
ature m
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This figure show
s the heat m
ap of log2 intensity of all individual probes identifying m
ature m
iR
s derived from
 both m
iR
-23~24~27 clusters. P
robe identities are listed 
below
. A
FFX
-C
reX
-3_at is a positive control probe. A
FFX
-ThrX
-3_st is a negative control probe. R
eference colour scale is represented on the right side (m
in – 1; m
ax - 
15).   
H
ealthy  
volunteers 
D
M
A
R
D
s  
responders 
D
M
A
R
D
s 
 resistant  
group 
B
iologics 
 resistant  
group 
173 
 
3.3.3 Primary miR-23a~24-2~27a but not pri-miR-23b~24-1~27b 
transcript is expressed in CD14+ monocytes. 
The miR-23a~24-2~27a cluster is expressed as a single transcript whereas miR-
23b~24-1~27b is thought to be co-expressed with its host C9ORF3. Differential 
expression of mature miRs prompted us to investigate the expression of primary 
miR transcript levels in the patient cohort.  
In the Affymetrix 3.0 miR Array, there are two hairpin loop probes for each 
member of the miR-23a~24-2~27a cluster and a single probe for each member of 
the primary miR-23b~24-1~27b sequence. Intensities of hairpin loop probes 
designed to identify primary miR sequences from both clusters are depicted in 
Figure 3.7.  
Surprisingly, the only strong hybridization signal was detected from extended 
primary miR-23a probe (hp_hsa-miR-23a_x_st probe, Mean±SD 6.94±0.23), with 
significantly lower expression detected by both miR-27a probes (hp_hsa-mir-
27a_st and hp_hsa-mir-27a_x_st, 1.85±0.39 and 1.62±0.35, p<0.0001, 
respectively). The mean intensity of all probes designed to detect primary 
transcript of miR-23b~24-1~27b was below the arbitrary cut-off of 1.3 (the log2 
intensity of control negative probes on the array, including AFFx-ThrX-3_st 
probe) and was significantly lower than pri-miR-23a probe above (Figure 3.7). 
The presence of mature miRs from miR-23b~24-1~27b cluster with absence of 
primary transcript could be explained by extended longer half-life of mature 
miRs compared to rapidly processed primary transcripts, but also there is a 
possibility that the methods used are not sensitive enough to fully distinguish 
one nucleotide difference between mature miRs of ‘a’ and ‘b’ cluster, therefore 
recognising miR-23a for miR-23b, for example. 
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Figure 3.7 Intensity of the prim
ary transcript probes for ‘a’ and ‘b’ m
iR
-23-24-27 clusters across all patient groups.   
This figure show
s the heat m
ap of log2 intensity of all probes identifying prim
ary m
iR
s transcripts of both m
iR
-23~24~27 clusters. P
robe identities are listed below
. 
A
FFX
-C
reX
-3_at is a positive control probe. A
FFX
-ThrX
-3_st is a negative control probe. R
eference colour scale is represented on the right side (m
in – 1; m
ax - 15).   
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3.3.4 Array probes lack specificity to distinguish between miRs 
with single nucleotide difference. 
To investigate the potential cross-reactivity of the miR probes we correlated 
probes with single nucleotide differences. Certainly, strong correlation between 
expression of mature miR-23a and miR-23b (r=0.75, p<0.0001) and miR-27a and 
miR-27b (r=0.66, p<0.0001) would support the hypothesis of probe cross-
reactivity. Furthermore, linear regression showed that overall 56.4% of detected 
miR-23b could be explained by the expression of miR-23a (r2=0.5637, p<0.0001) 
and 44% of the miR-27b level by miR-27a transcript (r2=0.4379, p<0.0001), Table 
3.6. This association, however, was not statistically significant in the healthy 
control group and DMARDs resistant patients with regards to miR-27a and miR-
27b expression (Table 3.6).  
To further explore the option of cross-reactivity between other mature miRs 
with similar sequences, we have identified miR-155 and miR-505 to have single 
nucleotide difference between the human and mouse forms, both of which are 
present on the Affymetrix 3.0 miR Array platform including probes for other 151 
organisms. As expected, mouse miR-155 and miR-505 probes were able to detect 
a human sample but with lesser intensity than original human probes (Mean±SD 
of log2 probe intensity, 2.61±0.64 vs. 9.91±0.29 for miR-155 and 1.32±0.36 vs. 
4.02±1.08 for miR-505, mouse and human probes respectively, Figure 3.8). Also, 
the significant correlation between human and mouse miR-155 (r2=0.3994, 
p<0.0001) was observed. Mouse and human miR-505 expressions exhibited weak 
correlation with only tendency for significance (r2=0.1823, p=0.0695) pointing 
towards lower limits of accuracy in lowly expressed probes (<1.5 log2 intensity). 
Overall, this example confirms that cross-hybridisation of sequences with single 
nucleotide difference occurs in the array platform used for the analysis of this 
cohort and, as such, significant degree of detection of mature members of miR-
23b~24-1~27b cluster depended on the intensity of the expression of miR-
23a~24-2~27a cluster, where highly expressed transcripts like miR-23a had 
higher chance of cross-hybridization. 
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Table 3.6 Correlation and linear regression between the expression of ‘a’ and ‘b’ forms of 
miR-23 and miR-27 across all samples or individual groups.  
This table shows correlation intensity (r), significance (p) and linear regression (R2) between miR-
23a and miR-23b in the left column and miR-27a and miR-27b in the right column. Numbers in bold 
mark statistically significant correlations (Pearson’s correlation coefficients) and linear regression. 
 
 
miR$23a(vs.(miR$23b( miR$27a(vs.(miR$27b(
Correla'on)
(r,)p))
Linear)
regression)
(R2))
Correla'on)
(r,)p))
Linear)
regression)
(R2))
All)groups) 0.75,(<0.0001( 0.5637( 0.66,(<0.0001( 0.4379(
Healthy)Controls) 0.33,)0.14) 0.1095) 0.01,)0.96) 0.0001)
DMARDs)
Responder)
Pa'ents)
0.73,(<0.0012( 0.5382( 0.51,(0.0423( 0.2629(
DMARDs)
Resistant))
Pa'ents)
0.70,(<0.0002( 0.4971( 0.33,)0.1280) 0.1120)
Biologics)
Resistant)
Pa'ents)
0.75,(<0.0001( 0.5621( 0.80,(<0.0001( 0.6414(
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Figure 3.8 Tw
o exam
ples of cross-hybridization of hum
an and m
ouse probes in m
iR
 species w
ith single nucleotide difference on A
ffym
etrix 3.0 m
iR
N
A
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rray. 
This figure show
s the heat m
ap of log2 intensity of all probes identifying hum
an (hsa-) and m
ouse (m
m
u-) probes of m
iR
-155 and m
iR
-505 (probe identities are listed 
on the x axis).  A
FFX
-C
reX
-3_at is a positive control probe. A
FFX
-ThrX
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3.4 Increased expression of miR-27a and miR-27b in 
DMARDs responders is validated by qPCR.  
Quantitative PCR is a more sensitive method of detecting transcript expression 
and is therefore widely accepted for validating results of the miR array. Before 
testing valuable clinical samples we explored the sensitivity of miR qPCR primers 
and their ability to distinguish sequences with a single nucleotide difference. I 
selected the option of testing this with Qiagen miR SYBR Green qPCR primers.  
For this purpose, we created miR standards from commercially available miR-27a 
and miR-27b mimics diluted with sterile RNase free water to the concentration 
of 109 – 107 – 105 - 103 molecules per 2µl of the solution. These miR standards 
were then detected with both miR-27a and miR-27b primers in qPCR reaction. 
Here we established that miR-27a primers can detect miR-27b mimic with a 
significantly lower efficacy resulting in 7 to 9 PCR cycles delay (Figure 3.9, A). As 
expected in this case, detected levels of miR-27b linearly correlated with miR-
27a and could be fully explained by the affinity of the miR-27a primer for the 
miR-27b sequence (r=0.9978, R2=0.9956, p=0.0022). Likewise, miR-27b primers 
were able to detect miR-27a sequence with equal 7 to 9 PCR cycles delay, again 
creating a 102-103 gap and significantly depending on the affinity of miR-27b 
primers (r=0.9977, R2=0.9954, p=0.0023), Figure 3.9, A. Although there is 
obvious cross-reactivity between these assays, our biological samples do not 
express more than 103-105 copies of miR per test, allowing us to account for the 
contamination which is in this case negligibly small. Meaning that qPCR method 
would be acceptable quantifying the expression of miRs with a single nucleotide 
difference like miR-23a/b and miR-27a/b.  
Quantitative PCR analysis of the RA patient samples confirmed significantly 
increased expression of miR-27a in DMARDs responders when compared to 
healthy controls (Median (25,75%) 0.96 (0.8, 1.3) vs. 0.54 (0.36, 0.69) 
respectively, p=0.01) and both groups failing treatments (0.23 (0.11,0.38) in 
DMARDs failures and 0.37(0.16,0.58) in Biologics failures, p<0.0001 in both 
comparisons, Figure 3.9, B left). Equally, miR-27b was found to be significantly 
higher in DMARDs responders when compared to healthy controls (Median 
(25,75%) 0.07 (0.06, 0.08) and 0.04 (0.03, 0.05) respectively, p=0.05) and both 
non-responder groups (0.04 (0.01, 0.05) in DMARD resistant and 0.04 (0.02, 0.09) 
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in Biologic resistant groups, p=0.01 in both comparisons, Figure 3.9 B, right). The 
miR-27b expression is on average 10-fold lower than of miR-27a and could not be 
explained solely by the cross reactivity of qPCR primers, indicating a minor 
presence of mature miR-27b in the samples. For this analysis, three samples 
from healthy controls and ten samples from Biologics resistant group were 
excluded from the testing due to the very low content and poor purity of RNA in 
the samples, confirmed by NanoDrop measurement.   
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Figure 3.9 Validating the expression of miR-27a and miR-27b by qPCR. 
Qiagen SYBR-green mature miR Assays were used for the qPCR of miR-27a and miR-27b in 
CD14+ cells from RA patients and healthy controls. (A) Representative amplification plots for the 
specificity of Qiagen miR primers detecting miR standards derived from mature miR mimic cDNA 
reconstituted with water to the concentration of 109, 107, 105 and 103 molecules/µl. Numbers in red 
represent assay detection threshold. MiR-27a standards detected with miR-27a primers (top left), 
miR-27a standards detected with miR-27b primers (top right), miR-27b standards detected with 
miR-27b primers (bottom left) and miR-27b standards detected with miR-27a primers (bottom 
right). (B). Expression of mature miR-27a and miR-27b in primary CD14+ monocytes from all RA 
patients and healthy controls. QPCR method, data displayed as Mean±SD of 2^-dCT normalized to 
RNU6 control gene. Data analyzed by Kruskal-Wallis test for multiple comparisons with Dunn’s 
correction, * - p<0.05, ** - p<0.01, **** - p<0.0001. 
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3.5 Expression of miR-27a but not miR-27b correlates 
with multiple clinical outcomes. 
One of the goals of this study was to identify single or multiple miRs that can, in 
future work, be evaluated for their biomarker potential and further inform 
clinical and therapeutic choices. Addressing this, we analysed the correlation of 
miR-27a and miR-27b qPCR expression with clinical measures captured during 
categorisation of the patient cohort.  
MiR-27a but not miR-27b showed significant negative correlation with multiple 
clinical outcomes and scores. Tender joint count (TJC) and swollen joint count 
(SJC) both correlated negatively with miR-27a expression (r=-0.3751 and r=-
0.4125, p<0.01 respectively), Figure 3.10 A. Although no correlation was found 
with inflammatory markers like ESR and CRP or subjective parameters like 
patients VAS pain score, miR-27a has significantly negatively correlated with 
both DAS28-ESR and DAS28-CRP scores (r=-0.3974 and r=-0.3974, p<0.002 
respectively), Figure 3.10 B.  
Likewise, miR-27a had significant negative correlation with SDAI and CDAI scores 
(r=-0.4531 and r=-0.4389, p<0.001 respectively), Figure 3.10 C. This is likely 
based on the correlation with TJC and SJC since there was no significant 
association of miR-27a expression with other individual components of SDAI or 
CDAI scores including patients or physician’s global scores. 
Reassuringly, there was no obvious correlation between miR-27a or miR-27b 
expression and patients/volunteers age indicating that expression of these miRs 
is not driven purely by senescence. Interestingly, no association was found with 
disease duration amongst patients, inflammatory markers (CRP and ESR) or 
autoimmune antibodies (RF or anti-CCP). This taken together with significant 
correlation with SJC and TJC points towards the specific association of miR-27a 
with synovial inflammation rather than general inflammation, serology or age. 
The negative correlation of miR-27a with these parameters further supports our 
hypothesis of the protective role of this miR in the monocyte-mediated synovial 
inflammation in the context of RA.  
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Figure 3.10 Expression of miR-27a correlates with clinical data from all RA patients. 
Plots show all RA patients recruited for the study. (A) Here, tender joint count (TJC) on the left and 
swollen joint count (SJC) on the right show moderate negative correlation with qPCR miR-27a 
expression (Pearson’s parametric correlation coefficient, r=-0.3751, p=0.0025 and r=-0.04125, 
p=0.0008, respectively). (B) Both clinical scores DAS28-ESR (left) and DAS28-CRP (right) 
negatively correlate with qPCR miR-27a expression (Pearson’s parametric correlation coefficient 
r=-0.3974, p=0.0014 and r=-0.3947, p=0.0016, respectively). (C) SDAI (left) and CDAI (right) 
clinical score also negatively correlate with qPCR miR-27a expression (r=-0.4531, p=0.0002 and                 
r=-0.4389, p0.0003, respectively). For this analysis Spearman’s non-parametric correlation 
coefficient was used since SDAI and CDAI scores exhibit non-parametric distribution.  
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3.6 Discussion 
RA is an autoimmune, chronic and likely pathogenically diverse disease. 
Treatment options are based on immune suppression. Whether it is DMARDs or 
biologic treatments, drug-free remission is too rare [630] [621]. More 
importantly, trials have shown that it is early recognition, clinical judgment and 
an aggressive treat to target approaches that are key factors in achieving 
remission in patients. For example, TICORA (Tight Control of RA) study showed 
that improving clinical practice and implementing tight control protocols can 
increase the clinical remission rate with DAS score <1.6 to 65% after 18 months, 
compared to only 16% success rate in the routine group [64]. The success of the 
routine group, in this case, is also comparable with the overall efficacy of 12 
months of TNFα treatment after DMARDs failure, with 26%, 21%, and 17% DAS28 
remission rates with adalimumab, etanercept and infliximab respectively [631]. 
The negative outcome of the Triple Therapy in Early RA (TEAR) study posing a 
valuable question whether remission rates could be further improved by starting 
the treatment with triple DMARD therapy in every patient, has taught us that 
“one drug for all” no matter how intense is not appropriate for the treatment of 
RA [65]. Moreover, it is still recommended that Methotrexate as a single 
agent should be the first line treatment for the majority of RA patients with 
expected efficacy in more than one-third of cases [632]. The clinical data 
above support the hypothesis of this study that “right patient and right 
treatment/treatments” should be identified early for the improved efficacy. To 
study this we have turned to the detailed clinical categorisation of patients with 
different treatment response to a variety of therapeutics.  
For this, we selected three patient groups and matched healthy controls. All 
patients met the ACR 1987 diagnostic RA criteria and had established disease. 
They were further subdivided into groups. The first clinical group involved good 
responders with low disease activity on DMARDs, mostly a single agent, with 
disease duration over ten years. These were patients with low disease activity 
(DAS28<3.2) rather than patients in remission (DAS28<2.6) which made recruiting 
in the given timescale possible. This group was then compared to the patients 
with high disease activity (DAS28>5.1) despite treatment with several DMARDs 
and shorter overall disease duration. Lastly, we have compared the good 
responders to a group involving patients with high disease activity (DAS>5.1) on 2 
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or more biologic treatments. Unfortunately we failed to recruit a group of 
patients with good response to biologic treatment, and this is a shortcoming of 
this study. However, the principle separation of patients into responders and 
non-responders is still valid. Although the separation of medical treatments to 
DMARDs and biologics therapies is a crude approach to segregating treatments, it 
is the most historically established one. DMARDs agents vary greatly in the 
mechanism of action, efficacy and side effects as described in Chapter 1. 
Similarly, a variety of biologic treatments could be easily separated further 
according to the cell type they affect. Moreover, new therapies like small 
molecule inhibitors have a distinct mechanism of action but do not strictly 
adhere to any of these categories and would pose a further dilemma on the 
classification of the treatments used. The major contribution of biologic agents 
was, therefore, a variety of treatment options for patients whose disease does 
not respond to a number of DMARD agents. Having further treatment options in 
such an evasive disease is critical for the clinical success which is why 
understanding the pathogenesis behind the clinical response to single treatment 
agent and direct comparison to the multiple treatment failures is a valuable 
characteristic of this study.  
Moreover, we selected CD14+ monocytes as blood derived precursors that are 
not only central to the pathogenesis of RA but also serve as a primary 
therapeutic target for the majority of treatments used from DMARDs to biologic 
agents. It has been shown that Methotrexate increases CD95 marker expression 
in blood mononuclear cells sensitising them to apoptosis [633]. Similar 
antiproliferative and apoptotic effect of Methotrexate was shown in the THP-1 
human monocytic cell line [43]. These findings could explain why the number of 
circulating CD14+high cells was predictive of clinical response to Methotrexate 
[634].  
Amongst biologic agents, most commonly used anti-TNFα treatment has a direct 
influence on monocytes recruitment and activity in the RA synovium. Earlier 
studies have clearly shown reduced number of CD68+ve macrophages in the 
lining and the sublining of the synovial joint as early as two weeks post first 
therapeutic infusion [365]. Further studies have confirmed that anti-TNFα 
treatment significantly reduces the influx of monocytes to the affected joints 
and likely increases the efflux, overall contributing to the reduction of 
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inflammation [635]. Responders to treatment with Tocilizumab, an anti-IL6R 
monoclonal antibody, were also shown to have less circulating monocytes and 
myeloid DCs [636]. Even Abatacept, a CTLA4 antagonist known for its effect on T 
cells has been shown to reduce the expression of adhesion molecules in 
monocytes and macrophages after few weeks of treatments and therefore 
reduce the endothelial adhesion and migration [637].  
From this, I conclude that the majority of current RA treatments primarily target 
peripheral blood monocytes and macrophages when exuding their therapeutic 
effect. Therefore this study is unique in the sense that it describes miR profiling 
of primary pathogenic CD14+ cells in clinically well-defined groups of difficult to 
treat patients with RA. Such studies including this number of patients are very 
laborious and represent a classic example of extensive bench to bedside 
collaboration. Often miR array results have a large number of confounding 
factors, yet, by narrowing the clinical criteria and isolating a specific cell 
population we were hoping to better address the question of miR-dysregulation 
in RA monocytes. Similar approaches have been taken in more recent studies 
investigated miR profiles of monocytes from patients with systemic juvenile 
idiopathic arthritis (sJIA), monocyte activation syndrome (MAS) and Sjögren’s 
syndrome [638] [639]. Another study, done on a significantly smaller scale, has 
compared the miR profile of CD14+ cells derived from synovial tissue obtained 
during joint replacement in RA and OA patients [640]. Here, authors identified 
miR-223 as critical regulator of aryl hydrocarbon receptor (AHR) in synovial 
macrophages from RA patients. The most recent study, published only as an 
abstract from 2015 ACR meeting has described a miR profile in CD14+CD16+ 
populations of peripheral blood monocytes from RA patients and healthy 
volunteers. However, they have predominantly focused on the atherogenic risk 
and cardiovascular disease in RA [641]. The most relevant study to date analysed 
circulating serum derived miRs in 95 RA patients undergoing combined TNFα and 
DMARDs treatment. Although no speculation was made to the cell types 
accounting for the differences found, this group has shown that non-responders 
to combination treatment failed to upregulate miR-23 and miR-223 in the serum, 
in concordance with our results and additionally underscoring prominent role of 
miRs in drug-disease interplay [642].  
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Our patient and healthy volunteer cohort includes predominantly women (56-
85%). This is consistent with previous reports of higher incidence of RA in the 
female sex. It is also well established that joint destruction as a result of 
inflammation is more pronounced in women (50%) than in men (27%) and 
requires more often surgical interventions [643]. Seropositivity for RF in our 
cohort (78-90%) was also comparable to that from the general population of RA 
patients (80%) and is highly predictive of more aggressive disease [644]. Between 
68-84% of recruited RA patients were positive for anti-CCP Ab, other hallmark 
antibodies in RA associated with joint destruction [645] [646] [647]. Healthy 
controls were predominantly younger women with mean age of 48 years, and all 
apart from one were seronegative. One seropositive healthy control had a low RF 
and anti-CCP titres and denied any clinical signs of the disease, therefore did not 
meet the exclusion criteria, Table 3.1. These data show no significant 
differences in age, sex or serological findings between patient groups indicating 
that these were not likely contributors to the disease resistance seen here. As 
mentioned before, patients in DMARDs responders group had longer disease than 
the two groups failing treatment also indicating that treatment resistance is an 
attribute of the disease pathogenesis rather than duration.  
Interestingly, inflammatory markers ESR and CRP were within normal limits in all 
patient groups. Nonetheless, CRP was significantly higher than in healthy 
controls group, likely indicating chronic low-grade inflammation. Large studies 
conducted in subjects with cardiovascular disease have clearly shown an 
association between the marginal rise in CRP and increased risk of a fatal 
cardiovascular outcome, despite overall ‘normal’ levels of the marker [648]. This 
points towards an overall cumulative effect of the low-grade chronic 
inflammation exemplified by the small increase in CRP we observed in patient 
groups. Other clinical parameters were measured only in patient groups where 
differences between treatment responders and non-responders were obvious. 
Namely, all clinical scores – DAS28 ESR and CRP, SDAI and CDAI scores as well as 
independent clinical parameters such as TJC and SJC, patients and physician’s 
global scales were indicating low disease activity in DMARDs responders and 
were significantly increased in both groups failing treatment confirming the 
severe on-going inflammatory process, Table 3.2. A separate analysis of DMARDs 
responder groups demonstrated the equal contribution of both sexes with 
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regards to low disease activity scores. Overall, we found no clinical 
idiosyncrasies that would render these data atypical and outcomes are suitable 
for generalizability to RA. 
Array technology on purified CD14+ve cells allows for broad, extensive profiling 
of the miR expression signatures. Group analysis showed a higher proportion of 
differentially expressed miRs in patients failing DMARDs and biologic treatment 
compared to DMARDs responders or healthy controls, Figure 3.2. The coherent 
nature of DMARDs responders was also evident from the principal component 
analysis when patients in these groups could be easily identified by the first 
principle component. Treatment-resistant groups and healthy controls group, 
were significantly more diverse, Figure 3.1. As Leo Tolstoy remarked, “Happy 
families are all alike; every unhappy family is unhappy in its own way”. Lack of 
other similar studies and no principle component analysis of those published 
limit the possibility of comparison and speculation on the coherence of miR 
expression patterns in drug resistant RA. True to the aim of this project, we 
investigated and compared drug-resistant and responder groups rather than how 
they relate to healthy controls.  
Comparing miR expression profiles from DMARDs responders and both groups 
failing treatment, we identified several miRs that have known association with 
autoimmune or inflammatory conditions. Amongst the top 50 differentially 
expressed miRs were miR-505, miR-128, miR-422, miR-378, miR-30, miR-29, miR-
27 and miR-23, Figure 3.3 and Figure 3.4. For example, miR-505 was recently 
recognised in a small group of patients as a potential serum biomarker for 
primary biliary cirrhosis [649]. The immunological role of miR-128 was described 
in overexpression transgenic mice model with reduced generation of precursors 
and mature B cells while seeing an increase in common lymphoid progenitor cells 
[650]. Existing data on miR-422a is limited to 23 reports overwhelmingly in the 
context of cancer cells. However, a recent publication has demonstrated direct 
targeting of kallikrein-related peptidase 4 and the role of miR in SLE nephritis 
[651]. MiR-378 is best known for its effect in muscle strain and certain cancers. 
However, its immunological role was recognised in the ability to negatively 
regulate NK cells cytotoxicity, the ability that it shares with miR-30e [652]. 
Additionally, overexpression of miR-30b has been shown to attenuate antigen 
presentation capacity of primary human macrophages and dendritic cells [595]. 
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MiR-29 has multiple roles in the immune and inflammatory processes. Our group 
has shown a decisive role of miR-29 in tendon inflammation and how it regulates 
the onset and perpetuation of tendinopathy [653]. MiR-29 is also well known for 
regulating wound healing and for its ability to influence fibrosis, including 
intestinal fibrosis in inflammatory bowel disease [654]. Lastly, miR-23 and miR-
27 are one of the first miRs to be discovered and as such have been studied in a 
variety of cancers [517] [655] [656]. There is a growing body of work highlighting 
their important role in autoimmune disease, described in detail in Chapter 1.  
Interestingly, there are a number of other miRs known for their importance in RA 
that have not featured in our analysis. Amongst them are miR-155, miR-146a, 
miR-223 and miR-34a. Mir-155 is a proinflammatory miR and overexpressed in RA 
patients. Our group has shown that miR-155 is expressed at a particularly high 
level in synovial tissue cells compared to PBMCs from RA patients [550]. 
Furthermore, we have shown that miR-155 expression has a profound effect on 
migration of monocytes through the regulation of chemokines and chemokine 
receptors [552]. Next, miR-146a and b are both known for their anti-
inflammatory properties in RA myeloid cells. MiR-146a expression is induced by 
proinflammatory cytokines like TNFα or through LPS stimulation, and in return, 
they inhibit NFκB signalling by directly binding to IRAK1 and TRAF6 [657]. A 
further report by Pauley et al. confirmed upregulated miR-146a expression in 
PBMCs from RA patients and the significant impact it exhibits on TNFα 
production [554]. Furthermore, miR-223 is known for its stimulating role in 
osteoclastogenesis by repressing the M-CSF inhibitor NF1A [562]. Both of these 
miRs were also detected RA and OA synovium [658]. Lastly, we have shown that 
miR-34a is expressed at high levels in RA SF macrophages and in PB monocytes in 
difficult to treat patients (Tange, C. E, unpublished data) [659]. The profound 
role of these miRs in maturation, activation and migration of macrophages may 
not be as readily reflected in circulating precursor monocytes, therefore 
explaining why they are not prominently featured in our dataset. Secondly, 
there is no significant body of data linking these miRs to the effect of 
medications in RA. Therefore, they might not play a role in treatment response 
for which this study was designed. As a result, we have focused our further 
effort on understanding the role of miR-23~24~27 in the treatment-resistant RA 
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as it contains two members prominently dysregulated in our miR array analysis 
that may exhibit a synergistic effect in CD14+ RA monocytes. 
Briefly, I will touch on the subject of the sensitivity of the miR array detection in 
the context of the miR-23~24~27 cluster which is of particular interest when 
accounting for significant similarities between the ‘a’ and ‘b’ miR forms. Three 
principle methods are used for detecting miRs: RT-qPCR, miR array hybridization 
and next generation sequencing methods. Amongst them, miR array is the least 
equipped method to distinguish between single nucleotide differences in mature 
miRs, predominantly because the entire sequence of the miR is used as a probe 
resulting in the great variability of melting temperatures [660]. Recent 
technological advancements include higher overall hybridization temperature to 
decrease the cross-hybridisation or, alternatively, the use of locked nucleic acid 
bases to increase specificity. However, single nucleotide difference could be 
distinctively evaluated only by the costly Next-Generation sequencing method 
[660]. Our data would certainly suggest that Affymetrix miR Array 3.0 platform is 
not sensitive enough to adequately distinguish between miR-23a and miR-23b or 
between miR-27a and miR-27b as a high degree of correlation was established in 
those pairs, Table 3.6. This finding was further exemplified by the clear 
hybridization signal from relevant murine miR probes in the absence of murine 
sequences, Figure 3.8. Despite limited sensitivity, it appears that all mature 
miRs from both ‘a’ and ‘b’ miR-23~24~27 clusters were present, even taking into 
account the higher expression levels of miR-23a and miR-27a compared to their 
counterparts from the miR-23b~24-1~27b cluster. Even so, we struggled to 
identify primary transcript identifying miR-23b~24-1~27b cluster. This 
phenomenon was previously explained in the literature by likely rapid processing 
of the primary transcript [517]. This is hardly surprising in the context of the 
overall lower expression of the miR-23b~24-1~27b cluster, which was shown to 
be expressed at low levels in myeloid cells [593].  
The expression of pri-miR-23a~24~27a did not correlate with the expression of 
mature miRs, Table 3.5. There are several possible explanations for this finding. 
Firstly, miR-24 is indistinguishable between both clusters and should not 
correlate with either pri-miR transcript. Secondly, mature miRs have greater 
stability and longer half-life than primary transcripts.  Thirdly, mature miRs from 
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these clusters are known to have differential processing of the mature forms 
dependent on the context [567].  
Validating this data with qPCR has confirmed that miR-27a and miR-27b are 
differentially expressed in different treatment groups. Taking into account the 
healthy controls group it appears that both miRs are upregulated in good 
responders to DMARDs treatment, Figure 3.9. Failure to upregulate the 
expression miR-27a in DMARDs and biologics treatment groups showed a negative 
correlation with all clinical scores – DAS28 ESR and CRP, SDAI and CDAI scores, 
Figure 3.10. MiR-27a but not miR-27b levels were also found to correlate with 
the essential clinical parameters – TJC and SJC. Blood-derived parameters that 
have the ability to correlate with clinical synovial inflammation are quite rare, 
and biomarker potential of miR-27a could be further explored in the plasma 
levels and tested in the independent RA cohort, although this would be beyond 
the spectrum of this investigation. The above-mentioned clinical correlations 
suggest that miR-23~24~27 cluster may play a role in treatment responses in RA 
patients.  
Summarising my data so far, we have found miR-23a~24-2~27a cluster to be 
highly expressed in CD14+ monocytes from healthy controls or good responders to 
DMARD treatment with low disease activity. On the contrary, miR-23a and miR-
27a expression was significantly reduced in patients failing all modes of 
treatment that have perpetually increased inflammatory burden, as evident 
from raised disease activity scores. This inverse correlation is summarised below 
in Figure 3.11. The next chapter will explore what regulates the miR-23a~24-
2~27a cluster in blood-derived monocytes and mature macrophages.  
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Figure 3.11 Depiction of inverse correlation of miR-23 and miR-27 in CD14+ monocytes from 
RA patients and healthy controls with disease activity.  
Study included 21 Healthy controls, 16 DMARDs responders patients, 22 DMARDs resistant 
patients and 41 Biologics resistant patients. Red colour represents ‘higher’ values; green colour 
represents ‘lower’ values. Arrows represent transformation from no or low disease activity in 
healthy controls and DMARDs responders (left two groups) to higher disease activity states in 
DMARDs and Biologics non-responders (right two groups), as measured by DAS28, SDAI and 
CDAI scores. In contrast, the expression of miR-23 and miR-27 exhibit the opposite distribution.  
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4  Factors regulating miR-23a~24-2~27a cluster in 
monocytes and macrophages 
4.1 Introduction 
MiR-23~24~27 clusters have been implicated in a variety of physiologic and 
pathologic processes including oncogenesis, tumour metastasis, apoptosis and 
myelopoiesis (Chapter 1)[567]. This versatility of functions and context-
dependent expression of miR-23~24~27 clusters is enabled by a range of 
regulatory transcription factors (TF). In myeloid cells, miR-23~24~27 was shown 
to play different roles depending on several TFs crucial to development, 
maturation and activation of the cells. Amongst them, PU.1 which is necessary 
for the myeloid lineage commitment [253]. It is the regulation of miR-23~24~27 
cluster by PU.1 that plays a decisive role in the promotion of myelopoiesis over B 
cell lymphopoiesis from progenitor cells in mice [568]. Additionally, miR-23a~24-
2~27a can also influence erythropoiesis when regulated by NFκB p65 in bone 
marrow-derived cells [661,662]. In maturation, terminating expression of miR-24 
was necessary to allow M-CSF-driven differentiation of human monocytes into 
macrophages [663]. Considering that M-CSF is a driving and survival force for the 
majority, if not all of recruited inflammatory monocytes, this suggests a prime 
role for miR-23~24~27 clusters in the regulation of innate immune response. This 
role was further confirmed by reports of direct binding of NFκB p65 to miR-23b 
promoter upon IL-17A and other cytokine stimulations [593]. Indeed, this data 
indicates that other pro-inflammatory cytokines acting through NFκB activation 
like TNFα or TLR ligands could have an effect on miR-23~24~27 clusters [664]. In 
fact, stimulating mature macrophages with TLR3, TLR4 and TLR9 ligands 
decreased the expression of miR-23a and relieved the repression on its direct 
target TNFAIP3 (A20), a negative regulator of NFκB [665]. Regulation of 
NFκB/A20 pathway is vital not only for autophagy and antifungal properties of 
macrophages but also for continuation of chronic inflammation [666,667]. 
Genome-wide association studies (GWAS) have linked polymorphisms in the A20 
loci with susceptibility to RA and other auto-immune diseases [668,669]. Further 
investigation of the regulation of miR-23~24~27 clusters in human myeloid cells 
will be informative of miR biology as well as of the regulation of monocyte 
activation under inflammatory conditions like RA. 
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Reassuringly, human myeloid cells were found to have all the necessary 
components to process miRs in the usual way, therefore limiting the mechanistic 
difficulties with interpretation of results [663]. MiR-23a~24-2~27a is expressed as 
single transcript under the control of its promoter [670]. Its paralogue, the miR-
23b~24-1~27b cluster has an intronic location within its host gene C9ORF3 with 
which it is thought to be exclusively co-expressed [567]. Despite being present in 
a variety of contexts, it seems that miR-23a-24-2~27a is primarily expressed in 
blood derived cells while its paralogue is predominantly present in tissues [567]. 
Investigating the transcriptional regulation of miR expression requires 
quantification of primary miR transcripts rather than mature forms. It is here we 
can measure rapid changes in the rate of expression that would otherwise be 
difficult to detect in what are often significant pools of relatively stable mature 
miRs [517,670]. This underscores the importance of focusing on early time points 
when investigating the stimuli and pathways responsible for regulating the 
expression of pri-miR-23a~24-2~27a [517,670]. In this chapter, I will elucidate 
the influence of pro-inflammatory cytokines on the expression of the primary 
miR-23~24~27 transcript in human monocytes and macrophages.   
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4.2 Results 
4.2.1 Expression of miR-23~24~27 clusters in CD14+ monocytes. 
Circulating monocytes are abundant and versatile blood cells typically 
distinguished by CD14+ cell surface marker [671]. Purified CD14+ cells from four 
buffy coats were tested for the expression of miR-23~24~27 clusters (Figure 4.1). 
Primary miR-23a~24-2~27a cluster transcript was expressed at significantly 
higher levels than pri-miR-23b~24-1~27b (Figure 4.1, A). Pri-miR-23a~24-2~27a 
was also found to be highly expressed in CD14+CD16- monocytes when compared 
to total CD14+ cells (Figure 4.1, B). These "classical" monocytes are thought to 
have less contribution to overall inflammation in such autoimmune diseases as 
RA and SLE than pro-inflammatory CD14lowCD16+ cells, in keeping with our 
hypothesis that miR-23a cluster may have an anti-inflammatory role in RA 
[672,673].  
While, mature miR-23a, miR-24 and miR-27a are readily detectable in CD14+ 
cells they do not appear to accumulate at equal numbers, with miR-24 levels 
being significantly higher than miR-23a or miR 27a (Figure 4.1, C). I also 
observed no significant difference between levels of miR-23a and miR-27a, this 
is in contrast to a previous report in mouse CD14+ monocytes which showed 
reduced expression of miR-23a compared to others [568]. Although found at 
similar levels, miR-23a and miR-27a did not correlate with their expression in 
these samples (r=0.495, p=0.505). As expected, mature members of the 
paralogue cluster, miR-23b and miR-27b, were expressed 100-fold less than the 
‘a’ cluster (Figure 4.1, D). Within this data, miR-23b is present at significantly 
higher levels than miR-27b (Figure 4.1, D). There is an almost linear correlation 
between the expression ‘a' and ‘b' miR family members, which strongly suggests 
there is significant primer cross-reactivity in the mature ‘a' and ‘b' qPCR assays 
in keeping with observations recorded in Chapter 3 (Figure 4.1, E). 
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Figure 4.1 Expression of the miR-23~24~27 cluster in buffy coat  derived monocytes. 
Primary human CD14+ monocytes were used for each experiment. Results are obtained by the 
qPCR method and displayed as 2^-dCT relative to GAPDH (control for mRNA) or RNU6 (control for 
miR) genes. (A) CD14+ cells were purified from 3 buffy coat donors and tested for expression of 
primary miR-23a~24-2~27a and miR-23b~24-1~27b transcripts. Data was analysed by Mann-
Whitney’s test. (B) CD14+ and CD14+CD16- cells from 4 buffy coat donors were tested for 
expression of pri-miR-23a~24-2~27a. Data was analysed by Mann-Whitney’s test. (C) CD14+ cells 
from 4 buffy coat donors were tested for the expression of mature members of miR-23a~24-2~27a 
cluster. Data was analysed by Kruskal-Wallis test with Dunn’s correction for multiple comparisons. 
(D) CD14+ cells from 4 buffy coat donors were tested for the expression of mature miR-23b and 
miR-27b. Data was analysed by Mann-Whitney's test. (E) Correlation plots between mature 
members of ‘a’ and ‘b’ cluster: miR-23a and miR-23b, r=0.9, p=0.068 (E); miR-27a and miR-27b, 
r=0.977, p=0.02. Data was analysed by Pearson’s correlation coefficient. * - p≤0.05, ** - p≤0.01. 
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4.2.2 Influence of cytokines on the expression of miR-23a~24-
2~27a cluster in monocytes. 
Inflammatory cytokines influence activation, expression of adhesion molecules, 
maturation and T cell priming abilities of monocytes [674]. For example, TNFα 
stimulation of CD14+ cells aides differentiation of monocyte and T cell priming 
through increased expression of IL-17A [675]. Both cytokines have been shown to 
activate NFκB and promote inflammation [676]. Antibody blockade of both is 
currently successfully used in the clinical practice of multiple inflammatory 
conditions (Chapter 1). In these experiments, neither TNFα nor IL-17A had any 
influence on the expression of pri-miR-23a~24-2~27a transcript in CD14+ cells 
form 4 buffy coat donors (Figure 4.2, A, B).  
4.2.2.1 Gamma and beta interferon stimulation of human CD14+ monocytes 
reduce miR-23a~24-2~27a cluster expression. 
I next sought to examine the effect that type I (IFNα and IFNβ) and type II (IFNγ) 
interferons had on miR-23a~24-2~27a cluster expression. CD14+ monocytes from 
4 buffy coat donors were treated separately with IFNα, IFNβ and IFNγ. IFNα 
showed no significant effect on pri-miR-23a expression, although did trend 
towards an increase (Figure 4.2, C). Treatment with IFNγ produced a significant 
reduction in pri-miR-23a expression after 4 and 24 hours of stimulation (Figure 
4.2, D). A similar reduction was also observed in IFNβ treated cells (Figure 4.2, 
E).   
JAK1-STAT1 are shared between IFNβ and IFNγ signalling pathways, suggesting 
that these maybe involved in the direct regulation of pri-miR-23a expression 
[677,678]. Even so, this is an unexpected observation given the apparent 
different functional effects elicited by type I and II interferons on monocyte 
function [678].  
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4.2.2.2 Interleukin 6 and CCL2 stimulation of human CD14+ monocytes 
reduces miR-23a~24-2~27a cluster expression  
Next, CD14+ monocytes were stimulated with IL-6, to assess its influence on pri-
miR-23a expression. IL-6 has a well-characterised role in the chronicity of RA, 
which is reflected in clinical practice where the biologic agent tocilizumab 
targeting IL-6R shows significant efficacy [679]. In CD14+ monocytes, IL-6 
reduced the expression of pri-miR-23a~24-2~27a after 24 hours of exposure 
(Figure 4.2, F). The lack of effect of IL-6 after 4 hours suggests that IL-6 may act 
indirectly.  
In contrast to this, treatment of CD14+ monocytes with the migratory 
inflammatory chemokine CCL2 led to the significant decrease in the expression 
of pri-miR-23a~24-2~27a transcript after 4 but not at 24 hours indicating the 
direct ability of the chemotactic molecule to regulate the expression of miR-23a 
in primary human monocytes (Figure 4.2, G). 
Interestingly, none of the inflammatory stimuli tested above led to the increased 
expression of this miR cluster, which may simply reflect the already high levels 
of miR expression within CD14+ cells. The reduction in pri-miR-23a transcript 
following stimulation with pro-inflammatory cytokines is in keeping with the low 
levels of miR-23a~24-2~27a found in the CD14+ cells derived from RA patients 
failing DMARD or biologic treatment. Analysis of the potential transcription 
factors mediating this is to follow. 
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Figure 4.2 Influence of proinflammatory cytokines and CCL2 chemokine on the expression 
of miR-23a~24-2~27a cluster in CD14+ monocytes. 
Primary human CD14+ monocytes from 4 buffy coat donors were used for A-F experiments, and 3 
buffy coat donors samples were used for the experiment G. Results are obtained by the qPCR 
method measuring pri-miR-23a~24-2~27a and displayed as Mean±SD of RQ (2^-ddCT) relative to 
18S or GAPDH genes and control cells. (A) Cells were incubated with 50 ng/ml of M-CSF and 10 
ng/ml of TNFα for 24H. (B) Cells were incubated with 50 ng/ml of M-CSF and 100ng/ml of IL-17A 
for 24H. (C,D) Cells were incubated with 50 ng/ml of M-CSF and 10ng/ml of IFNα (C) and 10 ng/ml 
of IFNγ (D) for 4 and 24 hours and (E) Cells were incubated with 50 ng/ml of M-CSF and 10 ng/ml 
of IFNβ for 4 hours. (F) Cells were incubated with 50 ng/ml of M-CSF and 50 ng/ml of IL-6 for 4 and 
24 hours. (G) Cells were incubated with 50 ng/ml of M-CSF and 100 ng/ml of CCL2 for 4 and 24 
hours. Data for A, B and E were analysed by Wilcoxon’s test; data for C-G were analysed by 
Kruskal-Wallis test with Dunn’s correction for multiple comparisons. * - p≤0.05, ** - p≤0.01.  
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4.2.3 Influence of TLR stimulants on the expression of miR-
23a~24-2~27a cluster in monocytes. 
Activation of monocyte/macrophages by microbial components and also by 
endogenously arising DAMPS, signaling via Toll-like receptors (TLRs 1-9) results in 
the production of a variety of proinflammatory responses many of which are 
hallmarks of RA [680,681]. A recent study reported that TLR3/4 induced 
NFκB/p65 directly regulated the miR-23a cluster expression in leukaemic cells 
and erythroid precursors [661]. With this in mind, I decided to explore the effect 
of TLR stimulation on miR-23a~24-2~27a expression. 
4.2.3.1 TLR activation does not regulate miR-23a~24-2~27a expression in 
human CD14+cells 
To examine the potential role of TLR signalling in the regulation of miR-23a~24-
2~27a cluster expression I stimulated CD14+ cells from 4 buffy coat donors and 
measured pri-miR-23a by qPCR.  
Pam3CSK4 (Pam3) a ligand for the TLR1/2 pathway had no effect on the 
expression of pri-miR-23a (Figure 4.3, A). TLR4 activation via LPS stimulation 
showed a non-significant increase in pri-miR-23a levels after 4 hours of 
exposure, but no effect after 24 hours (Figure 4.3, B). Upon closer scrutiny of 
this data revealed an upregulation of pri-miR-23a~24-2~27a by LPS in 3 out of 4 
samples (p=0.06). It is possible that the addition of more donors this study could 
have reached significance. Exposure of monocytes derived from peripheral blood 
of 3 healthy controls and 3 RA patients with active disease confirmed that TLR4 
activation has an inconsistent effect on miR-23~24~27 cluster expression with no 
statistically significant change in expression (Figure 4.3, C). Again, this could be 
due to the limited number of participants.  
TLR3 ligand, Poly(I:C) that mimics viral double-stranded RNA, was used to 
stimulate CD14+ cells. I found no change in miR-23a cluster expression (Figure 
4.3, D). Similarly, CLO97, which is structurally comparable to single-stranded 
RNA that activates TLR7/8 signaling, had no effect on the expression of pri-miR-
23a (Figure 4.3, E). TLR9 ligands were not included in this study as this receptor 
is largely absent from human monocytes, which are as a consequence 
unresponsive to them [682]. TNFα production was measured in each sample as a 
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positive control for TLR stimulation (Figure 4.3, F). In all cases, an increase in 
TNFα was observed in cells treated with TLR ligands, indicating that signaling 
had taken place in samples assessed for pri-miR-23a levels. As expected, TNFα 
production in cells stimulated by Pam3 resulted in a very modest escalation of 
the cytokine release, in keeping with previous reports [683].  
The results above show that pri-miR-23a expression is largely unaffected by TLR 
activation which is at odds with a report demonstrating that miR-23a cluster 
expression is up-regulated in response to NFκB/p65 activation [661]. Our failure 
to reproduce the author’s findings likely stems from the use of different cell 
types, monocytes rather than leukemic cell lines. I did note a trend towards 
increased expression upon LPS stimulation, which may have reached significance 
with the inclusion of more donors. Another potential reason that no increase in 
pri-miR-23a expression was observed may have been due to their already high 
expression, meaning that any induction could be difficult to detect.   
Lastly, I have investigated the effect of hypoxia on the levels of miR-23a cluster. 
Hypoxic conditions are present in the inflamed arthritic joints and are thought to 
be a powerful driver of angiogenesis, immune cell migration and perpetuation of 
inflammation [684,685]. With the lack of modular incubator, hypoxia in 
mammalian cells can be induced with cobalt (II) chloride hexahydrate solution 
(CoCl2) resulting in activation of hypoxia-induced factor 1α (HIF1α) [686]. 
Exposure of CD14+ monocytes from 7 buffy coat donors to CoCl2 solution for 24 
hours did not alter the expression of pri-miR-23a~24-2~27a transcript, negating 
the effect of chemically induced hypoxia (Figure 4.3, G). This experimental 
model of hypoxia also failed to induce TNFα expression during 24-hour 
stimulation by CoCl2 (Figure 4.3, H) 
Above investigations conclude that cytokine cross-talk rather than bacterial and 
viral danger signals modulate the expression of miR-23~24-2~27a cluster in 
peripheral blood monocytes. Other environmental stimuli such as hypoxia, are 
characteristic for arthritic joints and have no direct influence on the expression 
of miR-23a~24-2~27a.  
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Figure 4.3 Influence of TLR ligands on miR-23a~24-2~27a cluster expression in CD14+ 
monocytes. 
Primary CD14+ monocytes were used for each experiment. Results for A-E, G are obtained by the 
qPCR method measuring pri-miR-23~24~27 and displayed as RQ (2^-ddCT) relative to 18S or 
GAPDH genes and control cells, represented by Mean±SD. Results for F and H are obtained by 
ELISA method and are displayed as the concentration of TNFα cytokine (pg/ml) (A, B, D) CD14+ 
cells from 4 buffy coat donors were incubated for 4 and 24 hours with 50 ng/ml of M-CSF and 150 
ng/ml Pam3CSK4 (Pam3), 50 ng/ml LPS and 25 µg/ml Poly(I:C), respectively. (C) CD14+ cells from 
3 HC and 3 RA patients were incubated for 24 hours with 50ng/ml of M-CSF and 50 ng/ml of LPS. 
(E) CD14+ cells from 4 buffy coat donors were incubated with 50 ng/ml of M-CSF and 1 µg/ml of 
CL097. (F) Showing TNFα levels in the supernatant of cells after TLR stimulations from A, B, D and 
E. (G) CD14+ cells from 7 buffy coat donors were incubated with 50 ng/ml of M-CSF and 100 µM 
CoCl2 for 24 hours. (H) Showing TNFα levels in the supernatant of cells from experiment G. Data 
for A, B, D and F were analysed by Kruskal-Wallis test with Dunn’s correction for multiple 
comparisons. Data for C were analysed by Wilcoxon test for each pair. Data for E, G and H, were 
analysed by Mann-Whitney test. Non-significant p≥0.05 for A-E, G-H, * - p≤0.05, ** - p≤0.01. 
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4.2.4 Expression of miR-23a~24-2~27a cluster in macrophages. 
Macrophage-colony stimulating factor (M-CSF) is the accepted primary lineage 
regulator of almost all mononuclear phagocytes and resident macrophages [687]. 
M-CSF 1 receptor (CSF1R) is expressed on the majority if not all macrophages 
and some types of dendritic cells [245]. As such, M-CSF/CSF1R pathway is the 
main driver of maturation of monocytes into macrophages in response to 
inflammation [251]. Thus, I sought to determine if M-CSF-driven maturation of 
monocytes into macrophages had any effect on the expression levels of the miR-
23a~24-2~27a cluster. 
4.2.4.1 miR-23a~24-2~27a cluster is down regulated in M-CSF matured 
macrophages.  
To determine the effect of M-CSF-driven maturation of monocytes on the 
expression of pri-miR-23a cluster expression, CD14+ blood-derived monocytes 
were treated with M-CSF. Pri-miR-23a and pri-miR-23b cluster expressions were 
measured on 0, 3 and 7 days post stimulation with M-CSF. Exposure of monocytes 
with M-CSF resulted in significant downregulation of pri-miR-23a~24-2~27a by 
day 3 with expression levels dropping close to undetectable levels by day 7 of 
maturation (Figure 4.4, A). At the same time, primary transcript of the 
paralogue miR-23b~24-2~27b cluster shows a significant increase by day 3 and 
day 7 of M-CSF exposure in keeping with published data suggesting that miR-23b 
is relevant in joint derived tissue cells (Figure 4.4) [593]. 
4.2.4.2 miR-23a~24-2~27a cluster is down regulated in GM-CSF matured 
macrophages.  
GM-CSF is an alternative macrophage maturation factor and plays many roles in 
promoting innate and adaptive immune responses far beyond its traditional role 
in myelopoiesis [277]. So much so, that a substantial case has been made for a 
clinical targeting of GM-CSF in RA and initial clinical trial results remain hopeful 
[277,688]. GM-CSF polarised monocytes behaved in a similar way to M-CSF 
polarisation when assessed for the expression of primary transcripts of both miR 
clusters (Figure 4.4, B). GM-CSF significantly reduced the levels of pri-miR-23a 
transcript after 3 days of maturation and levels of miR expression remained low 
after 7 days (Figure 4.4, left). Pri-miR-23b cluster, on the other hand, was 
significantly increased after 3- and 7-day exposure to GM-CSF (Figure 4.4, right).  
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As expected, monocyte to macrophage maturation upon exposure to M-CSF or 
GM-CSF also resulted in the reduction of expression of all mature members of 
the miR-23a~24~27a cluster, although all miRs were still detectible on day 7 
(Figure 4.5, A-C). The longer half-life of mature miR species is likely ensuring 
continued functionality during the transition period from miR-23a~24-2~27a to 
miR-23b~4-1~27b cluster in mature macrophages. 
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Figure 4.4 Expression of both miR-23~24~27 clusters in maturation of macrophages 
Primary CD14+ monocytes from 3 buffy coat donors were used for each experiment. Expression of 
pri-miR-23a~24-2~27a (left) and pri-miR-23b~24-1~27b (right) transcripts was done on day 0, 3 
and 7. Results are obtained by the qPCR method and displayed as RQ (2^-ddCT) relative to 
GAPDH gene and control cells. (A) CD14+ cells were incubated for 7 days with 50ng/ml of M-CSF. 
(B) CD14+ cells were incubated for 7 days with 50ng/ml of GM-CSF. Data were analysed by 
Kruskal-Wallis test with Dunn’s correction for multiple comparisons. * - p≤0.05, ** - p≤0.01.   
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Figure 4.5 Expression of mature miRs from miR-23a~24-2~27a cluster in maturation of 
macrophages. 
Primary CD14+ monocytes from 3 buffy coat donors were used for each experiment. Cells were 
incubated for 7 days with 50ng/ml of M-CSF (left) or 50ng/ml of GM-CSF (right). Expression of 
mature miRs was done on day 0, 3 and 7. Results are obtained by the qPCR method and 
displayed as Mean±SD of RQ (2^-ddCT) relative to RNU6 gene and control cells. (A) Shows 
expression of miR-23a. (B) Shows expression of miR-24. (C) Shows expression of miR-27a. Data 
were analysed by Kruskal-Wallis test with Dunn’s correction for multiple comparisons. * - p≤0.05, ** 
- p≤0.01, *** - p≤0.001. 
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4.2.4.3 Expression of miR-23a~24-2~27a cluster in polarisation and 
activation of macrophages. 
Although part of the innate immune response, monocyte-derived macrophages 
have the ability to adapt to the environment guided by locally produced 
cytokines. Many reports have advocated a broad classification of activated 
macrophages into two main groups – classically activated with IFNγ or LPS (M1) 
and alternatively activated with IL-4 (M2) [257-259]. Recently, a revised 
nomenclature demanded a more detailed description of experimentally 
generated macrophages to understand the generated phenotype clearly as well 
as to encourage reproducibility of the results [260]. Here I sought to investigate 
the effect of further polarisation of M-CSF and GM-MSF macrophages into M1 and 
M2 phenotypes on miR-23a~24-2~27a expression. 
4.2.4.4 The polarisation of M-CSF and GM-CSF macrophages into M1 and M2 
phenotypes has no effect on miR-23a~24-2~27a cluster expression. 
CD14+ monocytes from 3 buffy coat donors were isolated and polarised for 6 days 
with either 50 ng/ml of M-CSF or GM-CSF. Upon differentiation into macrophages 
different polarising stimuli were added: IFNγ, LPS or the combination of the two 
for the classical activation and IL-4 for alternative activation. Polarising 
conditions were applied for 24 hours before cells were analysed for miR-23a~24-
2~27a cluster expression (Figure 4.6, A). The previous monocyte to macrophage 
differentiation showed a reduction in primary miR-23a~24-2~27a cluster 
transcript. This experiment indicates that further classical or alternative 
polarisation of macrophages does not influence the expression of pri-miR-23a 
cluster (Figure 4.6, A, B). Polarised macrophages were then assessed for the 
expression of pro-inflammatory TNFα and regulatory IL-10 cytokines (Figure 4.6, 
C-F). As expected, both M-CSF and GM-CSF differentiated cells stimulated with 
LPS and the combination with IFNγ expressed large levels of TNFα in keeping 
with M1 phenotype (Figure 4.6, C and D, respectively). Moreover, M-CSF driven 
macrophages also expressed IL-10 upon LPS and combination stimuli (Figure 4.6, 
E). This effect was not seen in GM-CSF polarised macrophages (Figure 4.6, F). 
Moreover, here observed minimal expression of IL-10 from M2 M-CSF and IL-4 
driven cells was likely due to the short exposure to IL-4 necessary for the 
measurement of primary miR-23a transcript. Further regulatory phenotype could 
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be obtained by longer exposure to IL-4 and IL-13 that has not been further 
pursued. 
Apart from the well-accepted polarising stimuli, monocytes and macrophages 
recruited into the chronic inflammatory environment can become activated by 
the variety of other cytokines. For example, IL-17A, TNFα and IL-6 are all highly 
expressed in the joint synovial inflammation and perpetuate inflammation [689]. 
24-hour stimulation of M-CSF matured macrophages with either TNFα (Figure 
4.7, A), IL-17A (Figure 4.7, B) or IL-6 (Figure 4.7, C) had little to no effect on the 
expression of pri-miR-23a~24-2~27a. Exposure of M-CSF polarised macrophages 
to LPS has again shown variable results with upregulation of pri-miR-23a~24-
2~27a in 2 out of 4 donors and no overall significant effect (Figure 4.7, D). These 
inconclusive results could be explained by the small concentration of the 
stimulant and by small power of the study, both of which could be clarified on 
further investigation. The effects of repetitive exposure to LPS, such as in 
tolerance induction, have not been explored here [690].  
Overall these results show that polarising stimuli or exposure to cytokines fails 
to recover the expression of miR-23a~24-2~27a cluster seen in blood derived 
monocytes, as it is unequivocally terminated by M-CSF and GM-CSF exposure 
during maturation process.       
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Figure 4.6 Influence of cytokine polarization on miR-23a~24-2~27a cluster expression in 
mature macrophages. 
Results for A and B are obtained by the qPCR method and displayed as of RQ (2^-ddCT) relative 
to GAPDH gene and control cells, Mean±SD. Results for C-F are obtained by ELISA method and 
display concentration of the measured cytokine (pg/ml), Mean±SD. (A, B) Purified CD14+ cells from 
3 buffy coat donors were incubated for 6 days with 50 ng/ml of M-CSF (A) or 50 ng/ml GM-CSF (B) 
than stimulated for 24 hours with 100ng/ml IL-4, 15 ng/ml LPS, 20ng/ml IFNγ and the combination 
of LPS with IFNγ. (C, D) Shows TNFα (pg/ml) levels in the supernatant solution of the cells after 24 
hours of stimulation as stated in A and B, respectively. (E, F) Shows IL-10 (pg/ml) levels in the 
supernatant solution of the cells after 24 hours of stimulation as stated in A and B, respectively. 
Data were analysed by Kruskal-Wallis test with Dunn’s correction for multiple comparisons. * - 
p≤0.05, ** - p≤0.01, 
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Figure 4.7 Influence of proinflammatory cytokines on miR-23a~24-2~27a cluster expression 
in mature macrophages. 
Results are obtained by the qPCR method and displayed as RQ (2^-ddCT) relative to GAPDH 
gene and control cells (Mean±SD). Purified CD14+ cells from 4 buffy coat donors were incubated 
for 7 days with 50ng/ml of M-CSF than stimulated with 1ng/ml TNFα (A), 10ng/ml IL-17A (B), 
1ng/ml IL-6 (C) and 1ng/ml LPS (D). Data were analysed by Mann-Whitney test. Non-significant 
p≥0.05 for all comparisons 
 
Cells only +1ng/ml TNFα
0.0
0.5
1.0
1.5
Pr
i-m
iR
-2
3a
~2
4-
2~
27
a
R
Q
, n
or
m
al
iz
ed
 to
 G
A
PD
H
Cells only +1ng/ml IL-6
0.0
0.5
1.0
1.5
Pr
i-m
iR
-2
3a
~2
4-
2~
27
a
R
Q
, n
or
m
al
iz
ed
 to
 G
A
PD
H
Cells only +10ng/ml IL-17A
0.0
0.5
1.0
1.5
Pr
i-m
iR
-2
3a
~2
4-
2~
27
a
R
Q
, n
or
m
al
iz
ed
 to
 G
A
PD
H
Cells only +1ng/ml LPS
0.8
1.0
1.2
1.4
1.6
Pr
i-m
iR
-2
3a
~2
4-
2~
27
a
R
Q
, n
or
m
al
iz
ed
 to
 G
A
PD
H
A 
C D 
B 
210 
 
4.2.5 Cytokines influencing miR-23a~24-2~27a expression in 
serum of patients with RA 
Reproducing the cytokine milieu that is present in vivo in the chronic 
inflammatory conditions is not without difficulty, therefore understanding what 
impacted the expression of miR-23a~24-2~27a cluster in the patients with the 
drug-resistant RA is challenging. Previous data from this chapter has identified 
IL-6, CCL2, IFNβ, and IFNγ as regulating the expression of miR-23a~24~27a 
cluster in blood-derived monocytes. Here, these and other potent 
proinflammatory cytokines were assessed in the serum samples from patients 
with drug responsive or resistant RA and healthy controls described in detail in 
Chapter 3.  
4.2.5.1 IL-6 is increased in serum of DMARDs and biologic resistant 
patients. 
The levels of pro-inflammatory cytokines present in cohort samples were 
measured by Luminex. IL-6 was significantly increased in the serum of DMARDs 
and biologics resistant patients when compared to levels found in healthy 
controls (Figure 4.8, A). Intermediate IL-6 levels detected in DMARDs responder 
patients were not significantly different from other groups. I next analysed 
TNFα, which was elevated in DMARDs resistant patients when compared to 
healthy controls, reflecting increased level of inflammation in these patients 
(Figure 4.8, B). As expected, TNFα levels in biologics resistant group were 
reduced due to the current treatment with anti-TNFα agents in some patients 
(Figure 4.8, B).  
Following this, members of the interferon family were analysed. IFNα, a type I 
interferon, was found at higher levels in DMARDs failures when compared to both 
control groups (Figure 4.8, C). Similarly, IFNα was raised in biologics resistant 
patients compared to healthy controls (Figure 4.8, C). Association of type I 
interferon’s with RA is well established, although their therapeutic and 
biomarker potentials remain somewhat controversial [691]. Type II member, 
IFNγ, was detected in only 3 patients from DMARDs resistant group and in 1 
patient amongst DMARDs responders (Figure 4.8, D). The absence of IFNγ from 
majority of the cohort serum samples indicates that it was not a key driver 
influencing the expression of pri-miR-23a~24-2~27a in this cohort of RA patients. 
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Unfortunately, IFNβ was not included on the Luminex panel. Therefore this and 
limited sample availability meant that I could not assess its levels in these 
patient groups.    
The high presence of inflammatory cytokines results in activation of peripheral 
blood monocytes, however, it is the growth factors and chemokines that ensure 
migration into affected tissues and differentiation into macrophages. Data shown 
in this chapter confirms previously published finding that maturation of 
monocytes with either M-CSF or as seen above with GM-CSF results in a decrease 
in the expression of pri-miR-23a~24-2~27a cluster as cells progress to become 
macrophages (Figure 4.5). Unfortunately, assessment of M-CSF growth factor in 
the serum samples from RA patients was not available on the platform used, 
however, levels of GM-CSF and a chemotactic chemokine CCL2 were measured. 
Serum GM-CSF was not detected in any healthy control subjects, while all three 
patient groups had insignificant elevation of the cytokine (Figure 4.8, E). 
Interestingly, chemokine CCL2, otherwise named monocyte chemoattractant 
protein (MCP1), was raised in both groups failing multiple modes of treatment 
compared to good responders and healthy controls, overall mirroring the 
expression pattern of miR-23~24~27 clusters (Figure 4.8, F).  
To explore the link between expression of miR-27a in CD14+ monocytes and 
levels of pro-inflammatory cytokines and chemokines in patient’s serum, 
correlation coefficients were calculated. Unfortunately, miR-27a expression in 
monocytes failed to reach significance when correlated with IL-6 expression (r=-
0.25, p=0.06 in biologics resistant patients). Furthermore, both miR-27a and 
miR-27b failed to correlate with IL-6 or CCL2 and representative plots in biologic 
resistant patients are shown below (Figure 4.9, A and B). This is possibly caused 
by the longer half-life of miRs, which can be sequestered in the cell for 
prolonged periods of time, therefore, creating cumulative picture of the 
expression, unlike secretable cytokines. As a control, IL-6 had significant 
correlation with acute inflammatory response marker CRP (r=0.5908, p=0.0003), 
but not with the disease activity score DAS28-CRP, since it involves additional 
components, not dependant on IL-6 expression (Figure 4.9, E and F).   
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Figure 4.8 Expression of proinflammatory cytokines in serum samples from RA patient 
cohort.  
RA patient and healthy controls cohort involve 4 groups: 21 healthy controls, 16 DMARDs 
responders, 22 DMARDs resistant and 41 biologics resistant patients. Results are obtained by the 
Luminex method and displayed as concentration of the cytokine in the 1ml of the serum (pg/ml). 
Measured cytokines involve IL-6 pg/ml (A), TNFα pg/ml (B), IFNα pg/ml (C), IFNγ pg/ml (D), GM-
CSF pg/ml (E) and chemokine CCL2 pg/ml (F). Data were analysed by Kruskal-Wallis test with 
Dunn’s correction for multiple comparisons. * - p≤0.05, ** - p≤0.01, *** - p≤0.001. 
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Figure 4.9 Correlation of IL-6 and CCL2 from RA biologics resistant patient’s serum with 
expression of miR-27a and miR-27b in CD14+ monocytes.  
Correlation plots between mature miR expression in CD14+ monocytes (qPCR, 2^-ddCT) and 
serum samples from 38 RA patient resistant to biologics treatment. (A) Correlation between IL-6 
(pg/ml) and miR-27a (r=-0.25, p=0.06) (B) Correlation between IL-6 (pg/ml) and miR-27b (r=-0.16, 
p=0.17). (C) Correlation between CCL2 (pg/ml) and miR-27a (r=-0.1, p=0.27). (D) Correlation 
between CCL2 (pg/ml) and miR-27b (r=0.02, p=0.44). (E) Correlation between CRP (mg/dl) and IL-
6 (pg/ml) (r=0.5908, p=0.0003). (F) Correlation between DAS28-CRP clinical score and IL-6 (pg/ml) 
(r=0.1955, p=0.2677). Data were analyzed by Spearman’s correlation coefficient, p≥0.05 is non-
significant. 
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4.2.6 MiR-23a~24-2~27a cluster promoter analysis 
4.2.6.1  In silico characterisation of the miR-23a~24-2~27a promoter. 
Here I sought to identify the regulatory elements in the promoter of miR-
23a~miR-27a~miR-24-2 that could be responsible for regulation of the cluster 
described in the previous sections. Typically this requires the identification of 
the promoter followed by the bioinformatic prediction of putative transcription 
factor binding sites. The miR-23a~24-2~27a clusters promoter and transcriptional 
start site (TSS) has been previously described in Hela cells [570]. Current 
methodologies such as Cap Analysis of Gene Expression (CAGE), which can 
precisely capture the sequences associated with 5' cap, are inadequate for the 
detection of primary miR transcripts as they are below detectable level in their 
capped form. The authors used 5' RACE to capture the TSS in this cell line 
showing it to be located 7bp upstream from the miR-23a’s coding sequence. As 
TSS often vary between cell types, bringing the expression of the associated 
genes under the control of different promoter elements it is important to define 
the miR-23a~24-2~27a cluster promoter within the context of myeloid linage 
cells.  
As miR primary transcripts exist only transiently before being rapidly processed 
into their trimmed precursor forms, capturing their 5' ends and inferred 
transcriptional start sites represents a significant challenge. To overcome this, 
Drosha, a protein that is essential for the processing of pri-miR to pre-miR forms 
was knocked-down by siRNA in THP-1 cells resulting in an increase in the levels 
of the primary miR-23a~24-2~27a cluster transcript (Figure 4.10, A-B). 5'RACE 
performed on the total RNA purified from these cells yielded a single band which 
when sequenced revealed a TSS that was identical to the one previously 
described in Hela cells (Figure 4.10, C) [570]. 
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Figure 4.10 Characterization of 5' transcriptional start site by 5'Rapid Extension of cDNA 
Ends.  
Experiments done in THP-1 cells in 3 technical replicates. (A) THP-1 cells transfected with 
DROSHA siRNA. Results obtained by qPCR method showing Mean±SD of 2^-ΔΔCT of DROSHA 
expression normalised to GAPDH and control cells. (B) THP-1 cells transfected with DROSHA 
siRNA. Results obtained by qPCR method showing Mean±SD of 2^-ΔΔCT of pri-miR-23a~24-
2~27a expression normalised to GAPDH and control cells. (C) Schematic of 5’Cap, TSS and pri-
mir-23a~24-2~27a cluster sequence with underlying data from 5'RACE sequencing showing 
intensity of the signal starting from 124 bp preceding pre-miR-23a sequence.  
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Next, bioinformatic analysis using MatInspector was performed on the 2kb 
sequence directly upstream of the TSS. The aim of this was to identify putative 
regulatory elements that had potential relevance to monocyte/macrophage 
biology (Table 4.1). MatInspector identified potential IRF and STAT binding sites 
both of which are known to regulate target gene expression within Interferon 
gamma and IL-6 signalling pathways [387,692]. A number of putative SMAD 
binding sites were also highlighted suggesting that the cluster could be regulated 
by TGFβ [693]. This observation is supported by the finding that the miR-23a 
cluster is up-regulated in monocyte-derived DCs and CD8 T cells stimulated with 
TGFβ [577,609]. 
Intriguingly, there are 13 predicted retinoic X receptor (RXR) binding sites within 
2kb upstream from miR-23a’s TSS. There is a large body of literature relating to 
RXR’s role in monocyte/macrophage biology [694]. RXR acts as a homodimer or 
as a heterodimer with a number of binding partners (LXRα, PPARγ, VDR and 
others). It also plays a vital role in the regulation of cholesterol, fatty acid and 
glucose metabolism [695]. Recent studies have shown that vitamin D inhibits the 
production of pro-inflammatory cytokines by monocytes and macrophages 
through the action of heterodimers of RXRα and VDR [696,697]. A heterodimer of 
RXRα/liver X receptor alpha (LXRα) pathway has been shown to be upregulated 
in the synovial macrophages of patients with RA, and this pathway increased the 
production of pro-inflammatory cytokines [698]. Interestingly, the alpha subunit 
of RXRα is predicted to have binding sites for both miR-27a and miR-24. A 
common feature of miR biology is auto-regulatory feedback loops in which the 
expression of a miR is regulated by a transcription factor which is in turn 
targeted by the same miR [699]. 
There are two predicted Activator protein-1 (AP1) sites in miR-23a’s promoter. 
AP1 activity is induced by a variety of stimuli affecting a wide range of cellular 
processes. However, one important role is the regulation of cell proliferation 
and survival [700]. Pertinently, methotrexate has been shown to induce the 
activity of AP1 in RA patients and could potentially effect the expression of miR-
23a cluster in treated cells [701].   
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Transcription 
factor Family Information 
Matrix 
SIM SEQ 
V$RXRF RXR heterodimer binding sites 0.91 gcggatcacctgaggtcaggaggtc 
V$RORA 
v-ERB and RAR-related orphan receptor 
alpha 0.92 atcacctgaggtcaggaggtcgaga 
V$RXRF RXR heterodimer binding sites 0.82 tcacctgaggtcaggaggtcgagac 
V$EREF Estrogen response elements 0.917 tgaggtcaggaggtcgaga 
V$SMAD 
Vertebrate SMAD family of transcription 
factors 0.967 ctggtctcgac 
V$RXRF RXR heterodimer binding sites 0.742 gtagctgggattacaggtgcccgcc 
V$RXRF RXR heterodimer binding sites 0.838 ttgcttgaactctggaggtggaggt 
V$SMAD 
Vertebrate SMAD family of transcription 
factors 0.974 agagtctcgcc 
V$IRFF Interferon regulatory factors 0.941 aaaaaaaaaaaaaagaaaagaaaaa 
V$IRFF Interferon regulatory factors 0.932 aaagaaaagaaaaagaaaaaattag 
V$RXRF RXR heterodimer binding sites 0.886 gcaggggtgcaatcacagctcactg 
V$RXRF RXR heterodimer binding sites 0.877 gagagtcacctgaggccaggagttc 
V$AP1F AP1, Activating protein 1 0.861 aggagagtcacct 
V$P53F p53 tumor suppressor 0.862 acaggcgtgagccgccatgcttggc 
V$GREF 
Glucocorticoid responsive and related 
elements 0.893 aatgaacacgtggtcctct 
V$GREF 
Glucocorticoid responsive and related 
elements 0.921 agaggaccacgtgttcatt 
V$HIFF 
Hypoxia inducible factor, bHLH/PAS protein 
family 0.96 gaggaccacgtgttcat 
V$FAST FAST-1 SMAD interacting proteins 0.848 ccacgtgttcattttgc 
V$RXRF RXR heterodimer binding sites 0.794 tatcttgccctggtgctgggcactt 
V$RXRF RXR heterodimer binding sites 0.784 gtaagtgcccagcaccagggcaaga 
V$AP1F AP1, Activating protein 1 0.87 tactgagtgacat 
V$HIFF 
Hypoxia inducible factor, bHLH/PAS protein 
family 0.934 tccccccccgtggcccg 
V$MZF1 Myeloid zinc finger 1 factors 0.996 ggggggaggcc 
V$NFKB Nuclear factor kappa B/c-rel 0.932 ggggggaggccctgg 
V$STAT 
Signal transducer and activator of 
transcription 0.964 ccacttcctagaagcctgg 
V$STAT 
Signal transducer and activator of 
transcription 0.951 aggcttctaggaagtggcg 
V$SMAD 
Vertebrate SMAD family of transcription 
factors 0.963 agtggcgccag 
V$RXRF RXR heterodimer binding sites 0.783 ccccatggccccatttggcctgccc 
V$RXRF RXR heterodimer binding sites 0.76 tgggcaggccaaatggggccatggg 
V$RXRF RXR heterodimer binding sites 0.774 ccatttggcctgcccagggctcaat 
V$RXRF RXR heterodimer binding sites 0.756 cattgagccctgggcaggccaaatg 
V$MZF1 Myeloid zinc finger 1 factors 0.996 ggggggagctt 
V$P53F p53 tumor suppressor 0.826 gggagcttggccatgcaagttgctg  
V$SMAD 
Vertebrate SMAD family of transcription 
factors 0.953 ggtggctcctg 
V$MZF1 Myeloid zinc finger 1 factors 0.992 gaggggaggtg 
V$MZF1 Myeloid zinc finger 1 factors 0.992 gaggggagaaa 
V$GLIF GLI zinc finger family 0.903 ggtgcccccctcacccc 
V$RXRF RXR heterodimer binding sites 0.763 gccggccgtggcacaggggtgaggg 
Table 4.1 The list of potential binding sites upstream of the miR-23a~24-2~27a cluster. 
A 2kb sequence upstream from the TSS was subjected to bioinformatics analysis using the 
MatInspector algorithm from Genomatix -https://www.genomatix.de/online_help/help_matinspector. 
This searches for known transcription factor binding site sequences. Matrix Sim is a measure of 
similarity to the consensus sequences, with perfect matches scoring 1. Transcription factor gene 
symbols used by the program are listed on the left, with the description in the centre, predictive 
binding score (Sim) to the centre right and binding sequence in context to the right.    
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There are two predicted response elements for hypoxia-inducible factor 1 
(HIF1). My data suggests that, at least in monocytes, hypoxia does not influence 
the expression of miR-23a cluster (Figure 4.3, F). However, this may not be the 
case in other cell types. 
A single NFκB site lies within the 400 bp upstream from the TSS. NFκB is the 
down stream regulators of IL-1β, TLR1-9 and TNFα signalling pathways [664,702]. 
My data does not support a role for this, neither TLR ligands nor TNFα induced 
changes in the expression levels of miR-23a~27a~24-2. Despite this, NFκB has 
been shown to directly regulate miR-23a cluster expression in Jurkat cells [662]. 
A more recent study showed that NFκB regulated miR-23a expression in murine 
macrophages [665,703].  
The archetypal tumour suppressor p53 has a single predicted binding site in the 
miR-23a promoter. It has been reported that p53 increased the expression of 
miR-23a in human hepatocellular carcinoma cells treated with the cytotoxic 
agent etoposide [614]. In turn, miR-23a directly targets p53 transcripts 
completing an auto-regulatory feed back loop.  
The prediction of a STAT binding site in the miR-23a cluster promoter is 
particularly interesting. STAT1, 3 and 5 lie downstream of the IFNγ signalling 
pathway in monocytes and macrophages [461,704]. It is an obvious candidate for 
the transcription factor responsible for the down regulation of miR-23a cluster 
expression seen in IFNγ treated cells (Figure 4.2, B and C). As different STAT 
family members bind to similar sequences, it is possible that other STATs can 
also bind to the promoter of miR-23a cluster. Thus the decrease in miR-23a 
expression seen in IFNβ stimulated monocytes may be influenced by STAT1 or 
STAT2 [678]. A schematic of miR-23a promoter and associated binding sites is 
illustrated in the Figure 4.11, A. 
A comparison of miR-23a promoter sequences shows significant conservation 
between species (Figure 4.11, B). A well-conserved 200 bp region upstream from 
the TSS contains the predicted NFκB, RXR, SMAD and STAT binding sites hinting 
at their functional importance [681].  
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4.2.6.2  Characterization of the 3' end of pri-miR-23a~miR-24-2~miR-27a 
transcripts. 
Inspection of the miR-23a cluster in the UCSC Genome Browser poly(A) track 
identifies the presence of polyadenylation sites within each member of the 
cluster (Figure 4.12, A). These corresponded to data from polyASeq (Figure 4.12, 
B). PolyASeq is a targeted RNA sequencing technique of the 3' ends of 
polyadenylated transcripts first described by Derti et al [546]. As alternative 
polyadenylation could, in theory, uncouple the expression of poly-cistronic miR 
clusters, resulting in a post-transcriptional mechanism for modulating mature 
miR levels produced from a single primary transcript. As noted in Chapter 3, 
levels of the mature forms of the miR-23a cluster did not correlate with each 
other as one might expect given that they are derived from a single primary 
transcript. To see if the forms identified in polyASeq data are bona fide, 3'Rapid 
Extension of cDNA Ends (3'RACE) was performed to characterise the 3'ends of the 
pri-miR-23a transcript. The same RNA samples from the Drosha-depleted THP-1 
cells used previously for 5'RACE were used (Figure 4.10, A). Two different sets of 
forward primers were designed for the amplification of the 3' end, giving rise to 
individual bands (Figure 4.12, C). Each band was cloned and sequenced. Both 
amplicons had identical polyA tails that were not present in the genomic 
sequence, indicating that they were added post-transcriptionally (Figure 4.12, 
B). The beginning of the polyA tail was located 14 bp downstream from the 
predicted Drosha cleavage site. Surprisingly, there was no canonical polyA signal 
sequence upstream of the polyA tail, which is essential for polyadenylation 
[705]. As far as I am aware there are no reports of polyadenylation of Drosha 
generated pre-miRNAs. I could not detect any of the transcripts that 
corresponded to the species highlighted in UCSC Genome Browser poly(A) track. 
It may be that these forms are not present in THP-1 cells or that they are 
present at levels that even in Drosha-depleted samples are too low for detection 
using 3'RACE. Similarly, the previously reported polyadenylated species, which 
had a polyA signal at position +1752-1757 were also not detected [570]. The 
length of this species with respect to the forward primers used here may have 
been too long to be efficiently amplified. Repeating the 3'RACE with primers 
designed closer to the predicted end of this transcript may have increased the 
likelihood of detecting this transcript.   
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Figure 4.12 Characterization of 3' transcriptional polyadenylation sites by 3'RACE method.  
Experiments done in THP-1 cells in 3 technical replicates. (A) Shows polyAseq tract of the miR-23a 
cluster loci from ENCODE genome browser. (B) 3'RACE performed in THP-1 cells transfected with 
DROSHA siRNA; the resulting amplicon was then sequenced. Figure shows the sequence at the 
390 bp position in the pri-miR-23a transcript. (C) Schematic of the newly identified polyadenylation 
site proximal to Drosha cleavage site of pri-mir-23a~24-2~27a transcript. Schematic also shows the 
placement of 3'RACE primers for amplification. 
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4.3 Discussion 
Myeloid cells are the mainstay of the innate immune response. Although heavily 
studied in the context of provoked immunity, we still lack a full understanding 
of what drives monocytes and macrophages in the chronic inflammatory 
conditions and disables the termination of the process. This is of particular 
interest in inflammatory monocytes that not only change upon activation by 
certain stimuli but also have the ability to mature, migrate and differentiate 
into macrophages, further transferring the problem into tissues. The biology 
behind these processes involves a tight interplay between homeostatic 
maintenance and an acute response to an insult, most commonly involving 
change of TF and miR species to help regulate this process. Similar features have 
been clearly demonstrated in the priming of T cells when the turnover of the 
entire population of miR species in the cell is required to achieve a new 
phenotype [706]. Considering implications of miR-23~24~27 clusters in chronic 
inflammatory processes, understanding what regulates these clusters in 
monocytes is paramount to capturing the triggers of chronicity.  
Blood-derived myeloid cells are collectively labelled as CD14+ cells. This cell 
marker is a part of TLR4 pattern recognition receptor and is present on the 
majority of myeloid cells. Recently, expression of CD14 and CD16 (FcγRIII) 
markers on the surface of monocytes were utilised to describe three distinct cell 
populations. The most prevalent classical CD14+CD16- cells expressing CCR2 and 
resembling Ly6Chi murine monocytes; proinflammatory ‘intermediate’ 
CD14+CD16+ cells and non-classical CD14-CD16+ cells known for their ability to 
patrol vascular wall endothelial cells [212,221,707-710]. Both CD16+ populations 
account for less than 10% of all monocytes [710]. Nonetheless, CD14+CD16+ 
population has been implicated in autoimmune diseases such as RA [641]. Data 
above confirms that miR-23a~24-2~27a cluster is not only highly expressed in 
CD14+ blood-derived monocytes, but that it is present at particularly high levels 
in classical CD14+CD16- cells (Figure 4.1, B). Unfortunately, investigating the 
expression of miR-23a cluster in purified CD16+ cells was not performed at the 
time, yet, these data raise the possibility that the remaining highly 
inflammatory CD14+CD16+ population could have a very low expression of miR 
cluster which could be contributing to their aggressive phenotype and certainly 
requires further investigation. It is therefore also possible that treatment-
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resistant patients reviewed in Chapter 3 had a higher proportion of CD14+CD16+ 
cells resulting in lower overall expression of miR-23a and miR-27a than 
treatment responders or healthy controls. Unfortunately at the time of this 
study only CD14+ cells were analysed and the frequency of CD16+ cells in these 
samples was unknown. However, RA patients with active disease, such as 
patients in DMARDs and biologics resistant groups, were previously found to have 
an increased proportion of CD14+CD16+ population in peripheral blood [641].   
The importance of miR-23~24~27 clusters in myeloid cells was previously 
established with links to the promotion of myelopoiesis during lineage 
commitment, phagocytosis and antigen presentation during inflammation 
[568,595,711]. Even so, there are no studies to date that explore the role and 
regulation of miR-23~24~27 cluster in inflammatory monocytes, while several 
reports focus on the role in mature macrophages and dendritic cells [594,712]. 
Reports in cancer research and other studies have suggested regulators of miR-
23 clusters include NFκB and M-CSF. Here we set out to investigate if 
inflammatory cytokines and TLR stimuli have an effect on pri-miR-23a~24~27a 
expression in human monocytes. Unfortunately, variety of inflammatory stimuli 
including IL-17A, TNFα and LPS utilising NFκB signalling failed to exhibit any 
effect on the expression of primary miR-23a~24-2~27a transcript in monocytes 
(Figure 4.2, A; Figure 4.3, B). From these, it is the effect of LPS stimulation 
through TLR4 that is the most puzzling one. LPS stimulation in buffy coat derived 
CD14+ cells, healthy controls and RA patients resulted in the upregulation of 
primary miR-23a~24-2~27a transcript in a number of subjects, while others 
demonstrated no effect (Figure 4.3, B and C). This variability could be more 
prominent due to the small number of participants in each group. However, the 
possibility of other unknown factors, such as the availability of the CD14 
receptor following cell purification, for example, could be influencing the 
expression of miR-23a cluster in these circumstances and cannot be wholly 
excluded. Other TLR ligands to TLR1/2, TLR3 and TLR7/8, did not regulate the 
miR-23a cluster expression (Figure 4.3, A, D, E).   
Instead, the ability of IL-6 to downregulate the expression of miR-23a cluster 
was discovered (Figure 4.2, D). IL-6 is a genuinely pleiotropic cytokine expressed 
by almost all stromal and immune cells that exhibit hormone-like as well as 
proinflammatory functions [373]. Its effects are mediated through IL-6Rα/GP130 
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signalling involving JAK1/Tyk2 and STAT3 kinases [387]. This signalling cascade is 
negatively controlled by suppressors of cytokine signalling (SOCS) with the 
absence of SOCS3 leading to inhibitory effects of IL-6, resembling that of IL-10 
[391,410]. Nonetheless, lack of SOCS3 in the chronic inflammatory setting allows 
sustained STAT1 and STAT3 signalling causing exacerbated inflammation [713]. 
Activation of IL-6 pathway through STAT1 and STAT3 are good indicators of 
therapy response [714,715]. It is, therefore, understandable that patients failing 
DMARDs and biologics treatment had increased concentration of serum IL-6 
cytokine (Figure 4.8, A). High levels of IL-6 trended towards a negative 
correlation with low expression of miR-27a in biologics resistant patients. 
However, this has not reached statistical significance (r=-0.25, p=0.06) (Figure 
4.9, A). Cofounding factors of this analysis include some patients on treatment 
with tocilizumab targeting IL-6R and modifying IL-6 pathway and limited sample 
size to reflect the magnitude of this relationship. Nonetheless, in vitro 
experiments would support IL-6 as a candidate, capable of regulating the 
expression of miR-23a~24-2~27a cluster in this RA patient cohort.  
Involvement of the JAK1 signalling pathway is further supported by the discovery 
of the inhibitory effect of IFNγ, which strongly and continuously reduced the 
expression of primary miR-23a~24-2~27a transcript (Figure 4.2, C). This provides 
a new mechanism by which T cells, and in particular Th1 cells, mediate 
activation of monocytes and induce maturation similarly to M-CSF or GM-CSF 
growth factors. IFNγ and M-CSF both reduced the expression of miR-23a cluster; 
it would be interesting to explore if these stimuli lead to same functional 
outcome through miR pathway targeting that will be discussed later. Even 
though IFNγ significantly influenced miR-23a~24-2~27a cluster expression in in 
vitro experiments, it is not likely that it had a significant impact in monocytes 
from RA patients, given low serum concentrations of the cytokine in the majority 
of participants (Figure 4.8, D).  Contrary to this, type I interferon - IFNα was 
highly present in patient serum samples, however, had insignificant effect on 
miR-23a~24-2~27a expression when tested in in vitro (Figure 4.8, C and Figure 
4.2, B). The previous report would suggest that type I interferon can 
downregulate miR-27a expression in murine M-CSF exposed macrophages [596]. 
My data on human M-CSF-derived macrophages showed that differentiation 
significantly reduces miR-23a cluster expression in its own right, so much so that 
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further reduction obtained by IFNα exposure might not be relevant. The lack of 
reports on the impact of type I interferons on miR expression in monocytes does 
not allow comparison and requires further investigations. Especially when 
considering the puzzling effect of IFNβ which downregulated miR-23a cluster 
similarly to IFNγ rather than to its family member IFNα. This similarity might be 
explained by the involvement of JAK1 signalling cascade, shared by all cytokines 
exerting influence on miR-23a~24-2~27a expression and could be further tested 
by exposure of cytokine-stimulated monocytes to tofacitinib, a JAK1/JAK3 
inhibitor and a clinically used small molecule.  
Upon encountering pathogens, cytokines and other activators, blood-derived 
monocytes migrate to affected tissues guided by homing chemokines like CCL2.  
Exposure to tissue inflammation triggers the maturation of monocytes into 
phagocytic macrophages, and this process is primarily governed by M-CSF growth 
factor [245,716]. Previously published and this data have clearly demonstrated 
that miR-23a~24-2~27a is actively abolished during M-CSF guided maturation 
process and is at the limit of detection after 3 days of exposure (Figure 4.4, A) 
[594]. Instead, its functions are replaced by the newly triggered expression of 
pri-miR-23b~24-1~27b paralogue cluster (Figure 4.4, A). This switch is reflected 
in the expression of mature miRs (Figure 4.5). Both growth factors M-CSF and 
GM-CSF signal through reciprocal receptors and are responsible for the 
maintenance of myeloid cells [717]. Other potential ligands of CSF1R include 
VEGFA and IL-3. However, they are not considered a major influence in RA 
arthritis and were not tested here. GM-CSF guided maturation of monocytes also 
obliterated expression of pri-miR-23a cluster after 3 days of exposure (Figure 
4.4, B). Similarly, GM-CSF exposure led to a significant increase in the expression 
of the paralogue pri-miR-23b cluster (Figure 4.4, B). The intronic placement of 
miR-23b~24-1~27b cluster and likely co-expression with the host gene C9ORF3 
poses the question on the function of the host gene and its importance in 
macrophage growth. Nonetheless, the fact that miR-23a~24-2~27a expression 
was reduced by both M-CSF and GM-CSF exposure points towards critical role of 
this cluster in all myeloid maturation, including monocyte-derived DCs and 
alveolar macrophages that are in mice thought to be primarily governed by GM-
CSF [249,718]. Indeed, persistent expression of miR-24 in human M-CSF and GM-
CSF differentiated macrophages and DCs did not only influence the phenotype of 
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cells but also severely affected their ability to produce cytokines upon 
stimulation with LPS, ultimately impairing their function [594]. It is still unclear 
if instead expressed miR-23b~24-1~27b cluster differs in functions or serves as an 
equivalent to miR-23a~24-2~27a myeloid regulator in the tissues. In silico 
analysis of the potential miR functions will be analysed in the following chapter 
however one nucleotide difference in mature sequences between ‘a’ and ‘b’ 
miRs and identical ‘seed’ region would certainly suggest that they have a 
capacity to bind to the same mRNA targets.  
Maturation and migration into tissues allow monocyte-derived macrophages to 
encounter a variety of cytokines that help to decide future fate of the cells. 
Described in this manner classically activated with IFNγ and LPS macrophages 
exhibit proinflammatory phenotype and are designated M1 cells, while others 
activated by IL-4 and IL-13 are termed M2 macrophages, known for their 
regulatory abilities. In recent years a variety of laboratory protocols and the 
many ways in which one can grow and activate macrophages has led to some 
confusion between different phenotypes and difficulty in reproducing certain 
results. At best, this proposed scale should be viewed as shades of grey rather 
than monochrome absolute phenotypes. This has prompted Murray et al. to 
systematically review the nomenclature in attempt to limit confusion [260]. My 
data showed that neither LPS, IFNγ or LPS with IFNγ nor IL-4 exposure of M-CSF 
or GM-CSF grown macrophages led to recovery of primary miR-23a~24-2~27a 
transcript expression (Figure 4.6, A). Arguably, longer exposure to these stimuli 
could have had a different effect. However, a short 24 hour stimulation allows 
measurement of primary transcript and shows the initiation of transcription or 
lack there off in this case. M-CSF differentiated macrophages stimulated with 
other inflammatory cytokines including TNFα, IL-17A and IL-6 also failed to 
resume pri-miR-23a expression (Figure 4.6, B-D). These data collectively indicate 
that miR-23a~24-2~27a cluster is switched off during monocyte to macrophage 
differentiation. Therefore, it is possible that M-CSF exposure of peripheral blood 
monocytes from difficult to treat RA patients was the driving force behind the 
start of the migration process and caused decreased expression of miR-23a and 
miR-27a. Unfortunately, M-CSF measurement was not available to me at the 
time of the assay. However, high presence of migratory chemokine CCL2 in 
patients with high disease activity indicates increased recruitment of monocytes 
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to the inflamed tissues and could further explain the low expression of miR-23a 
and miR-27a in difficult to treat patients (Figure 4.8, F). Additionally, 
stimulation of monocytes with CCL2 chemokine also caused decrease of the pri-
miR-23a expression, as a part of cell maturation priming (Figure 4.2, G).  
Here we confirmed the TSS of miR-23a cluster in THP-1 monocytic cell line. 
Using the TSS site to define the likely location of the miR-23a cluster's promoter 
allowed us to take advantage of the up to date in silico analysis software 
(MatInspector) that could predict the presence of binding sites in the 2kB 
sequence immediately upstream of the TSS. This analysis revealed the presence 
of binding sites for a number of monocyte/macrophage transcription factors. 
The presence of NFκB and STAT binding sites was of particular interest. A recent 
study also identified the presence of NFκB and STAT binding sites in the murine 
miR-23a promoter [703]. The presence of regulatory elements for these 
transcription factors would provide a possible mechanism for the reduction in 
pri-miR-23a cluster expression seen in response to IL-6, IFNβ and IFNγ, all 3 of 
which are thought to induce JAK/STAT signalling [678] [719]. While in silico 
analysis, although suggestive, does not in itself prove the observed 
transcriptional changes are a direct result JAK/STAT, it does provide the 
framework for additional experiments that could. Cloning the miR-23a cluster 
promoter upstream of a luciferase promoter would allow the functional role of 
STAT signalling to be further interrogated. If for example, the transfection of a 
miR-23a promoter luciferase plasmid into a relevant cell type (e.g. THP-1) 
followed by treatment with IL-6/IFNγ re-capitulated the reduction in expression 
levels observed in primary CD14+ cells this would confirm that the necessary 
regulatory elements were present in the selected region. Mutation of the 
predicted STAT binding sites would further localise the elements essential for IL-
6/IFNγ regulation of miR-23a cluster expression. However, the ultimate de facto 
proof of STAT regulation of the cluster requires specific STAT Chromatin Immuno 
Precipitation (ChIP) of the miR-23a promoter or indeed an Electro Mobility Shift 
Assay. Unfortunately, due to time constraints, I was unable to perform these 
studies. However, this will be pursued in my future work.  
 Analysis of the polyAseq data on the UCSC Genome Browser revealed the 
presence of a number of polyA peaks between each member of the cluster 
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raising the possibility that the cluster could be controlled post-transcriptionally 
via alternative polyadenylation. While there are as far as I am aware no reports 
describing such a mechanism the possibility was too intriguing to ignore. To 
study this, I performed 3' RACE to capture the polyadenylated form of the pri-
miR-23a~24-2~27a transcript. I was able to identify a polyadenylated transcript 
from the miR-23a loci; it was not one that had previously been reported. The 3' 
end of this transcript corresponded to a site 14 bp down steam from the 
predicted Drosha cleavage site of miR-24-2. While this transcript did contain a 
non-genomic encoded polyA tail, it did not, however, include an associated 
polyA sequence (typically AAUAAA) [705].  
In this chapter, I have identified a number of key stimuli that influence the 
expression of the miR-23a cluster in primary human myeloid cells along with 
their potential regulatory elements within the miR-23a clusters promoter.  
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5  Validating THP-1 myeloid cell line as a model 
system to study miR-23~24~27 cluster 
interactions 
5.1 Introduction 
The human THP-1 myeloid cell line was established in 1980 from a patient with 
an acute monocytic leukaemia [720]. Ever since THP-1 cells have been 
extensively used for the modelling of human myeloid biology. Phenotypic studies 
confirmed that although cancerous, THP-1 cells did not loose their myeloid 
properties and morphologically resemble monocytes with distinctive surface 
markers [720]. Upon stimulation with phorbol-12-myristate-13-acetate (PMA) or 
vitamin D3 THP-1 cells mature into adherent phagocytizing cells resembling 
primary macrophages [721]. The PMA method is preferred as it leads to 
increased phagocytosis and higher expression of CD14 and CD11b surface 
markers resembling mature primary macrophages [722]. Also, similarly to 
macrophages, THP-1 cells secrete M-CSF and support maturation in an autocrine 
manner, yet in vitro stimulation with M-CSF leads to incomplete maturation of 
the cells, unlike those with PMA [723,724]. Other immortalised human myeloid 
cell lines include U937, ML-2 and Mono Mac 6 cells that exhibit more immature 
phenotypes and have not been used in this work.   
Technical advantages gained by studying THP-1 cells are many. Primarily, stable 
genetic background reduces phenotype variability often found in primary human 
specimens [725]. Secondly, THP-1 cells are significantly more suitable for 
transfections with DNA plasmids and miRs, while the efficacy of these 
procedures in primary human monocytes can be low and cause cell apoptosis 
[726]. Among transfection methods available, electroporation is a suitable way 
of delivering plasmid DNA into THP-1 cells without consequences to cell viability 
or function [727,728]. Thirdly, THP-1 cells are indefinitely stored in liquid 
nitrogen and can be recovered without damage to morphology or myeloid 
phenotype of the cells. Additionally, primary human monocytes account for up 
to 10% of peripheral blood leukocytes and can be difficult to recover in numbers 
suitable for an extensive mechanistic experiment In contrast THP-1 cells are 
easily maintained and readily available. 
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In inflammation, several functions of primary monocytes have been compared to 
that of THP-1 cells. TNFα stimulated THP-1s have been shown to adhere to 
endothelial cells in the same way as blood-derived monocytes [729]. The 
transcriptome of THP-1 cells after LPS activation is largely similar to that 
observed in primary human monocytes. Similarly, PMA differentiated THP-1s 
resembled M-CSF, and to a lesser extent, GM-CSF matured macrophages, 
although some subtle differences have been noted [730,731]. Some studies have 
reported that THP-1 cells retain the ability to differentiate into phenotypes that 
mimic M1 or M2 macrophages, depending on the cytokine exposure [732,733].  
Taking this into consideration I sought to explore the possibility of using THP-1 
cells to dissect the complex roles of the mIR-23a~24-2~27a cluster in 
monocyte/macrophage biology that would have otherwise been difficult to 
examine on primary monocytes. To this end, I tested the suitability of THP-1 
cells as a model system by reproducing the data obtained from primary human 
CD14+ cells in Chapter 4 along with a characterization of some of the most 
general features of monocyte biology. Having reassured myself as to the 
suitability of THP-1 cells to study the functional significance of the miR-23a~24-
2~27a cluster in monocyte/macrophage biology. I set about to create THP-1 cell 
lines that were deficient in miR-23, miR-24 and miR-27 activities by engineering 
THP-1 cells to express miR-sponge transcripts designed to bind and sequester 
endogenous miR-23, miR-24 and miR-27. This ambitious strategy allowed the 
functional depletion of each miR within the miR-23a cluster along with all 
possible combination of each from the relevant THP-1 cell line. 
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5.2 Results 
5.2.1 Demonstrating the suitability of THP-1 cells as a model 
system to study miR-23a~24-2~27a cluster’s role in 
monocyte function 
The aim of this study was to systematically explore the role that the miR-23a 
cluster plays in monocyte/macrophage biology. To accomplish this, I had to 
identify a human monocytic cell line that retained essential features of a 
primary monocyte, namely the abilities to respond to inflammatory stimuli, to 
produce pro-inflammatory and anti-inflammatory cytokines, to mature into a 
‘macrophage' like cell and express the miR-23a~24-2~27a cluster. The available 
literature would suggest that THP-1 cells meet most of these requirements. 
However, little is know about miR-23a cluster in these cells. To this end, I aimed 
to evaluate miR-23a cluster expression and regulation within THP-1 cells. 
5.2.1.1 THP-1 cells express miR-23a and miR-23b clusters THP-1 cells. 
Both miR-23~24~27 clusters were detected in undifferentiated THP-1 cells. As 
previously seen in blood-derived monocytes, they express higher levels of the 
primary miR-23a cluster than its paralogue, pri-miR-23b (Figure 5.1, A). The 
similarities with primary monocytes are also reflected in the expression of 
mature members, as miR-24 was found at significantly higher levels than miR-
23a or miR-27a (Figure 5.1, A).  
5.2.1.2 PMA maturation supresses pri-miR-23a~24~27a expression 
Next, I have explored the expression of both miR clusters during PMA driven 
maturation of THP-1 cells, which is thought to mimic M-CSF-driven maturation of 
primary human monocytes into macrophages. For this, THP-1 cells were cultured 
with 25 ng/ml of PMA for three days followed by the replacement of the 
medium, not containing any PMA for the next four days. This protocol was 
designed to allow full differentiation and adherence of THP-1 cells while 
minimising toxicity of the PMA that can occur if exposure exceeds 72 hours. 
Here, expression of primary miR-23a~24~27a transcript was significantly reduced 
after 4 and 24 hours, as well as after seven days of maturation (Figure 5.1, B). 
However, there was no significant difference in the pri-miR-23a expression after 
three days of maturation, possibly due to the developing toxicity of PMA before 
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the change of medium. On the contrary, the pri-miR-23b cluster expression was 
immediately reduced after 4 hours of exposure, followed by the steady increase 
in levels until day 7 (Figure 5.1, B). As a result, primary miR-23b cluster 
transcript was present at higher levels than pri-miR-23a after seven days of 
maturation, similarly to that observed in primary human M-CSF-derived 
macrophages. In contrast to this, I detected a significant steady increase in the 
expression of mature members of miR-23a cluster during the PMA exposure of 
THP-1 cells, with the highest change observed in the levels of miR-23a (Figure 
5.1, D-F).  
Together, these data confirm that THP-1 cells continuously express both miR 
clusters in a steady state or during cell differentiation. The pattern of 
expression in monocytic THP-1 cells largely mimics that of primary monocytes, 
while PMA matured THP-1 cells appear different from M-CSF or GM-CSF matured 
primary macrophages. Given that this work primarily focuses on the role of 
blood-derived monocytes, undifferentiated monocytic THP-1 cells will be the 
focus of this and next chapter.    
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Figure 5.1 The expression of miR-23a~24-2~27a cluster in THP-1 monocytic cell line 
THP-1 cells were used in each experiment. Data represented by Mean±SD, n=3. Results are 
obtained by the qPCR method and displayed as RQ (2^-ddCT) relative to GAPDH or RNU6 genes 
and control cells. (A) Expression of the primary transcript of miR-23a~24-2~27a and miR-23b~24-
1~27b clusters and mature miR-23a, miR-24, miR-27a in undifferentiated THP-1 cells (2^-dCT). 
Expression normalised to GAPDH and analysed by ordinary one-way ANOVA with Sidak's 
correction for multiple comparisons. (B) Expression of pri-miR-23a~24-2~27a transcript in THP-1 
cells during 7-day maturation with 25 ng/ml PMA normalised to GAPDH control. (C) Expression of 
the pri-miR-23b~24-1~27b transcript in THP-1 cells during 7-day maturation with 25 ng/ml PMA, 
normalised to GAPDH control. (D-F) Expression of mature miR-23a, miR-24 and miR-27a in THP-1 
cells during 7-day maturation with 25 ng/ml PMA, respectively; expression normalised to RNU6 
control. Data from experiments B-F analyzed by ordinary one-way ANOVA with Dunnett’s 
correction for multiple comparisons, * - p≤0.05, ** - p≤0.01, *** - p≤0.001, **** - p≤0.0001. 
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5.2.1.3 Expression of pri-miR-23a~24-2~27a in THP-1 cells under 
inflammatory stimuli. 
Like primary CD14+ cells, THP-1 cells have previously been shown to express 
TNFR1 and IL17RA and respond to TNFα and IL-17A cytokines, respectively 
[734,735]. THP-1 cells have also been shown to express both Interferon gamma 
(IFNGR1) and IL-6R receptors [736,737]. Thus, I went on to investigate whether 
miR-23a cluster expression within THP-1 cells respond in the same way as that 
observed in CD14+ cells upon pro-inflammatory cytokine stimulation.  
5.2.1.3.1 TNFα and IL-17A do not effect pri-miR-23a~24-2~27a expression in 
THP-1 cells. 
 
Dose-dependant stimulation of THP-1 cells with TNFα and IL-17A was used to 
explore their effect on NFκB signalling cytokines on miR-23a expression,  a dose-
dependent stimulation of THP-1 cells was performed. Despite a considerable 
range of doses, neither TNFα nor IL-17A had any significant effect on the 
expression of the primary transcript of miR-23a~24-2~27a cluster (Figure 5.2, A 
and B). This finding is in keeping with that previously observed in human blood-
derived monocytes (Chapter 4). Published work conducted in murine models 
would suggest that NFκB activation reduces the expression of miR-23a in murine 
macrophages and that IL-17A directly downregulates the expression of mature 
miR-23b in the embryonic kidney cell line [593,703]. However, neither of these 
was observed in human monocytes or THP-1 cells, which might reflect 
differences between the two species or simply reflect the different cell types 
studied. It is interesting to note that proposed NFκB binding site reported is 
conserved between species and that NFκB/p65 has been shown to bind to this 
site in an erythroblast cell line [661].  
5.2.1.3.2 IFNγ represses the expression of pri-miR-23a~24-2~27a cluster in 
THP-1 cells. 
 
Previous investigation of what impacts miR-23a cluster expression in primary 
human monocytes has identified IFNγ as having a significant repressive effect on 
the expression of the cluster at a concentration of 10 ng/ml. This finding was 
reproduced here in THP-1 cells where IFNγ stimulation resulted in 
downregulation of pri-miR-23a~24-2~27a expression in a dose-dependent manner 
(Figure 5.2, C). The dose of 50 ng/ml of IFNγ had a potentially toxic effect on 
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the THP-1 cells and failed to further downregulate the expression of the pri-miR-
23a cluster (Figure 5.2, C). Indeed, high levels of IFNγ have been reported to 
induce apoptosis in THP-1 cells [738]. In line with this, physiologic levels of IFNγ, 
detected in human serum samples, are significantly below 25 ng/ml and 
predominantly vary from 10 pg/ml to 150 pg/ml in patients with severe 
infection, such as leprosy [739].  
5.2.1.3.3 THP-1 cells express functional IL-6R. 
 
Next, I explored the effect of IL-6 on the expression of miR-23a cluster since it 
had the ability to suppress its expression in fresh human monocytes after 24 
hours of exposure. Unfortunately, exposure of THP-1 cells to various doses of IL-
6 failed to exhibit any effect on the levels of primary miR-23a transcript (Figure 
5.2, D). However, this lack of effect was not due to a non-functional IL-6R 
pathway as THP-1 cells as the surface expression of IL-6 receptor matched the 
levels found in PBMC derived CD14+ monocytes (Figure 5.3, A). Further 
assessment revealed that IL-6 receptor is fully functional in THP-1 cells and 
induces phosphorylation of STAT3 signalling upon encounter with a cocktail of 
cytokines or IL-6 cytokine alone (Figure 5.3, B). Interestingly, the strongest 
signal of STAT3 phosphorylation occurred after 13 minutes stimulation of THP-1 
cells with IL-6.  However, the combination of IL-6 and soluble IL-6R prolonged 
the window of STAT3 phosphorylation up to 30 minutes, most likely due to the 
trans-signaling through membrane-bound subunit GP130 (Figure 5.3, B) 
[740,741]. Thus providing evidence of a highly expressed and fully functional IL-
6R pathway in THP-1 cells. Although lacking the ability to regulate the miR-23a 
cluster expression in THP-1 cells, the presence of functional IL-6R pathway 
allows us to investigate further the effect that mature members of the miR-23a 
cluster have on targets within the IL-6R pathway in the inflammatory context.  
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Figure 5.2 Influence of proinflammatory cytokines on the expression of miR-23a~24-2~27a 
cluster in The THP-1 monocytic cell line. 
THP-1 cells were used for each experiment. Data represented by Mean±SD, experiments were 
conducted on 3 separate occasions. Results were obtained by the qPCR method measuring pri-
miR-23~24~27 and displayed as RQ (2^-ddCT) relative to 18S gene and control cells. (A) THP-1 
cells were incubated with 1, 5 or 10 ng/ml of TNFα for 24 hours. (B) THP-1 cells were incubated 
with 10, 50 or 100 ng/ml of IL-17A for 24 hours. (C) THP-1 cells were incubated with 2, 25 or 50 
ng/ml of IFNγ for 24 hours. (D) THP-1 cells were incubated with 10, 50 or 100 ng/ml of IL-6 for 24 
hours. On all occasions, data were analysed with One-Way ANOVA test with Dunnett's correction 
for multiple comparisons.  * - p≤0.05, ** - p≤0.01. 
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Figure 5.3 Functional assessment of IL-6/IL-6R pathway in THP-1 monocytic cell line. 
THP-1 cella were used for each experiment. Results were obtained by the FACS. (A) 
Representative histogram of surface IL-6R expression in PB CD14+ cells (left) and in THP-1 cells 
(right). Matching isotype is shown in red (left) and grey (right), IL-6R staining shown in green. (B) 
Representative plot of phosphorylated STAT3 staining in THP-1 cells: unstimulated cells (blue), 
upon stimulation with cytokine cocktail (25 ng/ml IFNγ, 50 ng/ml IL-6 and 20 ng/ml IL-4) (red), 50 
ng/ml IL-6 (orange) or 50 ng/ml IL-6 with 25 ng/ml soluble IL-6R (green) after 13' (left), 30' (middle) 
and 60' (right). 
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5.2.1.4 Expression of pri-miR-23a~24-2~27a in THP-1 cells under TLR 
stimuli. 
The ability to respond to pathogen-associated molecular pattern (PAMP) signals 
is a mainstay of monocytic function, which is preserved in THP-1 cells as they 
continue to express TLR receptors [742,743] [744,745]. Here I sought to examine 
the effect of TLR stimulation on miR-23a cluster expression.  
5.2.1.4.1 THP-1 cells up-regulate miR-23a~24-2~27a expression in response 
to stimulation with LPS or Pam3. 
 
Stimulation of THP-1 cells with Poly(I:C) and CL097 activators of the intracellular 
TLR3 and TLR7/8 pathways did not have any measurable impact on the 
expression of pri-miR-23a cluster, repeating the finding previously observed in 
primary human monocytes (Figure 5.4, B and C).  
However, stimulation of THP-1 cells with Pam3CSK4 surface TLR1/2 ligand led to 
increased expression of miR-23a cluster (Figure 5.4, A). Similarly, stimulation of 
THP-1 cells with LPS ligand to TLR4 has shown a dose-dependent increase in the 
expression of primary miR-23a cluster transcript (Figure 5.4, C).  
THP-1 cells produced proinflammatory cytokines TNFα, IL-6 and soluble IL-6R 
upon LPS stimulation in a dose-dependent manner (Figure 5.5, A-C).  Similar 
response is observed from primary human monocytes, which were shown to 
produce TNFα, IL-6 and IL-6R upon stimulation with LPS [746,747].   
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Figure 5.4 Influence of TLR ligands on the expression of miR-23a~24-2~27a cluster in the 
THP-1 monocytic cell line. 
THP-1 cells were for each experiment. Data represented by Mean±SD, experiments were 
conducted on 3 separate occasions. Results are obtained by the qPCR method measuring pri-miR-
23a~24~27a and displayed as RQ (2^-ddCT) relative to GAPDH gene and control cells. (A) THP-1 
cells were incubated with 150 ng/ml of Pam3 for 24 hours. (B) THP-1 cells were incubated with 50 
µg/ml Poly(I:C) for 24 hours. (C) THP-1 cells were incubated with 10, 50 or 100 ng/ml of LPS for 24 
hours. (D) THP-1 cells were incubated with 1 μg/ml of CL097 for 24 hours. On all occasions, data 
were analysed with One-Way ANOVA test with Dunnett’s correction for multiple comparisons.  * - 
p≤0.05, **** - p≤0.0001. 
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Figure 5.5 Expression of proinflammatory cytokines by THP-1 cells upon stimulation with 
TLR4 ligand LPS. 
THP-1 cells were used for each experiment. Data represented by Mean±SD, experiments were 
conducted on 3 separate occasions. Results are obtained by the ELISA method and displayed as 
concentration (pg/ml) of cytokines in the supernatant of the THP-1 cells stimulated with 10, 50 or 
100 ng/ml of LPS for 24 hours. (A) IL-6 levels (pg/ml). (B) Soluble IL-6R levels (pg/ml). (C) TNFα 
levels (pg/ml). On all occasions, data were analysed with One-Way ANOVA test with Dunnett’s 
correction for multiple comparisons.  * - p≤0.05, ** - p≤0.01. 
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5.2.2 Creating miR-23~24~27 knock-out THP-1 cell lines 
5.2.2.1 Principal of miR sponge for technical knock-out of miRs 
Ebert and colleagues first introduced the concept of miR sponges for the 
creation of loss of function of endogenously expressed miRs [618]. MicroRNA 
sponges inhibit miR function by swamping the cell with transcripts containing 
multiple (typically >5) high-affinity miR binding sites. These sponge transcripts 
compete with the endogenous miR targets, obscuring them from inhibition 
(Figure 5.6). In addition to this simple decoy role, sponges are typically designed 
to have a mismatch or a 3 base pair ‘bulge’ sequence at the 5' end of the seed 
region (Figure 5.6, B). The aim of this imperfect match is to induce the 
sequestering of the target rather than its degradation removing bound miRs from 
the active pool of the RISC-associated miRs, leaving their endogenous targets 
unregulated (Figure 5.6, A). One of the main advantages of miR sponges is that 
they have broad specificity for miR families i.e. a sponge against miR-23a will in 
most cases also target miR-23b and c species. 
Recently there have been some reports where the authors used miR-sponges 
against multiple miR targets to investigate the collective roles of these miRs in 
the cell function and diseases [748,749]. 
To study the miR-23a cluster miRs we designed sponges that would target each 
miR within the cluster along with all possible combinations (Figure 5.7). The 
resulting miR sponge constructs and stably transfected miR sponge cell lines 
were extensively validated for their ability to be targeted by both exogenous 
and endogenous miRs.  
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Figure 5.6 Schematic diagram of the principle of miR sponges. 
(A) Schematic showing of the mechanism by which miR sponges relieve the inhibition of 
endogenous target genes. (B) Sponge miR binding site units with imperfect pairing between a miR 
and a sponge ‘bulge’ sequences introduced to promote sequestration over endonucleolytic 
cleavage by Argonaute 2 complex.  
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Figure 5.7 Schematic representation of multiple combinations miR-23~24~27 sponges. 
Each green, yellow and blue square represents the individual miR binding site (MBS) for miR-23, 
miR-24 and miR-27, respectively. Each miR sponge construct contains 10 MBSs for each 
individual miR. See materials and methods for more details (Section 2.5.2). 
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5.2.2.2 Construction of miR sponge expression constructs 
The method used to generate the miR-23~24~27 sponge transgenes is described 
in detail in the material and methods (Chapter 2) and will be discussed only 
briefly here. Previously described methods for generating sponge transcripts 
involved the concatemerization of double-stranded oligonucleotides encoding 
optimised miR binding sites (MBS) [750]. MBS are designed to contain a 3 
nucleotide ‘bulge' or mismatch with positions 9-12 of the miR sequence which is 
thought to better mimic physiological miR:mRNA interaction (Figure 5.6, B). It is 
believed that these types of interactions promote sequestration rather than 
degradation, resulting in a more efficient loss of function of target miRs 
[618,751,752]. While this approach is adequate for the generation of sponges 
against single miR targets, it would have been laborious for the production of 
the various sponges required for this work. Taking advantage of recent 
developments in gene synthesis, I developed a novel design strategy in which 
sponge MBS arrays were synthesised using commercial gene synthesis 
technologies.  (Figure 5.8, A). One of the main limitations of gene synthesis is 
that they cannot contain significant repeat regions. At first glance, this should 
have precluded their use for the generation of miR sponges, which are 
effectively repeats of MBS. However, as mentioned above, as sponge MBS are 
designed to contain a 3 base bulge it was possible to alter this sequence along 
with a 5 bp ‘spacer' sequence between each MBS. Decreasing the level of 
repetitiveness in each sponge to the extent that it permitted the synthesis of a 
single sequence containing 5 MBS each of miR-23, miR-27 and miR-24. The 
spacers between each miRs sponge were designed to contain restriction sites for 
different blunt-cutting restriction enzymes that permitted the rapid generation 
of all possible sponge combinations simply by restriction enzyme digest followed 
by religation of the plasmid (Figure 5.8, A). Similarly, the number of MBS in each 
sponge was doubled to contain 10 MBS per miR by cloning the sponge sequence 
into the parental vector. The final step was to clone each of the seven sponge 
combinations downstream of the luciferase of pGLOMS2BD vector, 
transcriptionally fusing the sponge with a luciferase reporter gene under the 
control of the Phospho-Glycerate-Kinase (PGK) promoter (Figure 5.8, B). Linking 
each sponge to a luciferase reporter allowed sponge activity to be monitored 
and validated. The following sections will describe the functional validation of 
the miR sponge constructs.  
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Figure 5.8 Schematic showing the cloning strategy of miR-23, miR-24 and miR-27 sponge 
transgenes. (A) miR-23~24~27 sponge gene was created using Gene Synthesis method. 
Individual miR sponges were created using the combination of restriction enzymes (RE). (B) miR 
sponge gene was double using specially designed restriction sites. (C) miR Sponge gene was 
cloned into Luciferase expressing plasmid - pGLOMS2BD. See materials and methods for more 
details (Section 2.5.2).  
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5.2.2.3 Overview of functional validation of constructs and generation of 
stable THP-1 cells lines containing miR sponges.  
5.2.2.3.1 Testing sponge constructs in HEK293 cells  
 
As an initial step, I sought to confirm that each of the seven miR sponge 
constructs was targetable by the miRs to for which they were designed. To 
achieve this sponge constructs were co-transfected along with miR mimics and 
scrambled negative control mimic into HEK293 cells. One day later luciferase 
activity was measured. In all cases, the level of luciferase activity was 
significantly reduced compared to scrambled control (Figure 5.9, A-H). It is worth 
noting that while the luciferase activity of miR-23 sponge decreased with the 
addition of miR-23a mimic it was reduced less than in miR-24 and miR-27 
sponges with their corresponding miR-mimics, indicating that miR-23 sponge may 
be less efficient at reducing the miR-23a activity in high expressing cells. 
5.2.2.3.2 Creation of stable THP-1 miR sponge cell lines 
 
As previously described, THP-1 cells are a useful model system to study myeloid 
function. These cells are relatively easy to grow and, importantly for this study, 
to genetically modify. The seven sponge constructs along with empty vector 
control were electroporated into THP-1 cells. Stably transfected cells were 
selected for by their resistance to G418, which is conferred by the neomycin 
resistance gene contained with the sponge-expression constructs. G418-resistant 
cells emerged 3-4 weeks after electroporation and were grown continuously in 
the presence of G418 thereafter. Genotyping of sponge cells showed that they 
all contained the correct sponge transgenes (Figure 5.10, A). A luciferase assays 
performed on sponge cells revealed that they all expressed both luciferase and 
renilla (Figure 5.10, B). However, the normalised luciferase activity measured in 
miR-27 and miR-23+24+27 sponge cells was less than 10% that of the empty 
vector, suggesting that these sponge transcripts were saturated by endogenous 
miRs raising the possibility that target miRs were not entirely depleted in these 
cells (Figure 5.10, C). To overcome this potentially confounding problem I 
decided to make new constructs that would express sponge transcripts at higher 
levels. 
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Figure 5.9 MiR-23a~24-2~27a sponge constructs are efficiently targeted by miR-23a, miR-24 
and miR-27a mimics.  
HEK293 cells were co-transfected with sponge plasmids in pGLOMS5BD vector and with either 
scrambled control or miR mimics (miR-23am, miR-24m, miR-27am). Luciferase activities were 
measured after 24 hours. Data analysed by ordinary One way ANOVA and represented by 
Mean±SD of 3 separate experiments. **** - p≤0.0001 versus scrambled control, ns – p>0.05. 
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Figure 5.10 Characterization of stable THP-1 sponge cell lines.  
(A) PCR genotyping of THP-1 stables confirmed presence of sponge transgenes. (B) Schematic 
showing of genotyping strategy, arrows indicate the location of primers. (C) Luciferase and renilla 
activity measure (arbitrary units) on 100,000 sponge cells. (D) Luciferase activities of THP-1 
sponge cells normalised to renilla and expressed as a percentage of the pGLOMS2BD-LUC control 
vector.  
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5.2.2.3.3 Creation of miR sponge constructs with increased expression 
 
To increase sponge transcript expression levels the relatively weak PGK 
promoter was replaced with the stronger elongation factor 1 alpha (EF1a) 
promoter [753]. This was accomplished by replacing the PGK promoter of 
pGLOMS2BD with the human EF1α promoter. The EF1α promoter was synthesised 
as a G-block and cloned by Gibson Assembly using the strategy shown in Figure 
5.11, A. The resulting construct (pEF6-Luc) produced >10 fold increase in 
normalised luciferase activity compared to the original pGLOMS2BD plasmid 
when transfected into HEK293 cells (Figure 5.11, BC). The decision was 
therefore taken to convert the sponge plasmids to the new pEF6-Luc construct.  
5.2.2.3.4 pEF6-Sponge constructs are targeted by their corresponding miRs 
 
Once made, the pEF6-Sponge constructs were transfected into HEK293 to test 
their luciferase activity (Figure 5.12, A). All constructs showed increased 
luciferase compared to the equivalent pGLOMS2BD sponge constructs. To 
confirm that the pEF6 sponge targets were targeted by their corresponding miRs, 
sponge constructs along with miR mimics were co-transfected into HEK293 cells 
and luciferase activity measured (Figure 5.12, B). In all instances, miRs 
significantly reduced luciferase activity compared to scrambled control. Notably, 
luciferase activity in most cases did not drop below 50% of the control, 
suggesting that there was still ample sponge capacity remaining within the cell 
despite supra-physiological levels of target miRs introduced by transfection.  
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Figure 5.11 Creation of high-expressing sponge constructs.  
(A) Schematic showing the conversion of pGLOMS2BD to pEF6-Luc. (B) Comparison of relative 
luciferase activity produced by pGLOMS2BD and pEF6-Luc Vectors transfected into HEK293 cells. 
Luciferase activity measured using Dual-Glo luciferase assay, values normalised to Renilla. (C) 
Relative increased in normalised luciferase activity of pEF6-Luc Vector compared to pGLOMS2BD 
Vector. Data were analysed by ordinary Student’s t, **** - p≤0.0001. 
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Figure 5.12 EF6-Sponge constructs are targeted by their cognate miRs. 
HEK293 cell line was used for transfection experiments; luciferase activity was measured after 24 
hours using Dual-Glo Luciferase assay. Luciferase activities were normalised to renilla (A, B) and 
to scrambled control (B) and displayed as Mean±SD of Relative Luciferase Activity, n=3 for each 
experiment. (A) All pEF6-Luc sponge and pGLOMS2BD-sponge constructs were transfected into 
HEK293 cells. (B) HEK293 cells were co-transfected with sponge pEF6-Luc plasmids and with 
either miR mimics (miR-23am, miR-24m, miR-27am) or scrambled control mimic (SCRAM). Data 
were analysed by ordinary One way ANOVA test with Sidak’s correction for multiple comparisons, 
**** - p≤0.0001, ns – p>0.05.  
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5.2.2.4 Creation and validation of THP-1 pEF6-Sponge cell lines 
Stable THP-1 cells lines were made as described in Section 5.2.2.3.2. After 
electroporation with the 7 EF6-sponge constructs plus empty vector, each clone 
was genotyped by PCR and shown to contain the correct sponge transgene 
(Figure 5.13, A and B). Dual luciferase assays were performed on the resulting 
G418 resistant clones  (Figure 5.13, C). All EF6-sponge cell lines showed robust 
luciferase activity, indicating that they all contained functional EF6-sponge 
transgenes.  
  
253 
 
 
 
Figure 5.13 Characterization of stable THP-1 EF6-sponge cell lines.  
(A) PCR genotyping of THP-1 stably transfected cell lines (stables) confirmed presence of sponge 
transgenes. (B) Schematic showing of genotyping strategy, arrows indicate the location of primers. 
(C) Luciferase and renilla activity was measured on two separate occasions, displayed as 
Mean±SD of Relative Luciferase activity (RLU, arbitrary units) on 100,000 sponge cells. 
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5.2.2.4.1 THP-1 EF6-sponge cells are actively targeted by miR-23-miR-24-
miR-27 family miRs 
 
To further validate the THP-1 EF6-sponge cell lines, I transfected them with both 
miR mimics and miR-inhibitors. The ability of miR mimics to target or inhibitors 
to relieve the expression of sponge transcripts was inferred from measured 
luciferase activity compared to scrambled control (Figure 5.14, A-H). In all 
cases, mimics were able to reduce luciferase expression compared to scrambled 
control. Conversely, miR-inhibition resulted in a significant increase in luciferase 
expression as they alleviated the repression of endogenous miRs. Demonstrating 
sponge transcripts were being actively targeted by endogenous miRs. The only 
exception to this was EF6-miR-23-24-27 sponge cells which while showing a 
significant decrease in luciferase activity upon the overexpression of miR-23a, 
miR-24 and miR-27a were unaffected by the inhibition of individual miRs this 
was likely due to the targeting of the miR-23-24-27 sponge by all three 
endogenous miRs (Figure 6.8 H). Alleviation of the repressive activity of one miR 
was insufficient to de-repress the translation of luciferase ORF by the other two. 
However, the fact that it was able to bind further miRs when artificially 
introduced suggests that it has not reached its maximal ‘sponge' capacity and 
therefore may still be of use experimentally. 
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Figure 5.14 Stable THP-1 EF6-sponge cells are targeted by their corresponding miRs.  
Stable THP-1 sponge cell lines were transfected with scrambled control mimic (Scrambled), miR 
mimics (miR-23am, miR-24m, miR-27am), Control inhibitors (Ci) and miR inhibitors (miR-23ai, 
miR-24i, miR-27ai). Luciferase activity was measured after 24hours. Luciferase activities are 
normalised to renilla and corresponding control (Scrambled for miR mimics and Control inhibitor for 
miR inhibitors). Data is displayed as Mean±SD of Relative Luciferase activity of 3 separate 
experiments and analysed by ordinary One way ANOVA test, **** - p≤0.00001, ns – p>0.05. 
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5.2.2.5 THP-1 EF6-sponge transcripts are targeted by miRs from both ‘a' and 
‘b' clusters. 
As previously discussed, miR-23a and b and miR-27a and b paralogues are closely 
related and vary from each other by a single base at position 19. The sponge, 
while designed against the ‘a' cluster, should share sufficient complementarity 
with the ‘b' cluster miRs to target it with similar efficiency. To test this, miR 
mimics corresponding to miR-23 and miR-27 from both clusters were transfected 
into EF6-23+24+27 THP-1 cells, and their effect on luciferase activity measured 
(Figure 5.15). In all cases, mimics significantly reduced luciferase activity 
compared to scrambled control. However, there was no significant difference 
between ‘a' and ‘b' miRs, suggesting that the sponge transcripts bind both 
species with comparable efficiency.  
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Figure 5.15 pEF6-23-24-27 sponge is targeted with equal efficiency by family members of 
both miR-23a and miR-23b clusters.  
THP-1 cells expressing the miR-23-24-27 sponge were transfected with the scrambled control 
mimic (SCRAM) and with miR mimics of miR-23a, miR-23b, miR-24, miR-27a, miR-27b. Luciferase 
activity was measured after 24 hours. Luciferase activities are normalised to renilla and displayed 
as Mean±SD of the percentage of scrambled control vector from 3 separate experiments. Data 
were analysed by ordinary One way ANOVA test, ** - p≤0.01, *** - p≤0.001, ns – p≥0.05. 
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5.2.2.6 Mature miR-23a, miR-24 and miR-27a levels are increased in THP-1 
cells, containing their cognate sponge transcripts.  
There are a number of papers that have reported significant drops in mature miR 
levels in sponge expressing cells [749,754]. These reports are somewhat puzzling 
as miR sponges, unlike antagomir inhibition, are not thought to directly induce 
degradation of target miRs or by binding them change their chemical properties 
such that they are inefficiently purified using standard protocols [755]. There is 
no cellular process yet described that would provide a reasonable mechanistic 
explanation for the decreased levels of miRs reported in these publications. 
Taking an open-minded approach, I decided to see if the presence of sponge 
activity had any effect on the amount of mature miRs produced by the miR-23a 
cluster. Therefore the levels of the mature forms were quantified by qPCR on 
RNA prepared from THP-1 EF6-sponge cells (Figure 5.16, A). 
To my surprise, the levels of miR-24 and miR-27a were dramatically increased in 
cells containing compatible sponge transcripts up to 100 fold in the case of miR-
27a in the EF6-23-27 sponge cell line (Figure 5.16, A). MiR-23a sponge capacity 
did not have any significant effect on mature miR-23a levels. There have been 
other reports describing the imbalanced production of mature miRs from pri-
miR-23a cluster. Chhabra and colleagues reported that miR-23a was not 
generated from the over-expression of pri-miR-23a cluster while miR-27a and 
miR-24-2 were [574]. Similarly, another study described that miR-23a maturation 
was blocked when over-expressed in HEK293 cells but not in HeLa cells [756]. 
Neither authors postulated a mechanism for these observations.   
My findings could not be explained by an increase in the expression of the pri-
23a~24-2~27a transcript in THP-1 sponge cells (Figure 5.16, B). In fact, 
conversely pri-23a~24-2~27a levels were decreased rather than increased in 
sponge cells (Figure 5.16, B). MiR expression is often controlled by feedback 
loops, whereby transcription factors controlling the expression of the miR are 
themselves directly targeted by the same miRs [699]. In this instance a 
transcriptional repressor may be directly targeted by miR-23a/24-2/27a, de-
repression by sponge transcripts would result in increased levels of the 
transcriptional repressor and consequently a decrease in primary transcript 
levels. It is worth noting that earlier in this and previous chapters I described 
how IFNγ and IFNβ reduced pri-miR-23a cluster expression in THP-1 cells and 
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primary CD14 monocytes. It is tempting to speculate that TFs at the end of those 
signalling pathways may be direct targets of the miR-23a/miR-24/miR-27a. 
Indeed target analysis in chapter 6 predicted that the miRs in this cluster 
directly target various TFs including STATs and AP-1.  
This of course does not provide a mechanistic explanation for the observed 
increase in mature miRs seen in sponge cells. These changes must be due to 
some process operating post-transcriptionally, possibly by prolonging the 
stability of sponge-targeted miRs. Indeed, it has been reported that sequestered 
miRs containing ‘bulges’, as is the case with miR-23a/24/27a sponges, exhibit 
increased half-lives compared to those without [757]. This would provide an 
obvious mechanistic explanation for the increased levels miRs seen here.  
The observed increase in levels of mature miR-27a and miR-24 seen in sponge 
cells does raise concern as to the utility of these sponges to achieve an effective 
reduction in miR activity. Data produced from over-expression and inhibition 
studies in Section 5.2.2.4.1 would suggest that there is still sufficient ‘sponge' 
capacity to lower target miR activity within the THP-1 EF6-Sponge cells 
effectively. However, to directly address this concern I decided to measure 
absolute copy numbers of sponge transcripts in each of the sponge cell lines. 
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Figure 5.16 Expression levels of pri-miR-23a~24-2~27a cluster and mature miRs in THP-1 
sponge cells.  
pEF6 THP-1 Sponge cells were used for both experiments. (A) Mature miR-23a, miR-24 and miR-
27a levels were measured by SYBR green qPCR. Data shown as Mean±SD of RQ (2^-ddCT) 
normalised to house keeping gene RNU6 and relative to pEF6-Luc (Empty Vector control). (B) 
Levels of pri-miR-23a~24-~27a transcript were measured by SYBR green qPCR. Data shown as 
Mean±SD of RQ (2^-ddCT) normalised to house keeping gene GAPDH and relative to pEF6-Luc 
(Empty Vector control). Data were analyzed by ordinary One way ANOVA test, * - p≤0.05, ** - 
p≤0.01, *** - p≤0.001, **** - p≤0.0001. 
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5.2.2.7 Copies of sponge transcripts are present in excess of endogenous 
miR-23a, miR-24 and miR-27a in THP-1 EF6-sponge cells. 
Absolute quantification of sponge transcripts expressed within the THP-1 EF6-
sponge cells was performed along with the measurement of mature miR-23a, 
miR-24 and miR-27a levels. The pEF6-luc plasmid along with miR mimics of miR-
23a, miR-24 and miR-27a were used to generate a qPCR copy number standard 
curve. This allowed me to determine the copy numbers of sponge transcripts and 
mature miR-23a, miR-24 and miR-27a in sponge cells (Figure 5.17, A and B). It 
has been estimated that a single cell contains 10-30 pg of RNA; here I assumed 
20 pg [758]. The results clearly show that in each of the EF6-Sponge cell lines, 
except EF6-23+24+27sp, sponge transcripts are present at higher levels than the 
miRs to which they are designed. Given that each sponge contains 10 miR-
binding sites, the level of sponge capacity within these cells is far in excess of 
target miRs. However, some caution should be taken in the interpretation of 
data generated from EF6-23+24+27 cells, which may be inefficient at depleting 
the activity of miR-23a, miR-24 and mIR-27a. 
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Figure 5.17 Copy numbers of miR and Sponge transcripts per cell (20pg RNA).  
(A) Absolute Copies of each Sponge transcript was measured from cDNA prepared from THP-1 
sponge cell lines, by qPCR against a standard curve of know copies generated from the pEF6Luc 
plasmid. (B) Absolute copies of mature miR-23a, miR-24 and miR-27a were measured from THP-1 
sponge cell lines by qPCR against a standard curve of known copies of cDNA prepared from 
denatured miR mimics. In both A and B, values were normalised to 20 pg of input RNA and 
expressed as copies per cell where the assumed RNA per cell is 20 pg.   
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5.3 Discussion 
The aim of the work described in this chapter was to generate miR-23-24-27 
cluster deficient monocytic cell line for further functional and mechanistic 
studies.  
First I tested the suitability of THP-1 cells as a functional surrogate for human 
CD14+ monocytes. THP-1 cells have been exploited experimentally for over three 
decades in the study of monocyte biology [759]. I confirmed that THP-1s show 
many of the features synonymous with monocyte function: ability to respond to 
and produce pro-inflammatory stimuli and capacity to mature into macrophage 
like cells, being amongst the most carefully studied aspects.  
Here, I found that the THP-1 cells expressed pri-miR-23a transcript and resulting 
mature miR-23a, miR-24-2 and miR-27a forms; and that the ratio of the 
expression of each of the mature forms was similar to that of primary human 
CD14+ cells. Likewise, the miR-23a cluster was the predominant form expressed 
in THP-1 cells. THP-1s upon treatment with PMA, an activator of Protein Kinase 
C, quickly adopt a macrophage-like phenotype [722,760]. This process sees a 
sharp decrease in primary miR-23a cluster expression, which was also observed 
in M-CSF and GM-CSF matured primary macrophage cultures. In keeping with my 
previous data in primary monocytes, I found no change in pri-miR-23a cluster 
upon stimulation with either TNFα or IL-17A. NFκB is the primary transcriptional 
regulator downstream from both TNFα and IL-17a signalling pathways. The miR-
23a cluster has previously been shown to be directly upregulated by NFκB/P65 
via a binding site in the promoter [661]. In fact, stimulation of THP-1 cells with 
TLR2 and TLR4 ligands (Pam3 and LPS, respectively) also utilising NFκB/P65 
signalling did increase cluster expression levels, in concordance with previously 
published data. Curiously, treatment with IL-6 while having a significant 
negative effect on the expression of pri-miR-23a expression in CD14+ cells had no 
effect on THP-1 cells, despite the presence of an active IL-6R rapidly inducing 
phosphorylation of STAT3. A number of other studies have demonstrated the 
presence of robust IL-6 signalling in THP-1 cells [761]. The reason for the 
discrepancy between THP-1 and primary cells is not apparent. 
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Next, I described the generation of miR-sponge constructs designed to 
specifically deplete endogenous miR-23/miR-24/miR-27 in THP-1 cells. This 
decision has been made in attempt to stay true to investigating human biology, 
without resorting to mouse knock out models whilst deciphering the full scope of 
the miR-23a~24~27a functions. This approach involved the creation of a novel 
cloning strategy that for the first time describes a quick and reliable method for 
the production of sponge transcripts using commercially available gene synthesis 
[762]. This a significant improvement in terms of speed and ease of manufacture 
compared to previously described methods [762]. I went on to create and 
functionally validate constructs that would express miR-sponge transcripts 
targeting all 7 combinations of miRs produced from miR-23a cluster (Figure 5.7). 
In all cases the resulting miR-sponges were targeted with high efficiency by their 
corresponding miRs. THP-1 cells that stably expressed the 7 sponge transcripts 
along with the empty vector controls were created. Subsequently upon the 
characterization of these cell lines, I observed that in some instances (miR-27 
and miR-23+24+27) sponge transcript levels as measured by the expression of 
transcriptionally coupled luciferase gene were almost undetectable, suggesting 
that they had been completely saturated by endogenous miRs. Concerned that 
endogenous miRs might be expressed at levels higher than their corresponding 
sponge transcripts, I took the decision to remake the sponge constructs replacing 
the initial PGK promoter with the stronger EF1α promoter [753]. This resulted in 
a 10 fold increase in expression. THP-1 cells stably expressing the new pEF6-
sponge transgenes were created and subjected to an extensive set of 
experiments designed to confirm the identity and efficacy of the sponge 
expressing cells. In all cases over-expression or inhibition of miR-23a, miR-24 and 
miR-27a THP-1s expressing the corresponding sponge exhibited the expected 
change in the luciferase activity. Interestingly, mature levels of miR-24 and miR-
27a were significantly increased in THP-1s expressing sponges designed against 
them, while miR-23a levels were unaffected. This increase was not due to an 
increase in primary transcript expression. Indeed, primary transcript levels were 
decreased in the sponge expressing constructs. It is possible that this was due to 
a stabilisation of miR-24 and miR-27 that has been reported upon miR binding to 
transcripts that contain ‘bulge’ sequences [757]. The significant increase seen is 
potentially the result of long-term sponge expression in these cells that over 
time results in an accumulation of these miRs. 
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The sponge cell lines could provide an excellent platform to study the complex 
interaction of the miR-23a cluster. By measuring the differences that depletion 
of each of the miRs within the cluster in turn and in combination, make to the 
transcriptome, proteome and metabolome of THP-1 offers the opportunity to 
study their role in unparalleled detail. Taking a ‘Systems Biology' approach, 
using the latest bioinformatics analytic techniques to integrate these data sets 
would provide an incredible insight into the complex interplay of roles these 
miRs play in monocyte/macrophage biology [763]. 
In summary, THP-1 largely recapitulate the findings I observed in primary human 
CD14+ cells, suggesting that they are a rational model to study the role of miR-
23a~24-2~27a in monocyte function. To functionally study them in this context I 
created 7 THP-1 cell lines in which every combination of the miR-23a cluster was 
functionally depleted providing an excellent experimental platform for their 
study in a monocytic cell line. Investigation of the functional role of miR-
23a~24~27a cluster in THP-1 cells and primary human monocytes is to follow. 
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6  Identification and verification of miR-23a~24-
2~27a molecular targets. 
6.1 Introduction 
My previous data have shown that treatment-resistant RA patients lack the 
expression of the miR-23a cluster in CD14+ monocytes as a consequence of raised 
pro-inflammatory stimuli, such as IL-6, but also when stimulated by IFNγ and 
IFNβ in the in vitro setting. Moreover, a decrease in the expression of this miR 
cluster was observed during M-CSF and GM-CSF differentiation into macrophages, 
suggesting some possible role in monocyte maturation. Therefore, this chapter 
will look into the role of miR-23a~24~27a in peripheral blood monocytes and 
elucidate how this relates to the pathogenesis of RA in general, and, more 
specifically, to the drug resistance observed in the patient cohort. 
The key to understanding miR functions is the identification of their molecular 
targets. To identify potential interactions of this miR cluster, several in silico 
prediction algorithms were used including: Targetscan, MiRanda, miR22, Pictar2, 
PITA and miRwalk, all of which are described in detail the Chapter 1. Once 
potential targets were identified, they were integrated with pathways active in 
monocytes and macrophages using the Ingenuity pathway analysis platform. 
Ingenuity pathway analysis was initially based on published interactions, 
however recently this platform expanded to incorporate published and predicted 
miR:mRNA transcript interactions based on the validated interactions from 
TarBase and miRecords databases, as well as the in-silico analysis from 
TargetScan algorithm.  
From all identified interactions, relevant potential targets were experimentally 
validated for the ability to bind and be regulated by specific miRs. These 
interactions were then further tested in THP-1 cells as well as in generated miR-
23 cluster sponge THP-1 cells and primary inflammatory monocytes to elucidate 
the roles of miR-23a, miR-24 and miR-27a in immunity. 
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6.2 MiR-23a and miR-27a are predicted to target the IL-6R 
pathway 
In-silico prediction algorithms and Ingenuity pathway analysis highlighted the IL-
6 pathway as being heavily targeted by the miR-23a cluster (Figure 6.1). Zhu et 
al. demonstrated miR-23a’s interaction with IL-6R in gastric adenocarcinoma 
cells [764]. However, here I identified both miR-23a and miR-27a to have 
potential binding sites in the 3'UTR region of IL-6R. Further comprehensive 
analysis of the IL-6R pathway also identified IL-6R co-receptor GP130 as another 
possible target of both miR-23a and miR-27a. Additionally, ERAP1 
aminopeptidase, implicated in the cleavage of IL-6R into a soluble form, is a 
predicted target of miR-27a [397]. With regards to the intracellular 
compartment of this pathway, miR-23a is predicted to regulate key signalling 
molecules: JAK1/2 and STAT1/3, while miR-24 has two potential binding sites in 
the 3'UTR of STAT3. The coordinated suppression of JAK/STAT signalling by all 
members of this miR cluster was demonstrated this year in human acute 
erythroid leukaemia cells. Nevertheless implications for IL-6 signalling in the 
inflammatory context has not been explored [765].   
While suggestive, all algorithms used to predict miRNA target interactions suffer 
from significant false discovery rates; therefore experimental validation is 
required and will follow next.  
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Figure 6.1 Schematic showing the predicted miR23a~24-2~27a regulatory network of the IL-6 
signalling pathway. 
In silico predicted targets of miR-23a include IL-6R, GP130, JAK1, JAK2 and STAT1 molecules 
(depicted in orange). MiR-24 is predicted to target STAT3 signaling molecule (depicted in red), 
while miR-27a has predicted binding sites in the 3’UTR of IL-6R, GP130, STAT1 and ERAP1 
(depicted in green). In silico analysis was performed using available algorythms, such as 
Targetscan, miRanda, RNA22, miRWalk, PicTar2 and PITA.   
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6.2.1 Membrane and Soluble IL-6R transcripts share 
polyadenylation signals that contain miR-23 and miR-27 
binding sites  
Alternative splicing of IL-6R transcripts results in membrane-spanning IL-6R (mIL-
6R) and soluble-IL-6R (sIL-6R). Both of these forms form active receptor 
complexes with co-receptor IL-6ST (GP130). Secretion of the soluble form of IL-
6R can confer IL-6 responsiveness to cells that do not express IL-6R by utilising 
the ubiquitously expressed GP130 co-receptor trans-signalling. Trans-signalling 
was shown to have significant implications in RA pathogenesis and was reviewed 
in detail in Chapter 1 and in [373]. The analysis IL-6R transcripts using the 
ENSEMBL genome browser appeared to show that mIL-6R and sIL-6R transcripts 
vary not only in the inclusion or exclusion of exon 9 respectively but also in the 
length of their 3'UTR sequence by potentially utilising alternative 
polyadenylation signals (Figure 6.2, A). This raises the possibility that sIL-6R may 
be regulated by only a subset of miRs that target mIL-6R.  
To see if this was indeed the case I characterised the 3' ends of both sIL-6R and 
mIL-6R using 3'RACE. I designed primers that were specific for either variant. 
The resulting bands were cloned and sequenced. Inspection of the sequences in 
both cases corresponded to the shorter annotated sequences in the 3'UTR of IL-
6R (Figure 6.2, B). This strongly suggests that both soluble and membrane IL-6R 
variants use the same proximal polyadenylation signal, previously described only 
in the soluble form. Furthermore, both sequences contained stretches of non-
genomically encoded tracts of adenosines, which is a hallmark of 
polyadenylation. Finally, identification of a variant polyA signal (AAGAAA) 
upstream of the polyA tail provided the final evidence that the amplified 
sequences did indeed represent the 3' ends of both IL-6R transcripts (Figure 6.2, 
B).  
I did not, however, identify 3' species corresponding to the longer 4070 bp 3'UTR 
which is attributed to the mIL-6R in ENSEMBL (ENST00000368485.7). However, 
this may have been due to the length of amplification necessary to detect it. 
The 3'RACE strategy used here was designed to see if both IL-6R variants utilised 
the same polyadenylation signal and designing primers closer to the distal most 
polyA signal may have allowed the identification of longer 3'UTR forms.  
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Notably, the proximal 3'UTR identified in both forms lies adjacent to the polyA 
site reported for sIL-6R (ENST00000344086.8) (Figure 6.2, C). The previously 
annotated ENSEMBL transcript appears to be an artefact result from mispriming 
of oligodT to a genomically encoded stretch of adenosine residues rather than a 
true polyA tail added posttranscriptionally. Such events are well-described 
confounders of the 3'RACE method [619]. Significantly, this form and the 3' end 
of the annotated sIL-6R transcript in ENSEMBL lack obvious canonical or non-
canonical polyA signals, further supporting the conclusion that the transcript 
annotated in the ENSEMBL’s database is an artefact of oligodT primed reverse 
transcription.  
Superimposing identified miR-23a and miR-27a binding sites onto the longer and 
shorter 3'UTR sequences demonstrates that both mIL-6R and sIL-6R retain MBS to 
these miRs (Figure 6.2, C). Here I showed that both mIL-6R and sIL-6R share 
polyA signals, have similar 3'UTR and are therefore likely to be co-regulated by 
the same cadre of miRs. 
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Figure 6.2 Membrane and soluble IL6R utilise the same polyA signals. 
(A) A schematic showing of the exon structure of human soluble and membrane IL-6R transcripts 
annotated in ENSEMBL database. Blue arrows show the variant-specific primers used in 3'RACE. 
3'RACE was performed on total RNA purified from THP-1 cells, using variant-specific primers (blue 
arrows). Amplified 3'ends were cloned into pCR2.1 TOPO and sequenced. (B) The chromatogram 
shown is representative of the cloned sequences. The red box shows the position of predicted 
polyA signal. The position of the 3' end is mapped onto a schematic of the IL-6R 3'UTR showing 
the positions of predicted miR-23a and mIR-27a binding sites. Open triangles represent poorly 
conserved sites as determined by Targetscan. (C) 3'RACE product corresponding to the 3' end of 
the sIL-6R (ENST00000344086.8) is an artefact amplified from genomically encoded stretch of 
adenosine residues and is not a genuine polyadenylated species.  
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6.2.2 MiR-23a and miR-27a directly target membrane and soluble 
forms of IL-6R 
Here I set out to experimentally validate molecular targeting of IL-6R’s 3'UTR by 
miR-23a and miR-27a. Firstly, bioinformatic analysis using a number of miR 
target prediction algorithms (MiRWalk, miRanda, PicTar2, PITA, RNA22 and 
Targetscan) was done to identify miR-23a cluster binding sites within IL-6R 3'UTR 
(Table 6.1).  
 
Table 6.1 Summary of miR-23a and miR-27a predicted binding sites by selected algorithms  
Green and red indicate presence or absence of miR binding site respectively.  
 
Using these algorithms, I was able to identify two potential binding sites for both 
miR-23a and miR-27a in the IL-6R 3'UTR and each case these sites were 
predicted by at least 3 out of the 6 programs used (Figure 6.3, A). To 
experimentally validate these sites, I amplified a 2.1 kb region encompassing 3 
out of the 4 predicted sites (Figure 6.3, B). This region was cloned downstream 
from the luciferase reporter gene. The resulting plasmid was co-transfected into 
HEK293 cells along with miR mimics corresponding to miR-23a, miR-27a or 
scrambled control. After 24 hours the luciferase activity was measured using a 
dual-luciferase assay.  
These experiments showed that both miR-23a and miR-27a significantly reduced 
luciferase expression compared to scrambled control, suggesting that they 
directly target IL-6R (Figure 6.3, C). Subsequent mutation of the predicted 
binding site ameliorated the effect of miR mimics, demonstrating conclusively 
that this effect was due to the direct interaction of miR-23a and miR-27a with 
IL-6R 3'UTR (Figure 6.3, C).   
Gene	 miRNA	 miRWalk	 miRanda	 Pictar2	 PITA	 RNA22	 Targetscan	
IL6R#1	 miR-23a-3p	
IL6R#2	 miR-23a-3p	
IL6R#1	 miR-27a-3p	
IL6R#2	 miR-27a-3p	
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Figure 6.3 MiR-23a and miR-27a directly target IL-6R. 
(A) A schematic showing of the position and sequences of predicted miR-23a and miR-27a sites in 
the IL-6R 3'UTR. MiR-23a/b and miR-27a/b sites are indicated by orange and green triangles 
respectively. Open triangles represent poorly conserved sites as determined by Targetscan. (B) 
Shows region cloned into pmiRGLO luciferase reporter construct. Alignments of miRs with 
predicted binding sites are shown along with the changes made in the seed regions of mutated 
controls. (C) Luciferase activity in HEK293 cells co-transfected with wild-type or mutated IL6R 
3'UTR luciferase reporter and miR-23a, miR-27a or scrambled control mimics. Activities were 
normalised to renilla internal control and values expressed as % of scrambled controls, (n =3). 
Data analyzed by Student’s t-test, **p<0.01, ****p<0.0001 versus scrambled control. 
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6.2.3 Overexpression of miR-23a or miR-27a reduces IL-6R 
transcript levels in THP-1 cells 
Having demonstrated that miR-23a and miR-27a can functionally interact with 
sequences within the IL-6R 3'UTR I then set out to see if they could reduce 
transcript levels when over-expressed in THP-1 cells. THP-1 cells were 
transfected with miR-23a, miR-24, mIR-27a mimics and scrambled control and 
membrane, soluble and total IL-6R mRNA levels measured by q-PCR (Figure 6.4). 
In these experiments, miR-23a and miR-27a significantly reduced the levels of 
the membrane and total IL-6R transcript levels (Figure 6.4 A). However, only 
miR-27a significantly lowered soluble IL-6R levels (Figure 6.4 B). In keeping with 
target predictions, miR-24 did not alter IL-6R transcript levels (Figure 6.4, C). 
While artificial overexpression of miRs can demonstrate the potential of a miR to 
regulate its target mRNAs, it tells us nothing about whether it does so under 
normal physiological conditions. Generally, the pool of miRs is small in 
comparison to the number of potential target mRNAs meaning that most are not 
actively targeted [541]. Gaining insight into whether a specific miR is actively 
regulating a defined target requires the inhibition of miR. This can be 
accomplished using specific miR inhibitors or by over-expressing ‘sponge’ 
transcripts containing multiple high-affinity miR binding sites. In the previous 
chapter, I described the creation and validation of sponge constructs against 
miR-23/24/27. In this next section, I will use these cells to discover if miR-23a 
and miR-27a are actively regulating IL-6R expression in THP1 cells. To this end 
mIL-6R, sIL-6R and total IL-6R mRNAs were quantified by qPCR in THP-1 sponge 
expressing cells (Figure 6.5). 
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Figure 6.4 Overexpression of mIR-23a and miR-27a reduces IL-6R expression in THP-1 cells. 
Results obtained by qPCR method performed on RNA prepared from THP-1 cells, measuring (A) 
membrane IL-6R; (B) soluble IL-6R; (C) total IL-6R. Data represented by Mean±SD of a relative 
quantification (RQ, 2-^ddCT) relative to GAPDH control gene and scrambled control mimic, n=3. 
Data analysed by ordinary one-way ANOVA with Dunnett’s correction for multiple comparisons, *** 
- p≤0.001, **** - p≤0.0001. 
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6.2.4 MiR-23a and miR-27a are actively regulating IL-6R transcript 
levels in THP-1 sponge cells 
I have previously demonstrated that miR-23a and miR-27a have the potential to 
directly decrease IL-6R expression when over–expressed in THP-1 cells. Here I 
investigated whether they are actively doing so under normal homeostatic 
conditions. To test this, I measured IL-6R mRNA levels in THP-1 cells that stably 
express sponge transgenes targeting each of the miRs within the miR-23a cluster 
individually and in combination.   
QPCR measurements of the membrane, soluble and total IL-6R mRNAs in each of 
the sponge cell lines showed that both mIL-6R and sIL-6R levels were increased 
in cells with miR-23 sponge activity compared to empty vector control (Figure 
6.5). Cells expressing miR-27 sponges showed a significant increase in mIL-6R 
levels and trend towards increase in sIL-6R and total IL-6R levels. In keeping with 
the fact that miR-24 is not predicted to target IL-6R, miR-24-Sponge expressing 
cells had no effect on IL-6R mRNA levels. Interestingly, a sponge combination 
targeting both miR-23 and miR-27 yielded the most significant increase in IL-6R 
expression suggesting that IL-6R expression is being concurrently regulated by 
both miRs (Figure 6.5).  
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Figure 6.5 IL-6R mRNA expression is increased in miR-23 and miR-27 sponge expressing 
THP-1 cells.  
Results obtained by qPCR method performed on RNA prepared from THP-1 sponge cells 
measuring (A) membrane IL-6R; (B) soluble IL-6R; (C) total IL-6R. Data represented by Mean±SD 
of a RQ (2^ddCT) relative to GAPDH control gene and scrambled control mimic, n=3. Data 
analyzed by ordinary one-way ANOVA with Dunnett’s correction for multiple comparisons, 
**p≤0.01, *** - p≤0.001, **** - p≤0.0001, ns - p≥0.05. 
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6.2.5 Overexpression of miR-23a or miR-27a reduces IL-6R 
transcript levels in primary human CD14+ monocytes. 
Previously I have shown that overexpression of miR-23a and miR-27a in THP-1 
decreases IL-6R mRNA levels. Here I tested this observation in primary human 
CD14+ monocytes. To this end, CD14+ cells were isolated from the blood of 
healthy donors and transfected with miR-23a, miR-27a and scrambled negative 
control and the levels of the membrane, soluble and total IL-6R mRNAs levels 
measured by qPCR.  
Overexpression of miR-27a resulted in a significant decrease in both IL-6R 
variants suggesting that IL-6R transcripts are regulatable by miR-27a in primary 
CD14+ monocytes as well as in THP-1 cells (Figure 6.6). However, overexpression 
of miR-23a failed to exhibit the same effect. This finding appears at odds with 
the analogous experiment in THP-1 cells where miR-23a expression did reduce 
the expression of membrane and total IL-6R. From previous work, we know that 
miR-23a is expressed at a higher level in primary CD14+ monocytes than miR-27a 
creating a possibility that endogenous miR-23a is already saturating IL-6R MBSs. 
Thus overexpression of the miR did not have an additive effect (see Figure 4.1, 
C). This is also supported by data from THP-1 sponge cells which showed that IL-
6R levels are highest in miR-23-sponge expressing cells, suggesting that miR-23a 
is regulating IL-6R expression to a greater degree than miR-27a. That said, de-
repression of IL-6R expression is greatest in miR23+miR27 sponge expressing cells 
demonstrating that synergistic effect of both miRs takes place (Figure 6.5, A and 
B). Arguably, inhibition of endogenous miR-23a and miR-27a with the 
corresponding antagomir would have been more informative with regards to the 
effect of endogenous miRs.   
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Figure 6.6 Overexpression of miR-27a decreases IL-6R mRNA expression in human CD14+ 
monocytes. 
Results obtained by qPCR method performed on RNA prepared from isolated CD14+ cells 
measuring (A) membrane IL-6R; (B) soluble IL-6R; (C) total IL-6R. Data represented by Mean±SD 
of a fold change (2^ddCT) relative to GAPDH control gene and scrambled control mimic, n=3. Data 
analysed by ordinary one-way ANOVA with Dunnett’s correction for multiple comparisons, * - 
p≤0.05.
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6.2.6 Inhibition of miR-23a and miR-27a increases IL-6R surface 
expression in THP-1 cells and promotes pro-inflammatory 
phenotype  
With the effects of miR-23a and miR-27a on the IL-6R transcript levels evaluated 
previously, I next investigated the effect of miR-23a and miR-27a on the IL-6R 
protein level in miR sponge expressing cells as well as in THP-1 transfected with 
miR inhibitors.  
Surface IL-6R levels on THP-1 cells expressing various combinations of sponge 
transcripts were measured by FACS (Figure 6.7, A). Cells expressing miR-23 and 
miR-27 sponges showed significantly higher surface IL-6R staining compared to 
cells expressing the empty vector control demonstrating that loss of either miR-
23 or miR-27 activities from the cells resulted in a corresponding increase in IL-
6R protein expression. Again, in keeping with the fact that miR-24 is not 
predicted to target IL-6R and in concordance with previously seen lack of effect 
on the transcript level, miR-24 sponge THP-1 cells had levels of surface IL-6R 
identical to those of control reporter cells. THP-1 cells containing miR-23 and 
miR-27 double sponge also had raised levels of surface protein, similar to those 
of miR-23 sponge alone. Interestingly, the highest expression of surface IL-6R 
protein was found in the multiple sponge cells containing binding elements to all 
three miRs of the cluster.  
As miR-sponges seem to be agnostic whether they bind 'a' or 'b' miR species it is 
possible that the results presented here could represent the effect of the 
paralogue miR-23b-cluster activity. To test this, I transfected THP-1 cells with 
specific miR-27a and miR-27b inhibitors, which exhibit more sequence specificity 
than miR-sponges. Cells transfected with miR-27a inhibitors had increased 
surface IL-6R levels (Figure 6.7, B). In contrast, inhibition of miR-27b only had a 
tendency to affect surface IL-6R expression confirming miR-27a, and not miR-
27b, as the dominant species regulating IL-6R expression in THP-1 cells. These 
data demonstrate that modulation of endogenous miR-23a and miR-27a affect 
the IL-6R levels at the protein level as well as at the transcript level. 
Furthermore, to investigate if inhibition of miR-23 and miR-27 has an effect on 
the way cells respond to inflammatory stimuli they were exposed to a range of 
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concentrations of LPS. Firstly, THP-1 sponge cells were matured for 6 days with 
PMA, with the change of medium after day 3, as stated in the protocols. On day 
6, the medium was once again changed, and cells were stimulated with 1 ng/ml, 
10 ng/ml or 100 ng/ml of LPS for 24 hours. The next day, supernatants were 
collected, and levels of IL-6 and TNFα were measured (Figure 6.7, C and D, 
respectively). Indeed, matured miR-23 sponge cells produced significantly higher 
levels of IL-6 and TNFα, especially when stimulated with 100 ng/ml of LPS. 
However, stimulation of miR-27 sponge cells resulted in raised levels of IL-6, but 
not of TNFα. Nevertheless, double miR-23 and miR-27 sponge cells expressed 
significantly higher levels of both IL-6 and TNFα when exposed to as little as 1 
ng/ml of LPS. Suggesting that myeloid cells lacking miR-23 and miR-27 not only 
exhibit pro-inflammatory phenotype but also act synergistically to amplify this 
response if both miRs are inhibited, as is the case in biologic non-responder RA 
patients, described in Chapter 3.   
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Figure 6.7 Inhibition of miR-27a increases surface IL-6R expression in THP-1 cells. 
Results for (A) and (B) are obtained by FACS method and show surface IL-6R staining in (A) miR-
23a, miR-24 and miR-27a THP-1 sponge cells; (B) THP-1 cells transfected with control, miR-27a or 
miR-27b inhibitors (Control, miR-27ai or miR-27bi, respectively). Data displayed as Mean±SD of 
mean fluorescence intensity (MFI) of surface IL-6R staining (n=3). (C) Reporter and miR-23, miR-
27 and miR-23+27 sponge THP-1 cells were matured with PMA for 6 days (protocol described in 
Chapter 2) and then stimulated with 1 ng/ml, 10 ng/ml or 100ng/ml of LPS for 24 hours. After 
stimulation, supernatants were collected, and ELISA measurement of TNFα and IL-6 were done. 
Data displayed as Mean±SD of pg/ml concentration of IL-6 (C) and TNFα (D), (n=3). Data are 
analysed by Ordinary One-way ANOVA test with Dunnett’s correction for multiple comparisons, * - 
p≤0.05, **** - p≤).0001.    
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6.2.7 Biologic resistant patients have increased levels of 
membrane and soluble IL-6R compared to DMARDs 
responders  
Next, I investigated if the RA patients, described in Chapter 3, have altered 
levels of soluble or membrane IL-6R, as would the in-vitro data suggest. For this, 
the qPCR method was used to measure the transcript levels of mIL-6R, sIL-6R 
and miR-27a on the remaining RNA samples from the cohort (Figure 6.8). The 
results showed that mIL-6R levels were significantly increased in biologic 
resistant patients compared to all other groups, while soluble IL-6R transcript 
levels were significantly increased in both biologic and DMARD resistant patients 
compared to healthy controls (Figure 6.8, A and B, respectively). Measuring 
serum sIL-6R from the various patient groups showed that levels were increased 
in biologic resistant patients reflecting the observed increases in transcript 
levels (Figure 6.8, C). It is important to note that a part of the detected soluble 
IL-6R protein was also likely generated by the shedding from the membrane 
receptor by ADAM10 or 17 sheddases [373]. 
In Chapter 3 (Figure 6.9, A) I showed that miR-27a levels were decreased in the 
biologic resistant patients compared to DMARD responders. Microarray data also 
suggest that miR-23a levels were low in these patients (Figure 3.4). To 
investigate this relation, expression of the membrane and soluble IL-6R were 
correlated with the levels of miR-27a measured by qPCR in the same samples 
(Figure 6.8, D and E, respectively). Unfortunately, only 10 samples from the 
biologic resistant group of 41 patients had data available for this analysis, and 
although this is a very limited sample size, there was no indication that miR 
levels correlated with those of its target. This is not a surprising result, 
especially when one considers the differences in the turn over rate of these two 
very different RNA species.   
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Figure 6.8 IL-6R expression is increased in RA patients resistant to Biologic therapies. 
Expression of mIL-6R (A) and sIL-6R (B) was measured by qPCR method in samples from RA 
patient cohort and healthy controls, described in Chapter 3. Note lower numbers of samples in 
each group are due to the limited amount of available RNA following miRarray and other testes, 
performed previously. (C) Levels of soluble IL-6R were measured in serum samples from RA 
cohort patients and healthy controls. Results obtained by ELISA method and displayed in pg/ml. 
Expression of miR-27a, measured by qPCR was correlated with the levels of mIL-6R (D) and sIL-
6R (E) in 10 samples from Biologics resistant patients, which had both measurements available.   
 
Heal
thy C
ontro
ls
DMA
RD r
espo
nder
s
DMA
RD r
esist
ant
Biolo
gic r
esist
ant
-0.05
0.00
0.05
0.10
0.15
0.20
M
em
br
an
e 
IL
-6
R
2^
-d
C
T 
N
or
m
al
iz
ed
 to
 G
A
PD
H *
**
*
Heal
thy C
ontro
ls
Good
 Res
pond
ers
DMA
RDs 
resis
tant 
Biolo
gics 
resis
tant
0
100
200
300
So
lu
bl
e 
IL
-6
R
, p
g/
m
l
p=0.09
p=0.07
0.00 0.02 0.04 0.06 0.08
0.0
0.5
1.0
1.5
Biologics resistant group
sIL-6R
m
iR
-2
7a
r2=0.1 
p=0.37
Heal
thy C
ontro
ls
DMA
RD r
espo
nder
s
DMA
RD r
esist
ant
Biolo
gic r
esist
ant
0.00
0.02
0.04
0.06
0.08
0.10
So
lu
bl
e 
IL
-6
R
2^
-d
C
T 
N
or
m
al
iz
ed
 to
 G
A
PD
H P=0.059
*
0.00 0.05 0.10 0.15
0.0
0.5
1.0
1.5
Biologics resistant group
mIL-6R
m
iR
-2
7a
r2=0.08 
p=0.43
A B
C
D E
285 
 
6.2.8 Expression of IL-6R splice variants is more coordinated in 
patients failing DMARD and Biologic therapies.  
Membrane and soluble IL-6R isoforms are expressed primarily from the same 
gene via alternative splicing where the inclusion or exclusion of exon 9 produces 
transcripts that express mIL-6R or sIL-6R forms, respectively. Here I looked at 
the correlation of sIl-6R and mIL-6R mRNA levels in healthy controls, DMARD-
responsive, DMARD-resistant and biologics resistant patients.  
Strikingly I found that correlation coefficient increased in value and significance 
in every subsequent group compared to the previous one until there was an 
almost perfect correlation between mIL-6R vs. sIL-6R forms in patients resistant 
to DMARDs and Biologic therapies, r=0.9387 and r=0.9961 respectively (Figure 
6.9). Why IL-6R splice variant selection should become more coordinated in 
these patient groups is unclear. Moreover, this phenomenon could only be 
investigated by designing specific primers for each of the splicing forms 
separately and not by screening methods, such as mRNA array or even 
transcription sequencing as they lack required specificity. Whether this 
observation is related to a decrease in repression by miR-23a and miR-27a 
remains to be determined. This could be tested experimentally by examining the 
effect that inhibition of miR-23a and miR-27a has on the correlation between 
mIL-6R vs. sIL-6R in CD14+ monocytes. Whatever the cause of this phenomenon it 
evidentially involves some disease related mechanism that is worthy of further 
investigation. 
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Figure 6.9 mIL-6R vs. sIL-6R correlation increases in DMARD and Biologic resistant 
patients. 
qPCR CT values of soluble (sIL-6R) and membrane (mIL-6R) mRNA levels of IL-6R were 
correlated in (A) healthy controls, (B) DMARD-responders, (C) DMARD-resistant and (D) biologic 
resistant patients. Data were analysed by Pearson's correlation coefficient.  ** - p≤0.01, ****-
p≤0.0001. 
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6.3 IL-6RST (GP130) is not targeted by miR-23a or miR-
27a 
Having previously shown that IL-6R is targeted by both miR-23a and miR-27a I 
next sought to explore the possibility that members of the miR-23a cluster may 
also target its co-receptor IL-6R Signal Transducer (IL-6ST), otherwise known as 
GP130. IL-6ST is a ubiquitously expressed receptor and acts as co-receptor in 
receptor complexes for numerous cytokines including IL-27, IL-11, LIF, OSM and 
CNTF, cardiotrophin1, cardiotrophin-like cytokine and IL-6 (Reviewed in Chapter 
1). However, my interest stems from its fundamental role in the IL-6R signalling 
complex. Searching IL-6ST 3'UTR for potential miR-23a cluster MBSs revealed 
potential binding sites for both miR-23a and miR-27a (Table 6.2). 
 
Table 6.2 Summary of target predictions for IL-6ST. 
Green and red indicate presence or absence of miR binding site respectively.  
 
To functionally validate miR-23a and miR-27a targeting of IL-6ST I constructed 
two luciferase reporter assays. The first contained approximately 2kb region 
with both miR-27a binding sites (IL-6ST-1), while the other included a 400bp 
region containing the predicted miR-23a site (IL-6ST-2). Both regions were 
amplified by PCR before being cloned downstream of luciferase ORF in 
pGLOMS2BD vector (Figure 6.10 A). The resulting constructs were co-transfected 
along with either miR-23a, miR-27a mimic or scrambled control and luciferase 
activity was measured after 24 hours. Plasmids pGLOMS2BD-23sp and 
pGLOMS2BD-27sp sponge constructs were included as positive controls. Neither 
miR-23a nor miR-27a reduced luciferase activity when introduced along with the 
IL-6ST luciferase reporter constructs (Figure 6.10, B). These results would 
appear to conclusively show that IL-6ST is not directly regulated by miR-23a or 
miR-27a. However, a recent report by Su and colleagues present evidence in the 
form of luciferase assay that shows miR-27a does indeed directly target IL-6ST 
Gene	 miRNA	 miRWalk	 miRanda	 Pictar2	 PITA	 RNA22	 Targetscan	
GP130	 miR-23a-3p	
GP130	 miR-27a-3p	
GP130	 miR-27a-3p	
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[765]. Furthermore, the authors show that miR-27a regulates IL-6ST via the 
poorly conserved site and not highly conserved one. The reason for the 
discrepancies in our data is unclear. The region used by Su et al. in their 
luciferase reporter assay was smaller than the one used here (629 bp, versus 
1978bp) this could have influenced our results in a number of ways. The region 
that I amplified may have contained multiple polyA signals, which could have 
been active in the luciferase-IL-6ST(1) transcript effectively excising the active 
miR-27a MBS, rendering the reporter transcript insensitive to miR-27a 
regulation. Alternatively, Including a larger 3'UTR fragment might have 
inadvertently included another highly active miR MBS for a highly expressed miR 
that preferential targets the reporter transcript meaning that exogenous miR-
23a has little impact. 
Searches of HITS-CLIP and CLASH databases identified HITS-CLIP peaks 
corresponding to interactions between IL-6ST and miR-27a [766]. Interestingly 
the same study identified an interaction between miR-24 and IL-6ST. None of the 
target prediction algorithms I used here identified a miR-24 binding site in IL-
6ST. It is becoming increasingly clear that the dogma that miR-target 
interactions rely primarily on complementarity between target and seed region 
needs to be re-considered in light of the massive unbiased data sets generated 
from studies using HITS-CLIP, PAR-CLIP and CLASH technologies suggest that as 
many as 40% of miRNA/target interactions are non-canonical [767]. Therefore, it 
may be that a yet to be identified miR-24 binding site is waiting to be discovered 
that interacts with sequences other than the 3'UTR or via complimentary outside 
the seed region. 
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Figure 6.10 Neither miR-23a/b or miR-27a target IL-6ST 
(A) Schematic representation of IL-6ST's 3'UTR showing the location of predicted miR-23a/b and 
miR-27a binding sites. MiR-23a/b and miR-27a/b sites are indicated by orange and green triangles 
respectively. Open triangles represent poorly conserved sites; filled triangles well-conserved sites 
as determined by Targetscan. The arrows and dotted line show the regions amplified by PCR that 
were cloned into pmiRGLO. The alignment of miRs with their MBS is shown below in green. (B) 
Luciferase activity in HEK293 cells co-transfected with IL-6ST (1) and (2) luciferase reporter 
plasmids and miR-27a, miR-27b or scrambled control mimics. pGLOMS2BD-23Sp and 
pGLOMS2BD-27Sp were used as positive controls. Activities were normalised to Renilla internal 
control and values expressed as % of scrambled controls. (n =3). Data were analysed by Student’s 
t-test,  **** - p<0.0001 versus scrambled control. 
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6.4 ERAP-1 (ARTS1) is not targeted by miR-27a 
The bioinformatic analysis highlighted ERAP-1 as a predicted target of miR-27a. 
ERAP-1 is an aminopeptidase localised in the endoplasmic reticulum where it 
plays a role in the processing of antigen peptides for presentation by MHC class 1 
molecules [768]. Amongst its other activities are the cleavage of TNFRI, IL-1 
receptor II and mIL-6R where it acts by ‘shedding' them from the membrane 
[397]. Significantly, after HLA-B27, ERAP-1 has the second strongest association 
(26%) with ankylosing spondylitis. However, no implications for RA were found to 
date [769].  
Here I set out to determine if ERAP-1 was a direct target of miR-27a. As a first 
step, I searched for miR-27a binding sites in ERAP-1 3'UTR using 6 different 
target prediction algorithms. Two out of the 6 programs (Targetscan and PITA) 
identified a single poorly conserved miR-27a binding site (Table 6.3). 
 
Table 6.3 Summary of target predictions for ERAP-1. 
Green and red indicate presence or absence of miR binding site respectively.  
 
Given ERAP-1's association with IL-6 signalling, I have tested this interaction by 
constructing a luciferase reporter assay, in which a 450 bp region containing the 
predicted miR-27a binding site was cloned downstream of luciferase ORF. The 
resulting construct was co-transfected along with either miR-27a mimic or 
scrambled control and luciferase activity measured after 24 hours. The 
pGLOMS2BD-27 sponge was fused to miR-27 sponge were used as a positive 
control. Neither, miR-27a nor miR-27b reduced luciferase activity when 
introduced along with the ERAP-1 luciferase reporter (Figure 6.11). However, 
both significantly reduced luciferase activity of the positive control. This result 
strongly suggests that ERAP-1 is not a target of miR-27. Further bio-informatic 
analysis of HITS-CLIP and CLASH databases failed to pick up any interactions 
between ERAP-1 and miR-27a/b further supporting my conclusion that miR-27 
does not target ERAP-1. 
Gene	 miRNA	 miRWalk	 miRanda	 Pictar2	 PITA	 RNA22	 Targetscan	
ERAP1	 miR-27a-3p	
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Figure 6.11 ERAP-1 is not a direct target of miR-27a or miR-27b 
(A) Schematic representation of ERAP-1 3'UTR showing the location of predicted poorly conserved 
miR-27a binding site. The arrows and dotted line show the region amplified by PCR and cloned into 
pGLOMS2BD vector. The alignment of miR-27a with its MBS is shown in green. (B) Luciferase 
activity in HEK293 cells co-transfected with ERAP-1 luciferase reporter plasmid and miR-27a, miR-
27b or scrambled control mimics. pGLOMS2BD-27sp was used as positive control. Activities were 
normalised to Renilla and values expressed as % of scrambled controls. (n =3). Data were 
analysed by Student’s t-test,  **** - p<0.0001 versus scrambled control. 
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6.5 MiR-24 targets MTHFR, but not DHFR 
I have previously shown that the miR-23a cluster expression is lower in DMARD-
resistant and biologic-resistant patients compared to DMARD-responders and 
healthy controls. While it is unlikely that lower miR-23a cluster expression 
causes treatment failure in these patients, I decided to use Ingenuity Pathway 
analysis to see if there were any obvious targets/pathways that could contribute 
towards a resistant phenotype. This highlighted dihydrofolate reductase (DHFR) 
and methylene tetrahydrofolate reductase MTHFR genes, which are of particular 
relevance to my study since they are actively implicated in the methotrexate 
pathway.  
6.5.1 DHFR is not regulated by miR-24. 
DHFR is a predicted target of miR-24 as identified by various target prediction 
algorithms (Table 6.4). Initial screening of DHFR for miR-23a cluster binding sites 
identified a single predicted miR-24 site at position +2192 in the 3'UTR 
(annotated here as DHFR#2). However, Mishra and colleagues reported that 
DHFR was indeed targeted by miR-24 but at another site (+1258, annotated here 
as DHFR#1). Notably, the miR-24 site described in this work was not identified by 
any of the target predictions used here likely due to imperfect base-pairing in 
the seed region (Figure 6.12, A). As the authors did not use reporter assay to 
validate this target, I choose to investigate it along with the other predicted 
miR-24 site. Regions containing both MBS were synthesised as G-blocks and 
cloned directly into pGLOMS2BD using Gibson Assembly (Figure 6.12, A). 
 
Table 6.4 Summary of predicted miR-24 binding sites in DHFR.  
Green and red indicate presence or absence of miR binding site respectively.  
 
 
Gene	 miRNA	 miRWalk	 miRanda	 Pictar2	 PITA	 RNA22	 Targetscan	
DHFR#1	 miR-24-3p	
DHFR#2	
	
miR-24-3p	
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The resulting plasmids were co-transfected into HEK293 cells along with miR-24 
or scrambled control. The pGLOMS2BD-24 sponge construct was used as a 
positive control. After 24 hours the luciferase activity was measured using a 
dual-luciferase assay. In these experiments miR-24 did not reduce luciferase 
activity in either DHFR#1 or DHFR#2 reporter assays compared to scrambled 
control (Figure 6.12, B). In contrast luciferase activity in positive controls was 
significantly reduced. This data suggests that miR-24 does not target DHFR via 
either site.  
The reason for the disparity between my results and those described by Mishra 
et al. is unclear. Notably, the authors did not validate a miR-24 interaction with 
a DHFR by reporter assay. Instead, the authors showed that overexpression of 
miR-24 reduced DHFR protein levels by western blot. A limitation of this 
approach is that it does not differentiate between direct and indirect effects of 
miR-24 overexpression. They presented data showed that miR-24's interaction 
with DHFR was dependent on the sequence immediately downstream from the 
miR-24 binding site. Furthermore, authors state that C829T polymorphism 
abolishes this regulation by increasing local secondary structure (Figure 6.12, A). 
Significantly, the sequence used in my reporter assay corresponded to the 
‘active’ 829C variant meaning that it should be sensitive to miR-24.  
To further interrogate my finding I measured the effect that miR-24 modulation 
had on DHFR transcript levels in THP-1 and CD14+ cells (Figure 6.13). 
Overexpression of miR-24 in THP-1 cells and CD14+ monocytes did not 
significantly change the expression of DHFR compared to the scrambled control. 
Similarly, DHFR expression levels were unchanged in THP-1 expressing miR-24 
sponge cells compared to empty vector control. These experiments confirm that 
miR-24 modulation does not impact DHFR levels as measured by qPCR.  
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Figure 6.12 DHFR is not targeted by miR-24. 
(A) Schematic representation of the DHFR 3'UTR showing the location of predicted miR-24 binding 
sites, below alignments of miR-24 with MBS and location of the C829T polymorphism are shown. 
Double lines correspond to G-block sequences used to generate DHFR luciferase reporter assay.  
(B) Luciferase activity in HEK293 cells co-transfected with DHFR luciferase reporter plasmid and 
miR-24 or scrambled control mimics. PGLOMS2BD-24sp was used as positive control. Activities 
were normalised to Renilla and values expressed as % of scrambled controls. (n =3). Data were 
analysed by Student’s t-test,  **** - p<0.0001 versus scrambled control. (C) Chromatogram 
showing the sequence of DHFR#1 region from THP-1. 
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It is possible that miR-24 regulates DHFR strictly by translational repression 
leaving transcript levels unchanged. However, Mirsha and colleagues reported 
that transcripts carrying the 829T variant had a longer half-life than the 829C 
miR-24-senstive variant, suggesting that miR-24 regulates DHFR by transcript 
destabilisation. To rule out the possibility that DHFR in THP-1 cells carried the 
829T miR-24-insenstitive variant the corresponding genomic region was amplified 
by PCR and sequenced, showing that THP-1 cells encoded the 829C supposedly 
miR-24 sensitive variant (Figure 6.12 C). Furthermore, secondary structure 
analysis of the region surrounding C829T polymorphism showed that 829T, 
contrary to the findings of Mirsha et al., did not increase local secondary 
structure but rather reduced it compared to the 829C variant (Figure 6.14).  
Finally, searches of HITS-CLIP and CLASH databases failed to pick up any 
interactions between DHFR and miR-24 further supporting my conclusion that 
miR-24 does not target DHFR.  
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Figure 6.13 Modulation of miR-24 expression does not alter DHFR in THP-1 cells or CD14+ 
monocytes 
(A) THP-1 cells and (B) CD14+ monocytes were transfected with miR-24 mimic along with 
scrambled negative control and DHFR mRNA were measured by qPCR. (C) DHFR mRNA was 
measured in THP-1 cells expressing miR-24 sponge transcript. Measurements were conducted on 
3 separate occasions (A and C) or with cells derived from 3 buffy coat donors (B) and analysed by 
Paired student’s t test (A), Wilcoxon paired test (B) and Unpaired student’s t test (C). Transfection 
efficiencies were measured by FACS method, detecting fluorescent control mimic; only samples 
with >80% efficiency were processed further. 
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Figure 6.14 DHFR 829T reduces RNA secondary structure around potential miR-24 site 
Secondary structure prediction shows that 829T variant has lower free energy (ΔG=-38.1) than the 
829C variant (ΔG=-43.3), indicating that this isoform has less stable tertiary structure. Putative 
miR-24 is indicated by a red curved line. Secondary structures generated using RegRNA2 
program. 
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6.5.2 MiR-24 targets MTHFR  
As discussed briefly in the previous sections, patients fail DMARD treatments for 
two main reasons lack of efficacy and or lack of tolerance to the drugs. Studies 
have shown that around 40% of RA patients treated with MTX will experience 
adverse effects from the result of the treatment. Half of these patients will have 
severe adverse effects including worsening of nodulosis, pneumonitis, neurologic 
toxicity, gastrointestinal complications including nausea, vomiting and diarrhea, 
transaminitis, hematologic abnormalities, rash, stomatitis, and alopecia [770]. 
Methotrexate related toxicity in RA patients has been associated with two 
common polymorphisms (C667T and A1298C) that reduce the activity of MTHFR 
[771]. Along with DHFR, MTHFR is a critical enzyme in the folate pathway, 
converting 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate, which 
acts as the methyl donor for re-methylation of homocysteine to methionine. MTX 
inhibition of DHFR prevents the conversion of dihydrofolate to tetrahydrofolate 
(THF). The resulting depletion of THF consequently prevents MTHFR production 
of 5-methyltetrahydrofolate causing an accumulation of homocysteine (Figure 
6.15). It is ultimately increased serum homocysteine levels that are responsible 
for much of MTX toxicity [772].  
Here I have identified MTHFR as a target of miR-24 and speculate that increased 
miR-24 levels may play a role in MTX-associated toxicity.  
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Figure 6.15 Diagram showing methotrexate's effect on methionine biosynthesis pathways 
leading to increased homocysteine production and toxicity. 
Dihydrofolate reductase (DHFR), Dihydrofolate (DHF), Tetrahydrofolate (THF), 5,10-
methylenetetrahydrofolate (5,10-CH2-THF) and to 5-methyltetrahydrofolate (5-CH2-THF) 
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MTHFR has 2 predicted miR-24 binding sites in its 3'UTR, with the distal site 
(MTHFR#2) being highly conserved amongst vertebrates (Table 6.5). Analysis of 
these sites using the available target prediction programs showed that 5 out of 6 
algorithms predicted the MTHFR#2 site, while MTHFR#1 was only identified by 3 
of the 6. For this reason, I decided to focus my attention on validating the 
MTHFR#2 site as a miR-24 target. 
 
Table 6.5 Summary of predicted miR-24 binding sites in MTHFR.  
Green and red indicate presence or absence of miR binding site respectively.  
 
To that end, I made a luciferase reporter assay containing MTHFR#2 binding site 
using G-Blocks and Gibson assembly. In parallel, I created reporter assay in 
which the seed region of the putative miR-24 binding site was mutated (Figure 
6.16, A). The resulting plasmids were co-transfected into HEK293 cell along with 
miR-24 mimic or scrambled negative control. The following day, luciferase 
activity was measured by dual-luciferase assay. The results showed that miR-24 
significantly reduced luciferase activity of the wild-type MTHFR#2 reporter 
assay; this reduction was ameliorated by mutation of the seed region (Figure 
6.16, B).  
These results conclusively show that MTHFR is a direct target of miR-24 and that 
this interaction is mediated via a conserved site in its 3'UTR. Interestingly, 
analysis of microarray data from an experiment where miR-24 was over-
expressed in human keratinocytes showed a significant corresponding decrease 
in MTHFR expression [773].  
  
Gene	 miRNA	 miRWalk	 miRanda	 Pictar2	 PITA	 RNA22	 Targetscan	
MTHFR#1	 miR-24-3p	
MTHFR#2	
	
miR-24-3p	
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Figure 6.16 miR-24 targets MTHFR via a conserved site in 3'UTR 
(A) Schematic of the MTHFR 3'UTR showing location of predicted miR-24 binding sites, below are 
alignments of miR-24 with wild-type and mutated MBSs. Double lines correspond to G-block 
sequences used to generate MTHFR#2 luciferase reporter assay. (B) Luciferase activity in 
HEK293 cells co-transfected with wild-type or mutated MTHFR luciferase reporter plasmids along 
with miR-24 or scrambled control mimics. Activates were normalised to Renilla and values 
expressed as % of scrambled controls. (n =3). Data were analysed by Student’s t-test, * - p<0.01 
versus scrambled control. 
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6.5.3 Modulation of miR-24 alters MTHFR expression in THP-1 
cells 
To further characterise miR-24’s regulation of MTHFR, I next looked to see what 
effect overexpression of miR-24 had on the levels of endogenous MTHFR. For 
this, THP-1 cells were transfected with miR-24 mimic along with scrambled 
control mimic and grown for 24 hours. MTHFR transcript levels were measured 
by qPCR. Results showed a significant decrease in MTHFR expression compared 
to scrambled control (Figure 6.17, A). I then performed the analogous 
experiment in human CD14+ monocytes purified from fresh blood of 3 separate 
donors. Cells were allowed to rest overnight before being transfected with miR-
24 or scrambled control (transfection efficiencies were >80%). After 
transfection, cells were incubated for 24 hours before MTHFR transcript levels 
were measured by qPCR (Figure 6.17, B). Although the differences between 
scrambled and miR-24 treated samples were not significant, there was a trend 
towards lower MTHFR expression in miR-24 treated samples. Repeating this 
experiment with more donors may drive these data towards significance.  
Having over-expressed miR-24, I next looked at MTHFR expression in THP-1 miR-
24 sponge expressing cells in which miR-24 activity is functionally depleted 
(Figure 6.17, C). MTHFR levels were increased in miR-24 sponge cells compared 
to the control cell line (pEF6-luc). This further supports a role for miR-24 in the 
regulation of MTHFR. Moreover, it suggests that miR-24 is actively regulating it 
in THP-1 cells. 
Although the data presented here demonstrates a clear, direct effect of miR-24 
on MTHFR expression, its significance to toleration of MTX in RA patients has not 
yet been established. However, a number of studies have linked polymorphisms 
(C667T and A1298C) in MTHFR that affect or lower the activity of the enzyme 
with increased intolerance to methotrexate amongst RA patients [774]. 
Therefore it is tempting to speculate that patients with higher miR-24 expression 
would have lower MTHFR and consequently be less tolerant to MTX treatment. 
Patients in this category will more often than not be moved onto other DMARD 
treatments such as sulfasalazine (SSZ). While this clinical scenario will not apply 
to all patients on SSZ, it will do for many of them. While acknowledging these 
limitations I sought to test my hypothesis that higher miR-24 levels reduce 
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MTHFR expression driving MTX intolerance in RA patients by comparing miR-24 
expression in SSZ patients compared to those on MTX. Figure 6.17 shows the 
results of the analysis. While the difference between the two groups is not 
statistically significant, there is a clear trend towards lower levels or miR-24 in 
patients who are tolerating MTX treatment. While not by any means conclusive it 
does generally support my hypothesis.  
As discussed previously, this comparison is not ideal one to test miR-24’s role in 
MTX intolerance. Moreover, due to the lack of sufficient patient RNA miR-24 
probe intensities were used as a measure of miR-24 expression levels. This study 
requires further validation by qPCR. A better comparison would be qPCR 
quantification of miR-24 levels in patients who tolerate MTX with those suffering 
side effects.  
Given more time, I would carry out further studies on MTHFR. Specifically, I 
would like to see if miR-24 regulation affects MTHFR protein levels and 
ultimately its activity in THP-1 cells and CD14+ cells. Going further I would see if 
miR-24 repression of MTHFR activity within monocytes had any effect on the 
folate pathway. Specifically, MTHFR catalysed conversion of 5,10-
methylenetetrahydrofolate to 5-methyltetrahydrofolate production and 
accumulation of homocysteine in treated cells.  These studies could ultimately 
be extended to a comparison of miR-24 levels in patients tolerating MTX with 
those showing adverse effects. Further stratification of these patients for the 
presence of the common C667T and A1298C polymorphisms and high miR-24 
could also provide a valuable insight into RA patient MTX-insensitivity. 
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Figure 6.17 Modulation of miR-24 alters MTHFR expression in THP-1 cells  
(A) MTHFR mRNA was measured in THP-1 cells containing miR-24 sponge (pEF6-24SpX2) or 
control vector (pEF6-Luc). MTHFR mRNA was also measured by qPCR in Buffy coat CD14+ 
monocytes (B) and THP-1 cells (C) transfected with miR-24 mimic (miR-24) along with scrambled 
negative control (SCRAM) for 24 hours. Experiments were done on 3 separate occasions and 
analysed by Student’s t test for (A) and (C) and by Mann-Whitney’s test for (B). (D) MiR-24 probe 
intensities from samples taken from DMARD responder patients being treated with MTX or SSZ. 
Data analysed using Mann Whitney’s test. 
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6.6 Macrophage colony stimulating factor receptor 1 is a 
direct target of miR-24 
There are ample data supporting the hypothesis that IL-6 stimulation of 
monocytes triggers M-CSF dependant maturation into macrophages [401,402]. 
With now abundant evidence that the miR-23a~24~27a cluster is implicated in 
the IL-6 pathway and also with a rapid decrease in the clusters expression 
following exposure to M-CSF, observed in chapter 4, I have analysed the M-CSF 
pathway for potential direct targets these miRs, which would explain the 
observed interactions.  
Indeed, CSF1R has two conserved predicted miR-24 binding sites in its 3'UTR. 
Sites were identified by 2/6 and 3/6 target prediction algorithms used (Table 
6.6). While this did not look overly promising, given that greater consensus 
between target prediction programs correlates with lower false positive rates, 
the extended base-pairing outside the seed region encouraged me to 
experimentally validate miR-24 and CSF1R interaction (Figure 6.18, A). 
 
Table 6.6 Summary of predicted miR-24 binding sites in CSF1R.  
Green and red indicate presence or absence of miR binding site respectively.  
 
To functionally validate CSF1R as a miR-24 target I created a luciferase reporter 
assay in which the 3'UTR of CSF1R containing both putative miR-24 sites was 
amplified by PCR and cloned downstream of the luciferase ORF in pGLOMS2DB. A 
reporter assay in which the two miR-24 seed regions were mutated was also 
created (Figure 6.18 A). The resulting plasmids were co-transfected into HEK293 
cells along with miR-24 mimic or scrambled negative control. Luciferase activity 
was measured 24 hours later. The results showed that miR-24 significantly 
reduced the luciferase activity of the wild-type CSF1R reporter assay; this 
reduction was ameliorated by seed-region mutation (Figure 6.18, B).  
Gene	 miRNA	 miRWalk	 miRanda	 Pictar2	 PITA	 RNA22	 Targetscan	
CSF1R#1	 miR-24-3p	
CSF1R#1	
	
miR-24-3p	
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These results conclusively show that CSF1R is a direct target of miR-24. As both 
binding sites were mutated in the G-block used to create the mutated 
pGLOMS2BD-CSF1R assay it is not possible to say whether miR-24 targets via one 
or both of the predicted sites. Unfortunately, I did not have time during my PhD 
studies to further characterise miR-24 interactions with CSF1R. However, given 
that it is so fundamentally important to monocyte/macrophage biology it is an 
intriguing target worthy of further investigation. 
 
Figure 6.18 CSF1R is a direct target of miR-24  
(A). Schematic representation of the CSF1R 3'UTR showing location of predicted miR-24 binding 
sites. Below are alignments of miR-24 with wild-type and mutated MBSs. Dotted lines show the 
PCR amplified region used to generate pGLOMS2BD-CSF1R luciferase reporter assay. (B) 
Luciferase activity in HEK293 cells co-transfected with wild-type or mutated CSF1R luciferase 
reporter plasmids along with miR-24 or scrambled control mimics. Activity was normalised to 
Renilla and values expressed as % of scrambled controls. (n =3). Data were analysed by Student's 
t test, * - p<0.01, versus scrambled control. 
CSF1R
0.8kb 
5’GUCAGGGGCUGGGGG-CUGAGCCC
          |||      ||||||           
  3’GACAAGGACGACUUGACUCGGU
Gene   3’UTR 
5’ CUGGUACUGCUGUAAUGAGCCAA
   |||   ||||||   ||||||| 
3‘ GACAAGGACGACUUGACUCGGU 
miR-24 miR-24 
A 
B 
SC
RA
M 
mi
R-
24
m
SC
RA
M
mi
R-
24
m
0
50
100
R
el
at
iv
e 
Lu
ci
fe
ra
se
 A
ct
iv
ity
CSF1R is targeted by miR-24
****
wt 3'UTR mut 3'UTR
5’GUCAGGGGCUGGGGG-CgaAttCC
          |||      | |  |           
  3’GACAAGGACGACUUGACUCGGU
5’ CUGGUACUGCUGUAAggattCAA
   |||   ||||||    |   || 
3‘ GACAAGGACGACUUGACUCGGU 
Mutated 
MBS 
Wild-type 
MBS 
CSF1R#1 CSF1R#2 
6.7 Discussion 
Interleukin 6 is a potent activator of myeloid cells and contributes to overall 
inflammatory phenotype. Targeting of the IL-6 pathway has been particularly 
successful in the clinical setting [679]. Difficulties with cytokine inhibition as 
well as the complexity of the cis and trans IL-6 signalling meant that IL-6R 
receptor, and not the cytokine was a preferred clinical target [373]. Therefore, 
miR targeting of the receptor, as well as GP130, could have a profound impact 
on the IL-6 pathway in monocytes activation and its implications for IL-6R 
targeted treatment. 
Here I have identified IL-6R as a direct target of two members of this cluster – 
miR-23a and miR-27a. Further investigation has confirmed that these 
interactions have functional consequences for the IL-6 pathway in myeloid cells. 
Namely, overexpression of both miRs led to the reduction of IL-6R transcript 
levels. Moreover, THP-1 sponge cells lacking each of the miRs or both of them in 
combination had increased levels of IL-6R transcript and protein. Investigation of 
miR-23 and miR-27-sponge cells demonstrated synchronicity in the function of 
cluster miRs, by which combined repression of both miR-23a and miR-27a has an 
additive effect on levels of IL-6R protein. This finding is of particular importance 
since miRs from this cluster are co-expressed, and their function should be 
viewed in its entirety. 
Further investigation of single or combinatorial inhibition of miRs in THP-1 
sponge cells allowed assessment of overall phenotype of cells lacking the miR-
23a cluster. Thus, stimulation with LPS triggered significantly higher expression 
of IL-6 and TNFα cytokines in sponge cells lacking miR-23a, miR-27a or both. 
Roles of increased IL-6 and TNFα in RA are well recognised, not least as they are 
successfully targeted in the clinical setting (discussed in detail in Chapter 1). 
Therefore, lack of miR-23a and miR-27a that was previously demonstrated in 
CD14+ cells from biologics resistant patients are likely to perpetuate chronicity 
of the disease by increasing both soluble and membrane-bound forms of IL-6R 
and cells responsiveness to its cytokine. This was confirmed by both increased 
levels of circulating IL-6 and IL-6R found in biologics resistant patients and by 
raised expression of the membrane and soluble IL-6R transcripts. Unfortunately, 
I found that miR-27a levels did not correlate with those of IL-6R transcripts. 
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However, this could be due to the small number of patients receiving anti-IL-6 
treatment before the start of this study, which could have a potential impact on 
the levels of IL-6R found. Moreover, the relationship between miR-23a and miR-
27a expression and effects of Tocilizumab need to be explored in detail. Further 
experiments on miR-23a cluster in the regulation of JAK/STAT signalling 
pathways would also be of vital importance since recent work from Su et al. 
describing the role of miR-23a and miR-27a regulation of JAK1 and STAT3 [765]. 
If proven applicable to primary human monocytes, and particularly CD14+ cells 
derived from patients with the disease, these finding can have significant 
implications for the clinical use of new synthetic DMARDs, such as Jakinibs [452].  
The THP-1 sponge cells created and used in my work are a valuable tool in the 
investigation of other aspects of inflammatory response, such as chemokine 
secretion, migration, antigen presentation and maturation into macrophages 
[775,776]. Unfortunately, due to the time constraints, I did not explore these 
here. However, they would provide valuable insight into the role of miR-23a 
cluster in other traits of myeloid cells and would pose a challenge for future 
work. 
Interestingly, other predicted interactions of miR-23a cluster with members of 
IL-6R pathway, such as GP130 and ERAP-1 yielded negative results. In my 
analysis, miR-27a had a tendency to repress GP130 expression in the context of 
luciferase reporter assay. However, this finding was not statistically significant. 
This finding is in disagreement with recently published data that shows direct 
targeting of GP130 by miR-27a in an analogous luciferase reporter assay [765]. It 
is possible that the larger segment of GP130 3'UTR used in my experiments 
included other MBSs and as a result was targeted by highly expressed 
endogenous miRs in HEK293 cells. Therefore repeat of the evaluation of these 
particular binding site would be required for conclusive results. Lack of efficacy 
of miR-27a in the context of larger 3'UTR segment raises the question of its 
biological efficacy. For this, assessment of GP130 transcript and protein in THP-1 
sponge cells would be informative and will be assessed in the future. 
Detailed exploration of IL-6R transcripts revealed that presence of exon 9 coding 
for a membrane-spanning unit of the receptor distinguishes two distinct isoforms 
– soluble and membrane with their corresponding 3'UTRs. Our group and others 
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have demonstrated that transcripts can become insensitive to miR regulatory 
elements by shortening transcript's 3'UTR using alternative polyadenylation sites 
[653]. Given that miR-23a cluster binding sites where spread out along entire 
3'UTR of IL-6R, it was important to identify if the transcripts present in THP-1 
cells are sensitive to miR regulation. For this purpose 3'RACE method was utilised 
and contrary to the previously described long 3'UTR in membrane transcript and 
short 3'UTR in the soluble transcript, both IL-6R isoforms detected here utilised 
identical proximal polyadenylation site. Significantly, this shorter 3'UTR retained 
the active miR-23 and miR-27 sites identified here. Nevertheless, this 
discrepancy instigated a series of experiments in which I measured both soluble 
and membrane bound IL-6R transcripts. Although both mRNAs were 
constitutively expressed in THP-1 cells and isolated CD14+ monocytes, it is the 
results obtained in the RA patient cohort that is of particular interest. Membrane 
and soluble IL-6R transcripts exhibited no correlation in healthy control 
individuals and only mildly so in patients who are good responders to DMARD 
treatment. However, in both treatment failure groups and particularly in 
biologic resistant patients, mIL-6R and sIL-6R transcripts displayed an almost 
linear correlation. The mechanism behind this observation is unclear, and this 
phenomenon has, to my knowledge, not been described before. Further 
evaluation would be required to understand if this is associated with disease 
activity or drug resistance.   
Published data in cancer research has highlighted the role of miR-23a cluster in 
the regulation of apoptosis, but also in inhibition of topoisomerases and 
resistance to concomitant cancer treatments, such as etoposide. Work from 
Mishra et al. directly implicated miR-24 in the regulation of DHFR and sensitivity 
to MTX. Thus this pathway was assessed in the context of this RA cohort of drug-
resistant patients. As discussed in Chapter 3, patients fail DMARD and Biologic 
treatments for two broad clinical reasons, lack of efficacy and lack of tolerance 
to the drugs. MTX is in most cases the first line treatment for RA. While MTX's 
mode of action in RA is unclear a number of putative mechanisms have been 
proposed (reviewed in the introduction). One of these is its well-defined role as 
a folate antagonist via the inhibition of Dihydrofolate reductase (DHFR) and 
Thymidylate synthetase (TYMS) [777]. Loss of activity of these two enzymes 
results in a reduction of thymidine synthesis, causing reduced DNA synthesis and 
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ultimately cytostasis [778,779]. In vitro studies have shown that primary T 
lymphocytes treated with low doses of MTX have reduced levels of ATP and GTP 
compared to untreated controls. Consequently, MTX-treated T cells proliferate 
less and are more apoptotic, the same observations have been demonstrated in 
T cells isolated from RA patients [780]. 
Despite this, clinical studies in patients receiving MTX and concomitant folate 
showed no loss of clinical benefit suggesting that folate pathway inhibition was 
not central to the anti-inflammatory activity of MTX [781]. Furthermore, MTX 
resistance in oncological conditions arises from compensatory gene amplification 
and increases in DHFR expression. This indicates that significant alterations in 
DHFR levels could bind MTX and limit its effectiveness by reducing its 
intracellular availability. Therefore, lower levels of miR-24 could lead to a rise 
in intracellular DHFR and titrating out intracellular MTX limiting its activity. 
Unfortunately, despite the extensive analysis of DHFR pathway and miR-24 
associated SNPs, DHFR does not appear to be a direct target of miR-24. The lack 
of direct validation miR assay in previously published work makes it difficult to 
understand if our failure to find evidence of miR-24 regulation of DHFR were due 
to technical differences. The fact that I did not observe changes in DHFR 
transcript levels, when miR-24 was overexpressed or inhibited also suggest that 
this interaction does not occur. Genotyping of THP-1 showed that they carry the 
C829 polymorphism which should according to Mishra et al. be targetable by 
miR-24. Furthermore, the authors finding that the 829T variant increased local 
secondary structure making the miR-24 binding site inaccessible to miR-24-RISC 
complex was not the case, in fact, the opposite was true. Finally, none of the 
publically available HITS-CLIP, PAR-CLIP and CLASH databases identifies miR-
24:DHFR interactions. Taking this into account I can only conclude that DHFR is 
not targeted by miR-24.  
Nevertheless, further exploration of this pathway identified the closely related 
MTHFR gene as a direct target of miR-24. This interaction has potential 
implications for tolerability of MTX in RA patients rather than the efficacy of the 
drug. Several polymorphisms in MTHFR gene were previously described to have 
an effect on its activity, as well as on serum homocysteine levels, which 
mediates MTX-related toxicity. C677T polymorphism of MTFR is associated with 
decreased activity of the enzyme and raised homocysteine levels in the general 
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population [782]. In RA, an association of C677T effect on serum homocysteine 
levels remains controversial [783]. Second identified MTHFR polymorphism, 
A1298C, is shown to have a protective role in RA. Higher frequency of 1298CC 
was found in RA patients when compared to the general population (24,7% vs. 
12,8%) and was associated with lower rate of MTX side effects [771]. My data 
showed that miR-24 overexpression reduces levels of MTHFR transcript, while 
the level was increased in THP-1 sponge cells lacking this miR. Although this is 
by no means a conclusive analysis, it indicates that reduced expression of miR-24 
could improve MTX tolerability. For this, I have investigated the expression of 
miR-24 miRarray probe in patients from DMARDs responders group who have 
been tolerating long-term treatment with MTX for years. Indeed, this group of 
patients had a tendency towards reduced expression of miR-24 in PB CD14+ cells, 
compared to SSZ treated patients. Patients from DMARDs responders group had a 
long-standing disease with duration of ten years and had tried 2 or fewer 
DMARDs, therefore constitute true responders to a particular medication. 
Significantly, subjects included in this analysis were receiving a single DMARD at 
the time of recruitment, limiting the effect of polypharmacy. However, future 
work would require assessment of the miR-24 expression, serum homocysteine 
levels, MTHFR polymorphisms and MTX tolerability in a prospective study to 
evaluate biomarker potential of this miR. This is particularly relevant when real 
world data is considered since drug prescription analysis would suggest that 
many of our patients do not take MTX on a regular basis and lose valuable time 
to control the disease activity or maintain the benefits.   
Lastly, in silico analysis, but not Ingenuity pathway analysis has identified CSF1R 
as a direct target of miR-24. This was subsequently confirmed by the luciferase 
validation assay. Unfortunately, the lack of time has prevented me from 
exploring this interaction further. However, this finding could have considerable 
implications for the maturation and activation of blood-derived monocytes in the 
arthritic joint. As discussed in Chapter 1, CSF1R mediates maturation and 
survival of blood derived monocyte and synovial macrophages, which was clearly 
demonstrated in csf1rop/op mice [784]. M-CSF signalling through CSF1R is also 
required for expression of RANKL and differentiation of osteoclasts, implicating 
it in the development of bone erosions is RA [199]. Thus miR-24 regulation of the 
CSF pathway, or the lack of thereof could have important implications for 
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disease pathogenesis. Concordantly, new therapeutic strategies are being 
developed to target this pathway in RA [785].  
The observed interaction between miR-24 and M-CSF pathway in this work allows 
the postulation of a hypothesis, by which M-CSF and GM-CSF stimulation of 
blood-derived CD14+ monocytes reduce the expression of miR-24 and promotes 
differentiation of the cells, by de-repressing its receptor CSF1R. The fact that 
miR-24 plays an important role in these processes was recently demonstrated by 
Fordham et al. who showed that overexpression of miR-24 led to a significant 
reduction in levels of TNFα and IL-6 cytokines in M-CSF matured primary human 
macrophages [594]. Although the authors did not speculate on the mechanism 
behind this observation, miR-24's targeting of CSF1R could offer a mechanistic 
explanation. 
 
7  General Discussion 
The aim of my PhD project was to investigate miR signatures in peripheral blood 
monocytes of patients with therapy-resistant RA. We hypothesised that 
epigenetic changes, and in particular miR dysregulation, contributes to the 
pathogenic phenotype of difficult to treat disease. We believed that 
investigating peripheral blood monocytes would be of particular importance, 
since these cells serve as central orchestrators of the many other pathogenic 
cells in RA, including inflammatory macrophages, dendritic cells and osteoclasts.  
To study specific molecular signatures that may be associated with therapeutic 
resistance requires a meticulous approach using highly phenotyped patients. This 
phenotyping and the decision to opt for purification of a specific cell population 
were underlying factors designed to increase the likelihood of success for this 
project.   
Firstly we identified clinically distinct groups of patients with established RA 
who either had well-controlled disease on two or less first line medications or 
who had progressed to require multiple DMARDs and then biologic agents, and 
exhibited serial therapeutic resistance. It is now well established that 
approximately 30% of patients gain clinical benefit from treatment with a single 
DMARD agent such as MTX, and thereafter progress little and have limited need 
of other therapeutics. Others are progressors of variable rapidity, thus 
representing functionally distinct subsets of RA patients [63]. It has been 
thought that longstanding disease has a stable underlying pathogenic signature; 
failure of response to initial treatment is a poor prognostic factor for future 
therapies [355]. However, it should be noted that the underlying phenotype of 
immunity in RA need not necessarily be a constant over time and as such a 
reappraisal of the immune status in patients with discrete phenotypes seems 
reasonable. Therefore, patients with specific therapeutic responses were 
selected for this study in order to investigate whether underlying pathogenic 
signatures represent a possible route to identifying functionally relevant 
endotypes. 
For the purpose of this study profiling of the total CD14+ population was 
conducted. Recently, distinct monocyte subsets, such as CD14+CD16+ cells, were 
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implicated in RA pathogenesis [227]. Profiling of the miR signature of these 
subsets would be an interesting subject to explore in my future work. 
Nevertheless, the purified CD14+ peripheral blood monocytes isolated from the 
various patient groups were subjected to miR array analysis, and yielded 
dysregulated miR species. From these, I decided to further investigate the miR-
23a~24-27a cluster, which was downregulated in both groups of difficult to treat 
patients when compared to good responders.  
First and foremost, my analyses identified IL-6R pathway as a potential 
candidate target of this cluster. High IL-6 serum levels, mirroring cluster 
dysregulation were found in all treatment failure patients, supporting this 
hypothesis. Investigation of the function of miR-23a~24-2~27a cluster implicated 
miR-23a and miR-27a in an IL-6 regulatory pathway feedback loop. Specifically, 
IL-6 signalling of CD14+ monocytes reduces the expression of the miR-23a 
cluster, which in turn de-represses its direct targets namely IL-6R and JAK/STAT 
signalling molecules (demonstrated by [765]), thus rendering cells more 
responsive to IL-6. Compatible with this, I have demonstrated that functional 
knockdown of miR-23a and miR-27a in THP-1 sponge cells results in increased 
expression of soluble IL-6R, which serves as an (accessory) alarmin and 
empowers cells not otherwise expressing IL-6R to become sensitive to the effects 
of IL-6 cytokine by virtue of trans signalling. Commensurate with this, I found 
raised expression of IL-6R transcripts and serum levels of soluble IL-6R in the 
biologics resistant patient group, consistent with an important role for these 
pathways. During RA inflammation, activated macrophages, as well as activated 
FLSs and B cells, are the major source of IL-6; it is possible that this regulatory 
feedback loop could operate in other lineages and this should be investigated in 
future [90,160,786].  
Additionally, I have discovered that the miR-23a cluster expression is regulated 
by cytokines with dominant antiviral properties, namely IFNγ and IFNβ. Some 
years ago, raised levels of IFNγ were found in synovial fluid from patients with 
RA and were associated with a notional pathogenic TH1 response [90,93]. More 
recently, activated T cells producing both IFNγ and IL-17 were identified in RA 
providing another mechanism by which antiviral responses within a chronic 
inflammatory setting such as RA can potentially trigger suppression of miR-23a 
cluster in an IL-6 independent way [98]. This hypothesis needs further 
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exploration in primary blood-derived monocytes. Nevertheless, this is the first 
study to my knowledge to provide a mechanism by which antiviral cytokines such 
as the interferons can ultimately influence IL-6 pathway activation by regulating 
IL-6R levels via miR-23a and miR-27a.  
Interestingly, the ability to regulate the miR-23a cluster was demonstrated with 
IFNβ but not IFNα. This is somewhat contrary to what one would expect, not 
least of all as these cytokines share intracellular JAK/STAT signalling pathways 
[468]. Moreover, a distinct IFNα signature was reported in a subgroup of RA 
patients, which was associated with increased activity of the innate immune 
system, consistent with my hypothesis [457]. pDCs are a major source of INFα, 
while IFNβ expression is attributed to activated FLSs cells in RA [283,458]. This 
provides an interesting scenario whereby FLSs secrete mediators capable of 
suppressing miR-23a cluster expression in blood-derived monocytes and thus 
promoting IL-6 sensitivity (Figure 7.1). Exploring these pathways in primary cells, 
as well as understanding how this influences monocyte-T cell or -FLS cross talk in 
arthritic joints would be an interesting and enticing task for me, going forward.  
Next, I have identified that monocyte maturation processes governed by M-CSF 
or GM-CSF growth factors induce rapid suppression of miR-23a~24-2~27a cluster. 
Both of these cytokines are indispensable for maturation of inflammatory 
monocytes into macrophages, osteoclasts and DCs in the RA synovium. In turn, 
miR-24 directly targets and regulates expression of CSF1R. This suggests that 
stimulation with M-CSF could promote expression of its receptor by suppressing 
miR-24 (Figure 7.1). Additionally, blood-derived monocytes exposed to IL-6 or 
antiviral mediators like IFNβ and IFNγ could elevate CSF1R expression by 
inhibiting miR-23a cluster expression and promoting maturation of cells (Figure 
7.1). In fact, the ability of IL-6 to promote M-CSF-driven maturation has been 
recognised previously, however, a mechanism for this phenomenon was never 
described [373].  
Finally, my data implicate miR-24 in the regulation of MTHFR and potential 
implications for MTX tolerability. This again would require further assessment in 
an independent cohort of RA patients, receiving MTX as a first DMARD. This 
investigation would allow assessment of potential biomarker properties of the 
miR-23a~miR-24-2~27a cluster. 
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Figure 7.1 Summary of the proposed miR-23a~miR-27a~IL-6R in RA. 
(A) A steady state of circulating monocyte with high expression of miR-23a~24~27a cluster. (B) 
Shows proposed IL-6/IL-6R/miR-23a/miR-27a regulatory pathway in activated monocytes. (C) 
Depicts proposed effect of IFNβ and IFNγ on miR-23a~24~27a cluster expression in monocyte 
activation. (D) Summary of the effect of M-CSF driven monocyte maturation on miR-23a~24~27a 
cluster and expression of pro-inflammatory cytokines.   
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The stability of serum miRs and easy measurement renders them good potential 
biomarkers that could be of clinical use. In fact, upregulation of miR-23a 
alongside miR-223 was suggested as biomarkers of clinical response to 
TNFα/DMARDs combination treatment in patients with early RA [642]. Going 
forward I would like to explore the biomarker potential of miR-23a and miR-27a 
for prediction of IL-6 and JAK inhibitor treatments, while it would be interesting 
to evaluate miR-24 in the context of MTX tolerability. Having a clear idea of the 
mechanism behind the function of this miR cluster helps to understand how they 
interplay with disease pathogenesis and effect of drugs, thus improving their 
biomarker potential.   
In summary, data contained herein confirm a postulated anti-inflammatory role 
for the miR-23a~24-2~27a cluster in the context of RA monocytes and suggests 
that dysregulation of this miR cluster could impose significant consequences 
upon implicated cells, resulting in production of pro-inflammatory cytokines, 
such as TNFα and IL-6, via a pathogenic feedback loop thus promoting 
chronicity. My studies in the longer term have greater consequence beyond this 
specific pathway. They lay out a framework upon which to develop novel 
biomarker profiles that have functional coherence and plausibility. I am now 
about to embark on more detailed analyses using highly phenotyped clinical 
cohorts contained in the Scottish Early RA Cohort. Moreover they give reason to 
believe that there are endotypes contained within the wider RA population that 
will have functional, prognostic and therapeutic consequence. That discrete 
immunologic setpoints exist in RA manifest in discrete miR expression in 
monocytes in the blood compartment strongly alludes that the existence of such 
endotpyes has at least some epigenetic underpinning. This in turn can offer 
future therapeutic options – either by directly targeting miRs or by using them as 
bait to elucidate novel pathways by virtue of their identified target pathways.  
As such they speak to an exciting future in the area of integrated biomarker and 
pathogenesis studies.  
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